IL321062A - Immunopreparations containing capsular saccharide conjugate antigens and their uses - Google Patents
Immunopreparations containing capsular saccharide conjugate antigens and their usesInfo
- Publication number
- IL321062A IL321062A IL321062A IL32106225A IL321062A IL 321062 A IL321062 A IL 321062A IL 321062 A IL321062 A IL 321062A IL 32106225 A IL32106225 A IL 32106225A IL 321062 A IL321062 A IL 321062A
- Authority
- IL
- Israel
- Prior art keywords
- serotype
- glycoconjugate
- polysaccharide
- kda
- carrier protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Description
1 Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof Field of the Invention The present invention relates to new immunogenic compositions comprising conjugated capsular 5saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of thepresent invention will typically comprise glycoconjugates, wherein the saccharides are derivedfrom serotypes of Streptococcus pneumoniae. The invention also relates to vaccination of humansubjects, in particular infants and elderly, against pneumoccocal infections using said novelimmunogenic compositions. 10 Background of the Invention Infections caused by pneumococci are a major cause of morbidity and mortality all over the world.Pneumonia, febrile bacteraemia and meningitis are the most common manifestations of invasivepneumococcal disease, whereas bacterial spread within the respiratory tract may result in middle- 15ear infection, sinusitis or recurrent bronchitis. Compared with invasive disease, the non-invasivemanifestations are usually less severe, but considerably more common.In Europe and the United States, pneumococcal pneumonia is the most common community-acquired bacterial pneumonia, estimated to affect approximately 100 per 100,000 adults eachyear. The corresponding figures for febrile bacteraemia and meningitis are 15–19 per 100 000 20and 1–2 per 100,000, respectively. The risk for one or more of these manifestations is muchhigher in infants and elderly people, as well as immune compromised persons of any age. Evenin economically developed regions, invasive pneumococcal disease carries high mortality; foradults with pneumococcal pneumonia the mortality rate averages 10%–20%, whilst it may exceed50% in the high-risk groups. Pneumonia is by far the most common cause of pneumococcal death 25worldwide.The etiological agent of pneumococcal diseases, Streptococcus pneumoniae (pneumococcus),is a Gram-positive encapsulated coccus, surrounded by a polysaccharide capsule. Differences inthe composition of this capsule permit serological differentiation between about 91 capsular types,some of which are frequently associated with pneumococcal disease, others rarely. Invasive 30pneumococcal infections include pneumonia, meningitis and febrile bacteremia; among thecommon non-invasive manifestations are otitis media, sinusitis and bronchitis.Pneumococcal conjugate vaccines (PCVs) are pneumococcal vaccines used to protect againstdisease caused by S. pneumoniae (pneumococcus). There are currently five PCV vaccinesavailable on the global market: Prevnar® (called Prevenar in some countries) (heptavalent 35vaccine), SYNFLORIX® (a decavalent vaccine), Prevnar 13® (tridecavalent vaccine),VaxneuvanceTM (a 15-valent vaccine) and Prevnar 20TM (a 20-valent vaccine). 2The recent development of widespread microbial resistance to essential antibiotics and theincreasing number of immunocompromised persons underline the need for pneumococcalvaccines with even broader protection.In particular, there is a need to address remaining unmet medical need for coverage ofpneumococcal disease due to serotypes not found in Prevnar 13® and potential for serotype 5replacement over time. The specific serotypes causing disease beyond the 13 in Prevnar 13® vary by region, population, and may change over time due to acquisition of antibiotic resistance,pneumococcal vaccine introduction and secular trends of unknown origin. There is a need forimmunogenic compositions that can be used to induce an immune response against additionalStreptococcus pneumoniae serotypes in humans and in particular in children less than 2 years 10old.An object of the new immunogenic compositions of the present invention is to provide forappropriate protection against additional S. pneumoniae serotypes not found in Prevnar 13®. Inone aspect, an object of the immunogenic compositions of the present invention is to provide forappropriate protection against additional S. pneumoniae serotypes not found in PREVNAR®(heptavalent vaccine), SYNFLORIX® and/or PREVNAR 13® while maintaining an immuneresponse against serotypes currently covered by said vaccines.
Figures Figure 1 shows a repeating polysaccharide structure of S. pneumoniae serotype 23A (Pn-23A) 20capsular polysaccharide. Figure 2 shows 1D 1H proton spectra of Pn-23A polysaccharide sized using sonication(mechanical) and acid hydrolysis done for 2 hours (2hrs), 4 hours (4Hrs) and 6 hours (6Hrs). Leftpanel: anomeric region; Middle panel: increased threshold of the anomeric region; Right panel:methyl region of 1H spectrum of Pn-23A polysaccharide. The anomeric and methyl signals are 25annotated. Figure 3 shows the change in the normalized intensity of selected resonances chosen from eachsugar in the repeating unit of Pn-23A polysaccharide. Figure 4 Right panel: 1DP spectra of Pn-23A polysaccharide sized using sonication(mechanical) and acid hydrolysis done for 2 hours (2hrs), 4 hours (4hrs) and 6 hours (6hrs). Left 30panel: 2DH-P HMBC spectrum of hydrolyzed (6 hrs) Pn-23A polysaccharide. The phosphorus-carbon correlations in different populations are annotated using dotted lines. Figure 5 Structural changes observed upon hydrolysis of Pn-23A polysaccharide. Figure 6 1DH proton spectra of Pn-23A polysaccharide sized using sonication (SizedSonication), homogenization (Sized Homogenized) and hydrolysis done for 2hrs (Hydrolized 35(2hrs)). Left panel: anomeric region; Middle panel: increased threshold of the anomeric region;Right panel: methyl region ofH spectrum of Pn-23A polysaccharide. The anomeric and methylsignals are annotated. 3 Figure 7 shows a repeating polysaccharide structure of S. pneumoniae serotype 24F (Pn-24F)capsular polysaccharide. Figure 8 shows 1DH proton spectrum of Pn-24F polysaccharide following hydrolysis. Theanomeric and methyl signals are annotated. The table shows the excellent agreement betweenthe normalized and expected peak area for the anomeric and methyl protons except for the 5residue E1 suggesting a loss of Ribf sugar. Figure 9 shows 1DH proton spectrum of Pn-24F polysaccharide following hydrolysis. Theanomeric and methyl signals are annotated. The table shows the excellent agreement betweenthe normalized and expected peak area fo the anomeric and methyl protons (but for the Ribf sugar(E1)). 10 Figure 10 shows 1DH proton spectra of Pn-24F polysaccharide either mechanically sized (lowerspectra) or hydrolyzed using two different conditions (upper and middle spectra). The anomericand methyl signals are annotated in the reference spectra. The tables show the 1DH NMR signalof the anomeric protons. Figure 11 Structural changes seen in Pn-24F polysaccharide after hydrolysis. 15 1 Glycoconjugates of the invention The present invention is directed in part to conjugated capsular saccharide antigens (alsonamed glycoconjugates). For the purpose of the invention the term ‘glycoconjugate' indicates acapsular saccharide conjugated to a carrier protein via covalent or non-covalent bonds. In an 20embodiment, the capsular saccharide is conjugated to a carrier protein via non-covalent bonds(such as the rhizavidin/biotin system, see e.g. WO2012155007, WO2020056202). Preferably, thecapsular saccharide is conjugated via covalent bonds. In one embodiment the capsularsaccharide is conjugated directly to a carrier protein. In a second embodiment the capsularsaccharide is conjugated to a carrier protein through a spacer/linker. 25The term "saccharide" throughout this specification may indicate polysaccharide oroligosaccharide and includes both. In frequent embodiments, the saccharide is a polysaccharide,in particular a S. pneumoniae capsular polysaccharide.S. pneumoniae capsular saccharides can be prepared by techniques known to those ofordinary skill in the art (see for example methods disclosed in US2006/0228380, 30US2006/0228381, US2008/0102498, WO2008/118752 and WO2020170190). Typically, capsularpolysaccharides are produced by growing each S. pneumoniae serotype in a medium (e.g., in asoy-based medium), the polysaccharides are then prepared from the bacteria culture. Bacterialstrains of S. pneumoniae used to make the respective polysaccharides that are used in theglycoconjugates of the invention may be obtained from established culture collections (such as 35for example from the Streptococcal Reference Laboratory (Centers for Disease Control andPrevention, Atlanta, GA USA)) or clinical specimens. 4The population of the organism (each S. pneumoniae serotype) is often scaled up from aseed vial to seed bottles and passaged through one or more seed fermentors of increasingvolume until production scale fermentation volumes are reached. At the end of the growth cyclethe cells are lysed and the lysate broth is then harvested for downstream (purification) processing(see for example WO 2006/110381, WO 2008/118752, and U.S. Patent App. Pub. Nos. 52006/0228380, 2006/0228381, 2008/0102498 and 2008/0286838).The individual polysaccharides are typically purified through centrifugation, precipitation, ultra-filtration, and/or column chromatography (see for example WO 2006/110352, WO 2008/118752and WO2020170190).Purified polysaccharides may be activated (e.g., chemically activated) to make them 10capable of reacting (e.g., either directly to the carrier protein of via a linker such as an eTECspacer) and then incorporated into glycoconjugates of the invention, as further described herein.S. pneumoniae capsular polysaccharides comprise repeating oligosaccharide units whichmay contain up to 8 sugar residues.In an embodiment, capsular saccharide of the invention may be one oligosaccharide unit, 15or a shorter than native length saccharide chain of repeating oligosaccharide units. In anembodiment, capsular saccharide of the invention is one repeating oligosaccharide unit of therelevant serotype.In an embodiment, capsular saccharide of the invention may be oligosaccharides.Oligosaccharides have a low number of repeat units (typically 5-15 repeat units) and are typically 20derived synthetically or by hydrolysis of polysaccharides.In an embodiment, the capsular saccharides of the present invention are polysaccharides.High molecular weight capsular polysaccharides are able to induce certain antibody immuneresponses due to the epitopes present on the antigenic surface. The isolation and purification ofhigh molecular weight capsular polysaccharides is preferably contemplated for use in the 25conjugates, compositions and methods of the present invention. 1.1 S. pneumoniae serotype 15A glycoconjugate of the invention In an aspect the invention relates to S. pneumoniae serotype 15A glycoconjugates.The structure of Streptococcus pneumoniae serotype 15A polysaccharide is known in the 30art (see e.g. Geno K et al. (2015) Clin Microbiol Rev Vol 28:3, p 871-899).In an embodiment, the capsular S. pneumoniae serotype 15A saccharide used in thepresent invention is a synthetic carbohydrate.In a preferred embodiment though, the source of bacterial polysaccharide according tothis invention can be Streptococcus pneumoniae serotype 15A bacterial cells. Bacterial strains 35which can be used as source of Streptococcus pneumoniae serotype 15A polysaccharides maybe obtained from established culture collections (such as for example from the Streptococcal 5Reference Laboratory (Centers for Disease Control and Prevention, Atlanta, GA USA)) or clinicalspecimens.Serotype 15A saccharides can be obtained directly from bacteria using isolationprocedures known to one of ordinary skill in the art. They can also be purchased (such as forexample from the American Type Culture Collection (ATCC, Manassas, VA USA) (e.g., reference 5No. ATCC (537-X)).In case the serotype 15A saccharide is obtained directly from bacteria, the bacterial cellscan be grown in a medium, preferably in a soy based medium. Following fermentation of bacterialcells that produce S. pneumoniae serotype 15A capsular polysaccharides, the bacterial cells canbe lysed to produce a cell lysate. The serotype 15A polysaccharide may then be isolated from the 10cell lysate using purification techniques known in the art, including the use of centrifugation, depthfiltration, precipitation, ultra-filtration, treatment with activate carbon, diafiltration and/or columnchromatography (see, for example, US2006/0228380, US2006/0228381, WO2008/118752 andWO2020170190). The purified serotype 15A capsular polysaccharide can then be used for thepreparation of glycoconjugates. 15The isolated serotype 15A capsular saccharide obtained by purification of serotype 15Apolysaccharide from the S. pneumoniae lysate and optionally sizing of the purified polysaccharidecan be characterized by different parameters including, for example the weight average molecularweight (Mw).The molecular weight of the polysaccharide can be measured by Size Exclusion 20Chromatography (SEC) combined with Multiangle Laser Light Scattering detector (MALLS).In a preferred embodiment, the isolated serotype 15A capsular polysaccharide (i.e.purified before further treatment) has a weight average molecular weight between 100 kDa and2500 kDa. In an embodiment, the isolated serotype 15A capsular polysaccharide has a weightaverage molecular weight between 250 kDa and 1500 kDa. In an embodiment, the isolated 25serotype 15A capsular polysaccharide has a weight average molecular weight between 500 kDaand 1000 kDa.Any whole number integer within any of the above ranges is contemplated as anembodiment of the disclosure.In order to generate serotype 15A conjugates with advantageous filterability 30characteristics, immunogenicity and/or yields, sizing of the polysaccharide to a target molecularweight range can be performed prior to the conjugation to a carrier protein. Advantageously, thesize of the purified serotype 15A polysaccharide is reduced while preserving critical features ofthe structure of the polysaccharide. Mechanical or chemical sizing maybe employed.In an embodiment, the size of the purified serotype 15A polysaccharide is reduced by 35chemical hydrolysis. Chemical hydrolysis maybe conducted using a mild acid (e.g acetic acid,formic acid, propanoic acid). Chemical hydrolysis may also be conducted using a diluted strong 6acid (such as diluted hydrochloric acid, diluted sulfuric acid, diluted phosphoric acid, diluted nitricacid or diluted perchloric acid).Preferably though, the size of the purified serotype 15A polysaccharide is reduced bymechanical homogenization. In an embodiment, the size of the purified serotype 15Apolysaccharide is reduced by high pressure homogenization. High pressure homogenization 5achieves high shear rates by pumping the process stream through a flow path with sufficientlysmall dimensions. The shear rate is increased by using a larger applied homogenization pressure,and exposure time can be increased by recirculating the feed stream through the homogenizer.In an embodiment, the isolated serotype 15A capsular polysaccharide is sized to a weightaverage molecular weight of between 50 kDa and 500 kDa. In a preferred embodiment, the 10isolated serotype 15A capsular polysaccharide is sized to a weight average molecular weight ofbetween 75 kDa and 250 kDa. Preferably, the isolated serotype 15A capsular polysaccharide issized to a weight average molecular weight below 175 kDa. In an even preferred embodiment,the isolated serotype 15A capsular polysaccharide is sized to a weight average molecular weightof between 75 kDa and 175 kDa. In a most preferred embodiment, the isolated serotype 15A 15capsular polysaccharide is sized to a weight average molecular weight of between 100 kDa and175 kDa. Preferably, the isolated serotype 15A polysaccharide is sized by mechanicalhomogenization, preferably by high pressure homogenization.In an embodiment, the isolated serotype 15A capsular polysaccharide is not sized.In an embodiment, the isolated serotype 15A capsular polysaccharide before conjugation 20has a weight average molecular weight between 50 kDa and 500 kDa. In an embodiment, theisolated serotype 15A capsular polysaccharide before conjugation has a weight averagemolecular weight between 75 kDa and 250 kDa. In a preferred embodiment, the isolated serotype15A capsular polysaccharide before conjugation has a weight average molecular weight betweenkDa and 175 kDa. In an even preferred embodiment, the isolated serotype 15A capsular 25polysaccharide before conjugation has a weight average molecular weight between 90 kDa and150 kDa. In a most preferred embodiment, the isolated serotype 15A capsular polysaccharidebefore conjugation has a weight average molecular weight between 100 kDa and 175 kDa.The weight average molecular weight (Mw) of the saccharide before conjugation refers tothe Mw before activation of the polysaccharide (i.e. after an eventual sizing step but before 30reacting the polysaccharide with an activating agent). In the context of the present invention theMw of the 15A polysaccharide is not substantially modified by the activation step and the Mw ofthe 15A polysaccharide incorporated in the conjugate is similar to the Mw of the polysaccharideas measured before activation.In an embodiment, the serotype 15A glycoconjugate of the present invention comprises a 35serotype 15A capsular polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 50 kDa and 500 kDa. In an embodiment, the weightaverage molecular weight (Mw) is between 75 kDa and 250 kDa. In a preferred embodiment, the 7weight average molecular weight (Mw) is between 75 kDa and 175 kDa. In a most preferredembodiment, the weight average molecular weight (Mw) is between 90 kDa and 150 kDa.In some embodiments, the serotype 15A glycoconjugate of the invention has a weightaverage molecular weight (Mw) of between 500 kDa and 10,000 kDa. In other embodiments, theserotype 15A glycoconjugate has a weight average molecular weight (Mw) of between 1,000 kDa 5and 10,000 kDa. Preferably, the serotype 15A glycoconjugate has a weight average molecularweight (Mw) of between 1,000 kDa and 6,000 kDa.The serotype 15A glycoconjugates of the invention may also be characterized by the ratio(weight/weight) of saccharide to carrier protein. In some embodiments, the ratio of serotype 15Apolysaccharide to carrier protein in the glycoconjugate (w/w) is between 0.5 and 3.0. Preferably, 10the saccharide to carrier protein ratio (w/w) is between 0.5 and 1.5. Even more preferably, thesaccharide to carrier protein ratio (w/w) is between 0.7 and 1.1.Another way to characterize the serotype 15A glycoconjugates of the invention is by thenumber of lysine residues in the carrier protein (e.g., CRM197, DT or TT) that become conjugatedto the saccharide which can be characterized as a range of conjugated lysines (degree of 15conjugation). The evidence for lysine modification of the carrier protein, due to covalent linkagesto the polysaccharides, can be obtained by amino acid analysis using routine methods known tothose of skill in the art. Conjugation results in a reduction in the number of lysine residuesrecovered compared to the carrier protein starting material used to generate the conjugatematerials. In a preferred embodiment, the degree of conjugation of the serotype 15A 20glycoconjugate of the invention is between 2 and 20. Preferably, the degree of conjugation of theserotype 15A glycoconjugate of the invention is between 5 and 10.The serotype 15A glycoconjugates and immunogenic compositions of the invention maycontain free saccharide that is not covalently conjugated to the carrier protein but is neverthelesspresent in the glycoconjugate composition. The free saccharide may be noncovalently associated 25with (i.e., noncovalently bound to, adsorbed to, or entrapped in or with) the glycoconjugate.In an embodiment, the serotype 15A glycoconjugate comprises less than about 40% offree serotype 15A polysaccharide compared to the total amount of serotype 15A polysaccharide.In a preferred embodiment the serotype 15A glycoconjugate comprises less than about 25% offree serotype 15A polysaccharide compared to the total amount of serotype 15A polysaccharide. 30The serotype 15A glycoconjugates may also be characterized by their molecular sizedistribution (Kd). Size exclusion chromatography media (CL-4B) can be used to determine therelative molecular size distribution of the conjugate. Size Exclusion Chromatography (SEC) isused in gravity fed columns to profile the molecular size distribution of conjugates. Largemolecules excluded from the pores in the media elute more quickly than small molecules. 35Fraction collectors are used to collect the column eluate. The fractions are tested colorimetricallyby saccharide assay. For the determination of Kd, columns are calibrated to establish the fractionat which molecules are fully excluded (V0), (Kd=0), and the fraction representing the maximum 8retention (Vi), (Kd=1). The fraction at which a specified sample attribute is reached (Ve), is relatedto Kd by the expression, Kd = (Ve - V0)/ (Vi - V0).In an embodiment, at least 40% of the serotype 15A glycoconjugate has a Kd below orequal to 0.3 in a CL-4B column. In a preferred embodiment, at least 50% of the glycoconjugatehas a Kd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, between 50% and 590% of the serotype 15A glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.In an embodiment, the serotype 15A saccharide is activated with 1-cyano-4-dimethylamino pyridinium tetrafluoroborate (CDAP) to form a cyanate ester. The activatedpolysaccharide is then coupled directly or via a spacer (linker) group to an amino group on thecarrier protein (preferably CRM 197). For example, the spacer could be cystamine or cysteamine 10to give a thiolated polysaccharide which could be coupled to the carrier via a thioether linkageobtained after reaction with a maleimide-activated carrier protein (for example using N-[ γ-maleimidobutyrloxy]succinimide ester (GMBS)) or a haloacetylated carrier protein (for exampleusing iodoacetimide, N-succinimidyl bromoacetate (SBA; SIB), N-succinimidyl(4-iodoacetyl)aminobenzoate (SlAB), sulfosuccinimidyl(4-iodoacetyl)aminobenzoate (sulfo-SIAB), 15N-succinimidyl iodoacetate (SIA) or succinimidyl 3-[bromoacetamido]proprionate (SBAP)).Preferably, the cyanate ester is coupled with hexane diamine or adipic acid dihydrazide (ADH)and the amino-derivatised saccharide is conjugated to the carrier protein (e.g., CRM 197) usingcarbodiimide (e.g., EDAC or EDC) chemistry via a carboxyl group on the protein carrier. Suchconjugates are described for example in WO 93/15760, WO 95/08348 and WO 96/129094. 20Other suitable techniques for conjugation use carbodiimides, hydrazides, active esters,norborane, p-nitrobenzoic acid, N-hydroxysuccinimide, S--NHS, EDC, TSTU. Many are describedin International Patent Application Publication No. WO 98/42721. Conjugation may involve acarbonyl linker which may be formed by reaction of a free hydroxyl group of the saccharide with1,1’-carbonyldiimidazole (CDI) (see Bethell et al. (1979) J. Biol. Chern. 254:2572-2574; Hearn et 25al. (1981) J. Chromatogr. 218:509-518) followed by reaction with a protein to form a carbamatelinkage. This may involve reduction of the anomeric terminus to a primary hydroxyl group, optionalprotection/deprotection of the primary hydroxyl group, reaction of the primary hydroxyl group withCDI to form a CDI carbamate intermediate and coupling the CDI carbamate intermediate with anamino group on a protein. 30In a preferred embodiment, the serotype 15A glycoconjugates of the invention areprepared using reductive amination chemistry. According to the present invention, reductiveamination involves two steps, (1) oxidation (activation) of a purified saccharide, (2) reduction ofthe activated saccharide and a carrier protein to form a glycoconjugate (see e.g.WO2006/110381, WO2008/079653, WO2008/143709, WO2008/079732, WO2011/110531, 35WO2012/119972, WO2015110941, WO2015110940, WO2018/144439, WO2018/156491). 9In an embodiment, the serotype 15A glycoconjugates of the invention are prepared byconjugating an isolated serotype 15A capsular polysaccharide to a carrier protein by a processcomprising the step of:(a) reacting said isolated serotype 15A capsular polysaccharide with an oxidizing agent;(b) compounding the activated polysaccharide of step (a) with a carrier protein; and (c) reacting 5the compounded activated polysaccharide and carrier protein with a reducing agent to form aglycoconjugate.As mentioned above, before oxidation, sizing of the isolated serotype 15A capsularpolysaccharide to a target molecular weight (MW) range can be performed. Therefore, in anembodiment, the isolated serotype 15A capsular polysaccharide is sized before oxidation. 10In an embodiment, the isolated serotype 15A capsular polysaccharide is not sized beforeoxidation.In an embodiment, the oxidation step (a) is carried out at a pH of between 4.0 and 6.0.Preferably, the oxidation step (a) is carried out at a pH of between 4.5 and 5.5.In an embodiment, the oxidation step (a) is carried out at a pH of about 5.0. 15Following the oxidation step (a) the saccharide is said to be activated and is referred to as"activated polysaccharide".In an embodiment, the activated serotype 15A polysaccharide of the present invention hasa weight average molecular weight (Mw) of between 50 kDa and 500 kDa. In an embodiment, theweight average molecular weight (Mw) is between 75 kDa and 250 kDa. In a preferred 20embodiment, the weight average molecular weight (Mw) is between 75 kDa and 175 kDa. In amost preferred embodiment, the weight average molecular weight (Mw) is between 90 kDa and150 kDa.In an embodiment, the oxidizing agent is any oxidizing agent which oxidizes a terminalhydroxyl group to an aldehyde. In an embodiment, the oxidizing agent is periodate. For the 25purpose of the present invention, the term "periodate" includes both periodate and periodic acid;the term also includes both metaperiodate (IO4-) and orthoperiodate (IO65-) and the various saltsof periodate (e.g., sodium periodate and potassium periodate).In a preferred embodiment, the oxidizing agent is sodium periodate. In an embodiment,the periodate used for the oxidation is metaperiodate. In a most preferred embodiment, the 30periodate used for the oxidation is sodium metaperiodate.When a polysaccharide reacts with periodate, periodate oxidises vicinal hydroxyl groupsto form carbonyl or aldehyde groups and causes cleavage of a C-C bond. For this reason, theterm "reacting a polysaccharide with periodate" includes oxidation of vicinal hydroxyl groups byperiodate. 35In one embodiment step a) comprises reacting the polysaccharide with 0.1-2 molarequivalents of periodate. Preferably step a) comprises reacting the polysaccharide with 0.5-1.5 10molar equivalents of periodate. Most preferably, step a) comprises reacting the polysaccharidewith 0.8-1.2 molar equivalents of periodate.In an embodiment the degree of oxidation (also named "degree of activation" in the presentdocument) of the activated serotype 15A polysaccharide is between 2 and 20. In a preferredembodiment the degree of oxidation of the activated serotype 15A polysaccharide is between 2 5and 8. In a most preferred embodiment the degree of oxidation of the activated serotype 15Apolysaccharide is 5 ±2.5.In one embodiment the activated serotype 15A polysaccharide and the carrier protein arelyophilised before step b). Preferably lyophilisation occurs after step a). In one embodiment theactivated polysaccharide is lyophilised after step a) and the carrier protein is also lyophilised. 10In one embodiment the activated serotype 15A polysaccharide is lyophilised after step a) and thecarrier protein is also lyophilised, and the activated polysaccharide and the carrier protein arereconstituted in the same solution.In an embodiment, the activated serotype 15A polysaccharide and the carrier protein areIyophilised independently (discrete lyophilization). In an embodiment, the activated serotype 15A 15polysaccharide and the carrier protein are Iyophilised together (co-lyophilized).In one embodiment the Iyophilization takes place in the presence of a non-reducing sugar,possible non-reducing sugars include sucrose, trehalose, raffinose, stachyose, melezitose,dextran, mannitol, lactitol and palatinit. In an embodiment the sugar is selected from the groupconsisting of sucrose, trehalose, and mannitol. In an embodiment the sugar is sucrose, trehalose 20or mannitol. In an embodiment the sugar is sucrose.In an embodiment the initial input ratio (weight by weight) of activated serotype 15Acapsular polysaccharide to carrier protein at step b) is between 3:1 and 0.5:1. In an embodimentthe initial input ratio (weight by weight) of activated serotype 15A capsular polysaccharide tocarrier protein is between 1.5:1 and 0.5:1. Preferably, the initial input ratio (weight by weight) of 25activated serotype 15A capsular polysaccharide to carrier protein is between 1.1:1 and 0.9:1.In an embodiment, the reduction reaction (c) is carried out in aqueous solvent. Preferably,the reduction reaction (c) is carried out in aprotic solvent.In an embodiment, the reduction reaction (c) is carried out in the presence ofdimethylsulphoxide (DMSO) or dimethylformamide (DMF). Preferably, the reduction reaction (c) 30is carried out in the presence of dimethylsulphoxide (DMSO).In an embodiment, the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide)or in DMF (dimethylformamide)) solvent.Most preferably, the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide)solvent. 35In an embodiment, the reducing agent is sodium cyanoborohydride, sodiumtriacetoxyborohydride, sodium or zinc borohydride in the presence of Bronsted or Lewis acids,amine boranes such as pyridine borane, 2-Picoline Borane, 2,6-diborane-methanol, 11dimethylamine-borane, t-BuMeiPrN-BH3, benzylamine-BH3 or 5-ethyl-2-methylpyridine borane(PEMB). In an embodiment, the reducing agent is sodium triacetoxyborohydride. In anembodiment, the reducing agent is sodium cyanoborohydride in the present of nickel (seeWO2018144439). In a preferred embodiment, the reducing agent is sodium cyanoborohydride.In one embodiment between 0.2 and 5 molar equivalents of reducing agent is used in step 5c). Preferably, between 0.5 and 2 molar equivalents of reducing agent is used in step c). Mostpreferably, between 0.9 and 1.1 molar equivalents of reducing agent is used in step c).At the end of the reduction reaction, there may be unreacted aldehyde groups remainingin the conjugates, these may be capped using a suitable capping agent. In one embodiment thiscapping agent is sodium borohydride (NaBH4). 10In an embodiment capping is achieved by mixing the product of step c) with 1 to 20 molarequivalents of sodium borohydride. In an embodiment capping is achieved by mixing the productof step c) with 1 to 3 molar equivalents of sodium borohydride.Following conjugation to the carrier protein, the serotype 15A glycoconjugate can bepurified (enriched with respect to the amount of saccharide-protein conjugate) by a variety of 15techniques known to the skilled person. These techniques include dialysis,concentration/diafiltration operations, tangential flow filtration precipitation/elution, columnchromatography (DEAE or hydrophobic interaction chromatography), and depth filtration.Therefore, in one embodiment the process for producing the serotype 15A glycoconjugate of thepresent invention comprises the step of purifying the glycoconjugate after it is produced. 20 1.2 S. pneumoniae serotype 23A glycoconjugate of the invention In an aspect the invention relates to S. pneumoniae serotype 23A glycoconjugates.The structure of Streptococcus pneumoniae serotype 23A polysaccharide is known in theart (see e.g. Ravenscroft N et al. (2017) Carbohydrate Res. Vol. 450, p 19-29 and 25WO2019050814). The structure of the serotype 23A capsular polysaccharide is: →4)-β-D-Glcp-(1→3)-[[α-L-Rhap-(1 →2)]-[Gro-(2 →P →3)]- β-D-Galp-(1 →4)]-β-L-Rhap-(1 →.In an embodiment, the capsular S. pneumoniae serotype 23A saccharide used in thepresent invention is a synthetic carbohydrate.In a preferred embodiment though, the source of bacterial polysaccharide according to 30this invention can be Streptococcus pneumoniae serotype 23A bacterial cells. Bacterial strainswhich can be used as source of Streptococcus pneumoniae serotype 23A polysaccharides maybe obtained from established culture collections (such as for example from the StreptococcalReference Laboratory (Centers for Disease Control and Prevention, Atlanta, GA USA)) or clinicalspecimens. 35Serotype 23A saccharides can be obtained directly from bacteria using isolationprocedures known to one of ordinary skill in the art. They can also be purchased (such as for 12example from the American Type Culture Collection (ATCC, Manassas, VA USA) (e.g., referenceNo. ATCC 545-X, No. ATCC 546-X, No. ATCC 547-X)).In case the serotype 23A saccharide is obtained directly from bacteria, the bacterial cellscan be grown in a medium, preferably in a soy based medium. Following fermentation of bacterialcells that produce S. pneumoniae serotype 23A capsular polysaccharides, the bacterial cells can 5be lysed to produce a cell lysate. The serotype 23A polysaccharide may then be isolated from thecell lysate using purification techniques known in the art, including the use of centrifugation, depthfiltration, precipitation, ultra-filtration, treatment with activate carbon, diafiltration and/or columnchromatography (see, for example, US2006/0228380, US2006/0228381, WO2008/118752 andWO2020170190). The purified serotype 23A capsular polysaccharide can then be used for the 10preparation of glycoconjugates.The isolated serotype 23A capsular saccharide obtained by purification of serotype 23Apolysaccharide from the S. pneumoniae lysate and optionally sizing of the purified polysaccharidecan be characterized by different parameters including, for example the weight average molecularweight (Mw). 15The molecular weight of the polysaccharide can be measured by Size ExclusionChromatography (SEC) combined with Multiangle Laser Light Scattering detector (MALLS).In a preferred embodiment, the isolated serotype 23A capsular polysaccharide (i.e.purified before further treatment) has a weight average molecular weight between 100 kDa and2500 kDa. In an embodiment, the isolated serotype 23A capsular polysaccharide has a weight 20average molecular weight between 250 kDa and 1500 kDa. In an embodiment, the isolatedserotype 23A capsular polysaccharide has a weight average molecular weight between 500 kDaand 1000 kDa.Any whole number integer within any of the above ranges is contemplated as anembodiment of the disclosure. 25In order to generate serotype 23A conjugates with advantageous filterabilitycharacteristics, immunogenicity and/or yields, sizing of the polysaccharide to a target molecularweight range can be performed prior to the conjugation to a carrier protein. Advantageously, thesize of the purified serotype 23A polysaccharide is reduced while preserving critical features ofthe structure of the polysaccharide. Mechanical or chemical sizing maybe employed. 30Most preferably, the size of the purified serotype 23A polysaccharide is reduced bymechanical homogenization.It has been discovered that the use of acid hydrolysis, as for example recommended inWO2019050814 or in WO2019050818 is not appropriate to reduce the size of serotype 23Apolysaccharide. 35It has been found that acid hydrolysis can affect serotype 23A polysaccharide structureintegrity. Even relatively mild hydrolysis (e.g. treatment with acetic acid at 100mM at 80°C for 2 13hours) has been found to lead to a 25% loss of the branched rhamnose ( α-L-Rhap-(1 →2)) (seefigure 1).Mechanical sizing allows not to loose this residue, which can be important from animmunological point of view. Furthermore, this residue is the main activation site for periodateoxidation. It is therefore important to retain it in case periodate oxidation of the polysaccharide is 5used (e.g. activation step in the reductive amination chemistry).Therefore, is a preferred embodiment, the size of the purified serotype 23A polysaccharideis reduced by mechanical homogenization.In an embodiment, the size of the purified serotype 23A polysaccharide is reduced by highpressure homogenization. High pressure homogenization achieves high shear rates by pumping 10the process stream through a flow path with sufficiently small dimensions. The shear rate isincreased by using a larger applied homogenization pressure, and exposure time can beincreased by recirculating the feed stream through the homogenizer.In a most preferred embodiment, the process to prepare serotype 23A glycoconjugate ofthe invention does not comprise a step of sizing of the serotype 23A polysaccharide by acid 15hydrolysis.In an embodiment, the isolated serotype 23A capsular polysaccharide is sized to a weightaverage molecular weight of between 50 kDa and 500 kDa. In a preferred embodiment, theisolated serotype 23A capsular polysaccharide is sized to a weight average molecular weight ofbetween 75 kDa and 400 kDa. In an even preferred embodiment, the isolated serotype 23A 20capsular polysaccharide is sized to a weight average molecular weight of between 100 kDa and350 kDa. In a most preferred embodiment, the isolated serotype 23A capsular polysaccharide issized to a weight average molecular weight of between 125 kDa and 225 kDa. Preferably, theisolated serotype 23A polysaccharide is sized by mechanical homogenization, most preferably byhigh pressure homogenization. 25In an embodiment, the isolated serotype 23A capsular polysaccharide is not sized.In an embodiment, the isolated serotype 23A capsular polysaccharide before conjugationhas a weight average molecular weight between 50 kDa and 500 kDa. In an embodiment, theisolated serotype 23A capsular polysaccharide before conjugation has a weight averagemolecular weight between 75 kDa and 400 kDa. In an even preferred embodiment, the isolated 30serotype 23A capsular polysaccharide before conjugation has a weight average molecular weightbetween 100 kDa and 350 kDa. In a most preferred embodiment, the isolated serotype 23Acapsular polysaccharide before conjugation has a weight average molecular weight of between125 kDa and 225 kDa.The weight average molecular weight (Mw) of the saccharide before conjugation refers to 35the Mw before activation of the polysaccharide (i.e. after an eventual sizing step but beforereacting the polysaccharide with an activating agent). In the context of the present invention theMw of the 23A polysaccharide is not substantially modified by the activation step and the Mw of 14the 23A polysaccharide incorporated in the conjugate is similar to the Mw of the polysaccharideas measured before activation.In an embodiment, the serotype 23A glycoconjugate of the present invention comprises aserotype 23A capsular polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 50 kDa and 400 kDa. In an embodiment, the weight 5average molecular weight (Mw) is between 100 kDa and 300 kDa. In a most preferredembodiment, the weight average molecular weight (Mw) is between 120 kDa and 240 kDa.In some embodiments, the serotype 23A glycoconjugate of the invention has a weightaverage molecular weight (Mw) of between 500 kDa and 10,000 kDa. In other embodiments, theserotype 23A glycoconjugate has a weight average molecular weight (Mw) of between 1,000 kDa 10and 7,500 kDa. Preferably, the serotype 23A glycoconjugate has a weight average molecularweight (Mw) of between 2,000 kDa and 5,000 kDa.The serotype 23A glycoconjugates of the invention may also be characterized by the ratio(weight/weight) of saccharide to carrier protein. In some embodiments, the ratio of serotype 23Apolysaccharide to carrier protein in the glycoconjugate (w/w) is between 0.5 and 3.0. Preferably, 15the saccharide to carrier protein ratio (w/w) is between 0.7 and 1.5. Even more preferably, thesaccharide to carrier protein ratio (w/w) is between 0.8 and 1.4.Another way to characterize the serotype 23A glycoconjugates of the invention is by thenumber of lysine residues in the carrier protein (e.g., CRM197, DT or TT) that become conjugatedto the saccharide which can be characterized as a range of conjugated lysines (degree of 20conjugation). The evidence for lysine modification of the carrier protein, due to covalent linkagesto the polysaccharides, can be obtained by amino acid analysis using routine methods known tothose of skill in the art. Conjugation results in a reduction in the number of lysine residuesrecovered compared to the carrier protein starting material used to generate the conjugatematerials. In a preferred embodiment, the degree of conjugation of the serotype 23A 25glycoconjugate of the invention is between 2 and 20. Preferably, the degree of conjugation of theserotype 23A glycoconjugate of the invention is between 5 and 15.The serotype 23A glycoconjugates and immunogenic compositions of the invention maycontain free saccharide that is not covalently conjugated to the carrier protein but is neverthelesspresent in the glycoconjugate composition. The free saccharide may be noncovalently associated 30with (i.e., noncovalently bound to, adsorbed to, or entrapped in or with) the glycoconjugate.In an embodiment, the serotype 23A glycoconjugate comprises less than about 40% offree serotype 23A polysaccharide compared to the total amount of serotype 23A polysaccharide.In a preferred embodiment the serotype 23A glycoconjugate comprises less than about 25% offree serotype 23A polysaccharide compared to the total amount of serotype 23A polysaccharide. 35The serotype 23A glycoconjugates may also be characterized by their molecular sizedistribution (Kd). Size exclusion chromatography media (CL-4B) can be used to determine therelative molecular size distribution of the conjugate. Size Exclusion Chromatography (SEC) is 15used in gravity fed columns to profile the molecular size distribution of conjugates. Largemolecules excluded from the pores in the media elute more quickly than small molecules.Fraction collectors are used to collect the column eluate. The fractions are tested colorimetricallyby saccharide assay. For the determination of Kd, columns are calibrated to establish the fractionat which molecules are fully excluded (V0), (Kd=0), and the fraction representing the maximum 5retention (Vi), (Kd=1). The fraction at which a specified sample attribute is reached (Ve), is relatedto Kd by the expression, Kd = (Ve - V0)/ (Vi - V0).In an embodiment, at least 40% of the serotype 23A glycoconjugate has a Kd below orequal to 0.3 in a CL-4B column. In a preferred embodiment, at least 50% of the glycoconjugatehas a Kd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, between 50% and 1090% of the serotype 23A glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.The serotype 23A glycoconjugates may also be characterized by the amount of branchedRhamnose residue which remains in the 23A polysaccharide. As mentioned above, it has beenfound that serotype 23A polysaccharide can loose the branched Rhamnose residue (see figure1). 15Therefore, in an embodiment, the S. pneumoniae serotype 23A glycoconjugate of thepresent invention comprises a S. pneumoniae serotype 23A capsular polysaccharide whereinsaid S. pneumoniae serotype 23A capsular polysaccharide has a branched Rhamnose contentgreater than 75% when compared to native S. pneumoniae serotype 23A capsular polysaccharidewherein the branched Rhamnose content is considered to be about 100%. In an embodiment, the 20S. pneumoniae serotype 23A glycoconjugate of the present invention comprises a S. pneumoniaeserotype 23A capsular polysaccharide wherein said S. pneumoniae serotype 23A capsularpolysaccharide has a branched Rhamnose content greater than 90% when compared to nativeS. pneumoniae serotype 23A capsular polysaccharide wherein the branched Rhamnose contentis considered to be about 100%. Preferably, the S. pneumoniae serotype 23A glycoconjugate of 25the present invention comprises a S. pneumoniae serotype 23A capsular polysaccharide whereinsaid S. pneumoniae serotype 23A capsular polysaccharide has a branched Rhamnose contentgreater than 95% when compared to native S. pneumoniae serotype 23A capsular polysaccharidewherein the branched Rhamnose content is considered to be about 100%.In a most preferred embodiment, the S. pneumoniae serotype 23A glycoconjugate of the 30present invention comprises a S. pneumoniae serotype 23A capsular polysaccharide whereinsaid S. pneumoniae serotype 23A capsular polysaccharide has a branched Rhamnose contentof about 100% when compared to native S. pneumoniae serotype 23A capsular polysaccharidewherein the branched Rhamnose content is considered to be about 100%.In an embodiment, the serotype 23A saccharide is activated with 1-cyano-4- 35dimethylamino pyridinium tetrafluoroborate (CDAP) to form a cyanate ester. The activatedpolysaccharide is then coupled directly or via a spacer (linker) group to an amino group on thecarrier protein (preferably CRM 197). For example, the spacer could be cystamine or cysteamine 16to give a thiolated polysaccharide which could be coupled to the carrier via a thioether linkageobtained after reaction with a maleimide-activated carrier protein (for example using N-[ γ-maleimidobutyrloxy]succinimide ester (GMBS)) or a haloacetylated carrier protein (for exampleusing iodoacetimide, N-succinimidyl bromoacetate (SBA; SIB), N-succinimidyl(4-iodoacetyl)aminobenzoate (SlAB), sulfosuccinimidyl(4-iodoacetyl)aminobenzoate (sulfo-SIAB), 5N-succinimidyl iodoacetate (SIA) or succinimidyl 3-[bromoacetamido]proprionate (SBAP)).Preferably, the cyanate ester is coupled with hexane diamine or adipic acid dihydrazide (ADH)and the amino-derivatised saccharide is conjugated to the carrier protein (e.g., CRM 197) usingcarbodiimide (e.g., EDAC or EDC) chemistry via a carboxyl group on the protein carrier. Suchconjugates are described for example in WO 93/15760, WO 95/08348 and WO 96/129094. 10Other suitable techniques for conjugation use carbodiimides, hydrazides, active esters,norborane, p-nitrobenzoic acid, N-hydroxysuccinimide, S--NHS, EDC, TSTU. Many are describedin International Patent Application Publication No. WO 98/42721. Conjugation may involve acarbonyl linker which may be formed by reaction of a free hydroxyl group of the saccharide with1,1’-carbonyldiimidazole (CDI) (see Bethell et al. (1979) J. Biol. Chern. 254:2572-2574; Hearn et 15al. (1981) J. Chromatogr. 218:509-518) followed by reaction with a protein to form a carbamatelinkage. This may involve reduction of the anomeric terminus to a primary hydroxyl group, optionalprotection/deprotection of the primary hydroxyl group, reaction of the primary hydroxyl group withCDI to form a CDI carbamate intermediate and coupling the CDI carbamate intermediate with anamino group on a protein. 20In a preferred embodiment, the serotype 23A glycoconjugates of the invention areprepared using reductive amination chemistry. According to the present invention, reductiveamination involves two steps, (1) oxidation (activation) of a purified saccharide, (2) reduction ofthe activated saccharide and a carrier protein to form a glycoconjugate (see e.g.WO2006/110381, WO2008/079653, WO2008/143709, WO2008/079732, WO2011/110531, 25WO2012/119972, WO2015110941, WO2015110940, WO2018/144439, WO2018/156491).In an embodiment, the serotype 23A glycoconjugates of the invention are prepared byconjugating an isolated serotype 23A capsular polysaccharide to a carrier protein by a processcomprising the step of:(a) reacting said isolated serotype 23A capsular polysaccharide with an oxidizing agent; 30(b) compounding the activated polysaccharide of step (a) with a carrier protein; and (c) reactingthe compounded activated polysaccharide and carrier protein with a reducing agent to form aglycoconjugate.As mentioned above, before oxidation, sizing of the isolated serotype 23A capsularpolysaccharide to a target molecular weight (MW) range can be performed. Therefore, in an 35embodiment, the isolated serotype 23A capsular polysaccharide is sized before oxidation.In a preferred embodiment, the size of the isolated serotype 23A capsular polysaccharideis reduced by mechanical homogenization. In an embodiment, the size of the isolated serotype 1723A polysaccharide is reduced by high pressure homogenization. In a most preferredembodiment, the isolated serotype 23A capsular polysaccharide is not sized by acid hydrolysis.In an embodiment, the isolated serotype 23A capsular polysaccharide is not sized beforeoxidation.In an embodiment, the oxidation step (a) is carried out at a pH of between 4.5 and 6.5. 5Preferably, the oxidation step (a) is carried out at a pH of between 5.0 and 6.0.In an embodiment, the oxidation step (a) is carried out at a pH of about 5.0.Following the oxidation step (a) the saccharide is said to be activated and is referred to as"activated polysaccharide".In an embodiment, the activated serotype 23A polysaccharide of the present invention has 10a weight average molecular weight (Mw) of between 50 kDa and 400 kDa. In an embodiment, theweight average molecular weight (Mw) is between 100 kDa and 250 kDa. In a most preferredembodiment, the weight average molecular weight (Mw) is between 120 kDa and 200 kDa.In an embodiment, the activated serotype 23A polysaccharide of the present inventionretains at least 80% of the branched Rhamnose. In an embodiment, the activated serotype 23A 15polysaccharide of the present invention retains at least 85% of the branched Rhamnose. In anembodiment, the activated serotype 23A polysaccharide of the present invention retains at least90% of the branched Rhamnose. In a preferred embodiment, the activated serotype 23Apolysaccharide of the present invention retains at least 95% of the branched Rhamnose.In a preferred embodiment, the activated serotype 23A polysaccharide of the present 20invention retains at least 96% of the branched Rhamnose.In an embodiment, the oxidizing agent is any oxidizing agent which oxidizes a terminalhydroxyl group to an aldehyde. In an embodiment, the oxidizing agent is periodate. For thepurpose of the present invention, the term "periodate" includes both periodate and periodic acid;the term also includes both metaperiodate (IO4-) and orthoperiodate (IO65-) and the various salts 25of periodate (e.g., sodium periodate and potassium periodate).In a preferred embodiment, the oxidizing agent is sodium periodate. In an embodiment,the periodate used for the oxidation is metaperiodate. In a most preferred embodiment, theperiodate used for the oxidation is sodium metaperiodate.When a polysaccharide reacts with periodate, periodate oxidises vicinal hydroxyl groups 30to form carbonyl or aldehyde groups and causes cleavage of a C-C bond. For this reason, theterm "reacting a polysaccharide with periodate" includes oxidation of vicinal hydroxyl groups byperiodate.In one embodiment step a) comprises reacting the polysaccharide with 0.1-2 molarequivalents of periodate. Preferably step a) comprises reacting the polysaccharide with 0.2-1.5 35molar equivalents of periodate. Most preferably, step a) comprises reacting the polysaccharidewith 0.3-0.5 molar equivalents of periodate. 18In an embodiment the degree of oxidation (also named "degree of activation" in the presentdocument) of the activated serotype 23A polysaccharide is between 2 and 20. In a preferredembodiment the degree of oxidation of the activated serotype 23A polysaccharide is between 2and 8. In a most preferred embodiment the degree of oxidation of the activated serotype 23Apolysaccharide is 5 ±2.5. 5In one embodiment the activated serotype 23A polysaccharide and the carrier protein arelyophilised before step b). Preferably lyophilisation occurs after step a). In one embodiment theactivated polysaccharide is lyophilised after step a) and the carrier protein is also lyophilised.In one embodiment the activated serotype 23A polysaccharide is lyophilised after step a) and thecarrier protein is also lyophilised, and the activated polysaccharide and the carrier protein are 10reconstituted in the same solution.In an embodiment, the activated serotype 23A polysaccharide and the carrier protein areIyophilised independently (discrete lyophilization). In an embodiment, the activated serotype 23Apolysaccharide and the carrier protein are Iyophilised together (co-lyophilized).In one embodiment the Iyophilization takes place in the presence of a non-reducing sugar, 15possible non-reducing sugars include sucrose, trehalose, raffinose, stachyose, melezitose,dextran, mannitol, lactitol and palatinit. In an embodiment the sugar is selected from the groupconsisting of sucrose, trehalose, and mannitol. In an embodiment the sugar is sucrose, trehaloseor mannitol. In an embodiment the sugar is sucrose.In an embodiment the initial input ratio (weight by weight) of activated serotype 23A 20capsular polysaccharide to carrier protein at step b) is between 2:1 and 0.5:1. In an embodimentthe initial input ratio (weight by weight) of activated serotype 23A capsular polysaccharide tocarrier protein is between 1.2:1 and 0.6:1. Preferably, the initial input ratio (weight by weight) ofactivated serotype 23A capsular polysaccharide to carrier protein is between 0.9:1 and 0.7:1.In an embodiment, the reduction reaction (c) is carried out in aqueous solvent. Preferably, 25the reduction reaction (c) is carried out in aprotic solvent.In an embodiment, the reduction reaction (c) is carried out in the presence ofdimethylsulphoxide (DMSO) or dimethylformamide (DMF). Preferably, the reduction reaction (c)is carried out in the presence of dimethylsulphoxide (DMSO).In an embodiment, the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide) 30or in DMF (dimethylformamide)) solvent.Most preferably, the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide)solvent.In an embodiment, the reducing agent is sodium cyanoborohydride, sodiumtriacetoxyborohydride, sodium or zinc borohydride in the presence of Bronsted or Lewis acids, 35amine boranes such as pyridine borane, 2-Picoline Borane, 2,6-diborane-methanol,dimethylamine-borane, t-BuMeiPrN-BH3, benzylamine-BH3 or 5-ethyl-2-methylpyridine borane(PEMB). In an embodiment, the reducing agent is sodium triacetoxyborohydride. In an 19embodiment, the reducing agent is sodium cyanoborohydride in the present of nickel (seeWO2018144439). In a preferred embodiment, the reducing agent is sodium cyanoborohydride.In one embodiment between 0.2 and 5 molar equivalents of reducing agent is used in stepc). Preferably, between 0.2 and 1.5 molar equivalents of reducing agent is used in step c). Mostpreferably, between 0.5 and 1.0 molar equivalent of reducing agent is used in step c). 5At the end of the reduction reaction, there may be unreacted aldehyde groups remainingin the conjugates, these may be capped using a suitable capping agent. In one embodiment thiscapping agent is sodium borohydride (NaBH4).In an embodiment capping is achieved by mixing the product of step c) with 1 to 20 molarequivalents of sodium borohydride. In an embodiment capping is achieved by mixing the product 10of step c) with 1 to 3 molar equivalents of sodium borohydride.Following conjugation to the carrier protein, the serotype 23A glycoconjugate can bepurified (enriched with respect to the amount of saccharide-protein conjugate) by a variety oftechniques known to the skilled person. These techniques include dialysis,concentration/diafiltration operations, tangential flow filtration precipitation/elution, column 15chromatography (DEAE or hydrophobic interaction chromatography), and depth filtration.Therefore, in one embodiment the process for producing the serotype 23A glycoconjugate of thepresent invention comprises the step of purifying the glycoconjugate after it is produced. 1.3 S. pneumoniae serotype 23B glycoconjugate of the invention 20In an aspect the invention relates to S. pneumoniae serotype 23B glycoconjugates.The structure of Streptococcus pneumoniae serotype 23B polysaccharide is known in theart (see e.g. Ravenscroft N et al. (2017) Carbohydrate Res. Vol. 450, p 19-29 andWO2019050814). The structure of the serotype 23A capsular polysaccharide is:→4)- β-D-Glcp-(1 →4)-[Gro-(2→P →3)]- β-D-Galp-(1 →4)- β-L-Rhap-(1 →. 25In an embodiment, the capsular S. pneumoniae serotype 23B saccharide used in thepresent invention is a synthetic carbohydrate.In a preferred embodiment though, the source of bacterial polysaccharide according tothis invention can be Streptococcus pneumoniae serotype 23B bacterial cells. Bacterial strainswhich can be used as source of Streptococcus pneumoniae serotype 23B polysaccharides may 30be obtained from established culture collections (such as for example from the StreptococcalReference Laboratory (Centers for Disease Control and Prevention, Atlanta, GA USA)) or clinicalspecimens.Serotype 23B saccharides can be obtained directly from bacteria using isolationprocedures known to one of ordinary skill in the art. They can also be purchased (such as for 35example from the American Type Culture Collection (ATCC, Manassas, VA USA) (e.g., referenceNo. ATCC 548-X, No. ATCC 549-X, No. ATCC 550-X)). 20In case the serotype 23B saccharide is obtained directly from bacteria, the bacterial cellscan be grown in a medium, preferably in a soy based medium. Following fermentation of bacterialcells that produce S. pneumoniae serotype 23B capsular polysaccharides, the bacterial cells canbe lysed to produce a cell lysate. The serotype 23B polysaccharide may then be isolated from thecell lysate using purification techniques known in the art, including the use of centrifugation, depth 5filtration, precipitation, ultra-filtration, treatment with activate carbon, diafiltration and/or columnchromatography (see, for example, US2006/0228380, US2006/0228381, WO2008/118752 andWO2020170190). The purified serotype 23B capsular polysaccharide can then be used for thepreparation of glycoconjugates.The isolated serotype 23B capsular saccharide obtained by purification of serotype 23B 10polysaccharide from the S. pneumoniae lysate and optionally sizing of the purified polysaccharidecan be characterized by different parameters including, for example the weight average molecularweight (Mw).The molecular weight of the polysaccharide can be measured by Size ExclusionChromatography (SEC) combined with Multiangle Laser Light Scattering detector (MALLS). 15In a preferred embodiment, the isolated serotype 23B capsular polysaccharide (i.e.purified before further treatment) has a weight average molecular weight between 100 kDa and2500 kDa. In an embodiment, the isolated serotype 23B capsular polysaccharide has a weightaverage molecular weight between 250 kDa and 2000 kDa. In an embodiment, the isolatedserotype 23B capsular polysaccharide has a weight average molecular weight between 300 kDa 20and 1000 kDa.Any whole number integer within any of the above ranges is contemplated as anembodiment of the disclosure.In order to generate serotype 23B conjugates with advantageous filterabilitycharacteristics, immunogenicity and/or yields, sizing of the polysaccharide to a target molecular 25weight range can be performed prior to the conjugation to a carrier protein. Advantageously, thesize of the purified serotype 23B polysaccharide is reduced while preserving critical features ofthe structure of the polysaccharide. Mechanical or chemical sizing maybe employed.In an embodiment, the size of the purified serotype 23B polysaccharide is reduced bychemical hydrolysis. Chemical hydrolysis maybe conducted using a mild acid (e.g acetic acid, 30formic acid, propanoic acid). Chemical hydrolysis may also be conducted using a diluted strongacid (such as diluted hydrochloric acid, diluted sulfuric acid, diluted phosphoric acid, diluted nitricacid or diluted perchloric acid).Preferably though, the size of the purified serotype 23B polysaccharide is reduced bymechanical homogenization. In an embodiment, the size of the purified serotype 23B 35polysaccharide is reduced by high pressure homogenization. High pressure homogenizationachieves high shear rates by pumping the process stream through a flow path with sufficiently 21small dimensions. The shear rate is increased by using a larger applied homogenization pressure,and exposure time can be increased by recirculating the feed stream through the homogenizer.In an embodiment, the isolated serotype 23B capsular polysaccharide is sized to a weightaverage molecular weight of between 50 kDa and 750 kDa. In a preferred embodiment, theisolated serotype 23B capsular polysaccharide is sized to a weight average molecular weight of 5between 75 kDa and 400 kDa. In an even preferred embodiment, the isolated serotype 23Bcapsular polysaccharide is sized to a weight average molecular weight of between 100 kDa and250 kDa. Preferably, the isolated serotype 23B polysaccharide is sized by mechanicalhomogenization, most preferably by high pressure homogenization.In an embodiment, the isolated serotype 23B capsular polysaccharide is not sized. 10In an embodiment, the isolated serotype 23B capsular polysaccharide before conjugationhas a weight average molecular weight between 50 kDa and 750 kDa. In an embodiment, theisolated serotype 23B capsular polysaccharide before conjugation has a weight averagemolecular weight between 75 kDa and 400 kDa. In an even preferred embodiment, the isolatedserotype 23B capsular polysaccharide before conjugation has a weight average molecular weight 15between 100 kDa and 250 kDa.The weight average molecular weight (Mw) of the saccharide before conjugation refers tothe Mw before activation of the polysaccharide (i.e. after an eventual sizing step but beforereacting the polysaccharide with an activating agent). In the context of the present invention theMw of the 23B polysaccharide is not substantially modified by the activation step and the Mw of 20the 23B polysaccharide incorporated in the conjugate is similar to the Mw of the polysaccharideas measured before activation.In an embodiment, the serotype 23B glycoconjugate of the present invention comprises aserotype 23B capsular polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 40 kDa and 600 kDa. In an embodiment, the weight 25average molecular weight (Mw) is between 50 kDa and 300 kDa. In a most preferred embodiment,the weight average molecular weight (Mw) is between 100 kDa and 200 kDa.In some embodiments, the serotype 23B glycoconjugate of the invention has a weightaverage molecular weight (Mw) of between 250 kDa and 7,500 kDa. In other embodiments, theserotype 23B glycoconjugate has a weight average molecular weight (Mw) of between 500 kDa 30and 4,000 kDa. Preferably, the serotype 23B glycoconjugate has a weight average molecularweight (Mw) of between 700 kDa and 2,000 kDa.The serotype 23B glycoconjugates of the invention may also be characterized by the ratio(weight/weight) of saccharide to carrier protein. In some embodiments, the ratio of serotype 23Bpolysaccharide to carrier protein in the glycoconjugate (w/w) is between 0.4 and 3.0. Preferably, 35the saccharide to carrier protein ratio (w/w) is between 0.5 and 1.5. Even more preferably, thesaccharide to carrier protein ratio (w/w) is between 0.6 and 1.3. 22Another way to characterize the serotype 23B glycoconjugates of the invention is by thenumber of lysine residues in the carrier protein (e.g., CRM197, DT or TT) that become conjugatedto the saccharide which can be characterized as a range of conjugated lysines (degree ofconjugation). The evidence for lysine modification of the carrier protein, due to covalent linkagesto the polysaccharides, can be obtained by amino acid analysis using routine methods known to 5those of skill in the art. Conjugation results in a reduction in the number of lysine residuesrecovered compared to the carrier protein starting material used to generate the conjugatematerials. In a preferred embodiment, the degree of conjugation of the serotype 23Bglycoconjugate of the invention is between 2 and 15. Preferably, the degree of conjugation of theserotype 23B glycoconjugate of the invention is between 5 and 12. 10The serotype 23B glycoconjugates and immunogenic compositions of the invention maycontain free saccharide that is not covalently conjugated to the carrier protein but is neverthelesspresent in the glycoconjugate composition. The free saccharide may be noncovalently associatedwith (i.e., noncovalently bound to, adsorbed to, or entrapped in or with) the glycoconjugate.In an embodiment, the serotype 23B glycoconjugate comprises less than about 40% of 15free serotype 23B polysaccharide compared to the total amount of serotype 23B polysaccharide.In a preferred embodiment the serotype 23B glycoconjugate comprises less than about 25% offree serotype 23B polysaccharide compared to the total amount of serotype 23B polysaccharide.The serotype 23B glycoconjugates may also be characterized by their molecular sizedistribution (Kd). Size exclusion chromatography media (CL-4B) can be used to determine the 20relative molecular size distribution of the conjugate. Size Exclusion Chromatography (SEC) isused in gravity fed columns to profile the molecular size distribution of conjugates. Largemolecules excluded from the pores in the media elute more quickly than small molecules.Fraction collectors are used to collect the column eluate. The fractions are tested colorimetricallyby saccharide assay. For the determination of Kd, columns are calibrated to establish the fraction 25at which molecules are fully excluded (V0), (Kd=0), and the fraction representing the maximumretention (Vi), (Kd=1). The fraction at which a specified sample attribute is reached (Ve), is relatedto Kd by the expression, Kd = (Ve - V0)/ (Vi - V0).In an embodiment, at least 30% of the serotype 23B glycoconjugate has a Kd below orequal to 0.3 in a CL-4B column. In a preferred embodiment, at least 35% of the glycoconjugate 30has a Kd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, between 40% and60% of the serotype 23B glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.In an embodiment, the serotype 23B saccharide is activated with 1-cyano-4-dimethylamino pyridinium tetrafluoroborate (CDAP) to form a cyanate ester. The activatedpolysaccharide is then coupled directly or via a spacer (linker) group to an amino group on the 35carrier protein (preferably CRM 197). For example, the spacer could be cystamine or cysteamineto give a thiolated polysaccharide which could be coupled to the carrier via a thioether linkageobtained after reaction with a maleimide-activated carrier protein (for example using N-[ γ- 23maleimidobutyrloxy]succinimide ester (GMBS)) or a haloacetylated carrier protein (for exampleusing iodoacetimide, N-succinimidyl bromoacetate (SBA; SIB), N-succinimidyl(4-iodoacetyl)aminobenzoate (SlAB), sulfosuccinimidyl(4-iodoacetyl)aminobenzoate (sulfo-SIAB),N-succinimidyl iodoacetate (SIA) or succinimidyl 3-[bromoacetamido]proprionate (SBAP)).Preferably, the cyanate ester is coupled with hexane diamine or adipic acid dihydrazide (ADH) 5and the amino-derivatised saccharide is conjugated to the carrier protein (e.g., CRM 197) usingcarbodiimide (e.g., EDAC or EDC) chemistry via a carboxyl group on the protein carrier. Suchconjugates are described for example in WO 93/15760, WO 95/08348 and WO 96/129094.Other suitable techniques for conjugation use carbodiimides, hydrazides, active esters,norborane, p-nitrobenzoic acid, N-hydroxysuccinimide, S--NHS, EDC, TSTU. Many are described 10in International Patent Application Publication No. WO 98/42721. Conjugation may involve acarbonyl linker which may be formed by reaction of a free hydroxyl group of the saccharide with1,1’-carbonyldiimidazole (CDI) (see Bethell et al. (1979) J. Biol. Chern. 254:2572-2574; Hearn etal. (1981) J. Chromatogr. 218:509-518) followed by reaction with a protein to form a carbamatelinkage. This may involve reduction of the anomeric terminus to a primary hydroxyl group, optional 15protection/deprotection of the primary hydroxyl group, reaction of the primary hydroxyl group withCDI to form a CDI carbamate intermediate and coupling the CDI carbamate intermediate with anamino group on a protein.In a preferred embodiment, the serotype 23B glycoconjugates of the invention areprepared using reductive amination chemistry. According to the present invention, reductive 20amination involves two steps, (1) oxidation (activation) of a purified saccharide, (2) reduction ofthe activated saccharide and a carrier protein to form a glycoconjugate (see e.g.WO2006/110381, WO2008/079653, WO2008/143709, WO2008/079732, WO2011/110531,WO2012/119972, WO2015110941, WO2015110940, WO2018/144439, WO2018/156491).In an embodiment, the serotype 23B glycoconjugates of the invention are prepared by 25conjugating an isolated serotype 23B capsular polysaccharide to a carrier protein by a processcomprising the step of:(a) reacting said isolated serotype 23B capsular polysaccharide with an oxidizing agent;(b) compounding the activated polysaccharide of step (a) with a carrier protein; and (c) reactingthe compounded activated polysaccharide and carrier protein with a reducing agent to form a 30glycoconjugate.As mentioned above, before oxidation, sizing of the isolated serotype 23B capsularpolysaccharide to a target molecular weight (MW) range can be performed. Therefore, in anembodiment, the isolated serotype 23B capsular polysaccharide is sized before oxidation.In a preferred embodiment, the size of the isolated serotype 23B capsular polysaccharide 35is reduced by mechanical homogenization. In an embodiment, the size of the isolated serotype23B polysaccharide is reduced by high pressure homogenization. 24In an embodiment, the isolated serotype 23B capsular polysaccharide is not sized beforeoxidation.In an embodiment, the oxidation step (a) is carried out at a pH of between 4.0 and 6.5.Preferably, the oxidation step (a) is carried out at a pH of between 4.5 and 5.5.In an embodiment, the oxidation step (a) is carried out at a pH of about 5.0. 5Following the oxidation step (a) the saccharide is said to be activated and is referred to as"activated polysaccharide".In an embodiment, the activated serotype 23B polysaccharide of the present invention hasa weight average molecular weight (Mw) of between 40 kDa and 600 kDa. In an embodiment, theweight average molecular weight (Mw) is between 50 kDa and 300 kDa. In a most preferred 10embodiment, the weight average molecular weight (Mw) is between 100 kDa and 200 kDa.In an embodiment, the oxidizing agent is any oxidizing agent which oxidizes a terminalhydroxyl group to an aldehyde. In an embodiment, the oxidizing agent is periodate. For thepurpose of the present invention, the term "periodate" includes both periodate and periodic acid;the term also includes both metaperiodate (IO4-) and orthoperiodate (IO65-) and the various salts 15of periodate (e.g., sodium periodate and potassium periodate).In a preferred embodiment, the oxidizing agent is sodium periodate. In an embodiment,the periodate used for the oxidation is metaperiodate. In a most preferred embodiment, theperiodate used for the oxidation is sodium metaperiodate.When a polysaccharide reacts with periodate, periodate oxidises vicinal hydroxyl groups 20to form carbonyl or aldehyde groups and causes cleavage of a C-C bond. For this reason, theterm "reacting a polysaccharide with periodate" includes oxidation of vicinal hydroxyl groups byperiodate.In one embodiment step a) comprises reacting the polysaccharide with 0.05-1 molarequivalents of periodate. Preferably step a) comprises reacting the polysaccharide with 0.1-0.3 25molar equivalents of periodate. Most preferably, step a) comprises reacting the polysaccharidewith about 0.2 molar equivalents of periodate.In an embodiment the degree of oxidation (also named "degree of activation" in the presentdocument) of the activated serotype 23B polysaccharide is between 2 and 20. In a preferredembodiment the degree of oxidation of the activated serotype 23B polysaccharide is between 4 30and 15. In a most preferred embodiment the degree of oxidation of the activated serotype 23Bpolysaccharide is 9 ±3.In one embodiment the activated serotype 23B polysaccharide and the carrier protein arelyophilised before step b). Preferably lyophilisation occurs after step a). In one embodiment theactivated polysaccharide is lyophilised after step a) and the carrier protein is also lyophilised. 35In one embodiment the activated serotype 23B polysaccharide is lyophilised after step a) and thecarrier protein is also lyophilised, and the activated polysaccharide and the carrier protein arereconstituted in the same solution. 25In an embodiment, the activated serotype 23B polysaccharide and the carrier protein areIyophilised independently (discrete lyophilization). In an embodiment, the activated serotype 23Bpolysaccharide and the carrier protein are Iyophilised together (co-lyophilized).In one embodiment the Iyophilization takes place in the presence of a non-reducing sugar,possible non-reducing sugars include sucrose, trehalose, raffinose, stachyose, melezitose, 5dextran, mannitol, lactitol and palatinit. In an embodiment the sugar is selected from the groupconsisting of sucrose, trehalose, and mannitol. In an embodiment the sugar is sucrose, trehaloseor mannitol. In an embodiment the sugar is sucrose.In an embodiment the initial input ratio (weight by weight) of activated serotype 23Bcapsular polysaccharide to carrier protein at step b) is between 2:1 and 0.5:1. In an embodiment 10the initial input ratio (weight by weight) of activated serotype 23B capsular polysaccharide tocarrier protein is between 1.2:1 and 0.6:1. Preferably, the initial input ratio (weight by weight) ofactivated serotype 23B capsular polysaccharide to carrier protein is between 0.9:1 and 0.7:1.In an embodiment, the reduction reaction (c) is carried out in aqueous solvent. Preferably,the reduction reaction (c) is carried out in aprotic solvent. 15In an embodiment, the reduction reaction (c) is carried out in the presence ofdimethylsulphoxide (DMSO) or dimethylformamide (DMF). Preferably, the reduction reaction (c)is carried out in the presence of dimethylsulphoxide (DMSO).In an embodiment, the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide)or in DMF (dimethylformamide)) solvent. 20Most preferably, the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide)solvent.In an embodiment, the reducing agent is sodium cyanoborohydride, sodiumtriacetoxyborohydride, sodium or zinc borohydride in the presence of Bronsted or Lewis acids,amine boranes such as pyridine borane, 2-Picoline Borane, 2,6-diborane-methanol, 25dimethylamine-borane, t-BuMeiPrN-BH3, benzylamine-BH3 or 5-ethyl-2-methylpyridine borane(PEMB). In an embodiment, the reducing agent is sodium triacetoxyborohydride. In anembodiment, the reducing agent is sodium cyanoborohydride in the present of nickel (seeWO2018144439). In a preferred embodiment, the reducing agent is sodium cyanoborohydride.In one embodiment between 0.2 and 5 molar equivalents of reducing agent is used in step 30c). Preferably, between 0.5 and 1.5 molar equivalents of reducing agent is used in step c). Mostpreferably, between 0.9 and 1.1 molar equivalent of reducing agent is used in step c).At the end of the reduction reaction, there may be unreacted aldehyde groups remainingin the conjugates, these may be capped using a suitable capping agent. In one embodiment thiscapping agent is sodium borohydride (NaBH4). 35In an embodiment capping is achieved by mixing the product of step c) with 1 to 20 molarequivalents of sodium borohydride. In an embodiment capping is achieved by mixing the productof step c) with 1 to 3 molar equivalents of sodium borohydride. 26Following conjugation to the carrier protein, the serotype 23B glycoconjugate can bepurified (enriched with respect to the amount of saccharide-protein conjugate) by a variety oftechniques known to the skilled person. These techniques include dialysis,concentration/diafiltration operations, tangential flow filtration precipitation/elution, columnchromatography (DEAE or hydrophobic interaction chromatography), and depth filtration. 5Therefore, in one embodiment the process for producing the serotype 23B glycoconjugate of thepresent invention comprises the step of purifying the glycoconjugate after it is produced. 1.4 S. pneumoniae serotype 24F glycoconjugate of the invention In an aspect the invention relates to S. pneumoniae serotype 24F glycoconjugates. 10The structure of Streptococcus pneumoniae serotype 24F polysaccharide is known in theart (see e.g. WO2019050815).In an embodiment, the capsular S. pneumoniae serotype 24F saccharide used in thepresent invention is a synthetic carbohydrate.In a preferred embodiment though, the source of bacterial polysaccharide according to 15this invention can be Streptococcus pneumoniae serotype 24F bacterial cells. Bacterial strainswhich can be used as source of Streptococcus pneumoniae serotype 24F polysaccharides maybe obtained from established culture collections (such as for example from the StreptococcalReference Laboratory (Centers for Disease Control and Prevention, Atlanta, GA USA)) or clinicalspecimens. 20Serotype 24F saccharides can be obtained directly from bacteria using isolationprocedures known to one of ordinary skill in the art. They can also be purchased (such as forexample from the American Type Culture Collection (ATCC, Manassas, VA USA) (e.g., referenceNo. ATCC 551-X, No. ATCC 552-X, No. ATCC 553-X)).In case the serotype 24F saccharide is obtained directly from bacteria, the bacterial cells 25can be grown in a medium, preferably in a soy based medium. Following fermentation of bacterialcells that produce S. pneumoniae serotype 24F capsular polysaccharides, the bacterial cells canbe lysed to produce a cell lysate. The serotype 24F polysaccharide may then be isolated from thecell lysate using purification techniques known in the art, including the use of centrifugation, depthfiltration, precipitation, ultra-filtration, treatment with activate carbon, diafiltration and/or column 30chromatography (see, for example, US2006/0228380, US2006/0228381, WO2008/118752 andWO2020170190). The purified serotype 24F capsular polysaccharide can then be used for thepreparation of glycoconjugates.The isolated serotype 24F capsular saccharide obtained by purification of serotype 24Fpolysaccharide from the S. pneumoniae lysate and optionally sizing of the purified polysaccharide 35can be characterized by different parameters including, for example the weight average molecularweight (Mw). 27The molecular weight of the polysaccharide can be measured by Size ExclusionChromatography (SEC) combined with Multiangle Laser Light Scattering detector (MALLS).In a preferred embodiment, the isolated serotype 24F capsular polysaccharide (i.e.purified before further treatment) has a weight average molecular weight between 100 kDa and2500 kDa. In an embodiment, the isolated serotype 24F capsular polysaccharide has a weight 5average molecular weight between 250 kDa and 2000 kDa. In an embodiment, the isolatedserotype 24F capsular polysaccharide has a weight average molecular weight between 500 kDaand 1000 kDa.Any whole number integer within any of the above ranges is contemplated as anembodiment of the disclosure. 10In order to generate serotype 24F conjugates with advantageous filterabilitycharacteristics, immunogenicity and/or yields, sizing of the polysaccharide to a target molecularweight range can be performed prior to the conjugation to a carrier protein. Advantageously, thesize of the purified serotype 24F polysaccharide is reduced while preserving critical features ofthe structure of the polysaccharide. Mechanical or chemical sizing maybe employed. 15Most preferably, the size of the purified serotype 24F polysaccharide is reduced bymechanical homogenization.It has been discovered that the use of acid hydrolysis, as for example recommended inWO2019050815 or in WO2019050818 is not appropriate to reduce the size of serotype 24Fpolysaccharide. 20It has been found that acid hydrolysis can affect serotype 24F polysaccharide structureintegrity. Even relatively mild hydrolysis (e.g. treatment with acetic acid at 100mM at 80°C forabout 2 hour) has been found to lead to a 25% loss of the branched ribose residue (see figure 2).Mechanical sizing allows not to loose this residue, which can be important from animmunological point of view. 25Therefore, in a preferred embodiment, the size of the purified serotype 24F polysaccharideis reduced by mechanical homogenization.In an embodiment, the size of the purified serotype 24F polysaccharide is reduced by highpressure homogenization. High pressure homogenization achieves high shear rates by pumpingthe process stream through a flow path with sufficiently small dimensions. The shear rate is 30increased by using a larger applied homogenization pressure, and exposure time can beincreased by recirculating the feed stream through the homogenizer.In a most preferred embodiment, the process to prepare serotype 24F glycoconjugate ofthe invention does not comprise a step of sizing of the serotype 24F polysaccharide by acidhydrolysis. 35In an embodiment, the isolated serotype 24F capsular polysaccharide is sized to a weightaverage molecular weight of between 50 kDa and 500 kDa. In a preferred embodiment, theisolated serotype 24F capsular polysaccharide is sized to a weight average molecular weight of 28between 75 kDa and 400 kDa. In an even preferred embodiment, the isolated serotype 24Fcapsular polysaccharide is sized to a weight average molecular weight of between 125 kDa and275 kDa. In a most preferred embodiment, the isolated serotype 24F capsular polysaccharide issized to a weight average molecular weight of between 125 kDa and 225 kDa. Preferably, theisolated serotype 24F polysaccharide is sized by mechanical homogenization, most preferably by 5high pressure homogenization.In an embodiment, the isolated serotype 24F capsular polysaccharide is not sized.In an embodiment, the isolated serotype 24F capsular polysaccharide before conjugationhas a weight average molecular weight between 50 kDa and 500 kDa. In an embodiment, theisolated serotype 24F capsular polysaccharide before conjugation has a weight average 10molecular weight between 75 kDa and 400 kDa. In an even preferred embodiment, the isolatedserotype 24F capsular polysaccharide before conjugation has a weight average molecular weightbetween 125 kDa and 275kDa. In a most preferred embodiment, the isolated serotype 24Fcapsular polysaccharide before conjugation has a weight average molecular weight between 125kDa and 225 kDa. 15The weight average molecular weight (Mw) of the saccharide before conjugation refers tothe Mw before activation of the polysaccharide (i.e. after an eventual sizing step but beforereacting the polysaccharide with an activating agent). In the context of the present invention theMw of the 24F polysaccharide is not substantially modified by the activation step and the Mw ofthe 24F polysaccharide incorporated in the conjugate is similar to the Mw of the polysaccharide 20as measured before activation.In an embodiment, the serotype 24F glycoconjugate of the present invention comprises aserotype 24F capsular polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 50 kDa and 400 kDa. In an embodiment, the weightaverage molecular weight (Mw) is between 120 kDa and 250 kDa. In a most preferred 25embodiment, the weight average molecular weight (Mw) is between 120 kDa and 200 kDa.In some embodiments, the serotype 24F glycoconjugate of the invention has a weightaverage molecular weight (Mw) of between 500 kDa and 10,000 kDa. In other embodiments, theserotype 24F glycoconjugate has a weight average molecular weight (Mw) of between 1,500 kDaand 7,500 kDa. Preferably, the serotype 24F glycoconjugate has a weight average molecular 30weight (Mw) of between 3,000 kDa and 6,000 kDa.The serotype 24F glycoconjugates of the invention may also be characterized by the ratio(weight/weight) of saccharide to carrier protein. In some embodiments, the ratio of serotype 24Fpolysaccharide to carrier protein in the glycoconjugate (w/w) is between 0.5 and 3.0. Preferably,the saccharide to carrier protein ratio (w/w) is between 0.7 and 1.5. Even more preferably, the 35saccharide to carrier protein ratio (w/w) is between 0.8 and 1.4.Another way to characterize the serotype 24F glycoconjugates of the invention is by thenumber of lysine residues in the carrier protein (e.g., CRM197, DT or TT) that become conjugated 29to the saccharide which can be characterized as a range of conjugated lysines (degree ofconjugation). The evidence for lysine modification of the carrier protein, due to covalent linkagesto the polysaccharides, can be obtained by amino acid analysis using routine methods known tothose of skill in the art. Conjugation results in a reduction in the number of lysine residuesrecovered compared to the carrier protein starting material used to generate the conjugate 5materials. In a preferred embodiment, the degree of conjugation of the serotype 24Fglycoconjugate of the invention is between 2 and 15. Preferably, the degree of conjugation of theserotype 24F glycoconjugate of the invention is between 5 and 12.The serotype 24F glycoconjugates and immunogenic compositions of the invention maycontain free saccharide that is not covalently conjugated to the carrier protein but is nevertheless 10present in the glycoconjugate composition. The free saccharide may be noncovalently associatedwith (i.e., noncovalently bound to, adsorbed to, or entrapped in or with) the glycoconjugate.In an embodiment, the serotype 24F glycoconjugate comprises less than about 40% offree serotype 24F polysaccharide compared to the total amount of serotype 24F polysaccharide.In a preferred embodiment the serotype 24F glycoconjugate comprises less than about 25% of 15free serotype 24F polysaccharide compared to the total amount of serotype 24F polysaccharide.The serotype 24F glycoconjugates may also be characterized by their molecular sizedistribution (Kd). Size exclusion chromatography media (CL-4B) can be used to determine therelative molecular size distribution of the conjugate. Size Exclusion Chromatography (SEC) isused in gravity fed columns to profile the molecular size distribution of conjugates. Large 20molecules excluded from the pores in the media elute more quickly than small molecules.Fraction collectors are used to collect the column eluate. The fractions are tested colorimetricallyby saccharide assay. For the determination of Kd, columns are calibrated to establish the fractionat which molecules are fully excluded (V0), (Kd=0), and the fraction representing the maximumretention (Vi), (Kd=1). The fraction at which a specified sample attribute is reached (Ve), is related 25to Kd by the expression, Kd = (Ve - V0)/ (Vi - V0).In an embodiment, at least 40% of the serotype 24F glycoconjugate has a Kd below orequal to 0.3 in a CL-4B column. In a preferred embodiment, at least 50% of the glycoconjugatehas a Kd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, between 50% and90% of the serotype 24F glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column. 30The serotype 24F glycoconjugates may also be characterized by the amount of branchedRibose residue which remains in the 24F polysaccharide. As mentioned above, it has been foundthat serotype 24F polysaccharide can loose the branched ribose residue (see figure 7).Therefore, in an embodiment, the S. pneumoniae serotype 24F glycoconjugate of thepresent invention comprises a S. pneumoniae serotype 24F capsular polysaccharide wherein 35said S. pneumoniae serotype 24F capsular polysaccharide has a Ribose content greater than75% when compared to native S. pneumoniae serotype 24F capsular polysaccharide wherein theRibose content is considered to be about 100%. In an embodiment, the S. pneumoniae serotype 3024F glycoconjugate of the present invention comprises a S. pneumoniae serotype 24F capsularpolysaccharide wherein said S. pneumoniae serotype 24F capsular polysaccharide has a Ribosecontent greater than 90% when compared to native S. pneumoniae serotype 24F capsularpolysaccharide wherein the Ribose content is considered to be about 100%. Preferably, the S.pneumoniae serotype 24F glycoconjugate of the present invention comprises a S. pneumoniae 5serotype 24F capsular polysaccharide wherein said S. pneumoniae serotype 24F capsularpolysaccharide has a Ribose content greater than 95% when compared to native S. pneumoniaeserotype 24F capsular polysaccharide wherein the Ribose content is considered to be about100%.In a most preferred embodiment, the S. pneumoniae serotype 24F glycoconjugate of the 10present invention comprises a S. pneumoniae serotype 24F capsular polysaccharide whereinsaid S. pneumoniae serotype 24F capsular polysaccharide has a Ribose content of about 100%when compared to native S. pneumoniae serotype 24F capsular polysaccharide wherein theRibose content is considered to be about 100%. In an embodiment, the serotype 24F saccharide is activated with 1-cyano-4- 15dimethylamino pyridinium tetrafluoroborate (CDAP) to form a cyanate ester. The activatedpolysaccharide is then coupled directly or via a spacer (linker) group to an amino group on thecarrier protein (preferably CRM 197). For example, the spacer could be cystamine or cysteamineto give a thiolated polysaccharide which could be coupled to the carrier via a thioether linkageobtained after reaction with a maleimide-activated carrier protein (for example using N-[ γ- 20maleimidobutyrloxy]succinimide ester (GMBS)) or a haloacetylated carrier protein (for exampleusing iodoacetimide, N-succinimidyl bromoacetate (SBA; SIB), N-succinimidyl(4-iodoacetyl)aminobenzoate (SlAB), sulfosuccinimidyl(4-iodoacetyl)aminobenzoate (sulfo-SIAB),N-succinimidyl iodoacetate (SIA) or succinimidyl 3-[bromoacetamido]proprionate (SBAP)).Preferably, the cyanate ester is coupled with hexane diamine or adipic acid dihydrazide (ADH) 25and the amino-derivatised saccharide is conjugated to the carrier protein (e.g., CRM 197) usingcarbodiimide (e.g., EDAC or EDC) chemistry via a carboxyl group on the protein carrier. Suchconjugates are described for example in WO 93/15760, WO 95/08348 and WO 96/129094.Other suitable techniques for conjugation use carbodiimides, hydrazides, active esters,norborane, p-nitrobenzoic acid, N-hydroxysuccinimide, S--NHS, EDC, TSTU. Many are described 30in International Patent Application Publication No. WO 98/42721. Conjugation may involve acarbonyl linker which may be formed by reaction of a free hydroxyl group of the saccharide with1,1’-carbonyldiimidazole (CDI) (see Bethell et al. (1979) J. Biol. Chern. 254:2572-2574; Hearn etal. (1981) J. Chromatogr. 218:509-518) followed by reaction with a protein to form a carbamatelinkage. This may involve reduction of the anomeric terminus to a primary hydroxyl group, optional 35protection/deprotection of the primary hydroxyl group, reaction of the primary hydroxyl group withCDI to form a CDI carbamate intermediate and coupling the CDI carbamate intermediate with anamino group on a protein. 31In a preferred embodiment, the serotype 24F glycoconjugates of the invention areprepared using reductive amination chemistry. According to the present invention, reductiveamination involves two steps, (1) oxidation (activation) of a purified saccharide, (2) reduction ofthe activated saccharide and a carrier protein to form a glycoconjugate.In an embodiment, the serotype 24F glycoconjugates of the invention are prepared by 5conjugating an isolated serotype 24F capsular polysaccharide to a carrier protein by a processcomprising the step of: (a) reacting said isolated serotype 24F capsular polysaccharide with anoxidizing agent; (b) compounding the activated polysaccharide of step (a) with a carrier protein;and (c) reacting the compounded activated polysaccharide and carrier protein with a reducingagent to form a glycoconjugate. 10As mentioned above, before oxidation, sizing of the isolated serotype 24F capsularpolysaccharide to a target molecular weight (MW) range can be performed. Therefore, in anembodiment, the isolated serotype 24F capsular polysaccharide is sized before oxidation.In a preferred embodiment, the size of the isolated serotype 24F capsular polysaccharideis reduced by mechanical homogenization. In an embodiment, the size of the isolated serotype 1524F polysaccharide is reduced by high pressure homogenization. In a most preferredembodiment, the isolated serotype 24F capsular polysaccharide is not sized by acid hydrolysis.In an embodiment, the isolated serotype 24F capsular polysaccharide is not sized beforeoxidation.In an embodiment, the oxidation step (a) is carried out at a pH of between 4.5 and 6.5. 20Preferably, the oxidation step (a) is carried out at a pH of between 5.0 and 6.0.In an embodiment, the oxidation step (a) is carried out at a pH of about 5.0.Following the oxidation step (a) the saccharide is said to be activated and is referred to as"activated polysaccharide".In an embodiment, the activated serotype 24F polysaccharide of the present invention has 25a weight average molecular weight (Mw) of between 50 kDa and 400 kDa. In an embodiment, theweight average molecular weight (Mw) is between 120 kDa and 250 kDa. In a most preferredembodiment, the weight average molecular weight (Mw) is between 120 kDa and 200 kDa.In an embodiment, the activated serotype 24F polysaccharide of the present inventionretains at least 75% of the branched Ribose. In an embodiment, the activated serotype 24F 30polysaccharide of the present invention retains at least 90% of the branched Ribose. In apreferred embodiment, the activated serotype 24F polysaccharide of the present invention retainsat least 95% of the branched Ribose.In a most preferred embodiment, the activated serotype 24F polysaccharide of the presentinvention retains about 100% of the branched Ribose. 35In an embodiment, the oxidizing agent is any oxidizing agent which oxidizes a terminalhydroxyl group to an aldehyde. In an embodiment, the oxidizing agent is periodate. For thepurpose of the present invention, the term "periodate" includes both periodate and periodic acid; 32the term also includes both metaperiodate (IO4-) and orthoperiodate (IO65-) and the various saltsof periodate (e.g., sodium periodate and potassium periodate).In a preferred embodiment, the oxidizing agent is sodium periodate. In an embodiment,the periodate used for the oxidation is metaperiodate. In a most preferred embodiment, theperiodate used for the oxidation is sodium metaperiodate. 5When a polysaccharide reacts with periodate, periodate oxidises vicinal hydroxyl groupsto form carbonyl or aldehyde groups and causes cleavage of a C-C bond. For this reason, theterm "reacting a polysaccharide with periodate" includes oxidation of vicinal hydroxyl groups byperiodate.In one embodiment step a) comprises reacting the polysaccharide with 0.1-2 molar 10equivalents of periodate. Preferably step a) comprises reacting the polysaccharide with 0.5-1.5molar equivalents of periodate. Most preferably, step a) comprises reacting the polysaccharidewith 0.9-1.1molar equivalents of periodate.In an embodiment the degree of oxidation (also named "degree of activation" in the presentdocument) of the activated serotype 24F polysaccharide is between 2 and 20. In a preferred 15embodiment the degree of oxidation of the activated serotype 24F polysaccharide is between 4and 15. In a most preferred embodiment the degree of oxidation of the activated serotype 24Fpolysaccharide is 9 ±3.In one embodiment the activated serotype 24F polysaccharide and the carrier protein arelyophilised before step b). Preferably lyophilisation occurs after step a). In one embodiment the 20activated polysaccharide is lyophilised after step a) and the carrier protein is also lyophilised.In one embodiment the activated serotype 24Fpolysaccharide is lyophilised after step a) and thecarrier protein is also lyophilised, and the activated polysaccharide and the carrier protein arereconstituted in the same solution.In an embodiment, the activated serotype 24F polysaccharide and the carrier protein are 25Iyophilised independently (discrete lyophilization). In an embodiment, the activated serotype 24Fpolysaccharide and the carrier protein are Iyophilised together (co-lyophilized).In one embodiment the Iyophilization takes place in the presence of a non-reducing sugar,possible non-reducing sugars include sucrose, trehalose, raffinose, stachyose, melezitose,dextran, mannitol, lactitol and palatinit. In an embodiment the sugar is selected from the group 30consisting of sucrose, trehalose, and mannitol. In an embodiment the sugar is sucrose, trehaloseor mannitol. In an embodiment the sugar is sucrose.In an embodiment the initial input ratio (weight by weight) of activated serotype 24Fcapsular polysaccharide to carrier protein at step b) is between 2:1 and 0.5:1. In an embodimentthe initial input ratio (weight by weight) of activated serotype 24F capsular polysaccharide to 35carrier protein is between 1.2:1 and 0.6:1. Preferably, the initial input ratio (weight by weight) ofactivated serotype 24F capsular polysaccharide to carrier protein is between 0.9:1 and 0.7:1. 33In an embodiment, the reduction reaction (c) is carried out in aqueous solvent. Preferably,the reduction reaction (c) is carried out in aprotic solvent.In an embodiment, the reduction reaction (c) is carried out in the presence ofdimethylsulphoxide (DMSO) or dimethylformamide (DMF). Preferably, the reduction reaction (c)is carried out in the presence of dimethylsulphoxide (DMSO). 5In an embodiment, the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide)or in DMF (dimethylformamide)) solvent.Most preferably, the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide)solvent.In an embodiment, the reducing agent is sodium cyanoborohydride, sodium 10triacetoxyborohydride, sodium or zinc borohydride in the presence of Bronsted or Lewis acids,amine boranes such as pyridine borane, 2-Picoline Borane, 2,6-diborane-methanol,dimethylamine-borane, t-BuMeiPrN-BH3, benzylamine-BH3 or 5-ethyl-2-methylpyridine borane(PEMB). In an embodiment, the reducing agent is sodium triacetoxyborohydride. In anembodiment, the reducing agent is sodium cyanoborohydride in the present of nickel (see 15WO2018144439). In a preferred embodiment, the reducing agent is sodium cyanoborohydride.In one embodiment between 0.2 and 5 molar equivalents of reducing agent is used in stepc). Preferably, between 0.5 and 2.5 molar equivalents of reducing agent is used in step c). Mostpreferably, between 1.5 and 2.5 molar equivalent of reducing agent is used in step c).In one embodiment about 2 molar equivalents of reducing agent is used in step c). 20At the end of the reduction reaction, there may be unreacted aldehyde groups remainingin the conjugates, these may be capped using a suitable capping agent. In one embodiment thiscapping agent is sodium borohydride (NaBH4).In an embodiment capping is achieved by mixing the product of step c) with 1 to 20 molarequivalents of sodium borohydride. In an embodiment capping is achieved by mixing the product 25of step c) with 1 to 3 molar equivalents of sodium borohydride.In an embodiment capping is achieved by mixing the product of step c) with about 2 molarequivalents of sodium borohydride.Following conjugation to the carrier protein, the serotype 24F glycoconjugate can bepurified (enriched with respect to the amount of saccharide-protein conjugate) by a variety of 30techniques known to the skilled person. These techniques include dialysis,concentration/diafiltration operations, tangential flow filtration precipitation/elution, columnchromatography (DEAE or hydrophobic interaction chromatography), and depth filtration.Therefore, in one embodiment the process for producing the serotype 24F glycoconjugate of thepresent invention comprises the step of purifying the glycoconjugate after it is produced. 35 1.5 S. pneumoniae serotype 35B glycoconjugate of the invention In an aspect the invention relates to S. pneumoniae serotype 23B glycoconjugates. 34The structure of Streptococcus pneumoniae serotype 35B polysaccharide is known in theart (see e.g. Geno K et al. (2015) Clin Microbiol Rev Vol 28:3, p 871-899).In an embodiment, the capsular S. pneumoniae serotype 35B saccharide used in thepresent invention is a synthetic carbohydrate.In a preferred embodiment though, the source of bacterial polysaccharide according to 5this invention can be Streptococcus pneumoniae serotype 35B bacterial cells. Bacterial strainswhich can be used as source of Streptococcus pneumoniae serotype 35B polysaccharides maybe obtained from established culture collections (such as for example from the StreptococcalReference Laboratory (Centers for Disease Control and Prevention, Atlanta, GA USA)) or clinicalspecimens. 10Serotype 35B saccharides can be obtained directly from bacteria using isolationprocedures known to one of ordinary skill in the art. They can also be purchased (such as forexample from the American Type Culture Collection (ATCC, Manassas, VA USA) (e.g., referenceNo. ATCC 539-X, No. ATCC 540-X, No. ATCC 541-X)).In case the serotype 35B saccharide is obtained directly from bacteria, the bacterial cells 15can be grown in a medium, preferably in a soy based medium. Following fermentation of bacterialcells that produce S. pneumoniae serotype 35B capsular polysaccharides, the bacterial cells canbe lysed to produce a cell lysate. The serotype 35B polysaccharide may then be isolated from thecell lysate using purification techniques known in the art, including the use of centrifugation, depthfiltration, precipitation, ultra-filtration, treatment with activate carbon, diafiltration and/or column 20chromatography (see, for example, US2006/0228380, US2006/0228381, WO2008/118752 andWO2020170190). The purified serotype 35B capsular polysaccharide can then be used for thepreparation of glycoconjugates.The isolated serotype 35B capsular saccharide obtained by purification of serotype 35Bpolysaccharide from the S. pneumoniae lysate and optionally sizing of the purified polysaccharide 25can be characterized by different parameters including, for example the weight average molecularweight (Mw).The molecular weight of the polysaccharide can be measured by Size ExclusionChromatography (SEC) combined with Multiangle Laser Light Scattering detector (MALLS).In a preferred embodiment, the isolated serotype 35B capsular polysaccharide (i.e. 30purified before further treatment) has a weight average molecular weight between 100 kDa and5000 kDa. In an embodiment, the isolated serotype 35B capsular polysaccharide has a weightaverage molecular weight between 300 kDa and 2000 kDa. In a preferred embodiment, theisolated serotype 35B capsular polysaccharide has a weight average molecular weight between500 kDa and 1000 kDa. 35Any whole number integer within any of the above ranges is contemplated as anembodiment of the disclosure. 35The size of the purified serotype 35B polysaccharide may be reduced while preservingcritical features of the structure of the polysaccharide. Mechanical or chemical sizing maybeemployed.However, S. pneumoniae serotype 35B polysaccharide has been found to be cleavedduring activation with periodate, which is the classical oxidant used in the commonly used 5reductive amination process. It appears that periodate oxidation occurs on the backbone ofserotype 35B polysaccharide and cleaves the mannitol or ribitol, leading to size reduction. Theactivation with periodate results in a decrease in polysaccharide Mw. Therefore, in the case whereactivation with periodate, is used, the serotype 35B capsular polysaccharide is not sized.Therefore, in an embodiment, the isolated serotype 35B capsular polysaccharide is not 10sized.In an embodiment, the isolated serotype 35B capsular polysaccharide before conjugationhas a weight average molecular weight between 100 kDa and 5,000 kDa. In an embodiment, theisolated serotype 35B capsular polysaccharide before conjugation has a weight averagemolecular weight between 300 kDa and 2000 kDa. In an even preferred embodiment, the isolated 15serotype 35B capsular polysaccharide before conjugation has a weight average molecular weightbetween 500 kDa and 1000 kDa.The weight average molecular weight (Mw) of the saccharide before conjugation refers tothe Mw before activation of the polysaccharide (i.e. before reacting the polysaccharide with anactivating agent). 20In an embodiment, the serotype 35B glycoconjugate of the present invention comprises aserotype 35B capsular polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide is between 15 kDa and 100 kDa. In an embodiment, the weight average molecularweight (Mw) is between 25 kDa and 50 kDa. In a most preferred embodiment, the weight averagemolecular weight (Mw) is between about 30 kDa and about 40 kDa. 25In some embodiments, the serotype 35B glycoconjugate of the invention has a weightaverage molecular weight (Mw) of between 250 kDa and 7,500 kDa. In other embodiments, theserotype 35B glycoconjugate has a weight average molecular weight (Mw) of between 500 kDaand 5,000 kDa. Preferably, the serotype 35B glycoconjugate has a weight average molecularweight (Mw) of between 1,000 kDa and 4,000 kDa. 30The serotype 35B glycoconjugates of the invention may also be characterized by the ratio(weight/weight) of saccharide to carrier protein. In some embodiments, the ratio of serotype 35Bpolysaccharide to carrier protein in the glycoconjugate (w/w) is between 0.4 and 3.0. Preferably,the saccharide to carrier protein ratio (w/w) is between 0.4 and 2.0. Even more preferably, thesaccharide to carrier protein ratio (w/w) is between 0.5 and 1.5. 35Another way to characterize the serotype 35B glycoconjugates of the invention is by thenumber of lysine residues in the carrier protein (e.g., CRM197, DT or TT) that become conjugatedto the saccharide which can be characterized as a range of conjugated lysines (degree of 36conjugation). The evidence for lysine modification of the carrier protein, due to covalent linkagesto the polysaccharides, can be obtained by amino acid analysis using routine methods known tothose of skill in the art. Conjugation results in a reduction in the number of lysine residuesrecovered compared to the carrier protein starting material used to generate the conjugatematerials. In a preferred embodiment, the degree of conjugation of the serotype 35B 5glycoconjugate of the invention is between 2 and 15. Preferably, the degree of conjugation of theserotype 35B glycoconjugate of the invention is between 5 and 10.The serotype 35B glycoconjugates and immunogenic compositions of the invention maycontain free saccharide that is not covalently conjugated to the carrier protein but is neverthelesspresent in the glycoconjugate composition. The free saccharide may be noncovalently associated 10with (i.e., noncovalently bound to, adsorbed to, or entrapped in or with) the glycoconjugate.In an embodiment, the serotype 35B glycoconjugate comprises less than about 40% offree serotype 35B polysaccharide compared to the total amount of serotype 35B polysaccharide.In an embodiment, the serotype 35B glycoconjugate comprises less than about 20% of freeserotype 35B polysaccharide compared to the total amount of serotype 35B polysaccharide. In a 15preferred embodiment the serotype 35B glycoconjugate comprises less than about 10% of freeserotype 35B polysaccharide compared to the total amount of serotype 35B polysaccharide.The serotype 35B glycoconjugates may also be characterized by their molecular sizedistribution (Kd). Size exclusion chromatography media (CL-4B) can be used to determine therelative molecular size distribution of the conjugate. Size Exclusion Chromatography (SEC) is 20used in gravity fed columns to profile the molecular size distribution of conjugates. Largemolecules excluded from the pores in the media elute more quickly than small molecules.Fraction collectors are used to collect the column eluate. The fractions are tested colorimetricallyby saccharide assay. For the determination of Kd, columns are calibrated to establish the fractionat which molecules are fully excluded (V0), (Kd=0), and the fraction representing the maximum 25retention (Vi), (Kd=1). The fraction at which a specified sample attribute is reached (Ve), is relatedto Kd by the expression, Kd = (Ve - V0)/ (Vi - V0).In an embodiment, at least 40% of the serotype 35B glycoconjugate has a Kd below orequal to 0.3 in a CL-4B column. In a preferred embodiment, at least 60% of the glycoconjugatehas a Kd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, between 50% and 3080% of the serotype 35B glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.In an embodiment, the serotype 35B saccharide is activated with 1-cyano-4-dimethylamino pyridinium tetrafluoroborate (CDAP) to form a cyanate ester. The activatedpolysaccharide is then coupled directly or via a spacer (linker) group to an amino group on thecarrier protein (preferably CRM 197). For example, the spacer could be cystamine or cysteamine 35to give a thiolated polysaccharide which could be coupled to the carrier via a thioether linkageobtained after reaction with a maleimide-activated carrier protein (for example using N-[ γ-maleimidobutyrloxy]succinimide ester (GMBS)) or a haloacetylated carrier protein (for example 37using iodoacetimide, N-succinimidyl bromoacetate (SBA; SIB), N-succinimidyl(4-iodoacetyl)aminobenzoate (SlAB), sulfosuccinimidyl(4-iodoacetyl)aminobenzoate (sulfo-SIAB),N-succinimidyl iodoacetate (SIA) or succinimidyl 3-[bromoacetamido]proprionate (SBAP)).Preferably, the cyanate ester is coupled with hexane diamine or adipic acid dihydrazide (ADH)and the amino-derivatised saccharide is conjugated to the carrier protein (e.g., CRM 197) using 5carbodiimide (e.g., EDAC or EDC) chemistry via a carboxyl group on the protein carrier. Suchconjugates are described for example in WO 93/15760, WO 95/08348 and WO 96/129094.Other suitable techniques for conjugation use carbodiimides, hydrazides, active esters,norborane, p-nitrobenzoic acid, N-hydroxysuccinimide, S--NHS, EDC, TSTU. Many are describedin International Patent Application Publication No. WO 98/42721. Conjugation may involve a 10carbonyl linker which may be formed by reaction of a free hydroxyl group of the saccharide with1,1’-carbonyldiimidazole (CDI) (see Bethell et al. (1979) J. Biol. Chern. 254:2572-2574; Hearn etal. (1981) J. Chromatogr. 218:509-518) followed by reaction with a protein to form a carbamatelinkage. This may involve reduction of the anomeric terminus to a primary hydroxyl group, optionalprotection/deprotection of the primary hydroxyl group, reaction of the primary hydroxyl group with 15CDI to form a CDI carbamate intermediate and coupling the CDI carbamate intermediate with anamino group on a protein.In a preferred embodiment, the serotype 35B glycoconjugates of the invention areprepared using reductive amination chemistry. According to the present invention, reductiveamination involves two steps, (1) oxidation (activation) of a purified saccharide, (2) reduction of 20the activated saccharide and a carrier protein to form a glycoconjugate.In an embodiment, the serotype 35B glycoconjugates of the invention are prepared byconjugating an isolated serotype 35B capsular polysaccharide to a carrier protein by a processcomprising the step of: (a) reacting said isolated serotype 35B capsular polysaccharide with anoxidizing agent; (b) compounding the activated polysaccharide of step (a) with a carrier protein; 25and (c) reacting the compounded activated polysaccharide and carrier protein with a reducingagent to form a glycoconjugate.Preferably, the isolated serotype 35B capsular polysaccharide is not sized beforeoxidation.In a preferred embodiment, step (a) is quenched by addition of a quenching agent to stop 30oxidation.Therefore in a preferred embodiment, the serotype 35B glycoconjugates of the inventionare prepared by conjugating an isolated serotype 35B capsular polysaccharide to a carrier proteinby a process comprising the step of: (a) reacting said isolated serotype 35B capsularpolysaccharide with an oxidizing agent; (a’) quenching the oxidation reaction by addition of a 35quenching agent resulting in an activated serotype 35B capsular polysaccharide; (b)compounding the activated polysaccharide of step (a’) with a carrier protein; and (c) reacting the 38compounded activated polysaccharide and carrier protein with a reducing agent to form aglycoconjugate.
In an embodiment, the oxidation step (a) is carried out at a pH of between 5.0 and 7.0.Preferably, the oxidation step (a) is carried out at a pH of between 5.5 and 6.5. 5In an embodiment, the oxidation step (a) is carried out at a pH of about 6.0.Following the oxidation step (a)-(a’) the saccharide is said to be activated and is referredto as "activated polysaccharide".In an embodiment, the oxidizing agent is any oxidizing agent which oxidizes a terminalhydroxyl group to an aldehyde. In an embodiment, the oxidizing agent is periodate. For the 10purpose of the present invention, the term "periodate" includes both periodate and periodic acid;the term also includes both metaperiodate (IO4-) and orthoperiodate (IO65-) and the various saltsof periodate (e.g., sodium periodate and potassium periodate).In a preferred embodiment, the oxidizing agent is sodium periodate. In an embodiment,the periodate used for the oxidation is metaperiodate. In a most preferred embodiment, the 15periodate used for the oxidation is sodium metaperiodate.When a polysaccharide reacts with periodate, periodate oxidises vicinal hydroxyl groupsto form carbonyl or aldehyde groups and causes cleavage of a C-C bond. For this reason, theterm "reacting a polysaccharide with periodate" includes oxidation of vicinal hydroxyl groups byperiodate. 20In one embodiment step a) comprises reacting the polysaccharide with 0.05-0.2 molarequivalents of periodate. Preferably step a) comprises reacting the polysaccharide with 0.09-0.11molar equivalents of periodate. Most preferably, step a) comprises reacting the polysaccharidewith about 0.1 molar equivalents of periodate.In one embodiment, the quenching agent is selected from vicinal diols, 1,2-aminoalcohols, 25amino acids, glutathione, sulfite, bisulfate, dithionite, metabisulfite, thiosulfate, phosphites,hypophosphites or phosphorous acid.In one embodiment, the quenching agent is a 1,2-aminoalcohols of formula (I): N HOH R (I)wherein R is selected from H, methyl, ethyl, propyl or isopropyl. 30In one embodiment, the quenching agent is selected from sodium and potassium salts ofsulfite, bisulfate, dithionite, metabisulfite, thiosulfate, phosphites, hypophosphites or phosphorousacid.In one embodiment, the quenching agent is an amino acid. In such embodiments, saidamino acid may be selected from serine, threonine, cysteine, cystine, methionine, proline, 35hydroxyproline, tryptophan, tyrosine, and histidine. 39In one embodiment, the quenching agent is a sulfite such as bisulfate, dithionite,metabisulfite, thiosulfate.In one embodiment, the quenching agent is a compound comprising two vicinal hydroxylgroups (vicinal diols), i.e., two hydroxyl groups covalently linked to two adjacent carbon atoms.Preferably, the quenching agent is a compound of formula (II): 5 OH O H RR (II)wherein R and R are each independently selected from H, methyl, ethyl, propyl or isopropyl.In a preferred embodiment, the quenching agent is glycerol, ethylene glycol, propan-1,2-diol, butan-1,2-diol or butan-2,3-diol, or ascorbic acid. In a most preferred embodiment, thequenching agent is butan-2,3-diol. 10In a preferred embodiment, the isolated serotype 35B polysaccharide is activated by aprocess comprising the step of:(a) reacting the isolated serotype 35B polysaccharide with periodate;(b) quenching the oxidation reaction by addition of butan-2,3-diol resulting in an activated serotype35B polysaccharide. 15Following the oxidation step of the polysaccharide, the polysaccharide is said to beactivated and is referred to as "activated polysaccharide" here below.In an embodiment, the activated serotype 35B polysaccharide of the present invention hasa weight average molecular weight (Mw) of between 15 kDa and 100 kDa. In an embodiment, theweight average molecular weight (Mw) is between 25 kDa and 50 kDa. In a most preferred 20embodiment, the weight average molecular weight (Mw) is between 30 kDa and 40 kDa.In an embodiment the degree of oxidation (also named "degree of activation" in the presentdocument) of the activated serotype 35B polysaccharide is between 2 and 20. In a preferredembodiment the degree of oxidation of the activated serotype 35B polysaccharide is between 4and 15. In a most preferred embodiment the degree of oxidation of the activated serotype 35B 25polysaccharide is 9 ±3.In one embodiment the activated serotype 35B polysaccharide and the carrier protein arelyophilised before step b). Preferably lyophilisation occurs after step a). In one embodiment theactivated polysaccharide is lyophilised after step a) and the carrier protein is also lyophilised.In one embodiment the activated serotype 35B polysaccharide is lyophilised after step a) and the 30carrier protein is also lyophilised, and the activated polysaccharide and the carrier protein arereconstituted in the same solution.In an embodiment, the activated serotype 35B polysaccharide and the carrier protein areIyophilised independently (discrete lyophilization). In an embodiment, the activated serotype 35Bpolysaccharide and the carrier protein are Iyophilised together (co-lyophilized). 35 40In one embodiment the Iyophilization takes place in the presence of a non-reducing sugar,possible non-reducing sugars include sucrose, trehalose, raffinose, stachyose, melezitose,dextran, mannitol, lactitol and palatinit. In an embodiment the sugar is selected from the groupconsisting of sucrose, trehalose, and mannitol. In an embodiment the sugar is sucrose, trehaloseor mannitol. In an embodiment the sugar is sucrose. 5In an embodiment the initial input ratio (weight by weight) of activated serotype 35Bcapsular polysaccharide to carrier protein at step b) is between 2:1 and 0.5:1. In an embodimentthe initial input ratio (weight by weight) of activated serotype 35B capsular polysaccharide tocarrier protein is between 1.2:1 and 0.6:1. Preferably, the initial input ratio (weight by weight) ofactivated serotype 35B capsular polysaccharide to carrier protein is between 0.9:1 and 0.7:1. 10In an embodiment, the reduction reaction (c) is carried out in aqueous solvent. Preferably,the reduction reaction (c) is carried out in aprotic solvent.In an embodiment, the reduction reaction (c) is carried out in the presence ofdimethylsulphoxide (DMSO) or dimethylformamide (DMF). Preferably, the reduction reaction (c)is carried out in the presence of dimethylsulphoxide (DMSO). 15In an embodiment, the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide)or in DMF (dimethylformamide)) solvent.Most preferably, the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide)solvent.In an embodiment, the reducing agent is sodium cyanoborohydride, sodium 20triacetoxyborohydride, sodium or zinc borohydride in the presence of Bronsted or Lewis acids,amine boranes such as pyridine borane, 2-Picoline Borane, 2,6-diborane-methanol,dimethylamine-borane, t-BuMeiPrN-BH3, benzylamine-BH3 or 5-ethyl-2-methylpyridine borane(PEMB). In an embodiment, the reducing agent is sodium triacetoxyborohydride. In anembodiment, the reducing agent is sodium cyanoborohydride in the present of nickel (see 25WO2018144439). In a preferred embodiment, the reducing agent is sodium cyanoborohydride.In one embodiment between 0.2 and 5 molar equivalents of reducing agent is used in stepc). Preferably, between 0.5 and 1.5 molar equivalents of reducing agent is used in step c). Mostpreferably, between 0.9 and 1.1 molar equivalent of reducing agent is used in step c).At the end of the reduction reaction, there may be unreacted aldehyde groups remaining 30in the conjugates, these may be capped using a suitable capping agent. In one embodiment thiscapping agent is sodium borohydride (NaBH4).In an embodiment capping is achieved by mixing the product of step c) with 1 to 20 molarequivalents of sodium borohydride. In an embodiment capping is achieved by mixing the productof step c) with 1 to 3 molar equivalents of sodium borohydride. 35Following conjugation to the carrier protein, the serotype 35B glycoconjugate can bepurified (enriched with respect to the amount of saccharide-protein conjugate) by a variety oftechniques known to the skilled person. These techniques include dialysis, 41concentration/diafiltration operations, tangential flow filtration precipitation/elution, columnchromatography (DEAE or hydrophobic interaction chromatography), and depth filtration.Therefore, in one embodiment the process for producing the serotype 35B glycoconjugate of thepresent invention comprises the step of purifying the glycoconjugate after it is produced. 1.6 S. pneumoniae serotype 3 glycoconjugates of the invention In an aspect the invention relates to compositions comprising a S. pneumoniae serotypeglycoconjugate.The structure of Streptococcus pneumoniae serotype 3 polysaccharide is known in theart. The polysaccharide repeating unit of serotype 3 consists of a linear disaccharide unit with one 10glucopyranose (Glcp) and one glucuronic acid (GlcpA) (see e.g. Geno K et al. (2015) ClinMicrobiol Rev Vol 28:3, p 871-899).In an embodiment, the capsular S. pneumoniae serotype 3 saccharide used in the presentinvention is a synthetic carbohydrate. Preparation of a synthetic Streptococcus pneumoniae typecapsular saccharide can for example be conducted as disclosed in WO2017178664 or 15WO2015040140.In a preferred embodiment though, the source of bacterial polysaccharide according tothis invention can be Streptococcus pneumoniae serotype 3 bacterial cells. Bacterial strains whichcan be used as source of Streptococcus pneumoniae serotype 3 polysaccharides may beobtained from established culture collections (such as for example from the Streptococcal 20Reference Laboratory (Centers for Disease Control and Prevention, Atlanta, GA USA)) or clinicalspecimens.Serotype 3 polysaccharides can be obtained directly from bacteria using isolationprocedures known to one of ordinary skill in the art (see for example methods disclosed inUS2006/0228380, US2006/0228381, US2007/0184071, US2007/0184072, US2007/0231340, 25and US2008/0102498 and WO2008/118752). They can also be produced using syntheticprotocols known to the man skilled in the art. They can also be purchased (such as for examplefrom the American Type Culture Collection (ATCC, Manassas, VA USA) (e.g., reference No.ATCC 172-X or ATCC 33-X)).In case the serotype 3 polysaccharide is obtained directly from bacteria, the bacterial cells 30can be grown in a medium, preferably in a soy based medium. Following fermentation of bacterialcells that produce S. pneumoniae serotype 3 capsular polysaccharides, the bacterial cells can belysed to produce a cell lysate. The serotype 3 polysaccharide may then be isolated from the celllysate using purification techniques known in the art, including the use of centrifugation, depthfiltration, precipitation, ultra-filtration, treatment with activate carbon, diafiltration and/or column 35chromatography (see, for example, US2006/0228380, US2006/0228381 and WO2008/118752).The purified serotype 3 capsular polysaccharide can then be used for the preparation ofimmunogenic conjugates. 42The isolated serotype 3 capsular polysaccharide obtained by purification of serotype 3polysaccharide from the S. pneumoniae lysate and optionally sizing of the purified polysaccharidecan be characterized by different parameters including, for example the weight average molecularweight (Mw).The molecular weight of the polysaccharide can be measured by Size Exclusion 5Chromatography (SEC) combined with Multiangle Laser Light Scattering detector (MALLS).In an embodiment, the isolated serotype 3 capsular polysaccharide (i.e. purified beforefurther treatment) has a weight average molecular weight between 5 kDa and 5,000 kDa. In anembodiment, the isolated capsualr polysaccharide has a weight average molecular weightbetween 100 kDa and 4,000 kDa. In a preferred embodiment, the isolated capsular 10polysaccharide has a weight average molecular weight between 1,000 kDa and 3,500 kDa.Preferably, in order to generate serotype 3 conjugates with advantageous filterabilitycharacteristics, immunogenicity and/or yields, sizing of the polysaccharide to a target molecularweight range is performed prior to the conjugation to a carrier protein. Advantageously, the sizeof the purified serotype 3 polysaccharide is reduced while preserving critical features of the 15structure of the polysaccharide. Mechanical or chemical sizing maybe employed.In an embodiment, the size of the purified serotype 3 polysaccharide is reduced bychemical hydrolysis. Chemical hydrolysis maybe conducted using a mild acid ( e.g acetic acid,formic acid, propanoic acid). In an embodiement, chemical hydrolysis is conducted using formicacid. In an embodiement, chemical hydrolysis is conducted using propanoic acid. In a preferred 20embodiement, chemical hydrolysis is conducted using acetic acid. Chemical hydrolysis may alsobe conducted using a diluted strong acid (such as diluted hydrochloric acid, diluted sulfuric acid,diluted phosphoric acid, diluted nitric acid or diluted perchloric acid). In an embodiement, chemicalhydrolysis is conducted using diluted hydrochloric acid. In an embodiement, chemical hydrolysisis conducted using diluted sulfuric acid. In an embodiement, chemical hydrolysis is conducted 25using diluted phosphoric acid. In an embodiement, chemical hydrolysis is conducted using dilutednitric acid. In an embodiement, chemical hydrolysis is conducted using diluted perchloric acid.The size of the purified serotype 3 polysaccharide can also be reduced by mechanicalhomogenization. In an embodiment, the size of the purified serotype 3 polysaccharide is reducedby high pressure homogenization. High pressure homogenization achieves high shear rates by 30pumping the process stream through a flow path with sufficiently small dimensions. The shearrate is increased by using a larger applied homogenization pressure, and exposure time can beincreased by recirculating the feed stream through the homogenizer. The high-pressurehomogenization process can be appropriate for reducing the size of the purified serotype 3polysaccharide while preserving the structural features of the polysaccharide. 35In an embodiment, the isolated serotype 3 capsular polysaccharide is sized to a weightaverage molecular weight between 5 kDa and 1000 kDa. In an embodiment, the isolated serotypecapsular polysaccharide is sized to a weight average molecular weight between 50 kDa and 43300 kDa. In a preferred embodiment, the isolated serotype 3 capsular polysaccharide is sized toa weight average molecular weight between 100 kDa and 300 kDa.In an embodiment, the isolated serotype 3 capsular polysaccharide is sized to a weightaverage molecular weight of between about 200 kDa and about 300 kDa.In an embodiment, the isolated serotype 3 capsular polysaccharide is sized to a weight 5average molecular weight of between about 100 kDa and about 200 kDa.In an embodiment, the isolated serotype 3 capsular polysaccharide is not sized.
In an embodiment, the serotype 3 glycoconjugate of the present invention comprises aserotype 3 capsular polysaccharide wherein the weight average molecular weight (Mw) of said 10polysaccharide before conjugation is between 50 kDa and 1,000 kDa. Preferably, the weightaverage molecular weight (Mw) is between 100 kDa and 300 kDa.The weight average molecular weight (Mw) of the serotype 3 saccharide before conjugation refersto the Mw before the activation of the serotype 3 polysaccharide (i.e. after an eventual sizing stepbut before reacting the polysaccharide with an activating agent). In the context of the present 15invention the Mw of the serotype 3 polysaccharide is not substantially modified by the activationstep and the Mw of the serotype 3 polysaccharide incorporated in the conjugate is similar to theMw of the polysaccharide as measured before activation.In an embodiment, the serotype 3 glycoconjugate of the present invention comprises aserotype 3 capsular polysaccharide wherein the weight average molecular weight (Mw) of said 20polysaccharide before conjugation is between 100 kDa and 200 kDa.In an embodiment, the serotype 3 glycoconjugate of the present invention comprises aserotype 3 capsular polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 200 kDa and 300 kDa.In some embodiments, the serotype 3 glycoconjugate of the invention has a weight averagemolecular weight (Mw) of between 250 kDa and 20,000 kDa. In other embodiments, the serotypeglycoconjugate has a weight average molecular weight (Mw) of between 500 kDa and 15,000kDa. In yet other embodiments, the serotype 3 glycoconjugate has a weight average molecularweight (Mw) of between 500 kDa and 10,000 kDa. Preferably, the serotype 3 glycoconjugate has 30a weight average molecular weight (Mw) of between 500 kDa and 5,000 kDa.In an embodiment, the serotype 3 glycoconjugate has a weight average molecular weight(Mw) of between 600 kDa and 3,000 kDa.The molecular weight of the polysaccharide can be measured by Size Exclusion Chromatography(SEC) combined with Multiangle Laser Light Scattering detector (MALLS). 35Another way to characterize the serotype 3 glycoconjugates of the invention is by the number oflysine residues in the carrier protein (e.g., CRM 197 or SCP) that become conjugated to thesaccharide which can be characterized as a range of conjugated lysines (degree of conjugation). 44The evidence for lysine modification of the carrier protein, due to covalent linkages to thepolysaccharides, can be obtained by amino acid analysis using routine methods known to thoseof skill in the art. Conjugation results in a reduction in the number of lysine residues recoveredcompared to the carrier protein starting material used to generate the conjugate materials. In apreferred embodiment, the degree of conjugation of the serotype 3 glycoconjugate of the invention 5is between 2 and 15.In a preferred embodiment, the degree of conjugation of the serotype 3 glycoconjugate of theinvention is between 4 and 7. In some such embodiments, the carrier protein is CRM 197. In othersuch embodiments, the carrier protein is SCP.The serotype 3 glycoconjugates of the invention may also be characterized by the ratio 10(weight/weight) of saccharide to carrier protein. In some embodiments, the ratio of serotype 3polysaccharide to carrier protein in the glycoconjugate (w/w) is between 0.5 and 3.0. In otherembodiments, the saccharide to carrier protein ratio (w/w) is between 0.5 and 1.5. In a preferredembodiment, the ratio of serotype 3 capsular polysaccharide to carrier protein in the conjugate isbetween 0.9 and 1.1. 15The serotype 3 glycoconjugates of the invention may also be characterized by the numberof covalent linkages between the carrier protein and the saccharide as a function of repeat unitsof the saccharide. In one embodiment, the serotype 3 glycoconjugate of the invention comprisesat least one covalent linkage between the carrier protein and the polysaccharide for every 4saccharide repeat units of the polysaccharide. In another embodiment, the covalent linkage 20between the carrier protein and the polysaccharide occurs at least once in every 10 sacchariderepeat units of the polysaccharide. In another embodiment, the covalent linkage between thecarrier protein and the polysaccharide occurs at least once in every 15 saccharide repeat units ofthe polysaccharide. In a further embodiment, the covalent linkage between the carrier proteinand the polysaccharide occurs at least once in every 25 saccharide repeat units of the 25polysaccharide. In a further embodiment, the covalent linkage between the carrier protein and thepolysaccharide occurs at least once in every 50 saccharide repeat units of the polysaccharide. Inyet a further embodiment, the covalent linkage between the carrier protein and the polysaccharideoccurs at least once in every 100 saccharide repeat units of the polysaccharide.In other embodiments, the serotype 3 glycoconjugate of the invention comprises at least one 30covalent linkage between the carrier protein and the polysaccharide for every 5 to 10 sacchariderepeat units of the polysaccharide.In other embodiments, the serotype 3 glycoconjugate of the invention comprises at least onecovalent linkage between the carrier protein and the polysaccharide for every 10 to 20 sacchariderepeat units of the polysaccharide. 35In some embodiments, the carrier protein is CRM 197 and the covalent linkage between the CRM 197and the polysaccharide occurs at least once in every 4, 10, 15 or 25 saccharide repeat units ofthe polysaccharide. In frequent embodiments, the carrier protein is SCP and the covalent linkage 45between the SCP and the polysaccharide occurs at least once in every 4, 10, 15 or 25 sacchariderepeat units of the polysaccharide.The serotype 3 glycoconjugates and immunogenic compositions of the invention may contain freesaccharide that is not covalently conjugated to the carrier protein but is nevertheless present inthe glycoconjugate composition. The free saccharide may be noncovalently associated with (i.e., 5noncovalently bound to, adsorbed to, or entrapped in or with) the glycoconjugate.In a preferred embodiment, the serotype 3 glycoconjugate comprises less than about 50% of freeserotype 3 polysaccharide compared to the total amount of serotype 3 polysaccharide. In apreferred embodiment the serotype 3 glycoconjugate comprises less than about 40% of freeserotype 3 polysaccharide compared to the total amount of serotype 3 polysaccharide. In a yet 10preferred embodiment, the serotype 3 glycoconjugate comprises less than about 25% of freeserotype 3 polysaccharide compared to the total amount of serotype 3 polysaccharide. In an evenpreferred embodiment, the serotype 3 glycoconjugate comprises less than about 20% of freeserotype 3 polysaccharide compared to the total amount of serotype 3 polysaccharide. In a yetpreferred embodiment, the serotype 3 glycoconjugate comprises less than about 15% of free 15serotype 3 polysaccharide compared to the total amount of serotype 3 polysaccharide.The serotype 3 glycoconjugates may also be characterized by their molecular size distribution(Kd). Size exclusion chromatography media (CL-4B) can be used to determine the relativemolecular size distribution of the conjugate. Size Exclusion Chromatography (SEC) is used ingravity fed columns to profile the molecular size distribution of conjugates. Large molecules 20excluded from the pores in the media elute more quickly than small molecules. Fraction collectorsare used to collect the column eluate. The fractions are tested colorimetrically by saccharideassay. For the determination of Kd, columns are calibrated to establish the fraction at whichmolecules are fully excluded (V0), (Kd=0), and the fraction representing the maximum retention(Vi), (Kd=1). The fraction at which a specified sample attribute is reached (Ve), is related to Kd by 25the expression, Kd = (Ve - V0)/ (Vi - V0).In a preferred embodiment, at least 30% of the serotype 3 glycoconjugate has a Kd below or equalto 0.3 in a CL-4B column. In a preferred embodiment, at least 40% of the glycoconjugate has aKd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, at least 45%, 50%, 55%,60%, 65%, 70%, 75%, 80%, or 85% of the serotype 3 glycoconjugate has a Kd below or equal to 300.3 in a CL-4B column. In a preferred embodiment, at least 60% of the serotype 3 glycoconjugatehas a Kd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, between 50% and80% of the serotype 3 glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column. In apreferred embodiment, between 65% and 80% of the serotype 3 glycoconjugate has a Kd belowor equal to 0.3 in a CL-4B column. 35 46In an embodiment, the serotype 3 glycoconjugates of the present invention are preparedusing reductive amination chemistry (see WO2006110381, WO2008143709,PCT/IB2022/054920).According to the present invention, reductive amination involves two steps, (1) oxidation(activation) of a purified saccharide, (2) reduction of the activated saccharide and a carrier protein 5(e.g., CRM 197, TT or SCP) to form a glycoconjugate.As mentioned above, before oxidation, sizing of the polysaccharide to a target molecular weight(MW) range can be performed.Therefore, in an embodiment, the isolated polysaccharide is sized before oxidation.In an embodiment, the isolated polysaccharide is sized to any of the target molecular weight (MW) 10range defined above.In an embodiment, the isolated serotype 3 capsular polysaccharide is conjugated to acarrier protein by a process comprising the step of:(a) reacting said isolated polysaccharide with an oxidizing agent;(b) compounding the activated polysaccharide of step (a) with a carrier protein; and 15(c) reacting the compounded activated polysaccharide and carrier protein with a reducing agentto form a glycoconjugate.Following the oxidation step (a) the saccharide is said to be activated and is referred to as"activated polysaccharide".In an embodiment, the oxidizing agent is any oxidizing agent which oxidizes a terminal 20hydroxyl group to an aldehyde. In an embodiment, the oxidizing agent is periodate. For thepurpose of the present invention, the term "periodate" includes both periodate and periodic acid;the term also includes both metaperiodate (IO4-) and orthoperiodate (IO65-) and the various saltsof periodate (e.g., sodium periodate and potassium periodate).In an embodiment, the oxidizing agent is periodate in the presence of bivalent cations (see 25WO2008/143709).In an embodiment, the oxidizing agent is periodic acid. In an embodiment, the oxidizingagent is periodic acid in the presence of bivalent cations. In an embodiment, the oxidizing agentis periodic acid in the presence of Mg2+. In an embodiment, the oxidizing agent is periodic acid inthe presence of Ca2+. In an embodiment, the oxidizing agent is orthoperiodate. 30In an embodiment, the oxidizing agent is sodium periodate. In an embodiment, theperiodate used for the oxidation is metaperiodate. In an embodiment the periodate used for theoxidation is sodium metaperiodate.When a polysaccharide reacts with periodate, periodate oxidises vicinal hydroxyl groups to formcarbonyl or aldehyde groups and causes cleavage of a C-C bond. For this reason, the term 35"reacting a polysaccharide with periodate" includes oxidation of vicinal hydroxyl groups byperiodate. 47In one embodiment step a) comprises reacting the polysaccharide with 0.01-2 molar equivalentsof periodate. Preferably step a) comprises reacting the polysaccharide with 0.1-2 molarequivalents of periodate.In one embodiment step a) comprises reacting the polysaccharide with 0.01-2 molar equivalentsof periodic acid. Preferably step a) comprises reacting the polysaccharide with 0.2-2 molar 5equivalents of periodic acid.In a preferred embodiment the degree of oxidation (also named "degree of activation" inthe present document) of the activated serotype 3 polysaccharide is between 2 and 30. In apreferred embodiment the degree of oxidation of the activated serotype 3 polysaccharide isbetween 2 to 20. 10In an embodiment the degree of oxidation of the activated serotype 3 polysaccharide isbetween 2 to 8.In an embodiment the degree of oxidation of the activated serotype 3 polysaccharide isbetween 11 to 19.In one embodiment the activated polysaccharide and the carrier protein are lyophilised 15before step b). Preferably lyophilisation occurs after step a). In one embodiment the activatedpolysaccharide is lyophilised after step a) and the carrier protein is also lyophilised.In one embodiment the activated polysaccharide is lyophilised after step a) and the carrierprotein is also lyophilised, and the activated polysaccharide and the carrier protein arereconstituted in the same solution, this acts as compounding the activated polysaccharide and 20the carrier protein together.In an embodiment, the activated polysaccharide and the carrier protein are Iyophilisedindependently (discrete lyophilization). In an embodiment, the activated polysaccharide and thecarrier protein are Iyophilised together (co-lyophilized).In one embodiment the Iyophilization takes place in the presence of a non-reducing sugar, 25possible non-reducing sugars include sucrose, trehalose, raffinose, stachyose, melezitose,dextran, mannitol, lactitol and palatinit. In an embodiment the sugar is selected from the groupconsisting of sucrose, trehalose, and mannitol. In an embodiment the sugar is sucrose, trehaloseor mannitol. In an embodiment the sugar is trehalose. In an embodiment the sugar is sucrose.In an embodiment the initial input ratio (weight by weight) of activated serotype 3 capsular 30polysaccharide to carrier protein at step b) is between 4:1 and 0.1:1. In an embodiment the initialinput ratio (weight by weight) of activated serotype 3 capsular polysaccharide to carrier protein isbetween 2:1 and 0.4:1.In an embodiment, the reduction reaction (c) is carried out in aqueous solvent.In an embodiment, the reduction reaction (c) is carried out in aprotic solvent. In an 35embodiment, the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide) solvent.In an embodiment, the reducing agent is sodium cyanoborohydride, sodiumtriacetoxyborohydride, sodium or zinc borohydride in the presence of Bronsted or Lewis acids, 48amine boranes such as pyridine borane, 2-Picoline Borane, 2,6-diborane-methanol,dimethylamine-borane, t-BuMeiPrN-BH3, benzylamine-BH3 or 5-ethyl-2-methylpyridine borane(PEMB). In an embodiment, the reducing agent is sodium triacetoxyborohydride. In a preferredembodiment, the reducing agent is sodium cyanoborohydride. In an embodiment, the reducingagent is sodium cyanoborohydride in the present of nickel (see WO2018144439). 5In one embodiment between 0.2 and 20 molar equivalents of reducing agent is used instep c). In one embodiment between 0.5 and 3 molar equivalents of reducing agent is used instep c).At the end of the reduction reaction, there may be unreacted aldehyde groups remainingin the conjugates, these may be capped using a suitable capping agent. In one embodiment this 10capping agent is sodium borohydride (NaBH4).In an embodiment capping is achieved by mixing the product of step c) with 1 to 20 molarequivalents of sodium borohydride. In an embodiment capping is achieved by mixing the productof step c) with 1 to 3 molar equivalents of sodium borohydride.In an embodiment, the glycoconjugate of the present invention is prepared using CDIand/or CDT chemistry (see PCT/IB2022/054920).CDI and/or CDT chemistry involves two steps, (1) reacting the isolated saccharide with CDI and/orCDT in an aprotic solvent to produce an activated saccharide (activation), (2) reacting theactivated saccharide with a carrier protein (e.g. CRM 197 or SCP) to form a glycoconjugate. 20In an embodiment, the activating agent of step (1) is 1,1’-carbonyldiimidazole (CDI). In anembodiment, the activating agent of step (1) is 1,1'-Carbonyl-di-(1,2,4-triazole) (CDT).In an embodiment, the isolated serotype 3 capsular polysaccharide is conjugated to a carrierprotein by a process comprising the step of:(a) reacting said isolated polysaccharide with CDI and/or CDT in an aprotic solvent; 25(b) reacting the activated polysaccharide of step (a) with a carrier protein in an aprotic solvent toform a glycoconjugate.
In an embodiment, serotype 3 glycoconjugates of the present invention are prepared usingclick chemistry (see e.g. PCT/IB2022/054914). 30According to the present invention, click chemistry comprises three steps, (a) reacting anisolated serotype 3 capsular polysaccharide with a carbonic acid derivative and an azido linker inan aprotic solvent to produce an activated azido polysaccharide (activation of the polysaccharide),(b) reacting a carrier protein with an agent bearing an N-Hydroxysuccinimide (NHS) moiety andan alkyne group where the NHS moiety reacts with the amino groups to form an amide linkage 35thereby obtaining an alkyne functionalized carrier protein (activation of the carrier protein), (c)reacting the activated azido polysaccharide of step (a) with the activated alkyne-carrier protein ofstep (b) by Cu+1 mediated azide-alkyne cycloaddition reaction to form a glycoconjugate. 49Following step (a) the polysaccharide is said to be activated and is referred to herein as"activated polysaccharide" or "activated azido polysaccharide".Following step (b) the carrier is said to be activated and is referred to as "activated carrier".As mentioned above, before the activation (a), sizing of the polysaccharide to a targetmolecular weight (MW) range can be performed. 5Therefore, in an embodiment, the isolated polysaccharide is sized before activation with acarbonic acid derivative and an azido linker.In an embodiment, the isolated polysaccharide is sized to any of the target molecular weight (MW)range defined above.In an embodiment, said carbonic acid derivative is 1,1’-carbonyldiimidazole (CDI) or 1,1'- 10Carbonyl-di-(1,2,4-triazole) (CDT). Preferably, said carbonic acid derivative is 1,1’-carbonyldiimidazole (CDI).In an embodiment, said azido linker is a compound of formula (I), (I)wherein X is selected from the group consisting of CH2(CH2) n, (CH 2CH2O)mCH 2CH2, NHCO(CH2)n, 15NHCO(CH2CH2O)mCH 2CH2, OCH 2(CH 2)n and O(CH2CH2O)mCH2CH2; where n is selected from 1to 10 and m is selected from 1 to 4.In an embodiment, said azido linker is a compound of formula (II), (II)In an embodiment, said azido linker is 3-azido-propylamine. 20In an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety and analkyne group is an agent bearing an N-Hydroxysuccinimide (NHS) moiety and a terminal alkyne.In an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety and analkyne group is an agent bearing an N-Hydroxysuccinimide (NHS) moiety and a cycloalkyne.In an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety and an alkynegroup is a compound of formula (III), (III)where X is selected from the group consisting of CH2O(CH 2)nCH 2C=O andCH2O(CH 2CH2O)m(CH2)nCH2C=O, where n is selected from 0 to 10 and m is selected from 0 to4.In an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety and an 35alkyne group is a compound of formula (IV): X (IV) In an embodiment, step a) comprises reacting the polysaccharide with a carbonic acidderivative followed by reacting the carbonic acid derivative-activated polysaccharide with an azidolinker in an aprotic solvent to produce an activated azido polysaccharide. 5In an embodiment, at step a) the isolated polysaccharide is reacted with a carbonic acidderivative in an aprotic solvent.In a preferred embodiment the isolated polysaccharide is reacted with a carbonic acid derivativein a solution consisting essentially of dimethylsulphoxide (DMSO).In a preferred embodiment the isolated polysaccharide is reacted with CDI in dimethylsulphoxide 10(DMSO). In an embodiment the isolated polysaccharide is reacted with CDI in anhydrous DMSO.Once the polysaccharide has been reacted with carbonic acid derivative, and following aneventual quenching of carbonic acid derivative with water, the carbonic acid derivative-activatedpolysaccharide is reacted with an azido linker.In one embodiment step a) further comprises reacting the carbonic acid derivative- 15activated polysaccharide with an amount of azido linker that is between 0.01-10 molar equivalentto the amount of polysaccharide Repeat Unit of the activated polysaccharide (molar equivalent ofRU).In an embodiment, the conjugation reaction c) is carried out in aqueous buffer. In anembodiment, the conjugation reaction c) is carried out in aqueous buffer in the presence of copper 20(I) as catalyst. In an embodiment, the conjugation reaction c) is carried out in aqueous buffer inthe presence an oxidant and of copper (I) as catalyst. In a preferred embodiment, the conjugationreaction c) is carried out in aqueous buffer in the presence of copper (I) as catalyst and ascorbateas oxidant. In an embodiment, THPTA (tris(3-hydroxypropyltriazolylmethyl)amine) andaminoguanidine may be further added to protect the protein from side reactions. Therefore, in a 25preferred embodiment, the conjugation reaction c) is carried out in aqueous buffer in the presenceof copper (I) as catalyst and ascorbate as oxidant, wherein the reaction mixture further comprisesTHPTA (tris(3-hydroxypropyltriazolylmethyl)amine) and aminoguanidine.Following the click conjugation reaction, there may remain unreacted azido groups in theconjugates, these may be capped using a suitable azido group capping agent. Therefore, in an 30embodiment, following step c), unreacted azido groups in the conjugates, are capped using asuitable azido group capping agent. In one embodiment this azido group capping agent is anagent bearing an alkyne group. In one embodiment this azido group capping agent is an agentbearing a terminal alkyne. In one embodiment this azido group capping agent is an agent bearinga cycloalkyne. 35 51In an embodiment, said azido group capping agent is a compound of formula (V), (V)wherein X is (CH2)n wherein n is selected from 1 to 15.In one embodiment this azido group capping agent is propargyl alcohol.Therefore, in an embodiment, following step (c) the process further comprises a step of capping 5the unreacted azido groups remained in the conjugates with an azido group capping agent.Following the click conjugation reaction, unreacted alkyne groups may remain present inthe conjugates, these may be capped using a suitable alkyne group capping agent. In oneembodiment this alkyne group capping agent is an agent bearing an azido group.In an embodiment, said alkyne group capping agent is a compound of formula (VI), 10 (VI)wherein X is (CH2)n wherein n is selected from 1 to 15.In one embodiment this alkyne group capping agent is 3-azido-1-propanol.Therefore, in an embodiment, following step (c) the process further comprises a step of cappingthe unreacted alkyne groups remained in the conjugates with an alkyne group capping agent. 15 Following conjugation to the carrier protein, the glycoconjugate can be purified (enriched withrespect to the amount of saccharide-protein conjugate) by a variety of techniques known to theskilled person. These techniques include dialysis, concentration/diafiltration operations,tangential flow filtration precipitation/elution, column chromatography (DEAE or hydrophobic 20interaction chromatography), and depth filtration. Therefore, in one embodiment the process forproducing the glycoconjugate of the present invention comprises the step of purifying theglycoconjugate after it is produced.In an aspect, the serotype 3 glycoconjugate of the invention us produced according toclick chemistry as disclosed above and in application PCT/IB2022/054914, which is incorporated 25by referrnce in its entirety. Therefore, in an embodiment, the serotype 3 glycoconjugate of theinvention comprises a serotype 3 saccharide covalently conjugated to a carrier protein (CP)through a spacer and have the general formula (VII): (VII),wherein X is selected from the group consisting of CH2(CH2) n’, (CH 2CH 2O)mCH2CH 2, 30NHCO(CH2)n’, NHCO(CH2CH2O) mCH2CH2, OCH 2(CH2) n’ and O(CH 2CH2O)mCH2CH 2; where n’ isselected from 1 to 10 and m is selected from 1 to 4, 52and wherein X' is selected from the group consisting of CH2O(CH 2) n’’CH2C=O,CH2O(CH 2CH2O)m’(CH2)n’’CH2C=O, where n’’ is selected from 0 to 10 and m’ is selected from 0to 4.Formula (VII) is a schematic representation of serotype 3 glycoconjugates of the invention.It should not be understood that a linkage is present at every repeating unit of the saccharide. 5Rather, a majority of the S. pneumoniae serotype 3 saccharide repeating unit remains unmodifiedand covalent linkages between the carrier protein and the saccharide is for a minority of thesaccharide repeat units. Additionally, an individual carrier protein (CP) molecule may be linked tomore than one S. pneumoniae serotype 3 saccharide molecule and an individual S. pneumoniaeserotype 3 saccharide molecule can be linked to more than one individual carrier protein (CP) 10molecule.In a preferred embodiment, the serotype 3 glycoconjugate of the invention comprises aserotype 3 saccharide covalently conjugated to a carrier protein (CP) through a spacer and havethe general formula (VII), wherein X is CH2(CH2) n’, where n’ is 2 and wherein X' isCH2O(CH 2)n’’CH 2C=O where n’’ is 1. 15In an embodiment, the serotype 3 glycoconjugate of the invention comprises a serotype 3saccharide covalently conjugated to a carrier protein (CP) through a spacer and have the generalformula (VII), wherein X is CH2(CH2) n’, where n’ is selected from 1 to 10 and werein X' isCH2O(CH 2)n’’CH 2C=O where n’’ is selected from 0 to 10. In an embodiment, n’ is selected from 1to 5 and n’’ is selected from 0 to 10. In an embodiment, n’ is selected from 1 to 5 and n’’ is selected 20from 0 to 5. In an embodiment, n’ is selected from 1 to 3 and n’’ is selected from 0 to 3. In anembodiment, n’ is selected from 1 to 2 and n’’ is selected from 0 to 2. In a particular embodiment,n’ is 1 and n’’ is 0. In another embodiment, n’ is 2 and n’’ is 0.In an embodiment, the serotype 3 glycoconjugate of the invention comprises a serotype 3saccharide covalently conjugated to a carrier protein (CP) through a spacer and have the general 25formula (VII), wherein X is CH2(CH2) n’, where n’ is selected from 1 to 10 and wereinCH2O(CH 2CH2O)m’(CH2)n’’CH2C=O, where n’’ is selected from 0 to 10 and m’ is selected from 0to 4.In an embodiment, the serotype 3 glycoconjugate of the invention comprises a serotype 3saccharide covalently conjugated to a carrier protein (CP) through a spacer and have the general 30formula (VII), wherein X is (CH 2CH2O)mCH2CH2, where m is selected from 1 to 4 and werein X' isCH2O(CH 2)n’’CH 2C=O, where n’’ is selected from 0 to 10. In an embodiment, m is selected from 1to 3 and n’’ is selected from 0 to 10.In an embodiment, the serotype 3 glycoconjugate of the invention comprises a serotype 3saccharide covalently conjugated to a carrier protein (CP) through a spacer and have the general 35formula (VII), wherein X is (CH 2CH2O)mCH2CH2, where m is selected from 1 to 4 and werein X' isCH2O(CH 2CH2O)m’(CH2)n’’CH2C=O, where n’’ is selected from 0 to 10 and m’ is selected from 0to 4. 53In an embodiment, the serotype 3 glycoconjugate of the invention comprises a serotype 3saccharide covalently conjugated to a carrier protein (CP) through a spacer and have the generalformula (VII), wherein X is NHCO(CH2) n’, where n’ is selected from 1 to 10 and werein X' isCH2O(CH 2)n’’CH 2C=O, where n’’ is selected from 0 to 10.In an embodiment, the serotype 3 glycoconjugate of the invention comprises a serotype 3 5saccharide covalently conjugated to a carrier protein (CP) through a spacer and have the generalformula (VII), wherein X is NHCO(CH2) n’, where n’ is selected from 1 to 10 and werein X' isCH2O(CH 2CH2O)m’(CH2)n’’CH2C=O, where n’’ is selected from 0 to 10 and m’ is selected from 0to 4.In an embodiment, the serotype 3 glycoconjugate of the invention comprises a serotype 3 10saccharide covalently conjugated to a carrier protein (CP) through a spacer and have the generalformula (VII), wherein X is NHCO(CH2CH2O)mCH2CH2, where m is selected from 1 to 4 and wereinX' is CH2O(CH 2) n’’CH2C=O, where n’’ is selected from 0 to 10. In an embodiment, m is selectedfrom 1 to 3 and n’’ is selected from 0 to 10.In an embodiment, the serotype 3 glycoconjugate of the invention comprises a serotype 3 15saccharide covalently conjugated to a carrier protein (CP) through a spacer and have the generalformula (VII), wherein X is NHCO(CH2CH2O)mCH2CH2, where m is selected from 1 to 4 and wereinX' is CH2O(CH 2CH2O) m’(CH 2)n’’CH2C=O, where n’’ is selected from 0 to 10 and m’ is selected fromto 4.In an embodiment, the serotype 3 glycoconjugate of the invention comprises a serotype 3 20saccharide covalently conjugated to a carrier protein (CP) through a spacer and have the generalformula (VII), wherein X is OCH2(CH2) n’, where n’ is selected from 1 to 10 and werein X' isCH2O(CH 2)n’’CH 2C=O, where n’’ is selected from 0 to 10.In an embodiment, the serotype 3 glycoconjugate of the invention comprises a serotype 3saccharide covalently conjugated to a carrier protein (CP) through a spacer and have the general 25formula (VII), wherein X is OCH2(CH2) n’, where n’ is selected from 1 to 10 and werein X' isCH2O(CH 2CH2O)m’(CH2)n’’CH2C=O, where n’’ is selected from 0 to 10 and m’ is selected from 0to 4.In an embodiment, the serotype 3 glycoconjugate of the invention comprises a serotype 3saccharide covalently conjugated to a carrier protein (CP) through a spacer and have the general 30formula (VII), wherein X is O(CH 2CH2O)mCH2CH2, where m is selected from 1 to 4 and whereinX' is CH2O(CH 2) n’’CH2C=O, where n’’ is selected from 0 to 10.In an embodiment, the serotype 3 glycoconjugate of the invention comprises a serotype 3saccharide covalently conjugated to a carrier protein (CP) through a spacer and have the generalformula (VII), wherein X is O(CH 2CH2O)mCH2CH2, where m is selected from 1 to 4 and wherein 35X' is CH2O(CH 2CH2O) m’(CH 2)n’’CH2C=O, where n’’ is selected from 0 to 10 and m’ is selected fromto 4. 54Following conjugation to the carrier protein, the serotype 3 glycoconjugate can be purified(enriched with respect to the amount of saccharide-protein conjugate) by a variety of techniquesknown to the skilled person. These techniques include dialysis, concentration/diafiltrationoperations, tangential flow filtration precipitation/elution, column chromatography (DEAE orhydrophobic interaction chromatography), and depth filtration. Therefore, in one embodiment the 5process for producing the glycoconjugate of the present invention comprises the step of purifyingthe glycoconjugate after it is produced. 1.7 S. pneumoniae serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 15B, 14, 18C, 19A, 19F, 22F, 23F and 33F glycoconjugates of the invention 10In an aspect the invention relates to compositions comprising S. pneumoniae serotype 1,4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and/or 33Fglycoconjugate(s).The structures of Streptococcus pneumoniae serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A,11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F polysaccharides are known in the art (see 15e.g. Geno K et al. (2015) Clin Microbiol Rev Vol 28:3, p 871-899).In an embodiment, the S. pneumoniae serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F,14, 15B, 18C, 19A, 19F, 22F, 23F and/or 33F capsular saccharide used in the present inventionis a synthetic carbohydrate. Preparation of a synthetic S. pneumoniae type 1 capsular saccharidecan for example be conducted as disclosed in WO2015004041. Preparation of a synthetic S. 20pneumoniae type 4 capsular saccharide can for example be conducted as disclosed inWO2016091399. Preparation of a synthetic S. pneumoniae type 5 capsular saccharide can forexample be conducted as disclosed in WO2016198170. Preparation of a synthetic S.pneumoniae type 8 capsular saccharide can for example be conducted as disclosed inWO2017220753. 25In a preferred embodiment though, the source of bacterial polysaccharides according tothis invention can be S. pneumoniae bacterial cells. Bacterial strains which can be used as sourceof S. pneumoniae capsular polysaccharides may be obtained from established culture collections(such as for example from the Streptococcal Reference Laboratory (Centers for Disease Controland Prevention, Atlanta, GA USA)) or clinical specimens. 30S. pneumoniae serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A,19F, 22F, 23F and/or 33F capsular polysaccharides can be obtained directly from bacteria usingisolation procedures known to one of ordinary skill in the art. They can also be purchased (suchas for example from the American Type Culture Collection (ATCC, Manassas, VA USA) (e.g.,reference No. ATCC 13-X, ATCC 36-X, ATCC 41-X, ATCC 280-X, ATCC 107-X, ATCC 284-X, 35ATCC 505-X, ATCC 331-X, ATCC 511-X, ATCC 514-X, ATCC 517-X, ATCC 520-X, ATCC 81-X,ATCC 289-X, ATCC 304-X, ATCC 101-X, ATCC 527-X, ATCC 104-X, ATCC 535-X)). 55In case the capsular polysaccharide is obtained directly from bacteria, the bacterial cellscan be grown in a medium, preferably in a soy based medium. Following fermentation of bacterialcells that produce S. pneumoniae capsular polysaccharides, the bacterial cells can be lysed toproduce a cell lysate. The caspular polysaccharides may then be isolated from the cell lysateusing purification techniques known in the art, including the use of centrifugation, depth filtration, 5precipitation, ultra-filtration, treatment with activate carbon, diafiltration and/or columnchromatography (see, for example, US2006/0228380, US2006/0228381, WO2008/118752 andWO2020170190). The purified capsular polysaccharide can then be used for the preparation ofglycoconjugates.The isolated capsular saccharides can be characterized by different parameters including, 10for example the weight average molecular weight (Mw).The molecular weight of the capsular saccharides can be measured by Size ExclusionChromatography (SEC) combined with Multiangle Laser Light Scattering detector (MALLS).In a preferred embodiment, the isolated capsular polysaccharides (i.e. purified beforefurther treatment) have a weight average molecular weight between 5 kDa and 5,000 kDa. In an 15embodiment, the isolated capsualr polysaccharide has a weight average molecular weightbetween 10 kDa and 3,000 kDa. In an embodiment, the isolated capsular polysaccharide has aweight average molecular weight between 50 kDa and 1,000 kDa.Any whole number integer within any of the above ranges is contemplated as anembodiment of the disclosure. 20In order to generate conjugates with advantageous filterability characteristics,immunogenicity and/or yields, sizing of the capsular polysaccharide to a target molecular weightrange can be performed prior to the conjugation to a carrier protein. Advantageously, the size ofthe purified serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F,23F and/or 33F capsular polysaccharide is reduced while preserving critical features of the 25structure of the polysaccharide. Mechanical or chemical sizing maybe employed (see e.g.WO2006/110381, WO2015110941).In an embodiment, the size of the purified capsular polysaccharide is reduced by chemicalhydrolysis. Chemical hydrolysis maybe conducted using a mild acid ( e.g acetic acid, formic acid,propanoic acid). Chemical hydrolysis may also be conducted using a diluted strong acid (such as 30diluted hydrochloric acid, diluted sulfuric acid, diluted phosphoric acid, diluted nitric acid or dilutedperchloric acid).The size of the purified polysaccharide can also be reduced by mechanicalhomogenization. In an embodiment, the size of the purified polysaccharide is reduced by highpressure homogenization. High pressure homogenization achieves high shear rates by pumping 35the process stream through a flow path with sufficiently small dimensions. The shear rate isincreased by using a larger applied homogenization pressure, and exposure time can beincreased by recirculating the feed stream through the homogenizer. 56In an embodiment, the isolated serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23F and/or 33F capsular polysaccharide is not sized.The isolated serotype 1 capsular polysaccharide may be de-O-acetylated (see e.g. WO2008/079653). Therefore, in an embodiment, the isolated serotype 1 capsular polysaccharide ispartially de-O-acetyalted. In an embodiment, de-O-acetylation is conducted using a mild base. 5The partial de-O-acetylation can be performed using sodium bicarbonate/carbonate buffer.In an embodiment, the isolated serotype 1 capsular polysaccharide before conjugationhas a weight average molecular weight between 100 kDa and 1000 kDa. In an embodiment, theisolated serotype 1 capsular polysaccharide before conjugation has a weight average molecularweight between 150 kDa and 900 kDa. In a preferred embodiment, the isolated serotype 1 10capsular polysaccharide before conjugation has a weight average molecular weight between 150kDa and 700 kDa. The weight average molecular weight (Mw) of the isolated saccharide beforeconjugation refers to the Mw before activation of the polysaccharide (i.e. after an eventual sizingstep but before reacting the polysaccharide with an activating agent).In an embodiment, the isolated serotype 4 capsular polysaccharide before conjugation 15has a weight average molecular weight between 100 kDa and 1000 kDa. In an embodiment, theisolated serotype 4 capsular polysaccharide before conjugation has a weight average molecularweight between 300 kDa and 900 kDa.In an embodiment, the isolated serotype 5 capsular polysaccharide before conjugationhas a weight average molecular weight between 100 kDa and 1,000 kDa. In an embodiment, the 20isolated serotype 5 capsular polysaccharide before conjugation has a weight average molecularweight between 200 kDa and 600 kDa.In an embodiment, the isolated serotype 6A capsular polysaccharide before conjugationhas a weight average molecular weight between 100 kDa and 1000 kDa. In an embodiment, theisolated serotype 6A capsular polysaccharide before conjugation has a weight average molecular 25weight between 300 kDa and 900 kDa.In an embodiment, the isolated serotype 6B capsular polysaccharide before conjugationhas a weight average molecular weight between 100 kDa and 1000 kDa. In an embodiment, theisolated serotype 6B capsular polysaccharide before conjugation has a weight average molecularweight between 200 kDa and 900 kDa. 30In an embodiment, the isolated serotype 7F capsular polysaccharide before conjugationhas a weight average molecular weight between 100 kDa and 1000 kDa. In an embodiment, theisolated serotype 7F capsular polysaccharide before conjugation has a weight average molecularweight between 200 kDa and 900 kDa.In an embodiment, the isolated serotype 8 capsular polysaccharide before conjugation 35has a weight average molecular weight between 100 kDa and 1000 kDa. In an embodiment, theisolated serotype 8 capsular polysaccharide before conjugation has a weight average molecularweight between 200 kDa and 400 kDa. 57In an embodiment, the isolated serotype 9V capsular polysaccharide before conjugationhas a weight average molecular weight between 100 kDa and 1000 kDa. In an embodiment, theisolated serotype 9V capsular polysaccharide before conjugation has a weight average molecularweight between 200 kDa and 900 kDa.In an embodiment, the isolated serotype 10A capsular polysaccharide before conjugation 5has a weight average molecular weight between 100 kDa and 1000 kDa. In an embodiment, theisolated serotype 10A capsular polysaccharide before conjugation has a weight averagemolecular weight between 200 kDa and 900 kDa.In an embodiment, the isolated serotype 11A capsular polysaccharide before conjugationhas a weight average molecular weight between 100 kDa and 1000 kDa. In an embodiment, the 10isolated serotype 11A capsular polysaccharide before conjugation has a weight averagemolecular weight between 100 kDa and 400 kDa.In an embodiment, the isolated serotype 12F capsular polysaccharide before conjugationhas a weight average molecular weight between 100 kDa and 1000 kDa. In an embodiment, theisolated serotype 12F capsular polysaccharide before conjugation has a weight average 15molecular weight between 150 kDa and 400 kDa.In an embodiment, the isolated serotype 14 capsular polysaccharide before conjugationhas a weight average molecular weight between 100 kDa and 1000 kDa. In an embodiment, theisolated serotype 14 capsular polysaccharide before conjugation has a weight average molecularweight between 200 kDa and 900 kDa. 20In an embodiment, the isolated serotype 15B capsular polysaccharide before conjugationhas a weight average molecular weight between 100 kDa and 1000 kDa. In an embodiment, theisolated serotype 15B capsular polysaccharide before conjugation has a weight averagemolecular weight between 150 kDa and 300 kDa.In an embodiment, the isolated serotype 18C capsular polysaccharide before conjugation 25has a weight average molecular weight between 20 kDa and 1000 kDa. In an embodiment, theisolated serotype 18C capsular polysaccharide before conjugation has a weight averagemolecular weight between 20 kDa and 500 kDa.In an embodiment, the isolated serotype 19A capsular polysaccharide before conjugationhas a weight average molecular weight between 100 kDa and 1000 kDa. In an embodiment, the 30isolated serotype 19A capsular polysaccharide before conjugation has a weight averagemolecular weight between 250 kDa and 700 kDa.In an embodiment, the isolated serotype 19F capsular polysaccharide before conjugationhas a weight average molecular weight between 100 kDa and 1000 kDa. In an embodiment, theisolated serotype 19F capsular polysaccharide before conjugation has a weight average 35molecular weight between 250 kDa and 800 kDa.In an embodiment, the isolated serotype 22F capsular polysaccharide before conjugationhas a weight average molecular weight between 100 kDa and 1000 kDa. In an embodiment, the 58isolated serotype 22F capsular polysaccharide before conjugation has a weight averagemolecular weight between 400 kDa and 700 kDa.In an embodiment, the isolated serotype 23F capsular polysaccharide before conjugationhas a weight average molecular weight between 100 kDa and 1000 kDa. In an embodiment, theisolated serotype 23F capsular polysaccharide before conjugation has a weight average 5molecular weight between 200 kDa and 800 kDa.In an embodiment, the isolated serotype 33F capsular polysaccharide before conjugationhas a weight average molecular weight between 300 kDa and 2000 kDa. In an embodiment, theisolated serotype 33F capsular polysaccharide before conjugation has a weight averagemolecular weight between 500 kDa and 2000 kDa. 10In an embodiment, the serotype 1 glycoconjugate of the present invention comprises aserotype 1 capsular polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 50 kDa and 1,000 kDa. In an embodiment, theweight average molecular weight (Mw) is between 200 kDa and 750 kDa. In a preferredembodiment, the weight average molecular weight (Mw) is between 250 kDa and 600 kDa. Where 15the weight average molecular weight (Mw) before conjugation refers to the Mw after activation ofthe polysaccharide (i.e. after an eventual sizing step and after reacting the polysaccharide withan activating agent).In an embodiment, the serotype 4 glycoconjugate of the present invention comprises aserotype 4 capsular polysaccharide wherein the weight average molecular weight (Mw) of said 20polysaccharide before conjugation is between 50 kDa and 1,000 kDa. In an embodiment, theweight average molecular weight (Mw) is between 200 kDa and 1,000 kDa. In a preferredembodiment, the weight average molecular weight (Mw) is between 400 kDa and 900 kDa. Wherethe weight average molecular weight (Mw) before conjugation refers to the Mw after activation ofthe polysaccharide (i.e. after an eventual sizing step and after reacting the polysaccharide with 25an activating agent).In an embodiment, the serotype 5 glycoconjugate of the present invention comprises aserotype 5 capsular polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 100 kDa and 1,000 kDa. In an embodiment, theweight average molecular weight (Mw) is between 150 kDa and 800 kDa. In a preferred 30embodiment, the weight average molecular weight (Mw) is between 200 kDa and 500 kDa. Wherethe weight average molecular weight (Mw) before conjugation refers to the Mw after activation ofthe polysaccharide (i.e. after an eventual sizing step and after reacting the polysaccharide withan activating agent).In an embodiment, the serotype 6A glycoconjugate of the present invention comprises a 35serotype 6A capsular polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 50 kDa and 1,000 kDa. In an embodiment, theweight average molecular weight (Mw) is between 200 kDa and 1,000 kDa. In a preferred 59embodiment, the weight average molecular weight (Mw) is between 300 kDa and 800 kDa. Wherethe weight average molecular weight (Mw) before conjugation refers to the Mw after activation ofthe polysaccharide (i.e. after an eventual sizing step and after reacting the polysaccharide withan activating agent).In an embodiment, the serotype 6B glycoconjugate of the present invention comprises a 5serotype 6B capsular polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 50 kDa and 1,000 kDa. In an embodiment, theweight average molecular weight (Mw) is between 200 kDa and 1,000 kDa. In a preferredembodiment, the weight average molecular weight (Mw) is between 300 kDa and 800 kDa. Wherethe weight average molecular weight (Mw) before conjugation refers to the Mw after activation of 10the polysaccharide (i.e. after an eventual sizing step and after reacting the polysaccharide withan activating agent).In an embodiment, the serotype 7F glycoconjugate of the present invention comprises aserotype 7F capsular polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 50 kDa and 1,000 kDa. In an embodiment, the 15weight average molecular weight (Mw) is between 200 kDa and 1,000 kDa. In a preferredembodiment, the weight average molecular weight (Mw) is between 300 kDa and 800 kDa. Wherethe weight average molecular weight (Mw) before conjugation refers to the Mw after activation ofthe polysaccharide (i.e. after an eventual sizing step and after reacting the polysaccharide withan activating agent). 20In an embodiment, the serotype 8 glycoconjugate of the present invention comprises aserotype 8 capsular polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 50 kDa and 1,000 kDa. In an embodiment, theweight average molecular weight (Mw) is between 200 kDa and 800 kDa. In a preferredembodiment, the weight average molecular weight (Mw) is between 300 kDa and 600 kDa. In a 25most preferred embodiment, the weight average molecular weight (Mw) is between 200 kDa and400 kDa. Where the weight average molecular weight (Mw) before conjugation refers to the Mwafter activation of the polysaccharide (i.e. after an eventual sizing step and after reacting thepolysaccharide with an activating agent).In an embodiment, the serotype 9V glycoconjugate of the present invention comprises a 30serotype 9V capsular polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 50 kDa and 1,000 kDa. In an embodiment, theweight average molecular weight (Mw) is between 200 kDa and 900 kDa. In a preferredembodiment, the weight average molecular weight (Mw) is between 300 kDa and 600 kDa. In amost preferred embodiment, the weight average molecular weight (Mw) is between 100 kDa and 35400 kDa. Where the weight average molecular weight (Mw) before conjugation refers to the Mwafter activation of the polysaccharide (i.e. after an eventual sizing step and after reacting thepolysaccharide with an activating agent). 60In an embodiment, the serotype 10A glycoconjugate of the present invention comprises aserotype 10A capsular polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 50 kDa and 1,000 kDa. In an embodiment, theweight average molecular weight (Mw) is between 200 kDa and 800 kDa. In a preferredembodiment, the weight average molecular weight (Mw) is between 300 kDa and 600 kDa. In a 5most preferred embodiment, the weight average molecular weight (Mw) is between 100 kDa and400 kDa. Where the weight average molecular weight (Mw) before conjugation refers to the Mwafter activation of the polysaccharide (i.e. after an eventual sizing step and after reacting thepolysaccharide with an activating agent).In an embodiment, the serotype 11A glycoconjugate of the present invention comprises a 10serotype 11A capsular polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 50 kDa and 1,000 kDa. In an embodiment, theweight average molecular weight (Mw) is between 75 kDa and 600 kDa. In a preferredembodiment, the weight average molecular weight (Mw) is between 100 kDa and 400 kDa. Wherethe weight average molecular weight (Mw) before conjugation refers to the Mw after activation of 15the polysaccharide (i.e. after an eventual sizing step and after reacting the polysaccharide withan activating agent).In an embodiment, the serotype 12F glycoconjugate of the present invention comprises aserotype 12F capsular polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 100 kDa and 1,000 kDa. In an embodiment, the 20weight average molecular weight (Mw) is between 150 kDa and 600 kDa. In a preferredembodiment, the weight average molecular weight (Mw) is between 150 kDa and 400 kDa. In amost preferred embodiment, the weight average molecular weight (Mw) is between 250 kDa and350 kDa. Where the weight average molecular weight (Mw) before conjugation refers to the Mwafter activation of the polysaccharide (i.e. after an eventual sizing step and after reacting the 25polysaccharide with an activating agent).In an embodiment, the serotype 14 glycoconjugate of the present invention comprises aserotype 14 capsular polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 50 kDa and 1,000 kDa. In an embodiment, theweight average molecular weight (Mw) is between 100 kDa and 800 kDa. In a preferred 30embodiment, the weight average molecular weight (Mw) is between 200 kDa and 600 kDa. Wherethe weight average molecular weight (Mw) before conjugation refers to the Mw after activation ofthe polysaccharide (i.e. after an eventual sizing step and after reacting the polysaccharide withan activating agent).In an embodiment, the serotype 15B glycoconjugate of the present invention comprises a 35serotype 15B capsular polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 50 kDa and 1,000 kDa. In an embodiment, theweight average molecular weight (Mw) is between 100 kDa and 600 kDa. In a preferred 61embodiment, the weight average molecular weight (Mw) is between 150 kDa and 300 kDa. Wherethe weight average molecular weight (Mw) before conjugation refers to the Mw after activation ofthe polysaccharide (i.e. after an eventual sizing step and after reacting the polysaccharide withan activating agent).In an embodiment, the serotype 18C glycoconjugate of the present invention comprises a 5serotype 18C capsular polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 20 kDa and 800 kDa. In an embodiment, the weightaverage molecular weight (Mw) is between 20 kDa and 400 kDa. In a preferred embodiment, theweight average molecular weight (Mw) is between 20 kDa and 200 kDa. Where the weightaverage molecular weight (Mw) before conjugation refers to the Mw after activation of the 10polysaccharide (i.e. after an eventual sizing step and after reacting the polysaccharide with anactivating agent).In an embodiment, the serotype 19A glycoconjugate of the present invention comprises aserotype 19A capsular polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 50 kDa and 1,000 kDa. In an embodiment, the 15weight average molecular weight (Mw) is between 100 kDa and 700 kDa. In a preferredembodiment, the weight average molecular weight (Mw) is between 250 kDa and 500 kDa. Wherethe weight average molecular weight (Mw) before conjugation refers to the Mw after activation ofthe polysaccharide (i.e. after an eventual sizing step and after reacting the polysaccharide withan activating agent). 20In an embodiment, the serotype 19F glycoconjugate of the present invention comprises aserotype 19F capsular polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 50 kDa and 1,000 kDa. In an embodiment, theweight average molecular weight (Mw) is between 100 kDa and 900 kDa. In a preferredembodiment, the weight average molecular weight (Mw) is between 250 kDa and 600 kDa. Where 25the weight average molecular weight (Mw) before conjugation refers to the Mw after activation ofthe polysaccharide (i.e. after an eventual sizing step and after reacting the polysaccharide withan activating agent).In an embodiment, the serotype 22F glycoconjugate of the present invention comprises aserotype 22F capsular polysaccharide wherein the weight average molecular weight (Mw) of said 30polysaccharide before conjugation is between 50 kDa and 1,000 kDa. In an embodiment, theweight average molecular weight (Mw) is between 100 kDa and 900 kDa. In a preferredembodiment, the weight average molecular weight (Mw) is between 400 kDa and 700 kDa. Wherethe weight average molecular weight (Mw) before conjugation refers to the Mw after activation ofthe polysaccharide (i.e. after an eventual sizing step and after reacting the polysaccharide with 35an activating agent).In an embodiment, the serotype 23F glycoconjugate of the present invention comprises aserotype 23F capsular polysaccharide wherein the weight average molecular weight (Mw) of said 62polysaccharide before conjugation is between 50 kDa and 1,000 kDa. In an embodiment, theweight average molecular weight (Mw) is between 100 kDa and 900 kDa. In a preferredembodiment, the weight average molecular weight (Mw) is between 200 kDa and 600 kDa. Wherethe weight average molecular weight (Mw) before conjugation refers to the Mw after activation ofthe polysaccharide (i.e. after an eventual sizing step and after reacting the polysaccharide with 5an activating agent).In an embodiment, the serotype 33F glycoconjugate of the present invention comprises aserotype 33F capsular polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 50 kDa and 2,500 kDa. In an embodiment, theweight average molecular weight (Mw) is between 100 kDa and 2,000 kDa. In a preferred 10embodiment, the weight average molecular weight (Mw) is between 600 kDa and 2,000 kDa.Where the weight average molecular weight (Mw) before conjugation refers to the Mw afteractivation of the polysaccharide (i.e. after an eventual sizing step and after reacting thepolysaccharide with an activating agent).In some embodiments, the serotype 1 glycoconjugate of the invention has a weight 15average molecular weight (Mw) of between 500 kDa and 15,000 kDa. In other embodiments, theserotype 1 glycoconjugate has a weight average molecular weight (Mw) of between 1,000 kDaand 10,000 kDa. In preferred embodiments, the serotype 1 glycoconjugate has a weight averagemolecular weight (Mw) of between 2,000 kDa and 5,000 kDa.In some embodiments, the serotype 4 glycoconjugate of the invention has a weight 20average molecular weight (Mw) of between 500 kDa and 15,000 kDa. In other embodiments, theserotype 4 glycoconjugate has a weight average molecular weight (Mw) of between 1,000 kDaand 10,000 kDa. In preferred embodiments, the serotype 4 glycoconjugate has a weight averagemolecular weight (Mw) of between 2,000 kDa and 5,000 kDa.In some embodiments, the serotype 5 glycoconjugate of the invention has a weight 25average molecular weight (Mw) of between 500 kDa and 15,000 kDa. In other embodiments, theserotype 5 glycoconjugate has a weight average molecular weight (Mw) of between 1,000 kDaand 10,000 kDa. In preferred embodiments, the serotype 5 glycoconjugate has a weight averagemolecular weight (Mw) of between 2,000 kDa and 5,000 kDa.In some embodiments, the serotype 6A glycoconjugate of the invention has a weight 30average molecular weight (Mw) of between 500 kDa and 15,000 kDa. In other embodiments, theserotype 6A glycoconjugate has a weight average molecular weight (Mw) of between 1,000 kDaand 10,000 kDa. In preferred embodiments, the serotype 6A glycoconjugate has a weight averagemolecular weight (Mw) of between 2,000 kDa and 5,000 kDa.In some embodiments, the serotype 6B glycoconjugate of the invention has a weight 35average molecular weight (Mw) of between 500 kDa and 15,000 kDa. In other embodiments, theserotype 6B glycoconjugate has a weight average molecular weight (Mw) of between 1,000 kDa 63and 10,000 kDa. In preferred embodiments, the serotype 6B glycoconjugate has a weight averagemolecular weight (Mw) of between 2,000 kDa and 5,500 kDa.In some embodiments, the serotype 7F glycoconjugate of the invention has a weightaverage molecular weight (Mw) of between 500 kDa and 15,000 kDa. In other embodiments, theserotype 7F glycoconjugate has a weight average molecular weight (Mw) of between 1,000 kDa 5and 10,000 kDa. In preferred embodiments, the serotype 7F glycoconjugate has a weight averagemolecular weight (Mw) of between 2,000 kDa and 5,500 kDa.In some embodiments, the serotype 8 glycoconjugate of the invention has a weightaverage molecular weight (Mw) of between 500 kDa and 15,000 kDa. In other embodiments, theserotype 8 glycoconjugate has a weight average molecular weight (Mw) of between 1,000 kDa 10and 10,000 kDa. In preferred embodiments, the serotype 8 glycoconjugate has a weight averagemolecular weight (Mw) of between 2,500 kDa and 8,000 kDa.In some embodiments, the serotype 9V glycoconjugate of the invention has a weightaverage molecular weight (Mw) of between 500 kDa and 15,000 kDa. In other embodiments, theserotype 9V glycoconjugate has a weight average molecular weight (Mw) of between 1,000 kDa 15and 10,000 kDa. In preferred embodiments, the serotype 9V glycoconjugate has a weight averagemolecular weight (Mw) of between 2,000 kDa and 5,500 kDa.In some embodiments, the serotype 10A glycoconjugate of the invention has a weightaverage molecular weight (Mw) of between 500 kDa and 15,000 kDa. In other embodiments, theserotype 10A glycoconjugate has a weight average molecular weight (Mw) of between 1,000 kDa 20and 10,000 kDa. In preferred embodiments, the serotype 10A glycoconjugate has a weightaverage molecular weight (Mw) of between 2,000 kDa and 5,500 kDa.In some embodiments, the serotype 11A glycoconjugate of the invention has a weightaverage molecular weight (Mw) of between 500 kDa and 15,000 kDa. In other embodiments, theserotype 11A glycoconjugate has a weight average molecular weight (Mw) of between 1,000 kDa 25and 10,000 kDa. In preferred embodiments, the serotype 11A glycoconjugate has a weightaverage molecular weight (Mw) of between 700 kDa and 4,500 kDa.In some embodiments, the serotype 12F glycoconjugate of the invention has a weightaverage molecular weight (Mw) of between 500 kDa and 15,000 kDa. In other embodiments, theserotype 12F glycoconjugate has a weight average molecular weight (Mw) of between 1,000 kDa 30and 10,000 kDa. In preferred embodiments, the serotype 12F glycoconjugate has a weightaverage molecular weight (Mw) of between 1,500 kDa and 4,000 kDa.In some embodiments, the serotype 14 glycoconjugate of the invention has a weightaverage molecular weight (Mw) of between 500 kDa and 15,000 kDa. In other embodiments, theserotype 14 glycoconjugate has a weight average molecular weight (Mw) of between 1,000 kDa 35and 10,000 kDa. In preferred embodiments, the serotype 14 glycoconjugate has a weight averagemolecular weight (Mw) of between 2,000 kDa and 5,500 kDa. 64In some embodiments, the serotype 15B glycoconjugate of the invention has a weightaverage molecular weight (Mw) of between 1,000 kDa and 25,000 kDa. In other embodiments,the serotype 15B glycoconjugate has a weight average molecular weight (Mw) of between 2,000kDa and 20,000 kDa. In preferred embodiments, the serotype 15B glycoconjugate has a weightaverage molecular weight (Mw) of between 5,000 kDa and 15,000 kDa. 5In some embodiments, the serotype 18C glycoconjugate of the invention has a weightaverage molecular weight (Mw) of between 150 kDa and 15,000 kDa. In other embodiments, theserotype 18C glycoconjugate has a weight average molecular weight (Mw) of between 250 kDaand 7,000 kDa. In preferred embodiments, the serotype 18C glycoconjugate has a weight averagemolecular weight (Mw) of between 300 kDa and 4,000 kDa. 10In some embodiments, the serotype 19A glycoconjugate of the invention has a weightaverage molecular weight (Mw) of between 500 kDa and 15,000 kDa. In other embodiments, theserotype 19A glycoconjugate has a weight average molecular weight (Mw) of between 1,000 kDaand 10,000 kDa. In preferred embodiments, the serotype 19A glycoconjugate has a weightaverage molecular weight (Mw) of between 2,000 kDa and 7,500 kDa. 15In some embodiments, the serotype 19F glycoconjugate of the invention has a weightaverage molecular weight (Mw) of between 500 kDa and 15,000 kDa. In other embodiments, theserotype 19F glycoconjugate has a weight average molecular weight (Mw) of between 750 kDaand 10,000 kDa. In preferred embodiments, the serotype 19F glycoconjugate has a weightaverage molecular weight (Mw) of between 1,000 kDa and 7,500 kDa. 20In some embodiments, the serotype 22F glycoconjugate of the invention has a weightaverage molecular weight (Mw) of between 500 kDa and 10,000 kDa. In other embodiments, theserotype 22F glycoconjugate has a weight average molecular weight (Mw) of between 1,000 kDaand 7,500 kDa. In preferred embodiments, the serotype 22F glycoconjugate has a weight averagemolecular weight (Mw) of between 2,500 kDa and 5,500 kDa. 25In some embodiments, the serotype 23F glycoconjugate of the invention has a weightaverage molecular weight (Mw) of between 500 kDa and 15,000 kDa. In other embodiments, theserotype 23F glycoconjugate has a weight average molecular weight (Mw) of between 750 kDaand 10,000 kDa. In preferred embodiments, the serotype 23F glycoconjugate has a weightaverage molecular weight (Mw) of between 1,000 kDa and 7,500 kDa. 30In some embodiments, the serotype 33F glycoconjugate of the invention has a weightaverage molecular weight (Mw) of between 500 kDa and 15,000 kDa. In other embodiments, theserotype 33F glycoconjugate has a weight average molecular weight (Mw) of between 750 kDaand 10,000 kDa. In preferred embodiments, the serotype 33F glycoconjugate has a weightaverage molecular weight (Mw) of between 2,000 kDa and 6,000 kDa. 35The glycoconjugates of the invention may also be characterized by the ratio(weight/weight) of saccharide to carrier protein. 65In some embodiments, the ratio of serotype 1 polysaccharide to carrier protein in theglycoconjugate (w/w) is between 0.4 and 3.0. Preferably, the saccharide to carrier protein ratio(w/w) is between 0.6 and 2.0. In some such embodiments, the carrier protein is TT. Preferably,the carrier protein is CRM 197.In some embodiments, the ratio of serotype 4 polysaccharide to carrier protein in the 5glycoconjugate (w/w) is between 0.4 and 3.0. Preferably, the saccharide to carrier protein ratio(w/w) is between 0.9 and 2.1. Even more preferably, the saccharide to carrier protein ratio (w/w)is between 1.0 and 1.9. In some such embodiments, the carrier protein is TT. Preferably, thecarrier protein is CRM 197.In some embodiments, the ratio of serotype 5 polysaccharide to carrier protein in the 10glycoconjugate (w/w) is between 0.4 and 3.0. Preferably, the saccharide to carrier protein ratio(w/w) is between 1.3 and 2.5. In some such embodiments, the carrier protein is TT. Preferably,the carrier protein is CRM 197.In some embodiments, the ratio of serotype 6A polysaccharide to carrier protein in theglycoconjugate (w/w) is between 0.4 and 3.0. Preferably, the saccharide to carrier protein ratio 15(w/w) is between 0.7 and 1.6. In some such embodiments, the carrier protein is TT. Preferably,the carrier protein is CRM 197.In some embodiments, the ratio of serotype 6B polysaccharide to carrier protein in theglycoconjugate (w/w) is between 0.4 and 3.0. Preferably, the saccharide to carrier protein ratio(w/w) is between 0.4 and 0.8. In some such embodiments, the carrier protein is TT. Preferably, 20the carrier protein is CRM 197.In some embodiments, the ratio of serotype 7F polysaccharide to carrier protein in theglycoconjugate (w/w) is between 0.4 and 3.0. Preferably, the saccharide to carrier protein ratio(w/w) is between 0.7 and 1.5. In some such embodiments, the carrier protein is TT. Preferably,the carrier protein is CRM 197. 25In some embodiments, the ratio of serotype 8 polysaccharide to carrier protein in theglycoconjugate (w/w) is between 0.4 and 3.0. Preferably, the saccharide to carrier protein ratio(w/w) is between 0.6 and 1.6. In some such embodiments, the carrier protein is TT. Preferably,the carrier protein is CRM 197.In some embodiments, the ratio of serotype 9V polysaccharide to carrier protein in the 30glycoconjugate (w/w) is between 0.4 and 3.0. Preferably, the saccharide to carrier protein ratio(w/w) is between 1.2 and 2.3. In some such embodiments, the carrier protein is TT. Preferably,the carrier protein is CRM 197.In some embodiments, the ratio of serotype 10A polysaccharide to carrier protein in theglycoconjugate (w/w) is between 0.4 and 3.0. Preferably, the saccharide to carrier protein ratio 35(w/w) is between 0.7 and 1.6. In some such embodiments, the carrier protein is TT. Preferably,the carrier protein is CRM 197. 66In some embodiments, the ratio of serotype 11A polysaccharide to carrier protein in theglycoconjugate (w/w) is between 0.4 and 3.0. Preferably, the saccharide to carrier protein ratio(w/w) is between 0.9 and 1.5. In some such embodiments, the carrier protein is TT. Preferably,the carrier protein is CRM 197.In some embodiments, the ratio of serotype 12F polysaccharide to carrier protein in the 5glycoconjugate (w/w) is between 0.4 and 3.0. Preferably, the saccharide to carrier protein ratio(w/w) is between 0.7 and 1.5. In some such embodiments, the carrier protein is TT. Preferably,the carrier protein is CRM 197.In some embodiments, the ratio of serotype 14 polysaccharide to carrier protein in theglycoconjugate (w/w) is between 0.4 and 3.0. Preferably, the saccharide to carrier protein ratio 10(w/w) is between 1.4 and 2.6. In some such embodiments, the carrier protein is TT. Preferably,the carrier protein is CRM 197.In some embodiments, the ratio of serotype 15B polysaccharide to carrier protein in theglycoconjugate (w/w) is between 0.4 and 3.0. Preferably, the saccharide to carrier protein ratio(w/w) is between 0.6 and 1.6. In some such embodiments, the carrier protein is TT. Preferably, 15the carrier protein is CRM 197.In some embodiments, the ratio of serotype 18C polysaccharide to carrier protein in theglycoconjugate (w/w) is between 0.4 and 3.0. Preferably, the saccharide to carrier protein ratio(w/w) is between 0.7 and 1.5. In some such embodiments, the carrier protein is TT. Preferably,the carrier protein is CRM 197. 20In some embodiments, the ratio of serotype 19A polysaccharide to carrier protein in theglycoconjugate (w/w) is between 0.4 and 3.0. Preferably, the saccharide to carrier protein ratio(w/w) is between 0.4 and 0.9. In some such embodiments, the carrier protein is TT. Preferably,the carrier protein is CRM 197.In some embodiments, the ratio of serotype 19F polysaccharide to carrier protein in the 25glycoconjugate (w/w) is between 0.4 and 3.0. Preferably, the saccharide to carrier protein ratio(w/w) is between 0.5 and 1.0. In some such embodiments, the carrier protein is TT. Preferably,the carrier protein is CRM 197.In some embodiments, the ratio of serotype 22F polysaccharide to carrier protein in theglycoconjugate (w/w) is between 0.4 and 3.0. Preferably, the saccharide to carrier protein ratio 30(w/w) is between 0.8 and 1.2. In some such embodiments, the carrier protein is TT. Preferably,the carrier protein is CRM 197.In some embodiments, the ratio of serotype 23F polysaccharide to carrier protein in theglycoconjugate (w/w) is between 0.4 and 3.0. Preferably, the saccharide to carrier protein ratio(w/w) is between 0.4 and 1.0. In some such embodiments, the carrier protein is TT. Preferably, 35the carrier protein is CRM 197.In some embodiments, the ratio of serotype 33F polysaccharide to carrier protein in theglycoconjugate (w/w) is between 0.4 and 3.0. Preferably, the saccharide to carrier protein ratio 67(w/w) is between 1.0 and 2.2. In some such embodiments, the carrier protein is TT. Preferably,the carrier protein is CRM 197.Another way to characterize the glycoconjugates of the invention is by the number of lysineresidues in the carrier protein (e.g., CRM197, DT or TT) that become conjugated to the saccharidewhich can be characterized as a range of conjugated lysines (degree of conjugation). The 5evidence for lysine modification of the carrier protein, due to covalent linkages to thepolysaccharides, can be obtained by amino acid analysis using routine methods known to thoseof skill in the art. Conjugation results in a reduction in the number of lysine residues recoveredcompared to the carrier protein starting material used to generate the conjugate materials.In a preferred embodiment, the degree of conjugation of the serotype 1 glycoconjugate of 10the invention is between 2 and 15.In a preferred embodiment, the degree of conjugation of the serotype 4 glycoconjugate ofthe invention is between 2 and 15.In a preferred embodiment, the degree of conjugation of the serotype 5 glycoconjugate ofthe invention is between 2 and 15. 15In a preferred embodiment, the degree of conjugation of the serotype 6A glycoconjugateof the invention is between 2 and 15.In a preferred embodiment, the degree of conjugation of the serotype 6B glycoconjugateof the invention is between 2 and 15.In a preferred embodiment, the degree of conjugation of the serotype 7F glycoconjugate 20of the invention is between 2 and 15.In a preferred embodiment, the degree of conjugation of the serotype 8 glycoconjugate ofthe invention is between 2 and 15.In a preferred embodiment, the degree of conjugation of the serotype 9V glycoconjugateof the invention is between 2 and 15. 25In a preferred embodiment, the degree of conjugation of the serotype 10A glycoconjugateof the invention is between 2 and 15.In a preferred embodiment, the degree of conjugation of the serotype 11A glycoconjugateof the invention is between 2 and 15.In a preferred embodiment, the degree of conjugation of the serotype 12F glycoconjugate 30of the invention is between 2 and 15.In a preferred embodiment, the degree of conjugation of the serotype 14 glycoconjugateof the invention is between 2 and 15.In a preferred embodiment, the degree of conjugation of the serotype 15B glycoconjugateof the invention is between 2 and 15. 35In a preferred embodiment, the degree of conjugation of the serotype 18C glycoconjugateof the invention is between 2 and 15. 68In a preferred embodiment, the degree of conjugation of the serotype 19A glycoconjugateof the invention is between 2 and 15.In a preferred embodiment, the degree of conjugation of the serotype 19F glycoconjugateof the invention is between 2 and 15.In a preferred embodiment, the degree of conjugation of the serotype 22F glycoconjugate 5of the invention is between 2 and 15.In a preferred embodiment, the degree of conjugation of the serotype 23F glycoconjugateof the invention is between 2 and 15.In a preferred embodiment, the degree of conjugation of the serotype 33F glycoconjugateof the invention is between 2 and 15. 10The serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23For 33F glycoconjugate of the invention and immunogenic compositions comprising saidglycoconjugate(s) may contain free saccharide that is not covalently conjugated to the carrierprotein but is nevertheless present in the glycoconjugate composition. The free saccharide maybe noncovalently associated with (i.e., noncovalently bound to, adsorbed to, or entrapped in or 15with) the glycoconjugate.In an embodiment, the serotype 1 glycoconjugate of the invention comprises less thanabout 40% of free serotype 1 polysaccharide compared to the total amount of serotype 1polysaccharide. In a preferred embodiment the serotype 1 glycoconjugate comprises less thanabout 20% of free serotype 1 polysaccharide compared to the total amount of serotype 1 20polysaccharide.In an embodiment, the serotype 1 glycoconjugate of the invention comprises less thanabout 40% of free serotype 1 polysaccharide compared to the total amount of serotype 1polysaccharide. In a preferred embodiment the serotype 1 glycoconjugate comprises less thanabout 20% of free serotype 1 polysaccharide compared to the total amount of serotype 1 25polysaccharide.In an embodiment, the serotype 4 glycoconjugate of the invention comprises less thanabout 40% of free serotype 4 polysaccharide compared to the total amount of serotype 4polysaccharide. In a preferred embodiment the serotype 4 glycoconjugate comprises less thanabout 30% of free serotype 4 polysaccharide compared to the total amount of serotype 4 30polysaccharide.In an embodiment, the serotype 5 glycoconjugate of the invention comprises less thanabout 45% of free serotype 5 polysaccharide compared to the total amount of serotype 5polysaccharide. In a preferred embodiment the serotype 5 glycoconjugate comprises less thanabout 40% of free serotype 5 polysaccharide compared to the total amount of serotype 5 35polysaccharide.In an embodiment, the serotype 6A glycoconjugate of the invention comprises less thanabout 40% of free serotype 6A polysaccharide compared to the total amount of serotype 6A 69polysaccharide. In a preferred embodiment the serotype 6A glycoconjugate comprises less thanabout 30% of free serotype 6A polysaccharide compared to the total amount of serotype 6Apolysaccharide.In an embodiment, the serotype 6B glycoconjugate of the invention comprises less thanabout 30% of free serotype 6B polysaccharide compared to the total amount of serotype 6B 5polysaccharide. In a preferred embodiment the serotype 6B glycoconjugate comprises less thanabout 20% of free serotype 6B polysaccharide compared to the total amount of serotype 6Bpolysaccharide.In an embodiment, the serotype 7F glycoconjugate of the invention comprises less thanabout 30% of free serotype 7F polysaccharide compared to the total amount of serotype 7F 10polysaccharide. In a preferred embodiment the serotype 7F glycoconjugate comprises less thanabout 20% of free serotype 7F polysaccharide compared to the total amount of serotype 7Fpolysaccharide.In an embodiment, the serotype 8 glycoconjugate of the invention comprises less thanabout 30% of free serotype 8 polysaccharide compared to the total amount of serotype 8 15polysaccharide. In a preferred embodiment the serotype 8 glycoconjugate comprises less thanabout 20% of free serotype 8 polysaccharide compared to the total amount of serotype 8polysaccharide.In an embodiment, the serotype 9V glycoconjugate of the invention comprises less thanabout 40% of free serotype 9V polysaccharide compared to the total amount of serotype 9V 20polysaccharide. In a preferred embodiment the serotype 9V glycoconjugate comprises less thanabout 35% of free serotype 9V polysaccharide compared to the total amount of serotype 9Vpolysaccharide.In an embodiment, the serotype 10A glycoconjugate of the invention comprises less thanabout 40% of free serotype 10A polysaccharide compared to the total amount of serotype 10A 25polysaccharide. In a preferred embodiment the serotype 10A glycoconjugate comprises less thanabout 20% of free serotype 10A polysaccharide compared to the total amount of serotype 10Apolysaccharide.In an embodiment, the serotype 11A glycoconjugate of the invention comprises less thanabout 40% of free serotype 11A polysaccharide compared to the total amount of serotype 11A 30polysaccharide. In a preferred embodiment the serotype 11A glycoconjugate comprises less thanabout 30% of free serotype 11A polysaccharide compared to the total amount of serotype 11Apolysaccharide.In an embodiment, the serotype 12F glycoconjugate of the invention comprises less thanabout 40% of free serotype 12Fpolysaccharide compared to the total amount of serotype 12F 35polysaccharide. In a preferred embodiment the serotype 12F glycoconjugate comprises less thanabout 30% of free serotype 12F polysaccharide compared to the total amount of serotype 12Fpolysaccharide. 70In an embodiment, the serotype 14 glycoconjugate of the invention comprises less thanabout 40% of free serotype 14 polysaccharide compared to the total amount of serotype 14polysaccharide. In a preferred embodiment the serotype 14 glycoconjugate comprises less thanabout 35% of free serotype 14 polysaccharide compared to the total amount of serotype 14polysaccharide. 5In an embodiment, the serotype 15B glycoconjugate of the invention comprises less thanabout 40% of free serotype 15B polysaccharide compared to the total amount of serotype 15Bpolysaccharide. In a preferred embodiment the serotype 15B glycoconjugate comprises less thanabout 35% of free serotype 15B polysaccharide compared to the total amount of serotype 15Bpolysaccharide. 10In an embodiment, the serotype 18C glycoconjugate of the invention comprises less thanabout 30% of free serotype 18C polysaccharide compared to the total amount of serotype 18Cpolysaccharide. In a preferred embodiment the serotype 18C glycoconjugate comprises less thanabout 20% of free serotype 18C polysaccharide compared to the total amount of serotype 18Cpolysaccharide. 15In an embodiment, the serotype 19A glycoconjugate of the invention comprises less thanabout 40% of free serotype 19A polysaccharide compared to the total amount of serotype 19Apolysaccharide. In a preferred embodiment the serotype 19A glycoconjugate comprises less thanabout 30% of free serotype 19A polysaccharide compared to the total amount of serotype 19Apolysaccharide. 20In an embodiment, the serotype 19F glycoconjugate of the invention comprises less thanabout 30% of free serotype 19F polysaccharide compared to the total amount of serotype 19Fpolysaccharide. In a preferred embodiment the serotype 19F glycoconjugate comprises less thanabout 20% of free serotype 19F polysaccharide compared to the total amount of serotype 19Fpolysaccharide. 25In an embodiment, the serotype 22F glycoconjugate of the invention comprises less thanabout 40% of free serotype 22F polysaccharide compared to the total amount of serotype 22Fpolysaccharide. In a preferred embodiment the serotype 22F glycoconjugate comprises less thanabout 20% of free serotype 22F polysaccharide compared to the total amount of serotype 22Fpolysaccharide. 30In an embodiment, the serotype 23F glycoconjugate of the invention comprises less thanabout 30% of free serotype 23F polysaccharide compared to the total amount of serotype 23Fpolysaccharide. In a preferred embodiment the serotype 23F glycoconjugate comprises less thanabout 20% of free serotype 23F polysaccharide compared to the total amount of serotype 23Fpolysaccharide. 35In an embodiment, the serotype 33F glycoconjugate of the invention comprises less thanabout 30% of free serotype 33F polysaccharide compared to the total amount of serotype 33Fpolysaccharide. In a preferred embodiment the serotype 33F glycoconjugate comprises less than 71about 20% of free serotype 33F polysaccharide compared to the total amount of serotype 33Fpolysaccharide.The serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23For 33F glycoconjugate of the invention may also be characterized by their molecular sizedistribution (Kd). Size exclusion chromatography media (CL-4B) can be used to determine the 5relative molecular size distribution of the conjugate. Size Exclusion Chromatography (SEC) isused in gravity fed columns to profile the molecular size distribution of conjugates. Largemolecules excluded from the pores in the media elute more quickly than small molecules.Fraction collectors are used to collect the column eluate. The fractions are tested colorimetricallyby saccharide assay. For the determination of Kd, columns are calibrated to establish the fraction 10at which molecules are fully excluded (V0), (Kd=0), and the fraction representing the maximumretention (Vi), (Kd=1). The fraction at which a specified sample attribute is reached (Ve), is relatedto Kd by the expression, Kd = (Ve - V0)/ (Vi - V0).In an embodiment, at least 40% of the serotype 1 glycoconjugate has a Kd below or equalto 0.3 in a CL-4B column. In a preferred embodiment, at least 50% of the glycoconjugate has a 15Kd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, between 50% and 80%of the serotype 1 glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.In an embodiment, at least 30% of the serotype 4 glycoconjugate has a Kd below or equalto 0.3 in a CL-4B column. In a preferred embodiment, at least 40% of the glycoconjugate has aKd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, between 40% and 80% 20of the serotype 4 glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.In an embodiment, at least 40% of the serotype 5 glycoconjugate has a Kd below or equalto 0.3 in a CL-4B column. In a preferred embodiment, at least 55% of the glycoconjugate has aKd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, between 55% and 80%of the serotype 5 glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column. 25In an embodiment, at least 50% of the serotype 6A glycoconjugate has a Kd below orequal to 0.3 in a CL-4B column. In a preferred embodiment, at least 60% of the glycoconjugatehas a Kd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, between 60% and90% of the serotype 6A glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.In an embodiment, at least 30% of the serotype 6B glycoconjugate has a Kd below or 30equal to 0.3 in a CL-4B column. In a preferred embodiment, at least 35% of the glycoconjugatehas a Kd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, between 35% and80% of the serotype 6B glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.In an embodiment, at least 50% of the serotype 7F glycoconjugate has a Kd below orequal to 0.3 in a CL-4B column. In a preferred embodiment, at least 65% of the glycoconjugate 35has a Kd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, between 65% and90% of the serotype 7F glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column. 72In an embodiment, at least 60% of the serotype 8 glycoconjugate has a Kd below or equalto 0.3 in a CL-4B column. In a preferred embodiment, at least 70% of the glycoconjugate has aKd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, between 70% and 90%of the serotype 8 glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.In an embodiment, at least 30% of the serotype 9V glycoconjugate has a Kd below or 5equal to 0.3 in a CL-4B column. In a preferred embodiment, at least 40% of the glycoconjugatehas a Kd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, between 40% and80% of the serotype 9V glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.In an embodiment, at least 40% of the serotype 10A glycoconjugate has a Kd below orequal to 0.3 in a CL-4B column. In a preferred embodiment, at least 55% of the glycoconjugate 10has a Kd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, between 55% and85% of the serotype 10A glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.In an embodiment, at least 50% of the serotype 11A glycoconjugate has a Kd below orequal to 0.3 in a CL-4B column. In a preferred embodiment, at least 60% of the glycoconjugatehas a Kd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, between 60% and 1585% of the serotype 11A glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.In an embodiment, at least 40% of the serotype 12F glycoconjugate has a Kd below orequal to 0.3 in a CL-4B column. In a preferred embodiment, at least 50% of the glycoconjugatehas a Kd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, between 50% and80% of the serotype 12F glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column. 20In an embodiment, at least 40% of the serotype 14 glycoconjugate has a Kd below orequal to 0.3 in a CL-4B column. In a preferred embodiment, at least 50% of the glycoconjugatehas a Kd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, between 50% and80% of the serotype 14 glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.In an embodiment, at least 30% of the serotype 15B glycoconjugate has a Kd below or 25equal to 0.3 in a CL-4B column. In a preferred embodiment, at least 40% of the glycoconjugatehas a Kd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, between 40% and80% of the serotype 15B glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.In an embodiment, at least 30% of the serotype 18C glycoconjugate has a Kd below orequal to 0.3 in a CL-4B column. In a preferred embodiment, at least 40% of the glycoconjugate 30has a Kd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, between 40% and80% of the serotype 18C glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.In an embodiment, at least 40% of the serotype 19A glycoconjugate has a Kd below orequal to 0.3 in a CL-4B column. In a preferred embodiment, at least 50% of the glycoconjugatehas a Kd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, between 50% and 3580% of the serotype 19A glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.In an embodiment, at least 40% of the serotype 19F glycoconjugate has a Kd below orequal to 0.3 in a CL-4B column. In a preferred embodiment, at least 50% of the glycoconjugate 73has a Kd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, between 50% and80% of the serotype 19F glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.In an embodiment, at least 30% of the serotype 22F glycoconjugate has a Kd below orequal to 0.3 in a CL-4B column. In a preferred embodiment, at least 40% of the glycoconjugatehas a Kd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, between 40% and 580% of the serotype 22F glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.In an embodiment, at least 30% of the serotype 23F glycoconjugate has a Kd below orequal to 0.3 in a CL-4B column. In a preferred embodiment, at least 35% of the glycoconjugatehas a Kd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, between 35% and80% of the serotype 23F glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column. 10In an embodiment, at least 50% of the serotype 33F glycoconjugate has a Kd below orequal to 0.3 in a CL-4B column. In a preferred embodiment, at least 60% of the glycoconjugatehas a Kd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, between 60% and95% of the serotype 33F glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.In an embodiment, the serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 1519A, 19F, 22F, 23F and/or 33F saccharide is activated with 1-cyano-4-dimethylamino pyridiniumtetrafluoroborate (CDAP) to form a cyanate ester. The activated polysaccharide is then coupleddirectly or via a spacer (linker) group to an amino group on the carrier protein. For example, thespacer could be cystamine or cysteamine to give a thiolated polysaccharide which could becoupled to the carrier via a thioether linkage obtained after reaction with a maleimide-activated 20carrier protein (for example using N-[ γ-maleimidobutyrloxy]succinimide ester (GMBS)) or ahaloacetylated carrier protein (for example using iodoacetimide, N-succinimidyl bromoacetate(SBA; SIB), N-succinimidyl(4-iodoacetyl)aminobenzoate (SlAB), sulfosuccinimidyl(4-iodoacetyl)aminobenzoate (sulfo-SIAB), N-succinimidyl iodoacetate (SIA) or succinimidyl 3-[bromoacetamido]proprionate (SBAP)). Preferably, the cyanate ester is coupled with hexane 25diamine or adipic acid dihydrazide (ADH) and the amino-derivatised saccharide is conjugated tothe carrier protein (e.g., CRM 197) using carbodiimide (e.g., EDAC or EDC) chemistry via a carboxylgroup on the protein carrier. Such conjugates are described for example in WO 93/15760, WO95/08348 and WO 96/129094.Other suitable techniques for conjugation use carbodiimides, hydrazides, active esters, 30norborane, p-nitrobenzoic acid, N-hydroxysuccinimide, S--NHS, EDC, TSTU. Many are describedin International Patent Application Publication No. WO 98/42721. Conjugation may involve acarbonyl linker which may be formed by reaction of a free hydroxyl group of the saccharide with1,1’-carbonyldiimidazole (CDI) (see Bethell et al. (1979) J. Biol. Chern. 254:2572-2574; Hearn etal. (1981) J. Chromatogr. 218:509-518) followed by reaction with a protein to form a carbamate 35linkage. This may involve reduction of the anomeric terminus to a primary hydroxyl group, optionalprotection/deprotection of the primary hydroxyl group, reaction of the primary hydroxyl group with 74CDI to form a CDI carbamate intermediate and coupling the CDI carbamate intermediate with anamino group on a protein.In an embodiment, the serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C,19A, 19F, 22F, 23F and/or 33F glycoconjugates of the invention are prepared using reductiveamination chemistry. According to the present invention, reductive amination involves two steps, 5(1) oxidation (activation) of a purified saccharide, (2) reduction of the activated saccharide and acarrier protein to form a glycoconjugate (see e.g. WO2006/110381, WO2008/079653,WO2008/143709, WO2008/079732, WO2011/110531, WO2012/119972, WO2015110941,WO2015110940, WO2018/144439, WO2018/156491).In an embodiment, the serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 1019A, 19F, 22F, 23F and 33F glycoconjugates of the invention are prepared using reductiveamination chemistry.In another embodiment, the serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B,18C, 19A, 19F, 22F and 23F glycoconjugates of the invention are prepared using reductiveamination chemistry. 15As mentioned above, before oxidation, sizing of the isolated serotype 1, 4, 5, 6A, 6B, 7F,8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and/or 33F capsular polysaccharide toa target molecular weight (MW) range can be performed. Therefore, in an embodiment, theisolated serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23Fand/or 33F capsular polysaccharide is sized before oxidation. 20Therefore, in an embodiment, the isolated serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A,12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F capsular polysaccharide are sized beforeoxidation.In an embodiment, the isolated serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23F and/or 33F capsular polysaccharide is conjugated to a carrier 25protein by a process comprising the step of:(a) reacting said isolated serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C,19A, 19F, 22F, 23F and/or 33F capsular polysaccharide with an oxidizing agent to produce anactivated polysaccharide; (b) compounding the activated polysaccharide of step (a) with a carrierprotein; and (c) reacting the compounded activated polysaccharide and carrier protein with a 30reducing agent to form a glycoconjugate.Following the oxidation step (a) the saccharide is said to be activated and is referred to as"activated polysaccharide".In an embodiment, the oxidizing agent is any oxidizing agent which oxidizes a terminalhydroxyl group to an aldehyde. In an embodiment, the oxidizing agent is periodate. For the 35purpose of the present invention, the term "periodate" includes both periodate and periodic acid;the term also includes both metaperiodate (IO4-) and orthoperiodate (IO65-) and the various saltsof periodate (e.g., sodium periodate and potassium periodate). 75In an embodiment, the isolated serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23F and 33F capsular polysaccharides are reacted with periodate.In an embodiment, the isolated serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 14, 15B,18C, 19A, 19F, 22F and 23Fcapsular polysaccharides are reacted with periodate.In a preferred embodiment, the oxidizing agent is sodium periodate. In an embodiment, 5the periodate used for the oxidation is metaperiodate. In a most preferred embodiment theperiodate used for the oxidation is sodium metaperiodate.When a polysaccharide reacts with periodate, periodate oxidises vicinal hydroxyl groupsto form carbonyl or aldehyde groups and causes cleavage of a C-C bond. For this reason, theterm "reacting a polysaccharide with periodate" includes oxidation of vicinal hydroxyl groups by 10periodate.In one embodiment step a) comprises reacting the serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V,10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and/or 33F polysaccharide with periodate.In one embodiment step a) comprises reacting the serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V,10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and/or 33F polysaccharide with 0.05-2 molar 15equivalents of periodate.In one embodiment step a) comprises reacting the serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V,10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and/or 33F polysaccharide with 0.05-0.2 molarequivalents of periodate.In one embodiment step a) comprises reacting the serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 2010A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and/or 33F polysaccharide with 0.2-0.5 molarequivalents of periodateIn one embodiment step a) comprises reacting the serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V,10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and/or 33F polysaccharide with 0.5-1.5 molarequivalents of periodate 25In one embodiment step a) comprises reacting the serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V,10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and/or 33F polysaccharide with 1.5-2.0 molarequivalents of periodate.In some embodiment, the reaction of step (a) is quenched. Therefore, following step (a) aquenching step (a’) can be performed (see WO2015110940). Therefore, in an embodiment, the 30isolated serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23Fand/or 33F capsular polysaccharide is conjugated to a carrier protein by a process comprisingthe step of:(a) reacting said isolated serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A,19F, 22F, 23F and/or 33F capsular polysaccharide with an oxidizing agent to produce an activated 35polysaccharide; (a’) quenching the oxidation reaction by addition of a quenching agent resultingin an activated polysaccharide; (b) compounding the activated polysaccharide of step (a’) with a 76carrier protein; and (c) reacting the compounded activated polysaccharide and carrier protein witha reducing agent to form a glycoconjugate. In an embodiment, the oxidizing agent is 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO)free radical and N-Chlorosuccinimide (NCS) as the cooxidant. This oxidizing agent is particularlysuitable for oxidizing serotype 12F capsular polysaccharides. In such embodiment, the 5glycoconjugates from S. pneumoniae serotype 12F are prepared using 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) free radical to oxidize primary alcohols of the saccharide to aldehydesusing N-Chlorosuccinimide (NCS) as the cooxidant (hereinafter "TEMPO/NCS oxidation"), suchas described at Example 7 and in WO 2014/097099. Therefore, in one aspect, theglycoconjugates from S. pneumoniae serotype 12F of the invention are obtainable by a method 10comprising the steps of: a) reacting an isolated serotype 12F capsular polysaccharide with2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) and N-chlorosuccinimide (NCS) to produce anactivated polysaccharide; (b) compounding the activated polysaccharide of step (a) with a carrierprotein and (c) reacting the compounded activated polysaccharide and carrier protein with areducing agent to form a glycoconjugate (hereinafter "TEMPO/NCS-reductive amination"). In one 15aspect, the glycoconjugates from S. pneumoniae serotype 12F are obtained by said method.In an embodiment, the isolated serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 14, 15B,18C, 19A, 19F, 22F, 23F and 33F capsular polysaccharides are reacted with periodate and theisolated serotype 12F capsular polysaccharide is reacted with TEMPO/NCS.In an embodiment, the isolated serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 14, 15B, 2018C, 19A, 19F, 22F and 23F capsular polysaccharides are reacted with periodate and the isolatedserotype 12F capsular polysaccharide is reacted with TEMPO/NCS.In a preferred embodiment the degree of oxidation (also named "degree of activation" inthe present document) of the activated serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23F and/or 33F polysaccharide is between 2 and 30. 25In an embodiment the degree of oxidation of the activated serotype 1 polysaccharide isbetween 1 and 15 when the carrier protein is TT (see e.g. Table 2 of WO2019/152921).In a preferred embodiment the degree of oxidation of the activated serotype 1polysaccharide is between 4 and 10 when the carrier protein is CRM 197. See Table 1 ofWO2019/152921. 30In an embodiment the degree of oxidation of the activated serotype 4 polysaccharide isbetween 1 and 15. In a preferred embodiment the degree of oxidation of the activated serotype 4polysaccharide is between 1 and 5 when the carrier protein is CRM 197. See Table 1 ofWO2019/152921.In an embodiment the degree of oxidation of the activated serotype 5 polysaccharide is 35between 1 and 15. In a preferred embodiment the degree of oxidation of the activated serotype 5polysaccharide is between 2 and 6 when the carrier protein is CRM 197. See Table 1 ofWO2019/152921. 77In an embodiment the degree of oxidation of the activated serotype 5 polysaccharide isbetween 1 and 15 when the carrier protein is TT. See Table 2 of WO2019/152921.In an embodiment the degree of oxidation of the activated serotype 6A polysaccharide isbetween 1 and 15. In a preferred embodiment the degree of oxidation of the activated serotype6A polysaccharide is between 5 and 15 when the carrier protein is CRM 197. See Table 1 of 5WO2019/152921.In an embodiment the degree of oxidation of the activated serotype 6B polysaccharide isbetween 1 and 15. In a preferred embodiment the degree of oxidation of the activated serotype6B polysaccharide is between 7 and 13 when the carrier protein is CRM 197. See Table 1 ofWO2019/152921. 10In an embodiment the degree of oxidation of the activated serotype 7F polysaccharide isbetween 1 and 15. In a preferred embodiment the degree of oxidation of the activated serotype7F polysaccharide is between 2 and 8 when the carrier protein is CRM 197. See Table 1 ofWO2019/152921.In an embodiment the degree of oxidation of the activated serotype 8 polysaccharide is 15between 1 and 20. In a preferred embodiment the degree of oxidation of the activated serotype 8polysaccharide is between 1 and 17 when the carrier protein is CRM 197. See Table 1 ofWO2019/152921.In an embodiment the degree of oxidation of the activated serotype 9V polysaccharide isbetween 1 and 15. In a preferred embodiment the degree of oxidation of the activated serotype 209V polysaccharide is between 4 and 9 when the carrier protein is CRM 197. See Table 1 ofWO2019/152921.In an embodiment the degree of oxidation of the activated serotype 10A polysaccharide isbetween 1 and 15. In a preferred embodiment the degree of oxidation of the activated serotype10A polysaccharide is between 1 and 12 when the carrier protein is CRM 197. See Table 1 of 25WO2019/152921.In an embodiment the degree of oxidation of the activated serotype 11A polysaccharide isbetween 1 and 20. In a preferred embodiment the degree of oxidation of the activated serotype11A polysaccharide is between 1 and 15 when the carrier protein is CRM 197. See Table 1 ofWO2019/152921. 30In an embodiment the degree of oxidation of the activated serotype 12F polysaccharide isbetween 1 and 15. In a preferred embodiment the degree of oxidation of the activated serotype12F polysaccharide is between 1 and 9 when the carrier protein is CRM 197. See Table 1 ofWO2019/152921.In an embodiment the degree of oxidation of the activated serotype 14 polysaccharide is 35between 1 and 20. In a preferred embodiment the degree of oxidation of the activated serotypepolysaccharide is between 6 and 13 when the carrier protein is CRM 197. See Table 1 ofWO2019/152921. 78In an embodiment the degree of oxidation of the activated serotype 15B polysaccharide isbetween 1 and 20. In a preferred embodiment the degree of oxidation of the activated serotype15B polysaccharide is between 1 and 17 when the carrier protein is CRM 197. See Table 1 ofWO2019/152921.In an embodiment the degree of oxidation of the activated serotype 15B polysaccharide is 5between 1 and 15 when the carrier protein is TT. See Table 2 of WO2019/152925.In an embodiment the degree of oxidation of the activated serotype 18C polysaccharideis between 1 and 20. In a preferred embodiment the degree of oxidation of the activated serotype18C polysaccharide is between 6 and 14 when the carrier protein is CRM 197. See Table 1 ofWO2019/152921. 10In an embodiment the degree of oxidation of the activated serotype 19A polysaccharide isbetween 1 and 20. In a preferred embodiment the degree of oxidation of the activated serotype19A polysaccharide is between 7 and 13 when the carrier protein is CRM 197. See Table 1 ofWO2019/152921.In an embodiment the degree of oxidation of the activated serotype 19F polysaccharide is 15between 1 and 20. In a preferred embodiment the degree of oxidation of the activated serotype19F polysaccharide is between 6 and 12 when the carrier protein is CRM 197. See Table 1 ofWO2019/152921.In an embodiment the degree of oxidation of the activated serotype 22F polysaccharide isbetween 1 and 20. In a preferred embodiment the degree of oxidation of the activated serotype 2022F polysaccharide is between 1 and 16 when the carrier protein is CRM 197. See Table 1 ofWO2019/152921.In an embodiment the degree of oxidation of the activated serotype 22F polysaccharide isbetween 1 and 20 when the carrier protein is TT. See Table 2 of WO2019/152925.In an embodiment the degree of oxidation of the activated serotype 23F polysaccharide is 25between 1 and 20. In a preferred embodiment the degree of oxidation of the activated serotype23F polysaccharide is between 6 and 14 when the carrier protein is CRM 197. See Table 1 ofWO2019/152921.In an embodiment the degree of oxidation of the activated serotype 33F polysaccharide isbetween 1 and 20. In a preferred embodiment the degree of oxidation of the activated serotype 3033F polysaccharide is between 1 and 15 when the carrier protein is CRM 197. See Table 1 ofWO2019/152921.The activated polysaccharide and the carrier protein may be Iyophilised (freeze-dried),either independently (discrete lyophilization) or together (co-lyophilized). In one embodiment theactivated polysaccharide and the carrier protein are co-Iyophilized. In another embodiment the 35activated polysaccharide and the carrier protein are Iyophilized independently. 79In one embodiment the Iyophilization takes place in the presence of a non-reducing sugar,possible non-reducing sugars include sucrose, trehalose, raffinose, stachyose, melezitose,dextran, mannitol, lactitol and palatinit.In an embodiment the initial input ratio (weight by weight) of activated serotype 1, 4, 5, 6A,6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and/or 33F capsular 5polysaccharide to carrier protein at step b) is between 4:1 and 0.1:1. In an embodiment the initialinput ratio (weight by weight) of activated serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23F and/or 33F capsular polysaccharide to carrier protein is between1.5:1 and 0.5:1.In an embodiment, the reduction reaction (c) is carried out in aprotic solvent. In one 10embodiment the reduction reaction (c) is carried out in a solution consisting essentially ofdimethylsulphoxide (DMSO). In an embodiment, the reduction reaction (c) is carried out in DMSO(dimethylsulfoxide) solvent.In an embodiment, the reduction reaction (c) is carried out in aqueous solvent.In an embodiment, the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide) 15solvent for serotypes 6A, 6B, 7F, 8, 10A,15B, 19A, 19F, 22F and 23F and the reduction reaction(c) is carried out in aqueous solvent for serotypes 1, 4, 5, 9V, 11A, 12F, 14 and 18C.In an embodiment, the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide)solvent for serotypes 6A, 6B, 7F, 8, 10A,15B, 19A, 19F, 22F and 23F and the reduction reaction(c) is carried out in aqueous solvent for serotypes 1, 4, 5, 9V, 11A, 12F, 14, 18C and 33F. 20In an embodiment, the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide)solvent for serotypes 6A, 6B, 7F, 18C, 19A, 19F and 23F and the reduction reaction (c) is carriedout in aqueous solvent for serotypes 1, 4, 5, 9V, 14, 22F and 33F.In an embodiment, the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide)solvent for serotypes 6A, 6B, 7F, 11A, 12F, 19A, 19F and 23F and the reduction reaction (c) is 25carried out in aqueous solvent for serotypes 1, 4, 5, 8, 9V, 10A,14, 15B, 18C, 22F and 33F.In an embodiment, the reducing agent is sodium cyanoborohydride, sodiumtriacetoxyborohydride, sodium or zinc borohydride in the presence of Bronsted or Lewis acids,amine boranes such as pyridine borane, 2-Picoline Borane, 2,6-diborane-methanol,dimethylamine-borane, t-BuMeiPrN-BH3, benzylamine-BH3 or 5-ethyl-2-methylpyridine borane 30(PEMB). In an embodiment, the reducing agent is sodium triacetoxyborohydride. In a preferredembodiment, the reducing agent is sodium cyanoborohydride. In an embodiment, the reducingagent is sodium cyanoborohydride in the present of nickel (see WO2018144439).In one embodiment between 0.2 and 10 molar equivalents of reducing agent is used instep c). Preferably, between 0.5 and 5 molar equivalents of reducing agent is used in step c). 35At the end of the reduction reaction, there may be unreacted aldehyde groups remainingin the conjugates, these may be capped using a suitable capping agent. In one embodiment thiscapping agent is sodium borohydride (NaBH4). 80In an embodiment capping is achieved by mixing the product of step c) with 1 to 20 molarequivalents of sodium borohydride. In an embodiment capping is achieved by mixing the productof step c) with 1 to 3 molar equivalents of sodium borohydride.Following conjugation to the carrier protein, the serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A,11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and/or 33F glycoconjugate can be purified (enriched 5with respect to the amount of saccharide-protein conjugate) by a variety of techniques known tothe skilled person. These techniques include dialysis, concentration/diafiltration operations,tangential flow filtration precipitation/elution, column chromatography (DEAE or hydrophobicinteraction chromatography), and depth filtration. Therefore, in one embodiment the process forproducing the serotype 1 glycoconjugate of the present invention comprises the step of purifying 10the glycoconjugate after it is produced.In certain embodiments, the serotype 33F glycoconjugates of the invention are preparedusing reductive amination.In other embodiments, the serotype 33F glycoconjugates of the invention are preparedusing eTEC conjugation (herinafter "serotype 33F eTEC linked glycoconjugates"), such as 15described in WO 2014/027302 or WO2015110941 (see Examples 1, 2 and 3). Said 33Fglycoconjugates comprise a saccharide covalently conjugated to a carrier protein through one ormore eTEC spacers, wherein the saccharide is covalently conjugated to the eTEC spacer througha carbamate linkage, and wherein the carrier protein is covalently conjugated to the eTEC spacerthrough an amide linkage. The eTEC linked glycoconjugates of the invention may be represented 20by the general formula (III): (III)wherein the atoms that comprise the eTEC spacer are contained in the central box.The eTEC spacer includes seven linear atoms (i.e., –C(O)NH(CH2)2SCH 2C(O)- ) and providesstable thioether and amide bonds between the saccharide and carrier protein. Synthesis of the 25eTEC linked glycoconjugate involves reaction of an activated hydroxyl group of the saccharidewith the amino group of a thioalkylamine reagent, e.g., cystamine or cysteinamine or a saltthereof, forming a carbamate linkage to the saccharide to provide a thiolated saccharide.Generation of one or more free sulfhydryl groups is accomplished by reaction with a reducingagent to provide an activated thiolated saccharide. Reaction of the free sulfhydryl groups of the 30activated thiolated saccharide with an activated carrier protein having one or more α-haloacetamide groups on amine containing residues generates a thioether bond to form theconjugate, wherein the carrier protein is attached to the eTEC spacer through an amide bond.In the serotype 33F eTEC linked glycoconjugates of the invention, the saccharide may bea polysaccharide or an oligosaccharide. The carrier protein may be selected from any suitable 35carrier as described herein or known to those of skill in the art. Preferably, the saccharide is a 81polysaccharide. In some such embodiments, the carrier protein is CRM 197. In some suchembodiments, the eTEC linked glycoconjugate comprises a S. pneumoniae serotype 33Fcapsular polysaccharide.In particularly preferred embodiments, the eTEC linked glycoconjugate comprises a Pn-33F capsular polysaccharide, which is covalently conjugated to CRM 197 through an eTEC spacer 5(serotype 33F eTEC linked glycoconjugates).In an embodiment, the serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C,19A, 19F, 22F and 23F glycoconjugates of the invention are prepared using reductive aminationchemistry and the serotype 33F glycoconjugate of the invention is prepared using eTECconjugation. 10 1.8 Carrier protein of the invention A component of the glycoconjugate of the invention is a carrier protein to which thesaccharide is conjugated. The terms "protein carrier" or "carrier protein" or "carrier" may be usedinterchangeably herein. Carrier proteins should be amenable to standard conjugation procedures. 15A capsular saccharide can be conjugated to a carrier protein via covalent or non-covalent bonds.In an embodiment, the capsular saccharide is conjugated to a carrier protein via non-covalentbonds (such as the rhizavidin/biotin system, see e.g. WO2012155007, WO2020056202).Preferably, the capsular saccharide is conjugated via covalent bonds.In an embodiment, the carrier protein of the glycoconjugate of the invention is: DT 20(Diphtheria Toxoid), TT (Tetanus Toxoid) or fragment C of TT, CRM 197 (a nontoxic butantigenically identical variant of diphtheria toxin), other DT mutants (such as CRM 176, CRM 228,CRM 45 (Uchida et al. (1973) J. Biol. Chem. 218:3838-3844), CRM 9, CRM 102, CRM 103 or CRM 107;and other mutations described by Nicholls and Youle in Genetically Engineered Toxins, Ed:Frankel, Maecel Dekker Inc. (1992); deletion or mutation of Glu-148 to Asp, Gln or Ser and/or Ala 25158 to GIy and other mutations disclosed in U.S. Patent Nos. 4,709,017 and 4,950,740; mutationof at least one or more residues Lys 516, Lys 526, Phe 530 and/or Lys 534 and other mutationsdisclosed in U.S. Patent Nos. 5,917,017 and 6,455,673; or fragment disclosed in U.S. Patent No.5,843,711, pneumococcal pneumolysin (ply) (Kuo et al. (1995) Infect lmmun 63:2706-2713)including ply detoxified in some fashion, for example dPLY-GMBS (WO 2004/081515, WO 302006/032499) or dPLY-formol, PhtX, including PhtA, PhtB, PhtD, PhtE (sequences of PhtA, PhtB,PhtD or PhtE are disclosed in WO 00/37105 and WO 00/39299) and fusions of Pht proteins, forexample PhtDE fusions, PhtBE fusions, Pht A-E (WO 01/98334, WO 03/054007, WO2009/000826), OMPC (meningococcal outer membrane protein), which is usually extracted fromNeisseria meningitidis serogroup B (EP0372501), PorB (from N. meningitidis), PD (Haemophilus 35influenzae protein D; see, e.g., EP0594610 B), or immunologically functional equivalents thereof,synthetic peptides (EP0378881, EP0427347), heat shock proteins (WO 93/17712, WO94/03208), pertussis proteins (WO 98/58668, EP0471177), cytokines, lymphokines, growth 82factors or hormones (WO 91/01146), artificial proteins comprising multiple human CD4+ T cellepitopes from various pathogen derived antigens (Falugi et al. (2001) Eur J Immunol 31:3816-3824) such as N19 protein (Baraldoi et al. (2004) Infect lmmun 72:4884-4887) pneumococcalsurface protein PspA (WO 02/091998), iron uptake proteins (WO 01/72337), toxin A or B ofClostridium difficile (WO 00/61761), transferrin binding proteins, pneumococcal adhesion protein 5(PsaA) or recombinant Pseudomonas aeruginosa exotoxin A (in particular non-toxic mutantsthereof (such as exotoxin A bearing a substution at glutamic acid 553 (Douglas et al. (1987) J.Bacteriol. 169(11):4967-4971)). Other proteins, such as ovalbumin, keyhole limpet hemocyanin(KLH), bovine serum albumin (BSA) or purified protein derivative of tuberculin (PPD) also can beused as carrier proteins. Other suitable carrier proteins include inactivated bacterial toxins such 10as cholera toxoid (e.g., as described in WO 2004/083251), Escherichia coli LT, E. coli ST, andexotoxin A from P. aeruginosa. Another suitable carrier protein is a C5a peptidase fromStreptococcus (SCP).In an embodiment, the carrier protein of the glycoconjugates of the invention is the fusionprotein CP1. The CP1 fusion protein comprises a biotin-binding protein such as, e.g ., a truncated 15rhizavidin protein (e.g, amino acids 45-179 of a wild-type rhizavidin protein), a first linker (e.g, aGGGGSSS linker), a SP1500 polypeptide (e.g., amino acids 27-278 of a full-length S.pneumoniaeSP1500 polypeptide), a second linker (e.g, the amino acid sequence AAA), and a SP0785polypeptide (e.g, amino acids 33-399 of a full length S. pneumoniae SP0785 polypeptide) seee.g. WO2020056202. 20In another embodiment, the carrier protein of the glycoconjugate of the invention is PD (H.influenzae protein D; see, e.g., EP0594610 B).Preferably, the carrier protein of the glycoconjugates of the invention is DT, TT, CRM 197 ora C5a peptidase from Streptococcus (SCP).In an embodiment, the carrier protein of the glycoconjugate of the invention is DT 25(Diphtheria toxoid).In another embodiment, the carrier protein of the glycoconjugate of the invention is TT(tetanus toxoid).In a preferred embodiment, the carrier protein of the glycoconjugate of the invention isCRM 197 or a C5a peptidase from Streptococcus (SCP). 30In a preferred embodiment, the carrier protein of the glycoconjugate of the invention isCRM 197. The CRM 197 protein is a nontoxic form of diphtheria toxin but is immunologicallyindistinguishable from the diphtheria toxin. CRM 197 is produced by Corynebacterium diphtheriaeinfected by the nontoxigenic phage β197tox-created by nitrosoguanidine mutagenesis of thetoxigenic corynephage beta (Uchida et al. (1971) Nature New Biology 233:8-11). The CRM 197 35protein has the same molecular weight as the diphtheria toxin but differs therefrom by a singlebase change (guanine to adenine) in the structural gene. This single base change causes anamino acid substitution (glutamic acid for glycine) in the mature protein and eliminates the toxic 83properties of diphtheria toxin. The CRM 197 protein is a safe and effective T-cell dependent carrierfor saccharides. Further details about CRM 197 and production thereof can be found, e.g., in U.S.Patent No. 5,614,382.In an embodiment, the carrier protein of the glycoconjugate of the invention is the A chainof CRM 197 (see CN103495161). In an embodiment, the carrier protein of the glycoconjugate of 5the invention is the A chain of CRM 197 obtained via expression by genetically recombinant E. coli(see CN103495161).In other preferred embodiments, the carrier protein of the glycoconjugate of the inventionis SCP (Streptococcal C5a Peptidase). Two important species of β-hemolytic streptococci,Streptococcus pyogenes (group A Streptococcus, GAS) and Streptococcus agalactiae (group B 10Streptococcus, GBS), which cause a variety of serious human infections that range from mildcases of pharyngitis and impetigo to serious invasive diseases such as necrotizing fasciitis (GAS)and neonatal sepsis (GBS) have developed a way to defeat this immune response. All humanisolates of β-hemolytic streptococci, including GAS and GBS, produce a highly conserved cell-wall protein SCP (Streptococcal C5a Peptidase) that specifically inactivates C5a. The scp genes 15from GAS and GBS encode a polypeptide containing between 1,134 and 1,181 amino acids(Brown et al., PNAS, 2005, vol. 102, no. 51 pages 18391–18396). The first 31 residues are theexport signal presequence and are removed upon passing through the cytoplasmic membrane.The next 68 residues serve as a pro-sequence and must be removed to produce active SCP. Thenext 10 residues can be removed without loss of protease activity. At the other end, starting with 20Lys-1034, are four consecutive 17-residue motifs followed by a cell sorting and cell-wallattachment signal. This combined signal is composed of a 20-residue hydrophilic sequencecontaining an LPTTND sequence, a 17-residue hydrophobic sequence, and a short basiccarboxyl terminus.SCP can be divided in domains (see figure 1B of Brown et al., PNAS, 2005, vol. 102, no. 25pages 18391–18396). These domains are the Pre/Pro domain (which comprises the exportsignal presequence (commonly the first 31 residues) and the pro-sequence (commonly the nextresidues)), the protease domain (which is splitted in two part (protease part 1 commonlyresidues 89–333/334 and protease domain part 2 and commonly residues 467/468–583/584),the protease-associated domain (PA domain) (commonly residues 333/334–467/468), three 30fibronectin type III (Fn) domains (Fn1, commonly residues 583/584–712/713; Fn2, commonlyresidues 712/713–928/929/930; commonly Fn3, residues 929/930-1029/1030/1031) and a cellwall anchor domain (commonly redisues 1029/1030/1031 to the C-terminus).In an embodiment, the carrier protein of the glycoconjugate of the invention is an SCPfrom GBS (SCPB). An exemple of SCPB is provided at SEQ ID.NO: 3 of WO97/26008. See also 35SEQ ID NO: 3 of WO00/34487. 84In another preferred embodiments, the carrier protein of the glycoconjugate of theinvention is an SCP from GAS (SCPA). Examples of SCPA can be found at SEQ ID.No.1 andSEQ ID.No.2 of WO97/26008. See also SEQ ID NO: 1, 2 and 23 of WO00/34487.In a preferred embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive SCP. 5In other preferred embodiments, the carrier protein of the glycoconjugate of the inventionis an enzymatically inactive SCP from GBS (SCPB).In another preferred embodiments, the carrier protein of the glycoconjugate of theinvention is an enzymatically inactive SCP from GAS (SCPA).In an embodiment, the carrier protein of the glycoconjugate of the invention is a fragment 10of an SCP. In an embodiment, the carrier protein of the glycoconjugate of the invention is afragment of an SCPA. Preferably, the carrier protein of the glycoconjugate of the invention is afragment of an SCPB.In an embodiment, the carrier protein of the glycoconjugate of the invention is a fragmentof an SCP which comprises the protease domain, the protease-associated domain (PA domain) 15and the three fibronectin type III (Fn) domains but does not comprise the export signalpresequence, the pro-sequence and the cell wall anchor domain.In an embodiment, the carrier protein of the glycoconjugate of the invention is a fragmentof an SCP which comprises the protease domain, the protease-associated domain (PA domain)and the three fibronectin type III (Fn) domains but does not comprise the export signal 20presequence, the pro-sequence and the cell wall anchor domain.In an embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of an SCP which comprises the protease domain, the protease-associated domain (PA domain) and two of the three fibronectin type III (Fn) domains but doesnot comprise the export signal presequence, the pro-sequence and the cell wall anchor domain. 25In an embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of an SCP. In an embodiment, said enzymatically inactivefragment of SCP comprises the protease domain, the protease-associated domain (PA domain)and the three fibronectin type III (Fn) domains but does not comprise the export signalpresequence, the pro-sequence and the cell wall anchor domain. 30In an embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of an SCPA. In an embodiment, said enzymatically inactivefragment of an SCPA comprises the protease domain, the protease-associated domain (PAdomain) and the three fibronectin type III (Fn) domains but does not comprise the export signalpresequence, the pro-sequence and the cell wall anchor domain. 35In a preferred embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of SCPB. Preferably, said enzymatically inactive fragment ofSCPB comprises the protease domain, the protease-associated domain (PA domain) and the 85three fibronectin type III (Fn) domains but does not comprise the export signal presequence, thepro-sequence and the cell wall anchor domain.In an embodiment, the enzymatic activity of SCP is inactivated by replacing at least oneamino acid of the wild type sequence. In an embodiment, said replacement is selected from thegroup consisting of D130A, H193A, N295A and S512A. The numbers indicate the amino acid 5residue position in the peptidase according to the numbering of SEQ ID NO: 1 of WO00/34487.Therefore, in an embodiment, the carrier protein of the glycoconjugate of the invention isan enzymatically inactive SCP where said inactivation is accomplished by replacing at least oneamino acid of the wild type sequence. Preferably, said replacement of at least one amino acid isin the protease domain. In an embodiment, said replacement of at least one amino acid is in part 10of the protease domain. In an embodiment, said replacement of at least one amino acid is inpart 2 of the protease domain. In an embodiment, said replacement is selected from the groupconsisting of D130A, H193A, N295A and S512A. In an embodiment, said replacement is D130A.In another embodiment, said replacement is H193A. In another embodiment, said replacement isN295A. In yet another embodiment, said replacement is S512A. 15In an embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive SCPA where said inactivation is accomplished by replacing at least oneamino acid of the wild type sequence. Preferably, said replacement of at least one amino acid isin the protease domain. In an embodiment, said replacement of at least one amino acid is in partof the protease domain. In an embodiment, said replacement of at least one amino acid is in 20part 2 of the protease domain. In an embodiment, said replacement is selected from the groupconsisting of D130A, H193A, N295A and S512A. In an embodiment, said replacement is D130A.In another embodiment, said replacement is H193A. In another embodiment, said replacement isN295A. In yet another embodiment, said replacement is S512A.In an embodiment, the carrier protein of the glycoconjugate of the invention is an 25enzymatically inactive SCPB where said inactivation is accomplished by replacing at least oneamino acid of the wild type sequence. Preferably, said replacement of at least one amino acid isin the protease domain. In an embodiment, said replacement of at least one amino acid is in partof the protease domain. In an embodiment, said replacement of at least one amino acid is inpart 2 of the protease domain. In an embodiment, said replacement is selected from the group 30consisting of D130A, H193A, N295A and S512A. In an embodiment, said replacement is D130A.In another embodiment, said replacement is H193A. In another embodiment, said replacement isN295A. In yet another embodiment, said replacement is S512A.In an embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of an SCP where said inactivation is accomplished by replacing 35at least one amino acid of the wild type sequence. Preferably, said replacement of at least oneamino acid is in the protease domain. In an embodiment, said replacement of at least one aminoacid is in part 1 of the protease domain. In an embodiment, said replacement of at least one amino 86acid is in part 2 of the protease domain. In an embodiment, said replacement is selected from thegroup consisting of D130A, H193A, N295A and S512A. In an embodiment, said replacement isD130A. In another embodiment, said replacement is H193A. In another embodiment, saidreplacement is N295A. In yet another embodiment, said replacement is S512A.In an embodiment, the carrier protein of the glycoconjugate of the invention is an 5enzymatically inactive fragment of SCP which comprises the protease domain, the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains but does notcomprise the export signal presequence, the pro-sequence and the cell wall anchor domain,where said inactivation is accomplished by replacing at least one amino acid of the wild typesequence. Preferably, said replacement of at least one amino acid is in the protease domain. In 10an embodiment, said replacement of at least one amino acid is in part 1 of the protease domain.In an embodiment, said replacement of at least one amino acid is in part 2 of the protease domain.In an embodiment, said replacement is selected from the group consisting of D130A, H193A,N295A and S512A. In an embodiment, said replacement is D130A. In another embodiment, saidreplacement is H193A. In another embodiment, said replacement is N295A. In yet another 15embodiment, said replacement is S512A.In an embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of SCPA which comprises the protease domain, the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains but does notcomprise the export signal presequence, the pro-sequence and the cell wall anchor domain, 20where said inactivation is accomplished by replacing at least one amino acid of the wild typesequence. Preferably, said replacement of at least one amino acid is in the protease domain. Inan embodiment, said replacement of at least one amino acid is in part 1 of the protease domain.In an embodiment, said replacement of at least one amino acid is in part 2 of the protease domain.In an embodiment, said replacement is selected from the group consisting of D130A, H193A, 25N295A and S512A. In an embodiment, said replacement is D130A. In another embodiment, saidreplacement is H193A. In another embodiment, said replacement is N295A. In yet anotherembodiment, said replacement is S512A.In an embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of SCPB which comprises the protease domain, the protease- 30associated domain (PA domain) and the three fibronectin type III (Fn) domains but does notcomprise the export signal presequence, the pro-sequence and the cell wall anchor domain,where said inactivation is accomplished by replacing at least one amino acid of the wild typesequence. Preferably, said replacement of at least one amino acid is in the protease domain. Inan embodiment, said replacement of at least one amino acid is in part 1 of the protease domain. 35In an embodiment, said replacement of at least one amino acid is in part 2 of the protease domain.In an embodiment, said replacement is selected from the group consisting of D130A, H193A,N295A and S512A. In an embodiment, said replacement is D130A. In another embodiment, said 87replacement is H193A. In another embodiment, said replacement is N295A. In yet anotherembodiment, said replacement is S512A.In an embodiment, the enzymatic activity of SCP is inactivated by replacing at least twoamino acids of the wild type sequence. In an embodiment, said at least two amino acidsreplacements are selected from the group consisting of D130A, H193A, N295A and S512A. In an 5embodiment, said at least two amino acids replacements are D130A and H193A. In anembodiment, said at least two amino acids replacements are D130A and N295A. In anembodiment, said at least two amino acids replacements are D130A and S512A. In anembodiment, said at least two amino acids replacements are H193A and N295A. In anembodiment, said at least two amino acids replacements are H193A and S512A. In an 10embodiment, said at least two amino acids replacements are N295A and S512A.Therefore, in an embodiment, the carrier protein of the glycoconjugate of the invention isan enzymatically inactive SCP where said inactivation is accomplished by replacing at least twoamino acids of the wild type sequence. Preferably, said replacement of at least two amino acidsis in the protease domain. In an embodiment, said replacement of at least two amino acid is in 15part 1 of the protease domain. In an embodiment, said replacement of at least two amino acid isin part 2 of the protease domain. In an embodiment, said at least two amino acids replacementsare selected from the group consisting of D130A, H193A, N295A and S512A. In an embodiment,said at least two amino acids replacements are D130A and H193A. In an embodiment, said atleast two amino acids replacements are D130A and N295A. Preferably, said at least two amino 20acids replacements are D130A and S512A. In an embodiment, said at least two amino acidsreplacements are H193A and N295A. In an embodiment, said at least two amino acidsreplacements are H193A and S512A. In an embodiment, said at least two amino acidsreplacements are N295A and S512A.In an embodiment, the carrier protein of the glycoconjugate of the invention is an 25enzymatically inactive SCPA where said inactivation is accomplished by replacing at least twoamino acids of the wild type sequence. Preferably, said replacement of at least two amino acidsis in the protease domain. In an embodiment, said replacement of at least two amino acids is inpart 1 of the protease domain. In an embodiment, said replacement of at least two amino acid isin part 2 of the protease domain. In an embodiment, said at least two amino acids replacements 30are selected from the group consisting of D130A, H193A, N295A and S512A. In an embodiment,said at least two amino acids replacements are D130A and H193A. In an embodiment, said atleast two amino acids replacements are D130A and N295A. Preferably, said at least two aminoacids replacements are D130A and S512A. In an embodiment, said at least two amino acidsreplacements are H193A and N295A. In an embodiment, said at least two amino acids 35replacements are H193A and S512A. In an embodiment, said at least two amino acidsreplacements are N295A and S512A. 88In an embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive SCPB where said inactivation is accomplished by replacing at least twoamino acids of the wild type sequence. Preferably, said replacement of at least two amino acidsis in the protease domain. In an embodiment, said replacement of at least two amino acids is inpart 1 of the protease domain. In an embodiment, said replacement of at least two amino acid is 5in part 2 of the protease domain. In an embodiment, said at least two amino acids replacementsare selected from the group consisting of D130A, H193A, N295A and S512A. In an embodiment,said at least two amino acids replacements are D130A and H193A. In an embodiment, said atleast two amino acids replacements are D130A and N295A. Preferably, said at least two aminoacids replacements are D130A and S512A. In an embodiment, said at least two amino acids 10replacements are H193A and N295A. In an embodiment, said at least two amino acidsreplacements are H193A and S512A. In an embodiment, said at least two amino acidsreplacements are N295A and S512A.In an embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of an SCP where said inactivation is accomplished by replacing 15at least two amino acids of the wild type sequence. Preferably, said replacement of at least twoamino acids is in the protease domain. In an embodiment, said replacement of at least two aminoacids is in part 1 of the protease domain. In an embodiment, said replacement of at least twoamino acid is in part 2 of the protease domain. In an embodiment, said at least two amino acidsreplacements are selected from the group consisting of D130A, H193A, N295A and S512A. In an 20embodiment, said at least two amino acids replacements are D130A and H193A. In anembodiment, said at least two amino acids replacements are D130A and N295A. Preferably, saidat least two amino acids replacements are D130A and S512A. In an embodiment, said at leasttwo amino acids replacements are H193A and N295A. In an embodiment, said at least two aminoacids replacements are H193A and S512A. In an embodiment, said at least two amino acids 25replacements are N295A and S512A.In an embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of SCP which comprises the protease domain, the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains but does notcomprise the export signal presequence, the pro-sequence and the cell wall anchor domain, 30where said inactivation is accomplished by replacing at least two amino acids of the wild typesequence. Preferably, said replacement of at least two amino acids is in the protease domain. Inan embodiment, said replacement of at least two amino acids is in part 1 of the protease domain.In an embodiment, said replacement of at least two amino acid is in part 2 of the protease domain.In an embodiment, said at least two amino acids replacements are selected from the group 35consisting of D130A, H193A, N295A and S512A. In an embodiment, said at least two amino acidsreplacements are D130A and H193A. In an embodiment, said at least two amino acidsreplacements are D130A and N295A. Preferably, said at least two amino acids replacements are 89D130A and S512A. In an embodiment, said at least two amino acids replacements are H193Aand N295A. In an embodiment, said at least two amino acids replacements are H193A andS512A. In an embodiment, said at least two amino acids replacements are N295A and S512A.In an embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of SCPA which comprises the protease domain, the protease- 5associated domain (PA domain) and the three fibronectin type III (Fn) domains but does notcomprise the export signal presequence, the pro-sequence and the cell wall anchor domain,where said inactivation is accomplished by replacing at least two amino acids of the wild typesequence. Preferably, said replacement of at least two amino acids is in the protease domain. Inan embodiment, said replacement of at least two amino acids is in part 1 of the protease domain. 10In an embodiment, said replacement of at least one amino acids is in part 2 of the proteasedomain. In an embodiment, said at least two amino acids replacements are selected from thegroup consisting of D130A, H193A, N295A and S512A. In an embodiment, said at least two aminoacids replacements are D130A and H193A. In an embodiment, said at least two amino acidsreplacements are D130A and N295A. Preferably, said at least two amino acids replacements are 15D130A and S512A. In an embodiment, said at least two amino acids replacements are H193Aand N295A. In an embodiment, said at least two amino acids replacements are H193A andS512A. In an embodiment, said at least two amino acids replacements are N295A and S512A.In an embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of SCPB which comprises the protease domain, the protease- 20associated domain (PA domain) and the three fibronectin type III (Fn) domains but does notcomprise the export signal presequence, the pro-sequence and the cell wall anchor domain,where said inactivation is accomplished by replacing at least two amino acids of the wild typesequence. Preferably, said replacement of at least two amino acids is in the protease domain. Inan embodiment, said replacement of at least two amino acids is in part 1 of the protease domain. 25In an embodiment, said replacement of at least two amino acids is in part 2 of the proteasedomain. In an embodiment, said at least two amino acids replacements are selected from thegroup consisting of D130A, H193A, N295A and S512A. In an embodiment, said at least two aminoacids replacements are D130A and H193A. In an embodiment, said at least two amino acidsreplacements are D130A and N295A. Preferably, said at least two amino acids replacements are 30D130A and S512A. In an embodiment, said at least two amino acids replacements are H193Aand N295A. In an embodiment, said at least two amino acids replacements are H193A andS512A. In an embodiment, said at least two amino acids replacements are N295A and S512A.In an embodiment, the enzymatic activity of SCP is inactivated by replacing at least threeamino acids of the wild type sequence. In an embodiment, said at least three amino acids 35replacements are selected from the group consisting of D130A, H193A, N295A and S512A. In anembodiment, said at least three amino acids replacements are D130A, H193A and N295A. In anembodiment, said at least three amino acids replacements are D130A, H193A and S512A. In an 90embodiment, said at least three amino acids replacements are D130A, N295A and S512A. In anembodiment, said at least three amino acids replacements are H193A, N295A and S512A.Therefore, in an embodiment, the carrier protein of the glycoconjugate of the invention isan enzymatically inactive SCP where said inactivation is accomplished by replacing at least threeamino acids of the wild type sequence. Preferably, said replacement of at least three amino acids 5is in the protease domain. In an embodiment, said replacement of at least three amino acid is inpart 1 of the protease domain. In an embodiment, said replacement of at least three amino acidis in part 2 of the protease domain. In an embodiment, said at least three amino acidsreplacements are selected from the group consisting of D130A, H193A, N295A and S512A. In anembodiment, said at least three amino acids replacements are D130A, H193A and N295A. In an 10embodiment, said at least three amino acids replacements are D130A, H193A and S512A. In anembodiment, said at least three amino acids replacements are D130A, N295A and S512A. In anembodiment, said at least three amino acids replacements are H193A, N295A and S512A.In an embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive SCPA where said inactivation is accomplished by replacing at least three 15amino acids of the wild type sequence. Preferably, said replacement of at least three amino acidsis in the protease domain. In an embodiment, said replacement of at least three amino acids is inpart 1 of the protease domain. In an embodiment, said replacement of at least three amino acidis in part 2 of the protease domain. In an embodiment, said at least three amino acidsreplacements are selected from the group consisting of D130A, H193A, N295A and S512A. In an 20embodiment, said at least three amino acids replacements are D130A, H193A and N295A. In anembodiment, said at least three amino acids replacements are D130A, H193A and S512A. In anembodiment, said at least three amino acids replacements are D130A, N295A and S512A. In anembodiment, said at least three amino acids replacements are H193A, N295A and S512A.In an embodiment, the carrier protein of the glycoconjugate of the invention is an 25enzymatically inactive SCPB where said inactivation is accomplished by replacing at least threeamino acids of the wild type sequence. Preferably, said replacement of at least three amino acidsis in the protease domain. In an embodiment, said replacement of at least three amino acids is inpart 1 of the protease domain. In an embodiment, said replacement of at least three amino acidis in part 2 of the protease domain. In an embodiment, said at least three amino acids 30replacements are selected from the group consisting of D130A, H193A, N295A and S512A. In anembodiment, said at least three amino acids replacements are D130A, H193A and N295A. In anembodiment, said at least three amino acids replacements are D130A, H193A and S512A. In anembodiment, said at least three amino acids replacements are D130A, N295A and S512A. In anembodiment, said at least three amino acids replacements are H193A, N295A and S512A. 35In an embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of an SCP where said inactivation is accomplished by replacingat least three amino acids of the wild type sequence. Preferably, said replacement of at least 91three amino acids is in the protease domain. In an embodiment, said replacement of at least threeamino acids is in part 1 of the protease domain. In an embodiment, said replacement of at leastthree amino acid is in part 2 of the protease domain. In an embodiment, said at least three aminoacids replacements are selected from the group consisting of D130A, H193A, N295A and S512A.In an embodiment, said at least three amino acids replacements are D130A, H193A and N295A. 5In an embodiment, said at least three amino acids replacements are D130A, H193A and S512A.In an embodiment, said at least three amino acids replacements are D130A, N295A and S512A.In an embodiment, said at least three amino acids replacements are H193A, N295A and S512A.In an embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of SCP which comprises the protease domain, the protease- 10associated domain (PA domain) and the three fibronectin type III (Fn) domains but does notcomprise the export signal presequence, the pro-sequence and the cell wall anchor domain,where said inactivation is accomplished by replacing at least three amino acids of the wild typesequence. Preferably, said replacement of at least three amino acids is in the protease domain.In an embodiment, said replacement of at least three amino acids is in part 1 of the protease 15domain. In an embodiment, said replacement of at least three amino acid is in part 2 of theprotease domain. In an embodiment, said at least three amino acids replacements are selectedfrom the group consisting of D130A, H193A, N295A and S512A. In an embodiment, said at leastthree amino acids replacements are D130A, H193A and N295A. In an embodiment, said at leastthree amino acids replacements are D130A, H193A and S512A. In an embodiment, said at least 20three amino acids replacements are D130A, N295A and S512A. In an embodiment, said at leastthree amino acids replacements are H193A, N295A and S512A.In an embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of SCPA which comprises the protease domain, the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains but does not 25comprise the export signal presequence, the pro-sequence and the cell wall anchor domain,where said inactivation is accomplished by replacing at least three amino acids of the wild typesequence. Preferably, said replacement of at least three amino acids is in the protease domain.In an embodiment, said replacement of at least three amino acids is in part 1 of the proteasedomain. In an embodiment, said replacement of at least three amino acids is in part 2 of the 30protease domain. In an embodiment, said at least three amino acids replacements are selectedfrom the group consisting of D130A, H193A, N295A and S512A. In an embodiment, said at leastthree amino acids replacements are D130A, H193A and N295A. In an embodiment, said at leastthree amino acids replacements are D130A, H193A and S512A. In an embodiment, said at leastthree amino acids replacements are D130A, N295A and S512A. In an embodiment, said at least 35three amino acids replacements are H193A, N295A and S512A.In an embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of SCPB which comprises the protease domain, the protease- 92associated domain (PA domain) and the three fibronectin type III (Fn) domains but does notcomprise the export signal presequence, the pro-sequence and the cell wall anchor domain,where said inactivation is accomplished by replacing at least three amino acids of the wild typesequence. Preferably, said replacement of at least three amino acids is in the protease domain.In an embodiment, said replacement of at least three amino acids is in part 1 of the protease 5domain. In an embodiment, said replacement of at least three amino acids is in part 2 of theprotease domain. In an embodiment, said at least three amino acids replacements are selectedfrom the group consisting of D130A, H193A, N295A and S512A. In an embodiment, said at leastthree amino acids replacements are D130A, H193A and N295A. In an embodiment, said at leastthree amino acids replacements are D130A, H193A and S512A. In an embodiment, said at least 10three amino acids replacements are D130A, N295A and S512A. In an embodiment, said at leastthree amino acids replacements are H193A, N295A and S512A.In an embodiment, the enzymatic activity of SCP is inactivated by replacing at least four aminoacids of the wild type sequence. In an embodiment, said at least four amino acids replacementsare D130A, H193A, N295A and S512A. 15Therefore, in an embodiment, the carrier protein of the glycoconjugate of the invention isan enzymatically inactive SCP where said inactivation is accomplished by replacing at least fouramino acids of the wild type sequence. Preferably, said replacement of at least four amino acidsis in the protease domain. In an embodiment, said replacement of at least four amino acid is inpart 1 of the protease domain. In an embodiment, said replacement of at least four amino acid is 20in part 2 of the protease domain. In an embodiment, said at least four amino acids replacementsare D130A, H193A, N295A and S512AIn an embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive SCPA where said inactivation is accomplished by replacing at least fouramino acids of the wild type sequence. Preferably, said replacement of at least four amino acids 25is in the protease domain. In an embodiment, said replacement of at least four amino acids is inpart 1 of the protease domain. In an embodiment, said replacement of at least four amino acid isin part 2 of the protease domain. In an embodiment, said at least four amino acids replacementsare D130A, H193A, N295A and S512AIn an embodiment, the carrier protein of the glycoconjugate of the invention is an 30enzymatically inactive SCPB where said inactivation is accomplished by replacing at least fouramino acids of the wild type sequence. Preferably, said replacement of at least four amino acidsis in the protease domain. In an embodiment, said replacement of at least four amino acids is inpart 1 of the protease domain. In an embodiment, said replacement of at least four amino acid isin part 2 of the protease domain. In an embodiment, said at least four amino acids replacements 35are D130A, H193A, N295A and S512AIn an embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of an SCP where said inactivation is accomplished by replacing 93at least four amino acids of the wild type sequence. Preferably, said replacement of at least fouramino acids is in the protease domain. In an embodiment, said replacement of at least four aminoacids is in part 1 of the protease domain. In an embodiment, said replacement of at least fouramino acid is in part 2 of the protease domain. In an embodiment, said at least four amino acidsreplacements are D130A, H193A, N295A and S512A 5In an embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of SCP which comprises the protease domain, the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains but does notcomprise the export signal presequence, the pro-sequence and the cell wall anchor domain,where said inactivation is accomplished by replacing at least four amino acids of the wild type 10sequence. Preferably, said replacement of at least four amino acids is in the protease domain. Inan embodiment, said replacement of at least four amino acids is in part 1 of the protease domain.In an embodiment, said replacement of at least four amino acid is in part 2 of the protease domain.In an embodiment, said at least four amino acids replacements are D130A, H193A, N295A andS512A 15In an embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of SCPA which comprises the protease domain, the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains but does notcomprise the export signal presequence, the pro-sequence and the cell wall anchor domain,where said inactivation is accomplished by replacing at least four amino acids of the wild type 20sequence. Preferably, said replacement of at least four amino acids is in the protease domain. Inan embodiment, said replacement of at least four amino acids is in part 1 of the protease domain.In an embodiment, said replacement of at least one amino acids is in part 2 of the proteasedomain. In an embodiment, said at least four amino acids replacements are D130A, H193A,N295A and S512A 25In an embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of SCPB which comprises the protease domain, the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains but does notcomprise the export signal presequence, the pro-sequence and the cell wall anchor domain,where said inactivation is accomplished by replacing at least four amino acids of the wild type 30sequence. Preferably, said replacement of at least four amino acids is in the protease domain. Inan embodiment, said replacement of at least four amino acids is in part 1 of the protease domain.In an embodiment, said replacement of at least four amino acids is in part 2 of the proteasedomain. In an embodiment, said at least four amino acids replacements are D130A, H193A,N295A and S512A 35In a particular embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of SCP which consists of SEQ ID NO: 1. 94In a particular embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of SCP which consists of SEQ ID NO: 2.
SEQ ID NO: 1 : MAKTADTPATSKATIRDLNDPSQVKTLQEKAGKGAGTVVAVIAAGFDKNH 5 EAWRLTDKAKARYQSKEDLEKAKKEHGITYGEWVNDKVAYYHDYSKDGKT AVDQEHGTHVSGILSGNAPSETKEPYRLEGAMPEAQLLLMRVEIVNGLAD YARNYAQAIRDAINLGAKVINMSFGNAALAYANLPDETKKAFDYAKSKGV SIVTSAGNDSSFGGKTRLPLADHPDYGVVGTPAAADSTLTVASYSPDKQL TETVTVKTADQQDKEMPVLSTNRFEPNKAYDYAYANRGTKEDDFKDVKGK 10 IALIERGDIDFKDKIAKAKKAGAVGVLIYDNQDKGFPIELPNVDQMPAAF ISRKDGLLLKDNPQKTITFNATPKVLPTASGTKLSRFSSWGLTADGNIKP DIAAPGQDILSSVANNKYAKLSGTAMSAPLVAGIMGLLQEQYETQYPDMT PSERLDLAKKVLMSSATALYDEDEKAYFSPRQQGAGAVDAKKASAATMYV TDKDNTSSKVHLNNVSDKFEVTVTVHNKSDKPQELYYQATVQTDKVDGKH 15 FALAPKALYETSWQKITIPANSSKQVTVPIDASRFSKDLLAQMKNGYFLE GFVRFKQDPKKEELMSIPYIGFRGDFGNLSALEKPIYDSKDGSSYYHEAN SDAKDQLDGDGLQFYALKNNFTALTTESNPWTIIKAVKEGVENIEDIESS EITETIFAGTFAKQDDDSHYYIHRHANGKPYAAISPNGDGNRDYVQFQGT FLRNAKNLVAEVLDKEGNVVWTSEVTEQVVKNYNNDLASTLGSTRFEKTR 20 WDGKDKDGKVVANGTYTYRVRYTPISSGAKEQHTDFDVIVDNTTPEVATS ATFSTEDRRLTLASKPKTSQPVYRERIAYTYMDEDLPTTEYISPNEDGTF TLPEEAETMEGATVPLKMSDFTYVVEDMAGNITYTPVTKLLEGHSNKPEQ SEQ ID NO: 1 is 950 amino acids long. 25 SEQ ID NO: 2 : AKTADTPATSKATIRDLNDPSQVKTLQEKAGKGAGTVVAVIAAGFDKNH EAWRLTDKAKARYQSKEDLEKAKKEHGITYGEWVNDKVAYYHDYSKDGKT AVDQEHGTHVSGILSGNAPSETKEPYRLEGAMPEAQLLLMRVEIVNGLAD 30 YARNYAQAIRDAINLGAKVINMSFGNAALAYANLPDETKKAFDYAKSKGV SIVTSAGNDSSFGGKTRLPLADHPDYGVVGTPAAADSTLTVASYSPDKQL TETVTVKTADQQDKEMPVLSTNRFEPNKAYDYAYANRGTKEDDFKDVKGK IALIERGDIDFKDKIAKAKKAGAVGVLIYDNQDKGFPIELPNVDQMPAAF ISRKDGLLLKDNPQKTITFNATPKVLPTASGTKLSRFSSWGLTADGNIKP 35 DIAAPGQDILSSVANNKYAKLSGTAMSAPLVAGIMGLLQEQYETQYPDMT PSERLDLAKKVLMSSATALYDEDEKAYFSPRQQGAGAVDAKKASAATMYV TDKDNTSSKVHLNNVSDKFEVTVTVHNKSDKPQELYYQATVQTDKVDGKH 95 FALAPKALYETSWQKITIPANSSKQVTVPIDASRFSKDLLAQMKNGYFLE GFVRFKQDPKKEELMSIPYIGFRGDFGNLSALEKPIYDSKDGSSYYHEAN SDAKDQLDGDGLQFYALKNNFTALTTESNPWTIIKAVKEGVENIEDIESS EITETIFAGTFAKQDDDSHYYIHRHANGKPYAAISPNGDGNRDYVQFQGT FLRNAKNLVAEVLDKEGNVVWTSEVTEQVVKNYNNDLASTLGSTRFEKTR 5 WDGKDKDGKVVANGTYTYRVRYTPISSGAKEQHTDFDVIVDNTTPEVATS ATFSTEDRRLTLASKPKTSQPVYRERIAYTYMDEDLPTTEYISPNEDGTF TLPEEAETMEGATVPLKMSDFTYVVEDMAGNITYTPVTKLLEGHSNKPEQ SEQ ID NO: 2 is 949 amino acids long. 10 In a particular embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of SCP consisting of a polypeptide having at least 90% identitywith SEQ ID NO: 1.In a particular embodiment, the carrier protein of the glycoconjugate of the invention is an 15enzymatically inactive fragment of SCP consisting of a polypeptide having at least 95% identitywith SEQ ID NO: 1.In a particular embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of SCP consisting of a polypeptide having at least 99% identitywith SEQ ID NO: 1. 20In a particular embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of SCP consisting of a polypeptide having at least 99.5% identitywith SEQ ID NO: 1.In a particular embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of SCP consisting of a polypeptide having at least 99.8% identity 25with SEQ ID NO: 1.In a particular embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of SCP consisting of a polypeptide having at least 99.85% identitywith SEQ ID NO: 1.In a particular embodiment, the carrier protein of the glycoconjugate of the invention is an 30enzymatically inactive fragment of SCP consisting of a polypeptide having at least 90% identitywith SEQ ID NO: 2.In a particular embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of SCP consisting of a polypeptide having at least 95% identitywith SEQ ID NO: 2. 35In a particular embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of SCP consisting of a polypeptide having at least 99% identitywith SEQ ID NO: 2. 96In a particular embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of SCP consisting of a polypeptide having at least 99.5% identitywith SEQ ID NO: 2.In a particular embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of SCP consisting of a polypeptide having at least 99.8% identity 5with SEQ ID NO: 2.In a particular embodiment, the carrier protein of the glycoconjugate of the invention is anenzymatically inactive fragment of SCP consisting of a polypeptide having at least 99.85% identitywith SEQ ID NO: 2. 2 Immunogenic compositions of the invention 2.1 Combinations of glycoconjugates of the invention In an embodiment the invention relates to an immunogenic composition comprising aglycoconjugate of the invention (such as the ones disclosed at section 1 above).Preferably, the number of different S. pneumoniae capsular saccharides can range from 15different serotypes (or "v", valences) to 25 different serotypes (25v).If the protein carrier is the same for 2 or more saccharides in the composition, thesaccharides can be conjugated to the same molecule of the protein carrier (carrier moleculeshaving 2 or more different saccharides conjugated to it) [see for instance WO2020121159].In a preferred embodiment though, the saccharides are each individually conjugated to 20different molecules of the protein carrier (each molecule of protein carrier only having one type ofsaccharide conjugated to it). In said embodiment, the capsular saccharides are said to beindividually conjugated to the carrier protein.In an embodiment the invention relates to an immunogenic composition comprising 1 todifferent glycoconjugates of the invention (as disclosed at section 1 above). 25In an embodiment the invention relates to an immunogenic composition comprising 1 toglycoconjugates from different serotypes of S. pneumoniae of the invention (1 to 25pneumococcal conjugates).In an embodiment the invention relates to an immunogenic composition comprising onepneumococcal glycoconjugate of the invention. 30In an embodiment the invention relates to an immunogenic composition comprising twopneumococcal glycoconjugates of the invention.In an embodiment the invention relates to an immunogenic composition comprising threepneumococcal glycoconjugates of the invention.In an embodiment the invention relates to an immunogenic composition comprising four 35pneumococcal glycoconjugates of the invention.In an embodiment the invention relates to an immunogenic composition comprising fivepneumococcal glycoconjugates of the invention. 97In an embodiment the invention relates to an immunogenic composition comprising tenpneumococcal glycoconjugates of the invention.In an embodiment the invention relates to an immunogenic composition comprising elevenpneumococcal glycoconjugates of the invention.In an embodiment the invention relates to an immunogenic composition comprising 5thirteen pneumococcal glycoconjugates of the invention.In an embodiment the invention relates to an immunogenic composition comprising fifteenpneumococcal glycoconjugates of the invention.In an embodiment the invention relates to an immunogenic composition comprisingnineteen pneumococcal glycoconjugates of the invention. 10In an embodiment the invention relates to an immunogenic composition comprising twentypneumococcal glycoconjugates of the invention.In an embodiment the invention relates to an immunogenic composition comprisingtwenty-one pneumococcal glycoconjugates of the invention.In an embodiment the invention relates to an immunogenic composition comprising 15twenty-two pneumococcal glycoconjugates of the invention.In an embodiment the invention relates to an immunogenic composition comprisingtwenty-three pneumococcal glycoconjugates of the invention.In an embodiment the invention relates to an immunogenic composition comprisingtwenty-four pneumococcal glycoconjugates of the invention. 20In a preferred embodiment the invention relates to an immunogenic compositioncomprising twenty-five pneumococcal glycoconjugates of the invention.In an embodiment the invention relates to an immunogenic composition comprising aglycoconjugate from S. pneumoniae serotype 15A (such as the one of section 1 above).In an embodiment the invention relates to an immunogenic composition comprising a 25glycoconjugate from S. pneumoniae serotype 23A (such as the one of section 1 above).In an embodiment the invention relates to an immunogenic composition comprising aglycoconjugate from S. pneumoniae serotype 23B (such as the one of section 1 above).In an embodiment the invention relates to an immunogenic composition comprising aglycoconjugate from S. pneumoniae serotype 24F (such as the one of section 1 above). 30In an embodiment the invention relates to an immunogenic composition comprising aglycoconjugate from S. pneumoniae serotype 35B (such as the one of section 1 above).In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotype 15A and 23A (such as the ones of section 1above). 35In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotype 15A and 23B (such as the ones of section 1above). 98In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotype 15A and 24F (such as the ones of section 1above).In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotype 15A and 35B (such as the ones of section 1 5above).In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotype 23A and 23B (such as the ones of section 1above).In an embodiment the invention relates to an immunogenic composition comprising 10glycoconjugates from S. pneumoniae serotype 23A and 24F (such as the ones of section 1above).In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotype 23A and 35B (such as the ones of section 1above). 15In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotype 23B and 24F (such as the ones of section 1above).In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotype 23B and 35B (such as the ones of section 1 20above).In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotype 24F and 35B (such as the ones of section 1above).In an embodiment the invention relates to an immunogenic composition comprising 25glycoconjugates from S. pneumoniae serotype 15A, 23A and 23B (such as the ones of section 1above).In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotype 15A, 23A and 24F (such as the ones of section 1above). 30In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotype 15A, 23A and 35B (such as the ones of section 1above).In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotype 15A, 23B and 24F (such as the ones of section 1 35above). 99In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotype 15A, 23B and 35B (such as the ones of section 1above).In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotype 15A, 24F and 35B (such as the ones of section 1 5above).In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotype 23A, 23B and 24F (such as the ones of section 1above).In an embodiment the invention relates to an immunogenic composition comprising 10glycoconjugates from S. pneumoniae serotype 23A, 23B and 35B (such as the ones of section 1above).In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotype 23A, 24F and 35B (such as the ones of section 1above). 15In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotype 23B, 24F and 35B (such as the ones of section 1above).In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotype 15A, 23A, 23B and 24F (such as the ones of 20section 1 above).In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotype 15A, 23A, 23B and 35B (such as the ones ofsection 1 above).In an embodiment the invention relates to an immunogenic composition comprising 25glycoconjugates from S. pneumoniae serotype 15A, 23A, 24F and 35B (such as the ones ofsection 1 above).In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotype 15A, 23B, 24F and 35B (such as the ones ofsection 1 above). 30In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotype 23A, 23B, 24F and 35B (such as the ones ofsection 1 above).Preferably, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotype 15A, 23A, 23B, 24F and 35B (such as the ones of 35section 1 above).In an embodiment the invention relates to an immunogenic composition comprising 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 pneumococcal 100glycoconjugates from different serotypes of S. pneumoniae, wherein said serotypes are selectedfrom serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F,23A, 23B, 23F, 24F, 33F and 35B.In an embodiment the invention relates to an immunogenic composition comprising fromto 25 pneumococcal glycoconjugates from different serotypes of S. pneumoniae, wherein said 5serotypes are selected from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B,18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B.In an embodiment the invention relates to an immunogenic composition comprising fromto 25 pneumococcal glycoconjugates from different serotypes of S. pneumoniae, wherein saidserotypes are selected from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 1018C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B.In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23F and 33F and additionally comprises from 1 to 5 glycoconjugatesfrom S. pneumoniae serotypes 15A, 23A, 23B, 24F and/or 35B. In an embodiment the 15immunogenic composition is a 21, 22, 23, 24 or 25-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23F and 33F and additionally comprises one glycoconjugate from S.pneumoniae serotypes 15A, 23A, 23B, 24F or 35B. In an embodiment the immunogenic 20composition is a 21-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23F and 33F and additionally comprises 2 glycoconjugates selectedfrom S. pneumoniae serotypes 15A, 23A, 23B, 24F and 35B. In an embodiment the immunogenic 25composition is a 22-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23F and 33F and additionally comprises 3 glycoconjugates selectedfrom S. pneumoniae serotypes 15A, 23A, 23B, 24F and 35B. In an embodiment the immunogenic 30composition is a 23-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23F and 33F and additionally comprises 4 glycoconjugates selectedfrom S. pneumoniae serotypes 15A, 23A, 23B, 24F and 35B. In an embodiment the immunogenic 35composition is a 24-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 10115A, 15B, 18C, 19A, 19F, 22F, 23F and 33F. In an embodiment the immunogenic composition isa 21-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23A, 23F and 33F. In an embodiment the immunogenic composition is 5a 21-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23B, 23F and 33F. In an embodiment the immunogenic composition isa 21-valent pneumococcal conjugate compositions. 10In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23F, 24F and 33F. In an embodiment the immunogenic composition isa 21-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising 15glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23F, 33F and 35B. In an embodiment the immunogenic composition isa 21-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 2015A, 15B, 18C, 19A, 19F, 22F, 23A, 23F and 33F. In an embodiment the immunogeniccomposition is a 22-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23B, 23F and 33F. In an embodiment the immunogenic 25composition is a 22-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23F, 24F and 33F. In an embodiment the immunogeniccomposition is a 22-valent pneumococcal conjugate compositions. 30In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23F, 33F and 35B. In an embodiment the immunogeniccomposition is a 22-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising 35glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F and 33F. In an embodiment the immunogeniccomposition is a 22-valent pneumococcal conjugate compositions. 102In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23A, 23F, 24F and 33F. In an embodiment the immunogeniccomposition is a 22-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising 5glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23A, 23F, 33F and 35B. In an embodiment the immunogeniccomposition is a 22-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 1015B, 18C, 19A, 19F, 22F, 23B, 23F, 24F and 33F. In an embodiment the immunogeniccomposition is a 22-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23B, 23F, 33F and 35B. In an embodiment the immunogenic 15composition is a 22-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23F, 24F, 33F and 35B. In an embodiment the immunogeniccomposition is a 22-valent pneumococcal conjugate compositions. 20In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F and 33F. In an embodiment the immunogeniccomposition is a 23-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising 25glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23F, 24F and 33F. In an embodiment the immunogeniccomposition is a 23-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 3015A, 15B, 18C, 19A, 19F, 22F, 23A, 23F, 33F and 35B. In an embodiment the immunogeniccomposition is a 23-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23B, 23F, 24F and 33F. In an embodiment the immunogenic 35composition is a 23-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 10315A, 15B, 18C, 19A, 19F, 22F, 23B, 23F, 33F and 35B. In an embodiment the immunogeniccomposition is a 23-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23F, 24F, 33F and 35B. In an embodiment the immunogenic 5composition is a 23-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F and 33F. In an embodiment the immunogeniccomposition is a 23-valent pneumococcal conjugate compositions. 10In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 33F and 35B. In an embodiment the immunogeniccomposition is a 23-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising 15glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23A, 23F, 24F, 33F and 35B. In an embodiment the immunogeniccomposition is a 23-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 2015B, 18C, 19A, 19F, 22F, 23B, 23F, 24F, 33F and 35B. In an embodiment the immunogeniccomposition is a 23-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F and 33F. In an embodiment the immunogenic 25composition is a 24-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 33F and 35B. In an embodiment the immunogeniccomposition is a 24-valent pneumococcal conjugate compositions. 30In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23F, 33F, 24F and 35B. In an embodiment the immunogeniccomposition is a 24-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising 35glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23B, 23F, 24F, 33F and 35B. In an embodiment the immunogeniccomposition is a 24-valent pneumococcal conjugate compositions. 104In an embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B. In an embodiment the immunogeniccomposition is a 24-valent pneumococcal conjugate compositions.Preferably, the invention relates to an immunogenic composition comprising 5glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B. In a preferred embodiment theimmunogenic composition is a 25-valent pneumococcal conjugate compositions.In a preferred embodiment, the saccharides are each individually conjugated to differentmolecules of the protein carrier (each molecule of protein carrier only having one type of 10saccharide conjugated to it). In said embodiment, the capsular saccharides are said to beindividually conjugated to the carrier protein. Preferably, all the glycoconjugates of the aboveimmunogenic compositions are individually conjugated to the carrier protein.In an embodiment of any of the above immunogenic compositions, the glycoconjugates ofthe invention are conjugated to CRM 197. 15In an embodiment of any of the above immunogenic compositions, the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to CRM 197.In an embodiment of any of the above immunogenic compositions, the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP.In an embodiment of any of the above immunogenic compositions, the glycoconjugate 20from S. pneumoniae serotype 22F is conjugated to CRM 197. In an embodiment of any of the aboveimmunogenic compositions, the glycoconjugate from S. pneumoniae serotype 33F is conjugatedto CRM 197. In an embodiment of any of the above immunogenic compositions, the glycoconjugatefrom S. pneumoniae serotype 15B is conjugated to CRM197. In an embodiment of any of theabove immunogenic compositions, the glycoconjugate from S. pneumoniae serotype 12F is 25conjugated to CRM 197. In an embodiment of any of the above immunogenic compositions, theglycoconjugate from S. pneumoniae serotype 10A is conjugated to CRM197. In an embodimentof any of the above immunogenic compositions, the glycoconjugate from S. pneumoniae serotype11A is conjugated to CRM 197. In an embodiment of any of the above immunogenic compositions,the glycoconjugate from S. pneumoniae serotype 8 is conjugated to CRM 197. In an embodiment 30of any of the above immunogenic compositions, the glycoconjugates from S. pneumoniaeserotypes 4, 6B, 9V, 14, 18C, 19F and 23F are conjugated to CRM 197. In an embodiment of anyof the above immunogenic compositions, the glycoconjugates from S. pneumoniae serotypes 1,and 7F are conjugated to CRM 197. In an embodiment of any of the above immunogeniccompositions, the glycoconjugates from S. pneumoniae serotypes 6A and 19A are conjugated to 35CRM 197.In an embodiment of any of the above immunogenic compositions, the glycoconjugates ofany of the above immunogenic compositions are all individually conjugated to CRM 197. 105In an embodiment of any of the above immunogenic compositions, the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP and the other glycoconjugates are allindividually conjugated to CRM 197.In an embodiment of any of the above immunogenic compositions, the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP, at least one other glycoconjugate is 5conjugated to TT and the other glycoconjugate(s) is/are all individually conjugated to CRM 197.In an embodiment of any of the above immunogenic compositions, the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP, one other glycoconjugate is conjugated toTT and the other glycoconjugate(s) is/are all individually conjugated to CRM 197.In an embodiment of any of the above immunogenic compositions, the glycoconjugate 10from S. pneumoniae serotype 3 is conjugated to SCP, at least two other glycoconjugates areconjugated to TT and the other glycoconjugate(s) is/are all individually conjugated to CRM 197.In an embodiment of any of the above immunogenic compositions, the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP, two other glycoconjugates are conjugatedto TT and the other glycoconjugate(s) is/are all individually conjugated to CRM 197. 15In an embodiment of any of the above immunogenic compositions, the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP, at least three other glycoconjugates areconjugated to TT and the other glycoconjugate(s) is/are all individually conjugated to CRM 197.In an embodiment of any of the above immunogenic compositions, the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP, three other glycoconjugates areconjugated 20to TT and the other glycoconjugate(s) is/are all individually conjugated to CRM 197.In an embodiment of any of the above immunogenic compositions, the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP, at least four other glycoconjugates areconjugated to TT and the other glycoconjugate(s) is/are all individually conjugated to CRM 197.In an embodiment of any of the above immunogenic compositions, the glycoconjugate 25from S. pneumoniae serotype 3 is conjugated to SCP, four other glycoconjugates are conjugatedto TT and the other glycoconjugate(s) is/are all individually conjugated to CRM 197.In an embodiment of any of the above immunogenic compositions, the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP, at least five other glycoconjugates areconjugated to TT and the other glycoconjugate(s) is/are all individually conjugated to CRM 197. 30In an embodiment of any of the above immunogenic compositions, the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP, five other glycoconjugates are conjugatedto TT and the other glycoconjugate(s) is/are all individually conjugated to CRM 197.In an embodiment of any of the above immunogenic compositions, the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP, at least one other glycoconjugate is 35conjugated to SCP and the other glycoconjugate(s) is/are all individually conjugated to CRM 197. 106In an embodiment of any of the above immunogenic compositions, the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP, one other glycoconjugate is conjugated toSCP and the other glycoconjugate(s) is/are all individually conjugated to CRM 197.In an embodiment of any of the above immunogenic compositions, the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP, at least two other glycoconjugates are 5conjugated to SCP and the other glycoconjugate(s) is/are all individually conjugated to CRM 197.In an embodiment of any of the above immunogenic compositions, the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP, two other glycoconjugates are conjugatedto SCP and the other glycoconjugate(s) is/are all individually conjugated to CRM 197.In an embodiment of any of the above immunogenic compositions, the glycoconjugate 10from S. pneumoniae serotype 3 is conjugated to SCP, at least three other glycoconjugates areconjugated to SCP and the other glycoconjugate(s) is/are all individually conjugated to CRM 197.
In an embodiment of any of the above immunogenic compositions, the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP, three other glycoconjugates areconjugated 15to SCP and the other glycoconjugate(s) is/are all individually conjugated to CRM 197.In an embodiment of any of the above immunogenic compositions, the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP, at least four other glycoconjugates areconjugated to SCP and the other glycoconjugate(s) is/are all individually conjugated to CRM 197.In an embodiment of any of the above immunogenic compositions, the glycoconjugate 20from S. pneumoniae serotype 3 is conjugated to SCP, four other glycoconjugates are conjugatedto SCP and the other glycoconjugate(s) is/are all individually conjugated to CRM 197.In an embodiment of any of the above immunogenic compositions, the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP, at least five other glycoconjugates areconjugated to SCP and the other glycoconjugate(s) is/are all individually conjugated to CRM 197. 25In an embodiment of any of the above immunogenic compositions, the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP, five other glycoconjugates are conjugatedto SCP and the other glycoconjugate(s) is/are all individually conjugated to CRM 197.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 3015A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, wherein the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP and the other glycoconjugates are allindividually conjugated to CRM 197. In a preferred embodiment the immunogenic composition is a25-valent pneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprising 35glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, wherein the glycoconjugates 107are all individually conjugated to CRM 197. In a preferred embodiment the immunogeniccomposition is a 25-valent pneumococcal conjugate compositions.
Compositions of the invention may include a small amount of free carrier. When a given 5carrier protein is present in both free and conjugated form in a composition of the invention, theunconjugated form is preferably no more than 5% of the total amount of the carrier protein in thecomposition as a whole, and more preferably present at less than 2% by weight. 2.2 Dosage of the immunogenic compositions of the invention 10The amount of glycoconjugate(s) in each dose is selected as an amount which inducesan immunoprotective response without significant, adverse side effects in typical vaccinees. Suchamount will vary depending upon which specific immunogen is employed and how it is presented.The amount of a particular glycoconjugate in an immunogenic composition can becalculated based on total saccharide for that conjugate (conjugated and non-conjugated). For 15example, a glycoconjugate with 20% free saccharide will have about 80 µg of conjugatedsaccharide and about 20 µg of nonconjugated saccharide in a 100 µg saccharide dose. Theamount of glycoconjugate can vary depending upon the bacteria and bacteria serotype. Thesaccharide concentration can be determined by the uronic acid assay.The "immunogenic amount" of the different saccharide components in the immunogenic 20composition, may diverge and each may comprise about 0.5 µg, about 0.75 µg, about 1 µg, aboutµg, about 3 µg, about 4 µg, about 5 µg, about 6 µg, about 7 µg, about 8 µg, about 9 µg, aboutµg, about 15 µg, about 20 µg, about 30 µg, about 40 µg, about 50 µg, about 60 µg, about 70µg, about 80 µg, about 90 µg, or about 100 µg of any particular saccharide antigen.Generally, each dose will comprise 0.1 µg to 100 µg of saccharide for a given serotype. In 25a preferred embodiment each dose will comprise 0.5 µg to 20 µg of saccharide for a givenserotype. In an even preferred embodiment, each dose will comprise 2.0 µg to 10.0 µg ofsaccharide for a given serotype. Any whole number integer within any of the above ranges iscontemplated as an embodiment of the disclosure.In an embodiment, each dose will comprise about 0.5 µg of saccharide for each particular 30glycoconjugate. In an embodiment, each dose will comprise about 1.0 µg of saccharide for eachparticular glycoconjugate. In an embodiment, each dose will comprise about 1.1 µg of saccharidefor each particular glycoconjugate. In an embodiment, each dose will comprise about 1.5 µg ofsaccharide for each particular glycoconjugate. In an embodiment, each dose will comprise about2.0 µg of saccharide for each particular glycoconjugate. In an embodiment, each dose will 35comprise about 2.2 µg of saccharide for each particular glycoconjugate. In an embodiment, eachdose will comprise about 2.5 µg of saccharide for each particular glycoconjugate. In anembodiment, each dose will comprise about 3.0 µg of saccharide for each particular 108glycoconjugate. In an embodiment, each dose will comprise about 3.5 µg of saccharide for eachparticular glycoconjugate. In an embodiment, each dose will comprise about 4.0 µg of saccharidefor each particular glycoconjugate. In an embodiment, each dose will comprise about 4.4 µg ofsaccharide for each particular glycoconjugate. In an embodiment, each dose will comprise about5.0 µg of saccharide for each particular glycoconjugate. In an embodiment, each dose will 5comprise about 5.5 µg of saccharide for each particular glycoconjugate. In an embodiment, eachdose will comprise about 6.0 µg of saccharide for each particular glycoconjugate. In anembodiment, each dose will comprise about 6.5 µg of saccharide for each particularglycoconjugate. In an embodiment, each dose will comprise about 7.0 µg of saccharide for eachparticular glycoconjugate. In an embodiment, each dose will comprise about 7.5 µg of saccharide 10for each particular glycoconjugate. In an embodiment, each dose will comprise about 8.0 µg ofsaccharide for each particular glycoconjugate. In an embodiment, each dose will comprise about8.5 µg of saccharide for each particular glycoconjugate. In an embodiment, each dose willcomprise about 9.0 µg of saccharide for each particular glycoconjugate.In an embodiment, each dose will comprise about 0.5 µg, about 1.0 µg, about 1.5 µg, 15about 2.0 µg, about 2.2 µg, about 2.5 µg, about 3.0 µg, about 3.5 µg, about 4.0 µg, about 4.5 µg,or about 5.0 µg of polysaccharide for glycoconjugates from S. pneumoniae serotype 1, 3, 4, 5,6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33Fand/or 35B.In an embodiment, each dose will comprise about 2.0 µg or about 2.2 µg of polysaccharide 20for glycoconjugates from S. pneumoniae serotype 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and/or 35B.In an embodiment, each dose will comprise about 2.0 µg or about 2.2 µg of polysaccharidefor glycoconjugates from S. pneumoniae serotype 1, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A,15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and/or 35B. 25In an embodiment, each dose will comprise about 3.0 µg, about 3.5 µg, about 4.0 µg, about4.4 µg or about 5.0 µg of polysaccharide for glycoconjugate from S. pneumoniae serotype 6B.In an embodiment, each dose will comprise about 3.0 µg, about 3.5 µg, about 4.0 µg, about4.4 µg or about 5.0 µg of polysaccharide for glycoconjugate from S. pneumoniae serotype 3.In an embodiment, each dose will comprise about 2.0 µg of polysaccharide for 30glycoconjugate from S. pneumoniae serotype 3.In an embodiment, each dose will comprise about 2.2 µg of polysaccharide forglycoconjugate from S. pneumoniae serotype 3.In an embodiment, each dose will comprise about 4.0 µg of polysaccharide forglycoconjugate from S. pneumoniae serotype 3. 35In an embodiment, each dose will comprise about 4.4 µg of polysaccharide forglycoconjugate from S. pneumoniae serotype 3. 109In an embodiment, each dose will comprise about 8.0 µg of polysaccharide forglycoconjugate from S. pneumoniae serotype 3.In an embodiment, each dose will comprise about 8.8 µg of polysaccharide forglycoconjugate from S. pneumoniae serotype 3.In an embodiment, each dose will comprise about 2.0 µg to about 2.5 µg of polysaccharide 5for each glycoconjugate from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F,14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, and about 4.0 µg to about4.8 µg of polysaccharide for glycoconjugate from S. pneumoniae serotype 6B.In an embodiment, each dose will comprise about 2.0 µg to about 2.5 µg of polysaccharidefor each glycoconjugate from S. pneumoniae serotypes 1, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 1015A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, and about 4.0 µg to about 4.8µg of polysaccharide for glycoconjugate from S. pneumoniae serotypes 3 and 6B.In an embodiment, each dose will comprise about 2.0 µg to about 2.5 µg of polysaccharidefor each glycoconjugate from S. pneumoniae serotypes 1, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, about 4.0 µg to about 4.8 µg 15of polysaccharide for glycoconjugate from S. pneumoniae serotype 6B and about 6.0 µg to about7.5 µg of polysaccharide for glycoconjugate from S. pneumoniae serotype 3.In an embodiment, each dose will comprise about 2.0 µg to about 2.5 µg of polysaccharidefor each glycoconjugate from S. pneumoniae serotypes 1, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, about 4.0 µg to about 4.8 µg 20of polysaccharide for glycoconjugate from S. pneumoniae serotype 6B and about 8.0 µg to about10.0 µg of polysaccharide for glycoconjugate from S. pneumoniae serotype 3.In an embodiment, each dose will comprise about 2.0 µg of polysaccharide from eachglycoconjugate from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A,15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, and about 4.0 µg of polysaccharide 25for glycoconjugate from S. pneumoniae serotype 6B.In an embodiment, each dose will comprise about 2.2 µg of polysaccharide from eachglycoconjugate from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A,15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, and about 4.4 µg of polysaccharidefor glycoconjugate from S. pneumoniae serotype 6B. 30In an embodiment, each dose will comprise about 2.0 µg of polysaccharide from eachglycoconjugate from S. pneumoniae serotypes 1, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A,15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, and about 4.0 µg of polysaccharidefor glycoconjugate from S. pneumoniae serotypes 3 and 6B.In an embodiment, each dose will comprise about 2.2 µg of polysaccharide from each 35glycoconjugate from S. pneumoniae serotypes 1, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A,15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, and about 4.4 µg of polysaccharidefor glycoconjugate from S. pneumoniae serotypes 3 and 6B. 110In an embodiment, each dose will comprise about 2.0 µg of polysaccharide from eachglycoconjugate from S. pneumoniae serotypes 1, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A,15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, about 4.0 µg of polysaccharide forglycoconjugate from S. pneumoniae serotype 6B and about 6.0 µg of polysaccharide forglycoconjugate from S. pneumoniae serotype 3. 5In an embodiment, each dose will comprise about 2.2 µg of polysaccharide from eachglycoconjugate from S. pneumoniae serotypes 1, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A,15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, about 4.4 µg of polysaccharide forglycoconjugate from S. pneumoniae serotype 6B and about 6.6 µg of polysaccharide forglycoconjugate from S. pneumoniae serotype 3. 10In an embodiment, each dose will comprise about 2.0 µg of polysaccharide from eachglycoconjugate from S. pneumoniae serotypes 1, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A,15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, about 4.0 µg of polysaccharide forglycoconjugate from S. pneumoniae serotype 6B and about 8.0 µg of polysaccharide forglycoconjugate from S. pneumoniae serotype 3. 15In an embodiment, each dose will comprise about 2.2 µg of polysaccharide from eachglycoconjugate from S. pneumoniae serotypes 1, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A,15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, about 4.4 µg of polysaccharide forglycoconjugate from S. pneumoniae serotype 6B and about 8.8 µg of polysaccharide forglycoconjugate from S. pneumoniae serotype 3. 20In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, wherein the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP and the glycoconjugates from S.pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 2522F, 23A, 23B, 23F, 24F, 33F and 35B are conjugated to CRM 197, wherein each dose comprisesan amount (a) of polysaccharide for glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5,6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and35B which is about the same for said polysaccharides, wherein the amount of polysaccharide forglycoconjugate from S. pneumoniae serotype 6B is about two times said amount (a), and wherein 30the amount of polysaccharide for glycoconjugate from S. pneumoniae serotype 3 is also abouttwo times said amount (a). In a preferred embodiment the immunogenic composition is a 25-valent pneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 3515A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, wherein the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP and the glycoconjugates from S.pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 11122F, 23A, 23B, 23F, 24F, 33F and 35B are conjugated to CRM 197, wherein each dose comprisesan amount (a) of polysaccharide for glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5,6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and35B which is about the same for said polysaccharides, wherein the amount of polysaccharide forglycoconjugate from S. pneumoniae serotype 6B is about two times said amount (a), and wherein 5the amount of polysaccharide for glycoconjugate from S. pneumoniae serotype 3 is about threetimes said amount (a). In a preferred embodiment the immunogenic composition is a 25-valentpneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 1015A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, wherein the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP and the glycoconjugates from S.pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F,22F, 23A, 23B, 23F, 24F, 33F and 35B are conjugated to CRM 197, wherein each dose comprisesan amount (a) of polysaccharide for glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 156A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and35B which is about the same for said polysaccharides, wherein the amount of polysaccharide forglycoconjugate from S. pneumoniae serotype 6B is about two times said amount (a), and whereinthe amount of polysaccharide for glycoconjugate from S. pneumoniae serotype 3 is about fourtimes said amount (a). In a preferred embodiment the immunogenic composition is a 25-valent 20pneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B conjugated to CRM 197, whereineach dose comprises an amount (a) of polysaccharide for glycoconjugates from S. pneumoniae 25serotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B,23F, 24F, 33F and 35B which is about the same for said polysaccharides, wherein the amount ofpolysaccharide for glycoconjugate from S. pneumoniae serotype 6B is about two times saidamount (a), and wherein the amount of polysaccharide for glycoconjugate from S. pneumoniaeserotype 3 is also about two times said amount (a). In a preferred embodiment the immunogenic 30composition is a 25-valent pneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B conjugated to CRM 197, whereineach dose comprises an amount (a) of polysaccharide for glycoconjugates from S. pneumoniae 35serotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B,23F, 24F, 33F and 35B which is about the same for said polysaccharides, wherein the amount ofpolysaccharide for glycoconjugate from S. pneumoniae serotype 6B is about two times said 112amount (a), and wherein the amount of polysaccharide for glycoconjugate from S. pneumoniaeserotype 3 is about three times said amount (a). In a preferred embodiment the immunogeniccomposition is a 25-valent pneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 515A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B conjugated to CRM 197, whereineach dose comprises an amount (a) of polysaccharide for glycoconjugates from S. pneumoniaeserotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B,23F, 24F, 33F and 35B which is about the same for said polysaccharides, wherein the amount ofpolysaccharide for glycoconjugate from S. pneumoniae serotype 6B is about two times said 10amount (a), and wherein the amount of polysaccharide for glycoconjugate from S. pneumoniaeserotype 3 is about four times said amount (a). In a preferred embodiment the immunogeniccomposition is a 25-valent pneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 1515A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, wherein the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP and the glycoconjugates from S.pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F,22F, 23A, 23B, 23F, 24F, 33F and 35B are conjugated to CRM 197, wherein each dose comprisesan amount (a) of polysaccharide for glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 206A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and35B which is about the same for said polysaccharides, wherein said amount (a) is about 1.0 µgto about 3.0 µg of polysaccharide, wherein the amount of polysaccharide for glycoconjugate fromS. pneumoniae serotype 6B is about two times said amount (a), and wherein the amount ofpolysaccharide for glycoconjugate from S. pneumoniae serotype 3 is also about two times said 25amount (a). In a preferred embodiment the immunogenic composition is a 25-valentpneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, wherein the glycoconjugate 30from S. pneumoniae serotype 3 is conjugated to SCP and the glycoconjugates from S.pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F,22F, 23A, 23B, 23F, 24F, 33F and 35B are conjugated to CRM 197, wherein each dose comprisesan amount (a) of polysaccharide for glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5,6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 3535B which is about the same for said polysaccharides, wherein said amount (a) is about 1.0 µgto about 3.0 µg of polysaccharide, wherein the amount of polysaccharide for glycoconjugate fromS. pneumoniae serotype 6B is about two times said amount (a), and wherein the amount of 113polysaccharide for glycoconjugate from S. pneumoniae serotype 3 is about three times saidamount (a). In a preferred embodiment the immunogenic composition is a 25-valentpneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 515A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, wherein the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP and the glycoconjugates from S.pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F,22F, 23A, 23B, 23F, 24F, 33F and 35B are conjugated to CRM 197, wherein each dose comprisesan amount (a) of polysaccharide for glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 106A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and35B which is about the same for said polysaccharides, wherein said amount (a) is about 1.0 µgto about 3.0 µg of polysaccharide, wherein the amount of polysaccharide for glycoconjugate fromS. pneumoniae serotype 6B is about two times said amount (a), and wherein the amount ofpolysaccharide for glycoconjugate from S. pneumoniae serotype 3 is about four times said 15amount (a). In a preferred embodiment the immunogenic composition is a 25-valentpneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B conjugated to CRM 197, wherein 20each dose comprises an amount (a) of polysaccharide for glycoconjugates from S. pneumoniaeserotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B,23F, 24F, 33F and 35B which is about the same for said polysaccharides, wherein said amount(a) is about 1.0 µg to about 3.0 µg of polysaccharide,wherein the amount of polysaccharide forglycoconjugate from S. pneumoniae serotype 6B is about two times said amount (a), and wherein 25the amount of polysaccharide for glycoconjugate from S. pneumoniae serotype 3 is also abouttwo times said amount (a). In a preferred embodiment the immunogenic composition is a 25-valent pneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 3015A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B conjugated to CRM 197, whereineach dose comprises an amount (a) of polysaccharide for glycoconjugates from S. pneumoniaeserotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B,23F, 24F, 33F and 35B which is about the same for said polysaccharides, wherein said amount(a) is about 1.0 µg to about 3.0 µg of polysaccharide, wherein the amount of polysaccharide for 35glycoconjugate from S. pneumoniae serotype 6B is about two times said amount (a), and whereinthe amount of polysaccharide for glycoconjugate from S. pneumoniae serotype 3 is about three 114times said amount (a). In a preferred embodiment the immunogenic composition is a 25-valentpneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B conjugated to CRM 197, wherein 5each dose comprises an amount (a) of polysaccharide for glycoconjugates from S. pneumoniaeserotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B,23F, 24F, 33F and 35B which is about the same for said polysaccharides, wherein said amount(a) is about 1.0 µg to about 3.0 µg of polysaccharide, wherein the amount of polysaccharide forglycoconjugate from S. pneumoniae serotype 6B is about two times said amount (a), and wherein 10the amount of polysaccharide for glycoconjugate from S. pneumoniae serotype 3 is about fourtimes said amount (a). In a preferred embodiment the immunogenic composition is a 25-valentpneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 1515A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, wherein the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP and the glycoconjugates from S.pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F,22F, 23A, 23B, 23F, 24F, 33F and 35B are conjugated to CRM 197, wherein each dose comprisesan amount (a) of polysaccharide for glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 206A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and35B which is about the same for said polysaccharides, wherein said amount (a) is about 1.5 µgto about 2.5 µg of polysaccharide, wherein the amount of polysaccharide for glycoconjugate fromS. pneumoniae serotype 6B is about two times said amount (a), and wherein the amount ofpolysaccharide for glycoconjugate from S. pneumoniae serotype 3 is also about two times said 25amount (a). In a preferred embodiment the immunogenic composition is a 25-valentpneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, wherein the glycoconjugate 30from S. pneumoniae serotype 3 is conjugated to SCP and the glycoconjugates from S.pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F,22F, 23A, 23B, 23F, 24F, 33F and 35B are conjugated to CRM 197, wherein each dose comprisesan amount (a) of polysaccharide for glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5,6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 3535B which is about the same for said polysaccharides, wherein said amount (a) is about 1.5 µgto about 2.5 µg of polysaccharide, wherein the amount of polysaccharide for glycoconjugate fromS. pneumoniae serotype 6B is about two times said amount (a), and wherein the amount of 115polysaccharide for glycoconjugate from S. pneumoniae serotype 3 is about three times saidamount (a). In a preferred embodiment the immunogenic composition is a 25-valentpneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 515A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, wherein the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP and the glycoconjugates from S.pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F,22F, 23A, 23B, 23F, 24F, 33F and 35B are conjugated to CRM 197, wherein each dose comprisesan amount (a) of polysaccharide for glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 106A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and35B which is about the same for said polysaccharides, wherein said amount (a) is about 1.5 µgto about 2.5 µg of polysaccharide, wherein the amount of polysaccharide for glycoconjugate fromS. pneumoniae serotype 6B is about two times said amount (a), and wherein the amount ofpolysaccharide for glycoconjugate from S. pneumoniae serotype 3 is about four times said 15amount (a). In a preferred embodiment the immunogenic composition is a 25-valentpneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B conjugated to CRM 197, wherein 20each dose comprises an amount (a) of polysaccharide for glycoconjugates from S. pneumoniaeserotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B,23F, 24F, 33F and 35B which is about the same for said polysaccharides, wherein said amount(a) is about 1.5 µg to about 2.5 µg of polysaccharide,wherein the amount of polysaccharide forglycoconjugate from S. pneumoniae serotype 6B is about two times said amount (a), and wherein 25the amount of polysaccharide for glycoconjugate from S. pneumoniae serotype 3 is also abouttwo times said amount (a). In a preferred embodiment the immunogenic composition is a 25-valent pneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 3015A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B conjugated to CRM 197, whereineach dose comprises an amount (a) of polysaccharide for glycoconjugates from S. pneumoniaeserotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B,23F, 24F, 33F and 35B which is about the same for said polysaccharides, wherein said amount(a) is about 1.5 µg to about 2.5 µg of polysaccharide, wherein the amount of polysaccharide for 35glycoconjugate from S. pneumoniae serotype 6B is about two times said amount (a), and whereinthe amount of polysaccharide for glycoconjugate from S. pneumoniae serotype 3 is about three 116times said amount (a). In a preferred embodiment the immunogenic composition is a 25-valentpneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B conjugated to CRM 197, wherein 5each dose comprises an amount (a) of polysaccharide for glycoconjugates from S. pneumoniaeserotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B,23F, 24F, 33F and 35B which is about the same for said polysaccharides, wherein said amount(a) is about 1.5 µg to about 2.5 µg of polysaccharide, wherein the amount of polysaccharide forglycoconjugate from S. pneumoniae serotype 6B is about two times said amount (a), and wherein 10the amount of polysaccharide for glycoconjugate from S. pneumoniae serotype 3 is about fourtimes said amount (a). In a preferred embodiment the immunogenic composition is a 25-valentpneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 1515A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, wherein the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP and the glycoconjugates from S.pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F,22F, 23A, 23B, 23F, 24F, 33F and 35B are conjugated to CRM 197, wherein each dose comprisesan amount (a) of polysaccharide for glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 206A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and35B which is about the same for said polysaccharides, wherein said amount (a) is about 2.0 µgto about 2.2 µg of polysaccharide, wherein the amount of polysaccharide for glycoconjugate fromS. pneumoniae serotype 6B is about two times said amount (a), and wherein the amount ofpolysaccharide for glycoconjugate from S. pneumoniae serotype 3 is also about two times said 25amount (a). In a preferred embodiment the immunogenic composition is a 25-valentpneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, wherein the glycoconjugate 30from S. pneumoniae serotype 3 is conjugated to SCP and the glycoconjugates from S.pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F,22F, 23A, 23B, 23F, 24F, 33F and 35B are conjugated to CRM 197, wherein each dose comprisesan amount (a) of polysaccharide for glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5,6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 3535B which is about the same for said polysaccharides, wherein said amount (a) is about 2.0 µgto about 2.2 µg of polysaccharide, wherein the amount of polysaccharide for glycoconjugate fromS. pneumoniae serotype 6B is about two times said amount (a), and wherein the amount of 117polysaccharide for glycoconjugate from S. pneumoniae serotype 3 is about three times saidamount (a). In a preferred embodiment the immunogenic composition is a 25-valentpneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 515A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, wherein the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP and the glycoconjugates from S.pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F,22F, 23A, 23B, 23F, 24F, 33F and 35B are conjugated to CRM 197, wherein each dose comprisesan amount (a) of polysaccharide for glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 106A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and35B which is about the same for said polysaccharides, wherein said amount (a) is about 2.0 µgto about 2.2 µg of polysaccharide, wherein the amount of polysaccharide for glycoconjugate fromS. pneumoniae serotype 6B is about two times said amount (a), and wherein the amount ofpolysaccharide for glycoconjugate from S. pneumoniae serotype 3 is about four times said 15amount (a). In a preferred embodiment the immunogenic composition is a 25-valentpneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B conjugated to CRM 197, wherein 20each dose comprises an amount (a) of polysaccharide for glycoconjugates from S. pneumoniaeserotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B,23F, 24F, 33F and 35B which is about the same for said polysaccharides, wherein said amount(a) is about 2.0 µg to about 2.2 µg of polysaccharide,wherein the amount of polysaccharide forglycoconjugate from S. pneumoniae serotype 6B is about two times said amount (a), and wherein 25the amount of polysaccharide for glycoconjugate from S. pneumoniae serotype 3 is also abouttwo times said amount (a). In a preferred embodiment the immunogenic composition is a 25-valent pneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 3015A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B conjugated to CRM 197, whereineach dose comprises an amount (a) of polysaccharide for glycoconjugates from S. pneumoniaeserotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B,23F, 24F, 33F and 35B which is about the same for said polysaccharides, wherein said amount(a) is about 2.0 µg to about 2.2 µg of polysaccharide, wherein the amount of polysaccharide for 35glycoconjugate from S. pneumoniae serotype 6B is about two times said amount (a), and whereinthe amount of polysaccharide for glycoconjugate from S. pneumoniae serotype 3 is about three 118times said amount (a). In a preferred embodiment the immunogenic composition is a 25-valentpneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B conjugated to CRM 197, wherein 5each dose comprises an amount (a) of polysaccharide for glycoconjugates from S. pneumoniaeserotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B,23F, 24F, 33F and 35B which is about the same for said polysaccharides, wherein said amount(a) is about 2.0 µg to about 2.2 µg of polysaccharide, wherein the amount of polysaccharide forglycoconjugate from S. pneumoniae serotype 6B is about two times said amount (a), and wherein 10the amount of polysaccharide for glycoconjugate from S. pneumoniae serotype 3 is about fourtimes said amount (a). In a preferred embodiment the immunogenic composition is a 25-valentpneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 1515A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, wherein the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP and the glycoconjugates from S.pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F,22F, 23A, 23B, 23F, 24F, 33F and 35B are conjugated to CRM 197, wherein each dose comprisesabout 2.2 µg of polysaccharide from each glycoconjugate from S. pneumoniae serotypes 1, 3, 4, 205, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and35B, and about 4.4 µg of polysaccharide for glycoconjugate from S. pneumoniae serotype 6B. Ina preferred embodiment the immunogenic composition is a 25-valent pneumococcal conjugatecompositions.In an embodiment, the invention relates to an immunogenic composition comprising 25glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, wherein the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP and the glycoconjugates from S.pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F,22F, 23A, 23B, 23F, 24F, 33F and 35B are conjugated to CRM 197, wherein each dose comprises 30about 2.0 µg of polysaccharide from each glycoconjugate from S. pneumoniae serotypes 1, 3, 4,5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and35B, and about 4.0 µg of polysaccharide for glycoconjugate from S. pneumoniae serotype 6B. Ina preferred embodiment the immunogenic composition is a 25-valent pneumococcal conjugatecompositions. 35In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, wherein the glycoconjugate 119from S. pneumoniae serotype 3 is conjugated to SCP and the glycoconjugates from S.pneumoniae serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F,22F, 23A, 23B, 23F, 24F, 33F and 35B are conjugated to CRM 197, wherein each dose comprisesabout 2.2 µg of polysaccharide from each glycoconjugate from S. pneumoniae serotypes 1, 4, 5,6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 535B, and about 4.4 µg of polysaccharide for glycoconjugate from S. pneumoniae serotypes 3 and6B. In a preferred embodiment the immunogenic composition is a 25-valent pneumococcalconjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 1015A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, wherein the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP and the glycoconjugates from S.pneumoniae serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F,22F, 23A, 23B, 23F, 24F, 33F and 35B are conjugated to CRM 197, wherein each dose comprisesabout 2.0 µg of polysaccharide from each glycoconjugate from S. pneumoniae serotypes 1, 4, 5, 156A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and35B, and about 4.0 µg of polysaccharide for glycoconjugate from S. pneumoniae serotypes 3 and6B. In a preferred embodiment the immunogenic composition is a 25-valent pneumococcalconjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprising 20glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, wherein the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP and the glycoconjugates from S.pneumoniae serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F,22F, 23A, 23B, 23F, 24F, 33F and 35B are conjugated to CRM 197, wherein each dose comprises 25about 2.0 µg of polysaccharide from each glycoconjugate from S. pneumoniae serotypes 1, 4, 5,6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and35B, about 4.0 µg of polysaccharide for glycoconjugate from S. pneumoniae serotype 6B andabout 6.0 µg of polysaccharide for glycoconjugate from S. pneumoniae serotype 3. In a preferredembodiment the immunogenic composition is a 25-valent pneumococcal conjugate compositions. 30In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, wherein the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP and the glycoconjugates from S.pneumoniae serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 3522F, 23A, 23B, 23F, 24F, 33F and 35B are conjugated to CRM 197, wherein each dose comprisesabout 2.2 µg of polysaccharide from each glycoconjugate from S. pneumoniae serotypes 1, 4, 5,6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 12035B, about 4.4 µg of polysaccharide for glycoconjugate from S. pneumoniae serotype 6B andabout 6.6 µg of polysaccharide for glycoconjugate from S. pneumoniae serotype 3. In a preferredembodiment the immunogenic composition is a 25-valent pneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 515A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, wherein the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP and the glycoconjugates from S.pneumoniae serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F,22F, 23A, 23B, 23F, 24F, 33F and 35B are conjugated to CRM 197, wherein each dose comprisesabout 2.0 µg of polysaccharide from each glycoconjugate from S. pneumoniae serotypes 1, 4, 5, 106A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and35B, about 4.0 µg of polysaccharide for glycoconjugate from S. pneumoniae serotype 6B andabout 8.0 µg of polysaccharide for glycoconjugate from S. pneumoniae serotype 3. In a preferredembodiment the immunogenic composition is a 25-valent pneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprising 15glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B, wherein the glycoconjugatefrom S. pneumoniae serotype 3 is conjugated to SCP and the glycoconjugates from S.pneumoniae serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F,22F, 23A, 23B, 23F, 24F, 33F and 35B are conjugated to CRM 197, wherein each dose comprises 20about 2.2 µg of polysaccharide from each glycoconjugate from S. pneumoniae serotypes 1, 4, 5,6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and35B, about 4.4 µg of polysaccharide for glycoconjugate from S. pneumoniae serotype 6B andabout 8.8 µg of polysaccharide for glycoconjugate from S. pneumoniae serotype 3. In a preferredembodiment the immunogenic composition is a 25-valent pneumococcal conjugate compositions. 25In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B conjugated to CRM 197, whereineach dose comprises about 2.2 µg of polysaccharide from each glycoconjugate from S.pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 3022F, 23A, 23B, 23F, 24F, 33F and 35B, and about 4.4 µg of polysaccharide for glycoconjugatefrom S. pneumoniae serotype 6B. In a preferred embodiment the immunogenic composition is a25-valent pneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 3515A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B conjugated to CRM 197, whereineach dose comprises about 2.0 µg of polysaccharide from each glycoconjugate from S.pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 12122F, 23A, 23B, 23F, 24F, 33F and 35B, and about 4.0 µg of polysaccharide for glycoconjugatefrom S. pneumoniae serotype 6B. In a preferred embodiment the immunogenic composition is a25-valent pneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 515A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B conjugated to CRM 197, whereineach dose comprises about 2.2 µg of polysaccharide from each glycoconjugate from S.pneumoniae serotypes 1, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F,23A, 23B, 23F, 24F, 33F and 35B, and about 4.4 µg of polysaccharide for glycoconjugate fromS. pneumoniae serotypes 3 and 6B. In a preferred embodiment the immunogenic composition is 10a 25-valent pneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B conjugated to CRM 197, whereineach dose comprises about 2.0 µg of polysaccharide from each glycoconjugate from S. 15pneumoniae serotypes 1, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F,23A, 23B, 23F, 24F, 33F and 35B, and about 4.0 µg of polysaccharide for glycoconjugate fromS. pneumoniae serotypes 3 and 6B. In a preferred embodiment the immunogenic composition isa 25-valent pneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprising 20glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B conjugated to CRM 197, whereineach dose comprises about 2.2 µg of polysaccharide from each glycoconjugate from S.pneumoniae serotypes 1, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F,23A, 23B, 23F, 24F, 33F and 35B, about 4.4 µg of polysaccharide for glycoconjugate from S. 25pneumoniae serotype 6B and about 6.6 µg of polysaccharide for glycoconjugate from S.pneumoniae serotype 3. In a preferred embodiment the immunogenic composition is a 25-valentpneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 3015A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B conjugated to CRM 197, whereineach dose comprises about 2.0 µg of polysaccharide from each glycoconjugate from S.pneumoniae serotypes 1, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F,23A, 23B, 23F, 24F, 33F and 35B, about 4.0 µg of polysaccharide for glycoconjugate from S.pneumoniae serotype 6B and about 6.0 µg of polysaccharide for glycoconjugate from S. 35pneumoniae serotype 3. In a preferred embodiment the immunogenic composition is a 25-valentpneumococcal conjugate compositions. 122In an embodiment, the invention relates to an immunogenic composition comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B conjugated to CRM 197, whereineach dose comprises about 2.2 µg of polysaccharide from each glycoconjugate from S.pneumoniae serotypes 1, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 523A, 23B, 23F, 24F, 33F and 35B, about 4.4 µg of polysaccharide for glycoconjugate from S.pneumoniae serotype 6B and about 8.8 µg of polysaccharide for glycoconjugate from S.pneumoniae serotype 3. In a preferred embodiment the immunogenic composition is a 25-valentpneumococcal conjugate compositions.In an embodiment, the invention relates to an immunogenic composition comprising 10glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B conjugated to CRM 197, whereineach dose comprises about 2.0 µg of polysaccharide from each glycoconjugate from S.pneumoniae serotypes 1, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F,23A, 23B, 23F, 24F, 33F and 35B, about 4.0 µg of polysaccharide for glycoconjugate from S. 15pneumoniae serotype 6B and about 8.0 µg of polysaccharide for glycoconjugate from S.pneumoniae serotype 3. In a preferred embodiment the immunogenic composition is a 25-valentpneumococcal conjugate compositions.In a preferred embodiment, the invention relates to a 25-valent pneumococcal conjugateimmunogenic wherein said 25 glycoconjugates are glycoconjugates from S. pneumoniae 20serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A,23B, 23F, 24F, 33F and 35B, wherein the glycoconjugate from S. pneumoniae serotype 3 isconjugated to SCP and the glycoconjugates from S. pneumoniae serotypes 1, 4, 5, 6A, 6B, 7F,8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B areconjugated to CRM 197, wherein each dose comprises about 2.0 µg of polysaccharide from each 25glycoconjugate from S. pneumoniae serotypes 1, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A,15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B and about 4.0 µg of polysaccharidefor glycoconjugates from S. pneumoniae serotypes 3 and 6B. In a preferred embodiment saidglycoconjugate from S. pneumoniae serotype 3 is prepared using click chemistry, saidglycoconjugates from S. pneumoniae serotypes 1, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 3015B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F and 35B are prepared using reductive aminationand said serotype 33F glycoconjugate is prepared using eTEC conjugation.In a very preferred embodiment, the invention relates to a 25-valent pneumococcalconjugate immunogenic wherein said 25 glycoconjugates are glycoconjugates from S.pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 3522F, 23A, 23B, 23F, 24F, 33F and 35B, wherein the glycoconjugate from S. pneumoniae serotypeis conjugated to SCP and the glycoconjugates from S. pneumoniae serotypes 1, 4, 5, 6A, 6B,7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B 123are conjugated to CRM 197, wherein each dose comprises about 2.2 µg of polysaccharide fromeach glycoconjugate from S. pneumoniae serotypes 1, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B and about 4.4 µg ofpolysaccharide for glycoconjugates from S. pneumoniae serotypes 3 and 6B. In a preferredembodiment said glycoconjugate from S. pneumoniae serotype 3 is prepared using click 5chemistry, said glycoconjugates from S. pneumoniae serotypes 1, 4, 5, 6A, 7F, 8, 9V, 10A, 11A,12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F and 35B are prepared using reductiveamination and said serotype 33F glycoconjugate is prepared using eTEC conjugation. 2.3 Carrier amount 10Generally, each dose will comprise 10 µg to 150 µg of carrier protein, particularly 15 µg to100 µg of carrier protein, more particularly 25 µg to 75 µg of carrier protein, and even moreparticularly 40 µg to 60 µg of carrier protein.In an embodiment, each dose will comprise 50 µg to 70 µg of carrier protein.In an embodiment, each dose will comprise about 30 µg, about 35 µg, about 40 µg, about 15µg, about 50 µg, or about 60 µg of carrier protein.In an embodiment, each dose will comprise about 65 µg of carrier protein.Preferably, each dose will comprise from about 45 µg to about 55 µg of carrier protein.Very preferably, each dose will comprise from about 60 µg to about 70 µg of carrier protein.In an embodiment, each dose will comprise about 47 µg of carrier protein. In an 20embodiment, each dose will comprise about 48 µg of carrier protein. In an embodiment, eachdose will comprise about 49 µg of carrier protein. In an embodiment, each dose will compriseabout 50 µg of carrier protein. In an embodiment, each dose will comprise about 51 µg of carrierprotein. In an embodiment, each dose will comprise about 52 µg of carrier protein. In anembodiment, each dose will comprise about 53 µg of carrier protein. 25In an embodiment, each dose will comprise about 60 µg of carrier protein. In anembodiment, each dose will comprise about 61 µg of carrier protein. In an embodiment, eachdose will comprise about 62 µg of carrier protein. In an embodiment, each dose will compriseabout 63 µg of carrier protein. In an embodiment, each dose will comprise about 64 µg of carrierprotein. In an embodiment, each dose will comprise about 65 µg of carrier protein. In an 30embodiment, each dose will comprise about 66 µg of carrier protein. In an embodiment, eachdose will comprise about 67 µg of carrier protein. In an embodiment, each dose will compriseabout 68 µg of carrier protein. In an embodiment, each dose will comprise about 69 µg of carrierprotein. In an embodiment, each dose will comprise about 70 µg of carrier protein.In a preferred embodiment, each dose will comprise about 65 µg of carrier protein. 35In an embodiment, each dose will comprise from about 50 µg to about 70 µg of CRM 197and from about 2 µg to about 10 µg of SCP. In an embodiment, each dose will comprise fromabout 55 µg to about 65 µg of CRM 197 and from about 3 µg to about 7 µg of SCP. 124In a preferred embodiment, each dose will comprise about 60 µg of CRM 197 and about 5µg of SCP. 2.4 Further antigens Immunogenic compositions of the invention comprise conjugated S. pneumoniae 5saccharide antigen(s) (glycoconjugate(s)). They may also further include antigen(s) from otherpathogen(s), particularly from bacteria and/or viruses. Preferred further antigens are selectedfrom: a diphtheria toxoid (D), a tetanus toxoid (T), a pertussis antigen (P), which is typicallyacellular (Pa), a hepatitis B virus (HBV) surface antigen (HBsAg), a hepatitis A virus (HAV)antigen, a conjugated Haemophilus influenzae type b capsular saccharide (Hib), inactivated 10poliovirus vaccine (IPV).In an embodiment, the immunogenic compositions of the invention comprise D-T-Pa. Inan embodiment, the immunogenic compositions of the invention comprise D-T-Pa-Hib, D-T-Pa-IPV or D-T-Pa-HBsAg. In an embodiment, the immunogenic compositions of the inventioncomprise D-T-Pa-HBsAg-IPV or D-T-Pa-HBsAg-Hib. In an embodiment, the immunogenic 15compositions of the invention comprise D-T-Pa-HBsAg-IPV-Hib.Pertussis antigens: Bordetella pertussis causes whooping cough. Pertussis antigens invaccines are either cellular (whole cell, in the form of inactivated B. pertussis cells) or acellular.Preparation of cellular pertussis antigens is well documented (e.g., it may be obtained by heatinactivation of phase I culture of B. pertussis). Preferably, however, the invention uses acellular 20antigens. Where acellular antigens are used, it is preferred to use one, two or (preferably) threeof the following antigens: (1) detoxified pertussis toxin (pertussis toxoid, or PT); (2) filamentoushemagglutinin (FHA); (3) pertactin (also known as the 69 kilodalton outer membrane protein).FHA and pertactin may be treated with formaldehyde prior to use according to the invention. PTis preferably detoxified by treatment with formaldehyde and/or glutaraldehyde. Acellular pertussis 25antigens are preferably adsorbed onto one or more aluminum salt adjuvants. As an alternative,they may be added in an unadsorbed state. Where pertactin is added then it is preferably alreadyadsorbed onto an aluminum hydroxide adjuvant. PT and FHA may be adsorbed onto an aluminumhydroxide adjuvant or an aluminum phosphate. Adsorption of all of PT, FHA and pertactin toaluminum hydroxide is most preferred. 30Inactivated poliovirus vaccine: Poliovirus causes poliomyelitis. Rather than use oralpoliovirus vaccine, preferred embodiments of the invention use IPV. Prior to administration topatients, polioviruses must be inactivated, and this can be achieved by treatment withformaldehyde. Poliomyelitis can be caused by one of three types of poliovirus. The three typesare similar and cause identical symptoms, but they are antigenically different and infection by one 35type does not protect against infection by others. It is therefore preferred to use three poliovirusantigens in the invention: poliovirus Type 1 (e.g., Mahoney strain), poliovirus Type 2 (e.g., MEF-strain), and poliovirus Type 3 (e.g., Saukett strain). The viruses are preferably grown, purified 125and inactivated individually, and are then combined to give a bulk trivalent mixture for use withthe invention.Diphtheria toxoid: Corynebacterium diphtheriae causes diphtheria. Diphtheria toxin can betreated (e.g., using formalin or formaldehyde) to remove toxicity while retaining the ability toinduce specific anti-toxin antibodies after injection. These diphtheria toxoids are used in diphtheria 5vaccines. Preferred diphtheria toxoids are those prepared by formaldehyde treatment. Thediphtheria toxoid can be obtained by growing C. diphtheriae in growth medium, followed byformaldehyde treatment, ultrafiltration and precipitation. The toxoided material may then betreated by a process comprising sterile filtration and/or dialysis. The diphtheria toxoid is preferablyadsorbed onto an aluminum hydroxide adjuvant. 10Tetanus toxoid: Clostridium tetani causes tetanus. Tetanus toxin can be treated to give aprotective toxoid. The toxoids are used in tetanus vaccines. Preferred tetanus toxoids are thoseprepared by formaldehyde treatment. The tetanus toxoid can be obtained by growing C. tetani ingrowth medium, followed by formaldehyde treatment, ultrafiltration and precipitation. The materialmay then be treated by a process comprising sterile filtration and/or dialysis. 15Hepatitis A virus antigens: Hepatitis A virus (HAV) is one of the known agents whichcauses viral hepatitis. A preferred HAV component is based on inactivated virus, and inactivationcan be achieved by formalin treatment.Hepatitis B virus (HBV) is one of the known agents which causes viral hepatitis. The majorcomponent of the capsid is a protein known as HBV surface antigen or, more commonly, HBsAg, 20which is typically a 226-amino acid polypeptide with a molecular weight of ~24 kDa. All existinghepatitis B vaccines contain HBsAg, and when this antigen is administered to a normal vaccineeit stimulates the production of anti-HBsAg antibodies which protect against HBV infection. Forvaccine manufacture, HBsAg has been made in two ways: purification of the antigen in particulateform from the plasma of chronic hepatitis B carriers or expression of the protein by recombinant 25DNA methods (e.g., recombinant expression in yeast cells). Unlike native HBsAg (i.e., as in theplasma-purified product), yeast-expressed HBsAg is generally non-glycosylated, and this is themost preferred form of HBsAg for use with the invention.Conjugated Haemophilus influenzae type b antigens: Haemophilus influenzae type b (Hib)causes bacterial meningitis. Hib vaccines are typically based on the capsular saccharide antigen, 30the preparation of which is well documented. The Hib saccharide can be conjugated to a carrierprotein in order to enhance its immunogenicity, especially in children. Typical carrier proteins aretetanus toxoid, diphtheria toxoid, CRM 197, H.influenzae protein D, and an outer membrane proteincomplex from serogroup B meningococcus. The saccharide moiety of the conjugate maycomprise full-length polyribosylribitol phosphate (PRP) as prepared from Hib bacteria, and/or 35fragments of full-length PRP. Hib conjugates may or may not be adsorbed to an aluminum saltadjuvant. 126In an embodiment the immunogenic compositions of the invention further include aconjugated N. meningitidis serogroup Y capsular saccharide (MenY), and/or a conjugated N.meningitidis serogroup C capsular saccharide (MenC).In an embodiment the immunogenic compositions of the invention further include aconjugated N. meningitidis serogroup A capsular saccharide (MenA), a conjugated N. 5meningitidis serogroup W135 capsular saccharide (MenW135), a conjugated N. meningitidisserogroup Y capsular saccharide (MenY), and/or a conjugated N. meningitidis serogroup Ccapsular saccharide (MenC).In an embodiment the immunogenic compositions of the invention further include aconjugated N. meningitidis serogroup W135 capsular saccharide (MenW135), a conjugated N. 10meningitidis serogroup Y capsular saccharide (MenY), and/or a conjugated N. meningitidisserogroup C capsular saccharide (MenC). 2.5 Adjuvant(s) In some embodiments, the immunogenic compositions disclosed herein may further 15comprise at least one, two or three adjuvants. In some embodiments, the immunogeniccompositions disclosed herein may further comprise at least one adjuvant.In some embodiments, the immunogenic compositions disclosed herein may furthercomprise one adjuvant.In some embodiments, the immunogenic compositions disclosed herein may further 20comprise two adjuvants.The term "adjuvant" refers to a compound or mixture that enhances the immune responseto an antigen. Antigens may act primarily as a delivery system, primarily as an immune modulatoror have strong features of both. Suitable adjuvants include those suitable for use in mammals,including humans. 25Examples of known suitable delivery-system type adjuvants that can be used in humansinclude, but are not limited to, alum (e.g., aluminum phosphate, aluminum sulfate or aluminumhydroxide), calcium phosphate, liposomes, oil-in-water emulsions such as MF59 (4.3% w/vsqualene, 0.5% w/v polysorbate 80 (Tween 80), 0.5% w/v sorbitan trioleate (Span 85)), water-in-oil emulsions such as Montanide, and poly(D,L-lactide-co-glycolide) (PLG) microparticles or 30nanoparticles.In an embodiment, the immunogenic compositions disclosed herein comprise aluminumsalts (alum) as adjuvant (e.g., aluminum phosphate, aluminum sulfate or aluminum hydroxide).In a preferred embodiment, the immunogenic compositions disclosed herein comprisealuminum phosphate or aluminum hydroxide as adjuvant. In an even preferred embodiment, the 35immunogenic compositions disclosed herein comprise aluminum phosphate as adjuvant.Further exemplary adjuvants to enhance effectiveness of the immunogenic compositionsas disclosed herein include, but are not limited to: (1) oil-in-water emulsion formulations (with or 127without other specific immunostimulating agents such as muramyl peptides (see below) orbacterial cell wall components), such as for example (a) SAF, containing 10% Squalene, 0.4%Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP either microfluidized into a submicronemulsion or vortexed to generate a larger particle size emulsion, and (b) RIBI™ adjuvant system(RAS), (Ribi Immunochem, Hamilton, MT) containing 2% Squalene, 0.2% Tween 80, and one or 5more bacterial cell wall components such as monophosphorylipid A (MPL), trehalose dimycolate(TDM), and cell wall skeleton (CWS), preferably MPL + CWS (DETOX™); (2) saponin adjuvants,such as QS21, STIMULON™ (Cambridge Bioscience, Worcester, MA), ABISCO® (Isconova,Sweden), or ISCOMATRIX® (Commonwealth Serum Laboratories, Australia), may be used orparticles generated therefrom such as ISCOMs (immunostimulating complexes), which ISCOMS 10may be devoid of additional detergent (e.g., WO 00/07621); (3) Complete Freund's Adjuvant(CFA) and Incomplete Freund's Adjuvant (IFA); (4) cytokines, such as interleukins (e.g., IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12 (e.g., WO 99/44636)), interferons (e.g., gamma interferon),macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc.; (5)monophosphoryl lipid A (MPL) or 3-O-deacylated MPL (3dMPL) (see, e.g., GB-2220221, 15EP0689454), optionally in the substantial absence of alum when used with pneumococcalsaccharides (see, e.g., WO 00/56358); (6) combinations of 3dMPL with, for example, QS21 and/oroil-in-water emulsions (see, e.g., EP0835318, EP0735898, EP0761231); (7) a polyoxyethyleneether or a polyoxyethylene ester (see, e.g., WO 99/52549); (8) a polyoxyethylene sorbitan estersurfactant in combination with an octoxynol (e.g., WO 01/21207) or a polyoxyethylene alkyl ether 20or ester surfactant in combination with at least one additional non-ionic surfactant such as anoctoxynol (e.g., WO 01/21152); (9) a saponin and an immunostimulatory oligonucleotide (e.g., aCpG oligonucleotide) (e.g., WO 00/62800); (10) an immunostimulant and a particle of metal salt(see, e.g., WO 00/23105); (11) a saponin and an oil-in-water emulsion (e.g., WO 99/11241); (12)a saponin (e.g., QS21) + 3dMPL + IM2 (optionally + a sterol) (e.g., WO 98/57659); (13) other 25substances that act as immunostimulating agents to enhance the efficacy of the composition.Muramyl peptides include N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-25 acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutarninyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-gIycero-3-hydroxyphosphoryloxy)-ethylamine MTP-PE), etc.In an embodiment of the present invention, the immunogenic compositions as disclosed 30herein comprise a CpG Oligonucleotide as adjuvant. A CpG oligonucleotide as used herein refersto an immunostimulatory CpG oligodeoxynucleotide (CpG ODN), and accordingly these termsare used interchangeably unless otherwise indicated. Immunostimulatory CpGoligodeoxynucleotides contain one or more immunostimulatory CpG motifs that are unmethylatedcytosine-guanine dinucleotides, optionally within certain preferred base contexts. The methylation 35status of the CpG immunostimulatory motif generally refers to the cytosine residue in thedinucleotide. An immunostimulatory oligonucleotide containing at least one unmethylated CpGdinucleotide is an oligonucleotide which contains a 5' unmethylated cytosine linked by a 128phosphate bond to a 3' guanine, and which activates the immune system through binding to Toll-like receptor 9 (TLR-9). In another embodiment the immunostimulatory oligonucleotide maycontain one or more methylated CpG dinucleotides, which will activate the immune systemthrough TLR9 but not as strongly as if the CpG motif(s) was/were unmethylated. CpGimmunostimulatory oligonucleotides may comprise one or more palindromes that in turn may 5encompass the CpG dinucleotide. CpG oligonucleotides have been described in a number ofissued patents, published patent applications, and other publications, including U.S. Patent Nos.6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; and 6,339,068.In an embodiment of the present invention, the immunogenic compositions as disclosed hereincomprise any of the CpG Oligonucleotide described at page 3, line 22, to page 12, line 36, of WO 102010/125480.Different classes of CpG immunostimulatory oligonucleotides have been identified. Theseare referred to as A, B, C and P class, and are described in greater detail at page 3, line 22, topage 12, line 36, of WO 2010/125480. Methods of the invention embrace the use of these differentclasses of CpG immunostimulatory oligonucleotides. 15 3 Formulation The immunogenic compositions of the invention may be formulated in liquid form (i.e.,solutions or suspensions) or in a lyophilized form. In an embodiment, the immunogeniccomposition of the invention is formulated in a liquid form. In an embodiment, the immunogenic 20composition of the invention is formulated in a lyophilized form. Liquid formulations mayadvantageously be administered directly from their packaged form and are thus ideal for injectionwithout the need for reconstitution in aqueous medium as otherwise required for lyophilizedcompositions of the invention.Formulation of the immunogenic composition of the present disclosure can be accomplished 25using art-recognized methods. For instance, the individual polysaccharides and/or conjugates canbe formulated with a physiologically acceptable vehicle to prepare the composition. Examples ofsuch vehicles include, but are not limited to, water, buffered saline, polyols (e.g., glycerol,propylene glycol, liquid polyethylene glycol) and dextrose solutions.The present disclosure provides an immunogenic composition comprising any of 30combination of glycoconjugates disclosed herein and a pharmaceutically acceptable excipient,carrier, or diluent.In an embodiment, the immunogenic composition of the disclosure is in liquid form,preferably in aqueous liquid form.Immunogenic compositions of the disclosure may comprise one or more of a buffer, a salt, 35a divalent cation, a non-ionic detergent, a cryoprotectant such as a sugar, and an anti-oxidantsuch as a free radical scavenger or chelating agent, or any multiple combinations thereof. 129In an embodiment, the immunogenic compositions of the disclosure comprise a buffer. Inan embodiment, said buffer has a pKa of about 3.5 to about 7.5. In some embodiments, the bufferis phosphate, succinate, histidine or citrate. In some embodiments, the buffer is succinate. Insome embodiments, the buffer is histidine. In certain embodiments, the buffer is succinate at afinal concentration of 1 mM to 10 mM. In one particular embodiment, the final concentration of the 5succinate buffer is about 5 mM.In an embodiment, the immunogenic compositions of the disclosure comprise a salt. Insome embodiments, the salt is selected from the groups consisting of magnesium chloride,potassium chloride, sodium chloride and a combination thereof. In one particular embodiment,the salt is sodium chloride. In one particular embodiment, the immunogenic compositions of the 10invention comprise sodium chloride at 150 mM.In an embodiment, the immunogenic compositions of the disclosure comprise a surfactant.In an embodiment, the surfactant is selected from the group consisting of polysorbate 20(TWEENTM20), polysorbate 40 (TWEENTM40), polysorbate 60 (TWEEN™60), polysorbate 65(TWEEN™65), polysorbate 80 (TWEEN™80), polysorbate 85 (TWEEN™85), TRITON™ N-101, 15TRITON™ X-100, oxtoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptideoleate, polyoxyethylene-660 hydroxystearate (PEG-15, Solutol H 15), polyoxyethylene-35-ricinoleate (CREMOPHOR® EL), soy lecithin and a poloxamer.In one particular embodiment, the surfactant is polysorbate 80. In some said embodiment,the final concentration of polysorbate 80 in the formulation is at least 0.0001% to 10% polysorbate 20weight to weight (w/w). In some said embodiments, the final concentration of polysorbate 80in the formulation is at least 0.001% to 1% polysorbate 80 weight to weight (w/w). In some saidembodiments, the final concentration of polysorbate 80 in the formulation is at least 0.01% to 1%polysorbate 80 weight to weight (w/w). In other embodiments, the final concentration ofpolysorbate 80 in the formulation is 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 250.09% or 0.1% polysorbate 80 (w/w). In another embodiment, the final concentration of thepolysorbate 80 in the formulation is 0.02% polysorbate 80 (w/w). In another embodiment, the finalconcentration of the polysorbate 80 in the formulation is 0.01% polysorbate 80 (w/w). In anotherembodiment, the final concentration of the polysorbate 80 in the formulation is 0.03% polysorbate(w/w). In another embodiment, the final concentration of the polysorbate 80 in the formulation 30is 0.04% polysorbate 80 (w/w). In another embodiment, the final concentration of the polysorbatein the formulation is 0.05% polysorbate 80 (w/w). In another embodiment, the finalconcentration of the polysorbate 80 in the formulation is 1% polysorbate 80 (w/w).In one particular embodiment, the surfactant is polysorbate 20. In some said embodiment,the final concentration of polysorbate 20 in the formulation is at least 0.0001% to 10% polysorbate 35weight to weight (w/w). In some said embodiments, the final concentration of polysorbate 20in the formulation is at least 0.001% to 1% polysorbate 20 weight to weight (w/w). In some saidembodiments, the final concentration of polysorbate 20 in the formulation is at least 0.01% to 1% 130polysorbate 20 weight to weight (w/w). In other embodiments, the final concentration ofpolysorbate 20 in the formulation is 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%,0.09% or 0.1% polysorbate 20 (w/w). In another embodiment, the final concentration of thepolysorbate 20 in the formulation is 0.02% polysorbate 20 (w/w). In another embodiment, the finalconcentration of the polysorbate 20 in the formulation is 0.01% polysorbate 20 (w/w). In another 5embodiment, the final concentration of the polysorbate 20 in the formulation is 0.03% polysorbate(w/w). In another embodiment, the final concentration of the polysorbate 20 in the formulationis 0.04% polysorbate 80 (w/w). In another embodiment, the final concentration of the polysorbatein the formulation is 0.05% polysorbate 20 (w/w). In another embodiment, the finalconcentration of the polysorbate 20 in the formulation is 1% polysorbate 20 (w/w). 10In one particular embodiment, the surfactant is polysorbate 40. In some said embodiment,the final concentration of polysorbate 40 in the formulation is at least 0.0001% to 10% polysorbateweight to weight (w/w). In some said embodiments, the final concentration of polysorbate 40in the formulation is at least 0.001% to 1% polysorbate 40 weight to weight (w/w). In some saidembodiments, the final concentration of polysorbate 40 in the formulation is at least 0.01% to 1% 15polysorbate 40 weight to weight (w/w). In other embodiments, the final concentration ofpolysorbate 40 in the formulation is 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%,0.09% or 0.1% polysorbate 40 (w/w). In another embodiment, the final concentration of thepolysorbate 40 in the formulation is 1% polysorbate 40 (w/w).In one particular embodiment, the surfactant is polysorbate 60. In some said embodiment, 20the final concentration of polysorbate 60 in the formulation is at least 0.0001% to 10% polysorbateweight to weight (w/w). In some said embodiments, the final concentration of polysorbate 60in the formulation is at least 0.001% to 1% polysorbate 60 weight to weight (w/w). In some saidembodiments, the final concentration of polysorbate 60 in the formulation is at least 0.01% to 1%polysorbate 60 weight to weight (w/w). In other embodiments, the final concentration of 25polysorbate 60 in the formulation is 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%,0.09% or 0.1% polysorbate 60 (w/w). In another embodiment, the final concentration of thepolysorbate 60 in the formulation is 1% polysorbate 60 (w/w).In one particular embodiment, the surfactant is polysorbate 65. In some said embodiment,the final concentration of polysorbate 65 in the formulation is at least 0.0001% to 10% polysorbate 30weight to weight (w/w). In some said embodiments, the final concentration of polysorbate 65in the formulation is at least 0.001% to 1% polysorbate 65 weight to weight (w/w). In some saidembodiments, the final concentration of polysorbate 65 in the formulation is at least 0.01% to 1%polysorbate 65 weight to weight (w/w). In other embodiments, the final concentration ofpolysorbate 65 in the formulation is 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 350.09% or 0.1% polysorbate 65 (w/w). In another embodiment, the final concentration of thepolysorbate 65 in the formulation is 1% polysorbate 65 (w/w). 131In one particular embodiment, the surfactant is polysorbate 85. In some said embodiment,the final concentration of polysorbate 85 in the formulation is at least 0.0001% to 10% polysorbateweight to weight (w/w). In some said embodiments, the final concentration of polysorbate 85in the formulation is at least 0.001% to 1% polysorbate 85 weight to weight (w/w). In some saidembodiments, the final concentration of polysorbate 85 in the formulation is at least 0.01% to 1% 5polysorbate 85 weight to weight (w/w). In other embodiments, the final concentration ofpolysorbate 85 in the formulation is 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%,0.09% or 0.1% polysorbate 85 (w/w). In another embodiment, the final concentration of thepolysorbate 85 in the formulation is 1% polysorbate 85 (w/w).In certain embodiments, the immunogenic composition of the disclosure has a pH of 5.5 10to 7.5, more preferably a pH of 5.6 to 7.0, even more preferably a pH of 5.8 to 6.0.In one embodiment, the present disclosure provides a container filled with any of theimmunogenic compositions disclosed herein. In one embodiment, the container is selected fromthe group consisting of a vial, a syringe, a flask, a fermentor, a bioreactor, a bag, a jar, anampoule, a cartridge and a disposable pen. In certain embodiments, the container is siliconized. 15In an embodiment, the container of the present disclosure is made of glass, metals (e.g.,steel, stainless steel, aluminum, etc.) and/or polymers (e.g., thermoplastics, elastomers,thermoplastic-elastomers). In an embodiment, the container of the present disclosure is made ofglass.In one embodiment, the present disclosure provides a syringe filled with any of the 20immunogenic compositions disclosed herein. In certain embodiments, the syringe is siliconizedand/or is made of glass.A typical dose of the immunogenic composition of the invention for injection has a volumeof 0.1 mL to 2 mL. In an embodiment, the immunogenic composition of the invention for injectionhas a volume of 0.2 mL to 1 mL, even more preferably a volume of about 0.5 mL. 25 4 Uses of the glycoconjugate and immunogenic compositions of the invention The glycoconjugates disclosed herein may be use as antigens. For example, they may bepart of a vaccine.Therefore, in an embodiment, the immunogenic compositions of the invention are for use 30as a medicament.In an embodiment, the immunogenic compositions of the invention are for use as avaccine.Therefore, in an embodiment, the immunogenic compositions described herein are for usein generating an immune response in a subject. In one aspect, the subject is a mammal, such as 35a human, non-human primate, cat, sheep, pig, horse, bovine or dog. Preferably, the subject is ahuman. 132The immunogenic compositions described herein may be used in therapeutic orprophylactic methods for preventing, treating or ameliorating a bacterial infection, disease orcondition in a subject. In particular, immunogenic compositions described herein may be used toprevent, treat or ameliorate a S. pneumoniae infection, disease or condition in a subject.Preferably, the immunogenic compositions described herein may be used to prevent, treat or 5ameliorate S. pneumoniae infection, disease or condition by the serotypes contained in thecomposition in a subject.Thus, in one aspect, the disclosure provides a method of preventing, treating orameliorating an infection, disease or condition associated with S. pneumoniae serotypes 1, 3, 4,5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F 10and/or 35B in a subject, comprising administering to the subject an immunologically effectiveamount of an immunogenic composition of the disclosure.In an aspect, the disclosure provides a method of preventing, treating or ameliorating aninfection, disease or condition associated with S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8,9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B in a 15subject, comprising administering to the subject an immunologically effective amount of animmunogenic composition of the disclosure.In some such embodiments, the infection, disease or condition is selected from the groupconsisting of pneumonia, sinusitis, otitis media, acute otitis media, meningitis, bacteremia, sepsis,pleural empyema, conjunctivitis, osteomyelitis, septic arthritis, endocarditis, peritonitis, 20pericarditis, mastoiditis, cellulitis, soft tissue infection and brain abscess.In an embodiment, the disclosure provides a method of inducing an immune response toS. pneumoniae serotype 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A,19F, 22F, 23A, 23B, 23F, 24F, 33F and/or 35B in a subject comprising administering to thesubject an immunologically effective amount of an immunogenic composition of the invention. In 25one aspect, the subject is a mammal, such as a human, cat, sheep, pig, horse, bovine or dog.Preferably the subject is a human.In an embodiment, the disclosure provides a method of inducing an immune response toS. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A,19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B in a subject comprising administering to the subject 30an immunologically effective amount of an immunogenic composition of the invention. In oneaspect, the subject is a mammal, such as a human, cat, sheep, pig, horse, bovine or dog.Preferably the subject is a human.In an embodiment, the immunogenic compositions disclosed herein are for use as avaccine. In such embodiments the immunogenic compositions described herein may be used to 35prevent S. pneumoniae serotype 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C,19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and/or 35B infection in a subject. Thus, in one aspect,the invention provides a method of preventing an infection by S. pneumoniae serotype 1, 3, 4, 5, 1336A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33Fand/or 35B in a subject comprising administering to the subject an immunologically effectiveamount of an immunogenic composition of the disclosure. In some such embodiments, theinfection is selected from the group consisting of pneumonia, sinusitis, otitis media, acute otitismedia, meningitis, bacteremia, sepsis, pleural empyema, conjunctivitis, osteomyelitis, septic 5arthritis, endocarditis, peritonitis, pericarditis, mastoiditis, cellulitis, soft tissue infection and brainabscess. In one aspect, the subject is a mammal, such as a human, cat, sheep, pig, horse, bovineor dog. Preferably the subject is a human.In one aspect, the invention provides a method of preventing an infection by S.pneumoniae serotype 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 1022F, 23A, 23B, 23F, 24F, 33F and 35B in a subject comprising administering to the subject animmunologically effective amount of an immunogenic composition of the disclosure. In some suchembodiments, the infection is selected from the group consisting of pneumonia, sinusitis, otitismedia, acute otitis media, meningitis, bacteremia, sepsis, pleural empyema, conjunctivitis,osteomyelitis, septic arthritis, endocarditis, peritonitis, pericarditis, mastoiditis, cellulitis, soft tissue 15infection and brain abscess. In one aspect, the subject is a mammal, such as a human, cat, sheep,pig, horse, bovine or dog. Preferably the subject is a human.The immunogenic composition of the present disclosure can be used to protect or treat ahuman susceptible to a S. pneumoniae serotype 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and/or 35B infection, by means of 20administering the immunogenic composition via a systemic or mucosal route. In an embodiment,the immunogenic composition of the invention is administered by intramuscular, intraperitoneal,intradermal or subcutaneous routes. . In an embodiment, the immunogenic composition of theinvention is administered by intramuscular, intraperitoneal, intradermal or subcutaneous injection.In an embodiment, the immunogenic composition of the invention is administered by 25intramuscular or subcutaneous injection. In an embodiment, the immunogenic composition of theinvention is administered by intramuscular injection. In an embodiment, the immunogeniccomposition of the invention is administered by subcutaneous injection.The immunogenic composition of the present disclosure can be used to protect or treat ahuman susceptible to a S. pneumoniae serotype 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 3015A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B infection, by means ofadministering the immunogenic composition via a systemic or mucosal route. In an embodiment,the immunogenic composition of the invention is administered by intramuscular, intraperitoneal,intradermal or subcutaneous routes. . In an embodiment, the immunogenic composition of theinvention is administered by intramuscular, intraperitoneal, intradermal or subcutaneous injection. 35In an embodiment, the immunogenic composition of the invention is administered byintramuscular or subcutaneous injection. In an embodiment, the immunogenic composition of the 134invention is administered by intramuscular injection. In an embodiment, the immunogeniccomposition of the invention is administered by subcutaneous injection.
Subject to be treated with the immunogenic compositions of the invention As disclosed herein, the immunogenic compositions described herein may be used in 5various therapeutic or prophylactic methods for preventing, treating or ameliorating a bacterialinfection, disease or condition in a subject.In a preferred embodiment, said subject is a human. In a most preferred embodiment, saidsubject is a newborn (i.e., under three months of age), an infant (i.e., from 3 months to one yearof age) or a toddler (i.e., from one year to four years of age). In an embodiment, the immunogenic 10compositions disclosed herein are for use as a vaccine.In such embodiment, the subject to be vaccinated may be less than 1 year of age. Forexample, the subject to be vaccinated can be about 1, about 2, about 3, about 4, about 5, about6, about 7, about 8, about 9, about 10, about 11 or about 12 months of age. In an embodiment,the subject to be vaccinated is about 2, about 4 or about 6 months of age. In another embodiment, 15the subject to be vaccinated is less than 2 years of age. For example, the subject to be vaccinatedcan be about 12 to about 15 months of age. In some cases, as little as one dose of theimmunogenic composition according to the invention is needed, but under some circumstances,a second, third or fourth dose may be given (see section 8 below).In an embodiment of the present invention, the subject to be vaccinated is a human adult 20years of age or older, more preferably a human adult 55 years of age or older. In anembodiment, the subject to be vaccinated is a human adult 65 years of age or older, 70 years ofage or older, 75 years of age or older or 80 years of age or older.In an embodiment the subject to be vaccinated is an immunocompromised individual, inparticular a human. An immunocompromised individual is generally defined as a person who 25exhibits an attenuated or reduced ability to mount a normal humoral or cellular defense tochallenge by infectious agents.In an embodiment of the present invention, the immunocompromised subject to bevaccinated suffers from a disease or condition that impairs the immune system and results in anantibody response that is insufficient to protect against or treat pneumococcal disease. 30In an embodiment, said disease is a primary immunodeficiency disorder. Preferably, saidprimary immunodeficiency disorder is selected from the group consisting of: combined T- and B-cell immunodeficiencies, antibody deficiencies, well-defined syndromes, immune dysregulationdiseases, phagocyte disorders, innate immunity deficiencies, autoinflammatory disorders, andcomplement deficiencies. In an embodiment, said primary immunodeficiency disorder is selected 35from the one disclosed on page 24, line 11, to page 25, line 19, of WO 2010/125480.In a particular embodiment of the present invention, the immunocompromised subject tobe vaccinated suffers from a disease selected from the groups consisting of: HIV-infection, 135acquired immunodeficiency syndrome (AIDS), cancer, chronic heart or lung disorders, congestiveheart failure, diabetes mellitus, chronic liver disease, alcoholism, cirrhosis, spinal fluid leaks,cardiomyopathy, chronic bronchitis, emphysema, chronic obstructive pulmonary disease (COPD),spleen dysfunction (such as sickle cell disease), lack of spleen function (asplenia), bloodmalignancy, leukemia, multiple myeloma, Hodgkin’s disease, lymphoma, kidney failure, nephrotic 5syndrome and asthma.In an embodiment of the present invention, the immunocompromised subject to be vaccinatedsuffers from malnutrition.In a particular embodiment of the present invention, the immunocompromised subject tobe vaccinated is taking a drug or treatment that lowers the body’s resistance to infection. In an 10embodiment, said drug is selected from the one disclosed on page 26, line 33, to page 26, line 4,of WO 2010/125480.In a particular embodiment of the present invention, the immunocompromised subject tobe vaccinated is a smoker.In a particular embodiment of the present invention, the immunocompromised subject to 15be vaccinated has a white blood cell count (leukocyte count) below 5 x 10 cells per liter, or belowx 10 cells per liter, or below 3 x 10 cells per liter, or below 2 x 10 cells per liter, or below 1 x9 cells per liter, or below 0.5 x 10 cells per liter, or below 0.3 x 10 cells per liter, or below 0.1x 10 cells per liter.White blood cell count (leukocyte count): The number of white blood cells (WBC) in the 20blood. The WBC is usually measured as part of the CBC (complete blood count). White bloodcells are the infection-fighting cells in the blood and are distinct from the red (oxygen-carrying)blood cells known as erythrocytes. There are different types of white blood cells, includingneutrophils (polymorphonuclear leukocytes; PMN), band cells (slightly immature neutrophils), T-type lymphocytes (T-cells), B-type lymphocytes (B-cells), monocytes, eosinophils, and basophils. 25All the types of white blood cells are reflected in the white blood cell count. The normal range forthe white blood cell count is usually between 4,300 and 10,800 cells per cubic millimeter of blood.This can also be referred to as the leukocyte count and can be expressed in international unitsas 4.3 - 10.8 x 10 cells per liter.In a particular embodiment of the present invention, the immunocompromised subject to 30be vaccinated suffers from neutropenia. In a particular embodiment of the present invention, theimmunocompromised subject to be vaccinated has a neutrophil count below 2 x 10 cells per liter,or below 1 x 10 cells per liter, or below 0.5 x 10 cells per liter, or below 0.1 x 10 cells per liter,or below 0.05 x 10 cells per liter.A low white blood cell count or "neutropenia" is a condition characterized by abnormally low levels 35of neutrophils in the circulating blood. Neutrophils are a specific kind of white blood cell that helpto prevent and fight infections. The most common reason that cancer patients experience 136neutropenia is as a side effect of chemotherapy. Chemotherapy-induced neutropenia increasesa patient’s risk of infection and disrupts cancer treatment.In a particular embodiment of the present invention, the immunocompromised subject tobe vaccinated has a CD4+ cell count below 500/mm, or CD4+ cell count below 300/mm, orCD4+ cell count below 200/mm, CD4+ cell count below 100/mm, CD4+ cell count below 575/mm, or CD4+ cell count below 50/mm.CD4 cell tests are normally reported as the number of cells in mm. Normal CD4 counts arebetween 500 and 1,600, and CD8 counts are between 375 and 1,100. CD4 counts dropdramatically in people with HIV.In an embodiment of the invention, any of the immunocompromised subjects disclosed 10herein is a human male or a human female. 6 Regimen In some cases, as little as one dose of the immunogenic composition according to theinvention is needed, but under some circumstances, such as conditions of greater immunedeficiency, a second, third or fourth dose may be given. Following an initial vaccination, subjects 15can receive one or several booster immunizations adequately spaced.In an embodiment, the schedule of vaccination of the immunogenic composition accordingto the invention is a single dose. In a particular embodiment, said single dose schedule is forhealthy persons being at least 2 years of age.In an embodiment, the schedule of vaccination of the immunogenic composition according 20to the invention is a multiple dose schedule. In a particular embodiment, said multiple doseschedule consists of a series of 2 doses separated by an interval of about 1 month to about 2months. In a particular embodiment, said multiple dose schedule consists of a series of 2 dosesseparated by an interval of about 1 month, or a series of 2 doses separated by an interval of aboutmonths. 25In another embodiment, said multiple dose schedule consists of a series of 3 dosesseparated by an interval of about 1 month to about 2 months. In another embodiment, saidmultiple dose schedule consists of a series of 3 doses separated by an interval of about 1 month,or a series of 3 doses separated by an interval of about 2 months.In another embodiment, said multiple dose schedule consists of a series of 3 doses 30separated by an interval of about 1 month to about 2 months followed by a fourth dose about 10months to about 13 months after the first dose. In another embodiment, said multiple doseschedule consists of a series of 3 doses separated by an interval of about 1 month followed by afourth dose about 10 months to about 13 months after the first dose, or a series of 3 dosesseparated by an interval of about 2 months followed by a fourth dose about 10 months to about 35months after the first dose. 137In an embodiment, the multiple dose schedule consists of at least one dose (e.g., 1, 2 ordoses) in the first year of age followed by at least one toddler dose.In an embodiment, the multiple dose schedule consists of a series of 2 or 3 dosesseparated by an interval of about 1 month to about 2 months (for example 28-56 days betweendoses), starting at 2 months of age, and followed by a toddler dose at 12-18 months of age. In an 5embodiment, said multiple dose schedule consists of a series of 3 doses separated by an intervalof about 1 month to about 2 months (for example 28-56 days between doses), starting at 2 monthsof age, and followed by a toddler dose at 12-15 months of age. In another embodiment, saidmultiple dose schedule consists of a series of 2 doses separated by an interval of about 2 months,starting at 2 months of age, and followed by a toddler dose at 12-18 months of age. 10In an embodiment, the multiple dose schedule consists of a 4-dose series of vaccine at 2,4, 6, and 12-15 months of age.In an embodiment, a prime dose is given at day 0 and one or more boosts are given atintervals that range from about 2 to about 24 weeks, preferably with a dosing interval of 4-8 weeks.In an embodiment, a prime dose is given at day 0 and a boost is given about 3 months 15later. 7 Particular embodiments of the invention are set forth in the following numbered paragraphs 1 to 715: 1. A S. pneumoniae serotype 15A glycoconjugate comprising a serotype 15A capsular 20polysaccharide wherein the weight average molecular weight (Mw) of said polysaccharide isbetween 50 kDa and 500 kDa. 2. The S. pneumoniae serotype 15A glycoconjugate of paragraph 1 wherein the weight averagemolecular weight (Mw) of said polysaccharide is between 75 kDa and 250 kDa. 3. The S. pneumoniae serotype 15A glycoconjugate of paragraph 1 wherein the weight average 25molecular weight (Mw) of said polysaccharide is between 75 kDa and 175 kDa. 4. The S. pneumoniae serotype 15A glycoconjugate of paragraph 1 wherein the weight averagemolecular weight (Mw) of said polysaccharide is between 90 kDa and 150 kDa.5. The S. pneumoniae serotype 15A glycoconjugate of any one of paragraphs 1-4 having aweight average molecular weight (Mw) of between 500 kDa and 10,000 kDa. 306. The S. pneumoniae serotype 15A glycoconjugate of any one of paragraphs 1-4 having aweight average molecular weight (Mw) of between 1,000 kDa and 10,000 kDa.7. The S. pneumoniae serotype 15A glycoconjugate of any one of paragraphs 1-4 having aweight average molecular weight (Mw) of between 1,000 kDa and 6,000 kDa.8. The S. pneumoniae serotype 15A glycoconjugate of any one of paragraphs 1-7 wherein the 35serotype 15A polysaccharide to carrier protein ratio (w/w) in the glycoconjugate is between0.5 and 3.0. 1389. The S. pneumoniae serotype 15A glycoconjugate of any one of paragraphs 1-7 wherein theserotype 15A polysaccharide to carrier protein ratio (w/w) in the glycoconjugate is between0.5 and 1.5.10. The S. pneumoniae serotype 15A glycoconjugate of any one of paragraphs 1-7 wherein theserotype 15A polysaccharide to carrier protein ratio (w/w) in the glycoconjugate is between 50.7 and 1.1.11. The S. pneumoniae serotype 15A glycoconjugate of any one of paragraphs 1-10 wherein thedegree of conjugation is between 2 and 20.12. The S. pneumoniae serotype 15A glycoconjugate of any one of paragraphs 1-10 wherein thedegree of conjugation is between 5 and 10. 1013. The S. pneumoniae serotype 15A glycoconjugate of any one of paragraphs 1-12 comprisingless than about 40% of free serotype 15A polysaccharide compared to the total amount ofserotype 15A polysaccharide.14. The S. pneumoniae serotype 15A glycoconjugate of any one of paragraphs 1-12 comprisingless than about 25% of free serotype 15A polysaccharide compared to the total amount of 15serotype 15A polysaccharide.15. The S. pneumoniae serotype 15A glycoconjugate of any one of paragraphs 1-14 wherein atleast 40% of the serotype 15A glycoconjugate has a Kd below or equal to 0.3 in a CL-4Bcolumn.16. The S. pneumoniae serotype 15A glycoconjugate of any one of paragraphs 1-14 wherein at 20least 50% of the glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.17. The S. pneumoniae serotype 15A glycoconjugate of any one of paragraphs 1-14 whereinbetween 50% and 90% of the serotype 15A glycoconjugate has a Kd below or equal to 0.3 ina CL-4B column.18. The S. pneumoniae serotype 15A glycoconjugate of any one of paragraphs 1-14 wherein the 25carrier protein of the glycoconjugates is the fusion protein CP1.19. The S. pneumoniae serotype 15A glycoconjugate of any one of paragraphs 1-14 wherein thecarrier protein of the glycoconjugate is H. influenzae protein D.20. The S. pneumoniae serotype 15A glycoconjugate of any one of paragraphs 1-14 wherein thecarrier protein of the glycoconjugate is TT, DT, CRM 197 or a C5a peptidase from Streptococcus 30(SCP).21. The S. pneumoniae serotype 15A glycoconjugate of any one of paragraphs 1-14 wherein thecarrier protein of the glycoconjugate is DT.22. The S. pneumoniae serotype 15A glycoconjugate of any one of paragraphs 1-14 wherein thecarrier protein of the glycoconjugate is TT. 3523. The S. pneumoniae serotype 15A glycoconjugate of any one of paragraphs 1-14 wherein thecarrier protein of the glycoconjugate is CRM 197 or a C5a peptidase from Streptococcus (SCP). 13924. The S. pneumoniae serotype 15A glycoconjugate of any one of paragraphs 1-14 wherein thecarrier protein of the glycoconjugate is a C5a peptidase from Streptococcus (SCP).25. The S. pneumoniae serotype 15A glycoconjugate of any one of paragraphs 1-14 wherein thecarrier protein of the glycoconjugate is CRM 197.26. The S. pneumoniae serotype 15A glycoconjugate of any one of paragraphs 1-25 prepared 5using reductive amination chemistry.27. A process for preparing a S. pneumoniae serotype 15A glycoconjugate by conjugating anisolated serotype 15A capsular polysaccharide to a carrier protein comprising the step of:(a) reacting an isolated serotype 15A capsular polysaccharide with an oxidizing agent; (b)compounding the activated polysaccharide of step (a) with a carrier protein; and (c) reacting 10the compounded activated polysaccharide and carrier protein with a reducing agent to form aglycoconjugate.28. The process of paragraph 27, wherein before the oxidation step (a) the isolated serotype 15Acapsular polysaccharide is sized.29. The process of any one of paragraphs 27-28, wherein the oxidation step (a) is carried out at 15a pH of between 4.0 and 6.0.30. The process of any one of paragraphs 27-28, wherein the oxidation step (a) is carried out ata pH of between 4.5 and 5.5.31. The process of any one of paragraphs 27-28, wherein the oxidation step (a) is carried out ata pH about 5.0. 2032. The process of any one of paragraphs 27-31, wherein the activated serotype 15Apolysaccharide has a weight average molecular weight (Mw) of between 50 kDa and 500 kDa.33. The process of any one of paragraphs 27-31, wherein the activated serotype 15Apolysaccharide has a weight average molecular weight (Mw) of between 75 kDa and 250 kDa.34. The process of any one of paragraphs 27-31, wherein the activated serotype 15A 25polysaccharide has a weight average molecular weight (Mw) of between 75 kDa and 175 kDa.35. The process of any one of paragraphs 27-31, wherein the activated serotype 15Apolysaccharide has a weight average molecular weight (Mw) of between 90 kDa and 150 kDa.36. The process of any one of paragraphs 27-35, wherein the oxidizing agent is periodate.37. The process of any one of paragraphs 27-35, wherein the oxidizing agent is sodium periodate. 3038. The process of any one of paragraphs 27-35, wherein the oxidizing agent is sodiummetaperiodate.39. The process of any one of paragraphs 27-38, wherein the oxidation step (a) comprisesreacting the polysaccharide with 0.1-2 molar equivalents of periodate.40. The process of any one of paragraphs 27-38, wherein the oxidation step (a) comprises 35reacting the polysaccharide with 0.5-1.5 molar equivalents of periodate.41. The process of any one of paragraphs 27-38, wherein the oxidation step (a) comprisesreacting the polysaccharide with 0.8-1.2 molar equivalents of periodate. 14042. The process of any one of paragraphs 27-41, wherein the degree of oxidation of the activatedserotype 15A polysaccharide is between 2 and 20.43. The process of any one of paragraphs 27-41, wherein the degree of oxidation of the activatedserotype 15A polysaccharide is between 2 and 8.44. The process of any one of paragraphs 27-41, wherein the degree of oxidation of the activated 5serotype 15A polysaccharide is 5 ±2.5.45. The process of any one of paragraphs 27-44, wherein the activated serotype 15Apolysaccharide and the carrier protein are lyophilised before step b).46. The process of any one of paragraphs 27-45, wherein lyophilisation occurs after step a).47. The process of any one of paragraphs 27-45, wherein the activated polysaccharide is 10lyophilised after step a) and the carrier protein is also lyophilised.48. The process of any one of paragraphs 27-45, wherein the activated serotype 15Apolysaccharide is lyophilised after step a) and the carrier protein is also lyophilised, and theactivated polysaccharide and the carrier protein are reconstituted in the same solution.49. The process of any one of paragraphs 45-48, wherein the activated serotype 15A 15polysaccharide and the carrier protein are Iyophilised independently.50. The process of any one of paragraphs 45-48, wherein the activated serotype 15Apolysaccharide and the carrier protein are Iyophilised together (co-lyophilized).51. The process of any one of paragraphs 27-50, wherein the initial input ratio (weight by weight)of activated serotype 15A capsular polysaccharide to carrier protein at step b) is between 3:1 20and 0.5:1.52. The process of any one of paragraphs 27-50, wherein the initial input ratio (weight by weight)of activated serotype 15A capsular polysaccharide to carrier protein at step b) is between1.5:1 and 0.5:1.53. The process of any one of paragraphs 27-50, wherein the initial input ratio (weight by weight) 25of activated serotype 15A capsular polysaccharide to carrier protein at step b) is between1.1:1 and 0.9:1.54. The process of any one of paragraphs 27-53, wherein the reduction reaction (c) is carried outin aqueous solvent.55. The process of any one of paragraphs 27-53, wherein the reduction reaction (c) is carried out 30in aprotic solvent.56. The process of any one of paragraphs 27-53, wherein the reduction reaction (c) is carried outin the presence of dimethylsulphoxide (DMSO) or dimethylformamide (DMF).57. The process of any one of paragraphs 27-53, wherein the reduction reaction (c) is carried outin the presence of dimethylsulphoxide (DMSO). 3558. The process of any one of paragraphs 27-53, wherein the reduction reaction (c) is carried outin DMSO (dimethylsulfoxide) or in DMF (dimethylformamide)) solvent. 14159. The process of any one of paragraphs 27-53, wherein the reduction reaction (c) is carried outin DMSO (dimethylsulfoxide) solvent.60. The process of any one of paragraphs 27-59, wherein the reducing agent is sodiumcyanoborohydride, sodium triacetoxyborohydride, sodium or zinc borohydride in the presenceof Bronsted or Lewis acids, amine boranes such as pyridine borane, 2-Picoline Borane, 2,6- 5diborane-methanol, dimethylamine-borane, t-BuMeiPrN-BH3, benzylamine-BH3 or 5-ethyl-2-methylpyridine borane (PEMB).61. The process of any one of paragraphs 27-59, wherein the reducing agent is sodiumtriacetoxyborohydride.62. The process of any one of paragraphs 27-59, wherein the reducing agent is sodium 10cyanoborohydride in the present of nickel.63. The process of any one of paragraphs 27-59, wherein the reducing agent is sodiumcyanoborohydride.64. The process of any one of paragraphs 27-63, wherein between 0.2 and 5 molar equivalentsof reducing agent is used in step c). 1565. The process of any one of paragraphs 27-63, wherein between 0.5 and 2 molar equivalentsof reducing agent is used in step c).66. The process of any one of paragraphs 27-63, wherein between 0.9 and 1.1 molar equivalentof reducing agent is used in step c).67. The process of any one of paragraphs 27-66, wherein following the reduction reaction (c), 20unreacted aldehyde groups remaining in the conjugates are capped using a suitable cappingagent.68. The process of paragraph 67, wherein said capping agent is sodium borohydride (NaBH4).69. The process of any one of paragraphs 67-68, wherein capping is achieved by mixing theproduct of step c) with 1 to 3 molar equivalents of sodium borohydride. 2570. The process of any one of paragraphs 27-69, comprising the step of purifying theglycoconjugate after it is produced.71. The process of any one of paragraphs 27-70, wherein the carrier protein is the fusion proteinCP1.72. The process of any one of paragraphs 27-70, wherein the carrier protein is H. influenzae 30protein D.73. The process of any one of paragraphs 27-70, wherein the carrier protein is TT, DT, CRM 197or a C5a peptidase from Streptococcus (SCP).74. The process of any one of paragraphs 27-70, wherein the carrier protein is DT.75. The process of any one of paragraphs 27-70, wherein the carrier protein is TT. 3576. The process of any one of paragraphs 27-70, wherein the carrier protein is CRM 197 or a C5apeptidase from Streptococcus (SCP). 14277. The process of any one of paragraphs 27-70, wherein the carrier protein is a C5a peptidasefrom Streptococcus (SCP).78. The process of any one of paragraphs 27-70, wherein the carrier protein is CRM 197.79. A S. pneumoniae serotype 15A glycoconjugate obtained according to the process of any oneof paragraphs 27-78. 5 80. A S. pneumoniae serotype 23A glycoconjugate comprising a serotype 23A capsularpolysaccharide wherein the weight average molecular weight (Mw) of said polysaccharide isbetween 50 kDa and 400 kDa. 81. The S. pneumoniae serotype 23A glycoconjugate of paragraph 80 wherein the weight averagemolecular weight (Mw) of said polysaccharide is between 100 kDa and 300 kDa. 10 82. The S. pneumoniae serotype 23A glycoconjugate of paragraph 80 wherein the weight averagemolecular weight (Mw) of said polysaccharide is between 110 kDa and 250 kDa. 83. The S. pneumoniae serotype 23A glycoconjugate of paragraph 80 wherein the weight averagemolecular weight (Mw) of said polysaccharide is between 120 kDa and 240 kDa.84. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-83 having a 15weight average molecular weight (Mw) of between 500 kDa and 10,000 kDa.85. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-83 having aweight average molecular weight (Mw) of between 1,000 kDa and 7,500 kDa.86. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-83 having aweight average molecular weight (Mw) of between 2,000 kDa and 5,000 kDa. 2087. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-86 whereinthe serotype 23A polysaccharide to carrier protein ratio (w/w) in the glycoconjugate is between0.5 and 3.0.88. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-86 whereinthe serotype 23A polysaccharide to carrier protein ratio (w/w) in the glycoconjugate is between 250.5 and 1.7.89. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-86 whereinthe serotype 23A polysaccharide to carrier protein ratio (w/w) in the glycoconjugate is between0.8 and 1.4.90. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-89 wherein 30the degree of conjugation is between 2 and 20.91. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-89 whereinthe degree of conjugation is between 5 and 15.92. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-91 comprisingless than about 40% of free serotype 23A polysaccharide compared to the total amount of 35serotype 23A polysaccharide. 14393. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-91 comprisingless than about 25% of free serotype 23A polysaccharide compared to the total amount ofserotype 23A polysaccharide.94. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-93 wherein atleast 40% of the serotype 23A glycoconjugate has a Kd below or equal to 0.3 in a CL-4B 5column.95. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-93 wherein atleast 50% of the glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.96. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-93 whereinbetween 50% and 90% of the serotype 23A glycoconjugate has a Kd below or equal to 0.3 in 10a CL-4B column.97. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-96 comprisinga S. pneumoniae serotype 23A capsular polysaccharide wherein said S. pneumoniaeserotype 23A capsular polysaccharide has a branched Rhamnose content greater than 75%when compared to native S. pneumoniae serotype 23A capsular polysaccharide wherein the 15branched Rhamnose content is considered to be about 100%.98. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-96 comprisinga S. pneumoniae serotype 23A capsular polysaccharide wherein said S. pneumoniaeserotype 23A capsular polysaccharide has a branched Rhamnose content greater than 90%when compared to native S. pneumoniae serotype 23A capsular polysaccharide wherein the 20branched Rhamnose content is considered to be about 100%.99. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-96 comprisinga S. pneumoniae serotype 23A capsular polysaccharide wherein said S. pneumoniaeserotype 23A capsular polysaccharide has a branched Rhamnose content greater than 95%when compared to native S. pneumoniae serotype 23A capsular polysaccharide wherein the 25branched Rhamnose content is considered to be about 100%.100. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-96comprising a S. pneumoniae serotype 23A capsular polysaccharide wherein said S.pneumoniae serotype 23A capsular polysaccharide has a branched Rhamnose content ofabout 100% when compared to native S. pneumoniae serotype 23A capsular polysaccharide 30wherein the branched Rhamnose content is considered to be about 100%.101. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-100wherein the carrier protein of the glycoconjugates is the fusion protein CP1.102. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-100wherein the carrier protein of the glycoconjugate is H. influenzae protein D. 35103. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-100wherein the carrier protein of the glycoconjugate is TT, DT, CRM 197 or a C5a peptidase fromStreptococcus (SCP). 144104. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-100wherein the carrier protein of the glycoconjugate is DT.105. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-100wherein the carrier protein of the glycoconjugate is TT.106. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-100 5wherein the carrier protein of the glycoconjugate is CRM 197 or a C5a peptidase fromStreptococcus (SCP).107. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-100wherein the carrier protein of the glycoconjugate is a C5a peptidase from Streptococcus(SCP). 10108. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-100wherein the carrier protein of the glycoconjugate is CRM 197.109. The S. pneumoniae serotype 23A glycoconjugate of any one of paragraphs 80-108prepared using reductive amination chemistry.110. A process for preparing a S. pneumoniae serotype 23A glycoconjugate by conjugating an 15isolated serotype 23A capsular polysaccharide to a carrier protein comprising the step of:(a) reacting an isolated serotype 23A capsular polysaccharide with an oxidizing agent; (b)compounding the activated polysaccharide of step (a) with a carrier protein; and (c) reactingthe compounded activated polysaccharide and carrier protein with a reducing agent to form aglycoconjugate. 20111. The process of paragraph 110, wherein before the oxidation step (a) the isolated serotype23A capsular polysaccharide is sized.112. The process of paragraph 110, wherein the size of the isolated serotype 23A capsularpolysaccharide is reduced by mechanical homogenization.113. The process of paragraph 110, wherein the size of the isolated serotype 23A 25polysaccharide is reduced by high pressure homogenization.114. The process of any one of paragraphs 110-113, wherein the isolated serotype 23Acapsular polysaccharide is not sized by acid hydrolysis.115. The process of paragraph 110, wherein the isolated serotype 23A capsular polysaccharideis not sized before oxidation. 30116. The process of any one of paragraphs 110-115, wherein the oxidation step (a) is carriedout at a pH of between 4.5 and 6.5.117. The process of any one of paragraphs 110-115, wherein the oxidation step (a) is carriedout at a pH of between 5.0 and 6.0.118. The process of any one of paragraphs 110-115, wherein the oxidation step (a) is carried 35out at a pH about 5.0.119. The process of any one of paragraphs 110-118, wherein the activated serotype 23Apolysaccharide has a weight average molecular weight (Mw) of between 50 kDa and 400 kDa. 145120. The process of any one of paragraphs 110-118, wherein the activated serotype 23Apolysaccharide has a weight average molecular weight (Mw) of between 100 kDa and 250kDa.121. The process of any one of paragraphs 110-118, wherein the activated serotype 23Apolysaccharide has a weight average molecular weight (Mw) of between 120 kDa and 200 5kDa.122. The process of any one of paragraphs 110-121, wherein the activated serotype 23Apolysaccharide retains at least 80% of the branched Rhamnose.123. The process of any one of paragraphs 110-121, wherein the activated serotype 23Apolysaccharide retains at least 85% of the branched Rhamnose. 10124. The process of any one of paragraphs 110-121, wherein the activated serotype 23Apolysaccharide retains at least 90% of the branched Rhamnose.125. The process of any one of paragraphs 110-121, wherein the activated serotype 23Apolysaccharide retains at least 95% of the branched Rhamnose.126. The process of any one of paragraphs 110-121, wherein the activated serotype 23A 15polysaccharide retains at least 96% of the branched Rhamnose.127. The process of any one of paragraphs 110-126, wherein the oxidizing agent is periodate.128. The process of any one of paragraphs 110-126, wherein the oxidizing agent is sodiumperiodate.129. The process of any one of paragraphs 110-126, wherein the oxidizing agent is sodium 20metaperiodate.130. The process of any one of paragraphs 110-129, wherein the oxidation step (a) comprisesreacting the polysaccharide with 0.1-2 molar equivalents of periodate.131. The process of any one of paragraphs 110-129, wherein the oxidation step (a) comprisesreacting the polysaccharide with 0.2-1.5 molar equivalents of periodate. 25132. The process of any one of paragraphs 110-129, wherein the oxidation step (a) comprisesreacting the polysaccharide with 0.3-0.5 molar equivalents of periodate.133. The process of any one of paragraphs 110-132, wherein the degree of oxidation of theactivated serotype 23A polysaccharide is between 2 and 20.134. The process of any one of paragraphs 110-132, wherein the degree of oxidation of the 30activated serotype 23A polysaccharide is between 2 and 8.135. The process of any one of paragraphs 110-132, wherein the degree of oxidation of theactivated serotype 23A polysaccharide is 5 ±2.5.136. The process of any one of paragraphs 110-135, wherein the activated serotype 23Apolysaccharide and the carrier protein are lyophilised before step b). 35137. The process of any one of paragraphs 110-136, wherein lyophilisation occurs after stepa). 146138. The process of any one of paragraphs 110-136, wherein the activated polysaccharide islyophilised after step a) and the carrier protein is also lyophilised.139. The process of any one of paragraphs 110-136, wherein the activated serotype 23Apolysaccharide is lyophilised after step a) and the carrier protein is also lyophilised, and theactivated polysaccharide and the carrier protein are reconstituted in the same solution. 5140. The process of any one of paragraphs 136-139, wherein the activated serotype 23Apolysaccharide and the carrier protein are Iyophilised independently.141. The process of any one of paragraphs 136-139, wherein the activated serotype 23Apolysaccharide and the carrier protein are Iyophilised together (co-lyophilized).142. The process of any one of paragraphs 110-141, wherein the initial input ratio (weight by 10weight) of activated serotype 23A capsular polysaccharide to carrier protein at step b) isbetween 2:1 and 0.5:1.143. The process of any one of paragraphs 110-141, wherein the initial input ratio (weight byweight) of activated serotype 23A capsular polysaccharide to carrier protein at step b) isbetween 1.2:1 and 0.6:1. 15144. The process of any one of paragraphs 110-141, wherein the initial input ratio (weight byweight) of activated serotype 23A capsular polysaccharide to carrier protein at step b) isbetween 0.9:1 and 0.7:1.145. The process of any one of paragraphs 110-144, wherein the reduction reaction (c) iscarried out in aqueous solvent. 20146. The process of any one of paragraphs 110-144, wherein the reduction reaction (c) iscarried out in aprotic solvent.147. The process of any one of paragraphs 110-144, wherein the reduction reaction (c) iscarried out in the presence of dimethylsulphoxide (DMSO) or dimethylformamide (DMF).148. The process of any one of paragraphs 110-144, wherein the reduction reaction (c) is 25carried out in the presence of dimethylsulphoxide (DMSO).149. The process of any one of paragraphs 110-144, wherein the reduction reaction (c) iscarried out in DMSO (dimethylsulfoxide) or in DMF (dimethylformamide)) solvent.150. The process of any one of paragraphs 110-144, wherein the reduction reaction (c) iscarried out in DMSO (dimethylsulfoxide) solvent. 30151. The process of any one of paragraphs 110-150, wherein the reducing agent is sodiumcyanoborohydride, sodium triacetoxyborohydride, sodium or zinc borohydride in the presenceof Bronsted or Lewis acids, amine boranes such as pyridine borane, 2-Picoline Borane, 2,6-diborane-methanol, dimethylamine-borane, t-BuMeiPrN-BH3, benzylamine-BH3 or 5-ethyl-2-methylpyridine borane (PEMB). 35152. The process of any one of paragraphs 110-150, wherein the reducing agent is sodiumtriacetoxyborohydride. 147153. The process of any one of paragraphs 110-150, wherein the reducing agent is sodiumcyanoborohydride in the present of nickel.154. The process of any one of paragraphs 110-150, wherein the reducing agent is sodiumcyanoborohydride.155. The process of any one of paragraphs 110-154, wherein between 0.2 and 5 molar 5equivalents of reducing agent is used in step c).156. The process of any one of paragraphs 110-154, wherein between 0.2 and 1.5 molarequivalents of reducing agent is used in step c).157. The process of any one of paragraphs 110-154, wherein between 0.5 and 1.0 molarequivalent of reducing agent is used in step c). 10158. The process of any one of paragraphs 110-157, wherein following the reduction reaction(c), unreacted aldehyde groups remaining in the conjugates are capped using a suitablecapping agent.159. The process of paragraph 158, wherein said capping agent is sodium borohydride(NaBH4). 15160. The process of any one of paragraphs 158-159, wherein capping is achieved by mixingthe product of step c) with 1 to 20 molar equivalents of sodium borohydride.161. The process of any one of paragraphs 158-159, wherein capping is achieved by mixingthe product of step c) with 1 to 3 molar equivalents of sodium borohydride.162. The process of any one of paragraphs 110-161, comprising the step of purifying the 20glycoconjugate after it is produced.163. The process of any one of paragraphs 110-162, wherein the carrier protein is the fusionprotein CP1.164. The process of any one of paragraphs 110-162, wherein the carrier protein is H. influenzaeprotein D. 25165. The process of any one of paragraphs 110-162, wherein the carrier protein is TT, DT,CRM 197 or a C5a peptidase from Streptococcus (SCP).166. The process of any one of paragraphs 110-162, wherein the carrier protein is DT.167. The process of any one of paragraphs 110-162, wherein the carrier protein is TT.168. The process of any one of paragraphs 110-162, wherein the carrier protein is CRM 197 or a 30C5a peptidase from Streptococcus (SCP).169. The process of any one of paragraphs 110-162, wherein the carrier protein is a C5apeptidase from Streptococcus (SCP).170. The process of any one of paragraphs 110-162, wherein the carrier protein is CRM 197.171. A S. pneumoniae serotype 23A glycoconjugate obtained according to the process of any 35one of paragraphs 110-170. 148172. A S. pneumoniae serotype 23B glycoconjugate comprising a serotype 23B capsularpolysaccharide wherein the weight average molecular weight (Mw) of said polysaccharide isbetween 40 kDa and 600 kDa.173. The S. pneumoniae serotype 23B glycoconjugate of paragraph 172 wherein the weightaverage molecular weight (Mw) of said polysaccharide is between 50 kDa and 300 kDa. 5 174. The S. pneumoniae serotype 23B glycoconjugate of paragraph 172 wherein the weightaverage molecular weight (Mw) of said polysaccharide is between 75 kDa and 250 kDa. 175. The S. pneumoniae serotype 23B glycoconjugate of paragraph 172 wherein the weightaverage molecular weight (Mw) of said polysaccharide is between 100 kDa and 200 kDa.176. The S. pneumoniae serotype 23B glycoconjugate of any one of paragraphs 172-175 10having a weight average molecular weight (Mw) of between 250 kDa and 7,500 kDa.177. The S. pneumoniae serotype 23B glycoconjugate of any one of paragraphs 172-175having a weight average molecular weight (Mw) of between 500 kDa and 4,000 kDa.178. The S. pneumoniae serotype 23B glycoconjugate of any one of paragraphs 172-175having a weight average molecular weight (Mw) of between 700 kDa and 2,000 kDa. 15179. The S. pneumoniae serotype 23B glycoconjugate of any one of paragraphs 172-178wherein the serotype 23B polysaccharide to carrier protein ratio (w/w) in the glycoconjugateis between 0.4 and 3.0.180. The S. pneumoniae serotype 23B glycoconjugate of any one of paragraphs 172-178wherein the serotype 23B polysaccharide to carrier protein ratio (w/w) in the glycoconjugate 20is between 0.5 and 1.5.181. The S. pneumoniae serotype 23B glycoconjugate of any one of paragraphs 172-178wherein the serotype 23B polysaccharide to carrier protein ratio (w/w) in the glycoconjugateis between 0.6 and 1.3.182. The S. pneumoniae serotype 23B glycoconjugate of any one of paragraphs 172-181 25wherein the degree of conjugation is between 2 and 15.183. The S. pneumoniae serotype 23B glycoconjugate of any one of paragraphs 172-181wherein the degree of conjugation is between 5 and 12.184. The S. pneumoniae serotype 23B glycoconjugate of any one of paragraphs 172-183comprising less than about 40% of free serotype 23B polysaccharide compared to the total 30amount of serotype 23B polysaccharide.185. The S. pneumoniae serotype 23B glycoconjugate of any one of paragraphs 172-183comprising less than about 25% of free serotype 23B polysaccharide compared to the totalamount of serotype 23B polysaccharide.186. The S. pneumoniae serotype 23B glycoconjugate of any one of paragraphs 172-185 35wherein at least 30% of the serotype 23B glycoconjugate has a Kd below or equal to 0.3 in aCL-4B column. 149187. The S. pneumoniae serotype 23B glycoconjugate of any one of paragraphs 172-185wherein at least 35% of the glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.188. The S. pneumoniae serotype 23B glycoconjugate of any one of paragraphs 172-185wherein between 40% and 60% of the serotype 23B glycoconjugate has a Kd below or equalto 0.3 in a CL-4B column. 5189. The S. pneumoniae serotype 23B glycoconjugate of any one of paragraphs 172-188wherein the carrier protein of the glycoconjugates is the fusion protein CP1.190. The S. pneumoniae serotype 23B glycoconjugate of any one of paragraphs 172-188wherein the carrier protein of the glycoconjugate is H. influenzae protein D.191. The S. pneumoniae serotype 23B glycoconjugate of any one of paragraphs 172-188 10wherein the carrier protein of the glycoconjugate is TT, DT, CRM 197 or a C5a peptidase fromStreptococcus (SCP).192. The S. pneumoniae serotype 23B glycoconjugate of any one of paragraphs 172-188wherein the carrier protein of the glycoconjugate is DT.193. The S. pneumoniae serotype 23B glycoconjugate of any one of paragraphs 172-188 15wherein the carrier protein of the glycoconjugate is TT.194. The S. pneumoniae serotype 23B glycoconjugate of any one of paragraphs 172-188wherein the carrier protein of the glycoconjugate is CRM 197 or a C5a peptidase fromStreptococcus (SCP).195. The S. pneumoniae serotype 23B glycoconjugate of any one of paragraphs 172-188 20wherein the carrier protein of the glycoconjugate is a C5a peptidase from Streptococcus(SCP).196. The S. pneumoniae serotype 23B glycoconjugate of any one of paragraphs 172-188wherein the carrier protein of the glycoconjugate is CRM 197.197. The S. pneumoniae serotype 23B glycoconjugate of any one of paragraphs 172-196 25prepared using reductive amination chemistry.198. A process for preparing a S. pneumoniae serotype 23B glycoconjugate by conjugating anisolated serotype 23B capsular polysaccharide to a carrier protein comprising the step of:(a) reacting an isolated serotype 23B capsular polysaccharide with an oxidizing agent; (b)compounding the activated polysaccharide of step (a) with a carrier protein; and (c) reacting 30the compounded activated polysaccharide and carrier protein with a reducing agent to form aglycoconjugate.199. The process of paragraph 198, wherein before the oxidation step (a) the isolated serotype23B capsular polysaccharide is sized.200. The process of paragraph 198, wherein before the oxidation step (a) the isolated serotype 3523B capsular polysaccharide is sized by mechanical homogenization.201. The process of paragraph 198, wherein before the oxidation step (a) the isolated serotype23B capsular polysaccharide is by high pressure homogenization. 150202. The process of paragraph 198, wherein the isolated serotype 23B capsular polysaccharideis not sized before oxidation.203. The process of any one of paragraphs 198-202, wherein the oxidation step (a) is carriedout at a pH of between 4.0 and 6.5.204. The process of any one of paragraphs 198-202, wherein the oxidation step (a) is carried 5out at a pH of between 4.5 and 5.5.205. The process of any one of paragraphs 198-202, wherein the oxidation step (a) is carriedout at a pH about 5.0.206. The process of any one of paragraphs 198-206, wherein the activated serotype 23Bpolysaccharide has a weight average molecular weight (Mw) of between 40 kDa and 600 kDa. 10207. The process of any one of paragraphs 198-206, wherein the activated serotype 23Bpolysaccharide has a weight average molecular weight (Mw) of between 50 kDa and 300 kDa.208. The process of any one of paragraphs 198-206, wherein the activated serotype 23Bpolysaccharide has a weight average molecular weight (Mw) of between 75 kDa and 250 kDa.209. The process of any one of paragraphs 198-206, wherein the activated serotype 23B 15polysaccharide has a weight average molecular weight (Mw) of between 100 kDa and 200kDa.210. The process of any one of paragraphs 198-209, wherein the oxidizing agent is periodate.211. The process of any one of paragraphs 198-209, wherein the oxidizing agent is sodiumperiodate. 20212. The process of any one of paragraphs 198-209, wherein the oxidizing agent is sodiummetaperiodate.213. The process of any one of paragraphs 198-212, wherein the oxidation step (a) comprisesreacting the polysaccharide with 0.05-1 molar equivalents of periodate.214. The process of any one of paragraphs 198-212, wherein the oxidation step (a) comprises 25reacting the polysaccharide with 0.1-0.3 molar equivalents of periodate.215. The process of any one of paragraphs 198-212, wherein the oxidation step (a) comprisesreacting the polysaccharide with about 0.2 molar equivalents of periodate.216. The process of any one of paragraphs 198-215, wherein the degree of oxidation of theactivated serotype 23B polysaccharide is between 2 and 20. 30217. The process of any one of paragraphs 198-215, wherein the degree of oxidation of theactivated serotype 23B polysaccharide is between 4 and 15.218. The process of any one of paragraphs 198-215, wherein the degree of oxidation of theactivated serotype 23B polysaccharide is 9 ±3.219. The process of any one of paragraphs 198-218, wherein the activated serotype 23B 35polysaccharide and the carrier protein are lyophilised before step b).220. The process of any one of paragraphs 198-219, wherein lyophilisation occurs after stepa). 151221. The process of any one of paragraphs 198-220, wherein the activated polysaccharide islyophilised after step a) and the carrier protein is also lyophilised.222. The process of any one of paragraphs 198-220, wherein the activated serotype 23Bpolysaccharide is lyophilised after step a) and the carrier protein is also lyophilised, and theactivated polysaccharide and the carrier protein are reconstituted in the same solution. 5223. The process of any one of paragraphs 219-222, wherein the activated serotype 23Bpolysaccharide and the carrier protein are Iyophilised independently.224. The process of any one of paragraphs 219-222, wherein the activated serotype 23Bpolysaccharide and the carrier protein are Iyophilised together (co-lyophilized).225. The process of any one of paragraphs 198-224, wherein the initial input ratio (weight by 10weight) of activated serotype 23B capsular polysaccharide to carrier protein at step b) isbetween 2:1 and 0.5:1.226. The process of any one of paragraphs 198-224, wherein the initial input ratio (weight byweight) of activated serotype 23B capsular polysaccharide to carrier protein at step b) isbetween 1.2:1 and 0.6:1. 15227. The process of any one of paragraphs 198-224, wherein the initial input ratio (weight byweight) of activated serotype 23B capsular polysaccharide to carrier protein at step b) isbetween 0.9:1 and 0.7:1.228. The process of any one of paragraphs 198-228, wherein the reduction reaction (c) iscarried out in aqueous solvent. 20229. The process of any one of paragraphs 198-228, wherein the reduction reaction (c) iscarried out in aprotic solvent.230. The process of any one of paragraphs 198-228, wherein the reduction reaction (c) iscarried out in the presence of dimethylsulphoxide (DMSO) or dimethylformamide (DMF).231. The process of any one of paragraphs 198-228, wherein the reduction reaction (c) is 25carried out in the presence of dimethylsulphoxide (DMSO).232. The process of any one of paragraphs 198-228, wherein the reduction reaction (c) iscarried out in DMSO (dimethylsulfoxide) or in DMF (dimethylformamide)) solvent.233. The process of any one of paragraphs 198-228, wherein the reduction reaction (c) iscarried out in DMSO (dimethylsulfoxide) solvent. 30234. The process of any one of paragraphs 198-233, wherein the reducing agent is sodiumcyanoborohydride, sodium triacetoxyborohydride, sodium or zinc borohydride in the presenceof Bronsted or Lewis acids, amine boranes such as pyridine borane, 2-Picoline Borane, 2,6-diborane-methanol, dimethylamine-borane, t-BuMeiPrN-BH3, benzylamine-BH3 or 5-ethyl-2-methylpyridine borane (PEMB). 35235. The process of any one of paragraphs 198-233, wherein the reducing agent is sodiumtriacetoxyborohydride. 152236. The process of any one of paragraphs 198-233, wherein the reducing agent is sodiumcyanoborohydride in the present of nickel.237. The process of any one of paragraphs 198-233, wherein the reducing agent is sodiumcyanoborohydride.238. The process of any one of paragraphs 198-237, wherein between 0.2 and 5 molar 5equivalents of reducing agent is used in step c).239. The process of any one of paragraphs 198-237, wherein between 0.5 and 1.5 molarequivalents of reducing agent is used in step c).240. The process of any one of paragraphs 198-237, wherein between 0.9 and 1.1 molarequivalent of reducing agent is used in step c). 10241. The process of any one of paragraphs 198-240, wherein following the reduction reaction(c), unreacted aldehyde groups remaining in the conjugates are capped using a suitablecapping agent.242. The process of paragraph 241, wherein said capping agent is sodium borohydride(NaBH4). 15243. The process of any one of paragraphs 241-242, wherein capping is achieved by mixingthe product of step c) with 1 to 20 molar equivalents of sodium borohydride.244. The process of any one of paragraphs 241-242, wherein capping is achieved by mixingthe product of step c) with 1 to 3 molar equivalents of sodium borohydride.245. The process of any one of paragraphs 198-244, comprising the step of purifying the 20glycoconjugate after it is produced.246. The process of any one of paragraphs 198-245, wherein the carrier protein is the fusionprotein CP1.247. The process of any one of paragraphs 198-245, wherein the carrier protein is H. influenzaeprotein D. 25248. The process of any one of paragraphs 198-245, wherein the carrier protein is TT, DT,CRM 197 or a C5a peptidase from Streptococcus (SCP).249. The process of any one of paragraphs 198-245, wherein the carrier protein is DT.250. The process of any one of paragraphs 198-245, wherein the carrier protein is TT.251. The process of any one of paragraphs 198-245, wherein the carrier protein is CRM 197 or a 30C5a peptidase from Streptococcus (SCP).252. The process of any one of paragraphs 198-245, wherein the carrier protein is a C5apeptidase from Streptococcus (SCP).253. The process of any one of paragraphs 198-245, wherein the carrier protein is CRM 197.254. A S. pneumoniae serotype 23B glycoconjugate obtained according to the process of any 35one of paragraphs 198-253. 153255. A S. pneumoniae serotype 24F glycoconjugate comprising a serotype 24F capsularpolysaccharide wherein the weight average molecular weight (Mw) of said polysaccharide isbetween 50 kDa and 400 kDa. 256. The S. pneumoniae serotype 24F glycoconjugate of paragraph 255 wherein the weightaverage molecular weight (Mw) of said polysaccharide is between 120 kDa and 250 kDa. 5 257. The S. pneumoniae serotype 24F glycoconjugate of paragraph 255 wherein the weightaverage molecular weight (Mw) of said polysaccharide is between 120 kDa and 200 kDa.258. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-257having a weight average molecular weight (Mw) of between 500 kDa and 10,000 kDa.259. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-257 10having a weight average molecular weight (Mw) of between 1,500 kDa and 7,500 kDa.260. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-257having a weight average molecular weight (Mw) of between 3,000 kDa and 6,000 kDa.261. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-260wherein the serotype 24F polysaccharide to carrier protein ratio (w/w) in the glycoconjugate 15is between 0.5 and 3.0.262. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-260wherein the serotype 24F polysaccharide to carrier protein ratio (w/w) in the glycoconjugateis between 0.7 and 1.5.263. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-260 20wherein the serotype 24F polysaccharide to carrier protein ratio (w/w) in the glycoconjugateis between 0.8 and 1.4.264. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-263wherein the degree of conjugation is between 2 and 15.265. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-263 25wherein the degree of conjugation is between 5 and 12.266. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-265comprising less than about 40% of free serotype 24F polysaccharide compared to the totalamount of serotype 24F polysaccharide.267. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-265 30comprising less than about 25% of free serotype 24F polysaccharide compared to the totalamount of serotype 24F polysaccharide.268. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-267wherein at least 40% of the serotype 24F glycoconjugate has a Kd below or equal to 0.3 in aCL-4B column. 35269. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-267wherein at least 50% of the glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column. 154270. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-267wherein between 50% and 90% of the serotype 24F glycoconjugate has a Kd below or equalto 0.3 in a CL-4B column.271. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-270comprising a S. pneumoniae serotype 24F capsular polysaccharide wherein said S. 5pneumoniae serotype 24F capsular polysaccharide has a Ribose content greater than 75%when compared to native S. pneumoniae serotype 24F capsular polysaccharide wherein theRibose content is considered to be about 100%.272. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-270comprising a S. pneumoniae serotype 24F capsular polysaccharide wherein said S. 10pneumoniae serotype 24F capsular polysaccharide has a Ribose content greater than 90%when compared to native S. pneumoniae serotype 24F capsular polysaccharide wherein theRibose content is considered to be about 100%.273. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-270comprising a S. pneumoniae serotype 24F capsular polysaccharide wherein said S. 15pneumoniae serotype 24F capsular polysaccharide has a Ribose content greater than 95%when compared to native S. pneumoniae serotype 24F capsular polysaccharide wherein theRibose content is considered to be about 100%.274. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-270comprising a S. pneumoniae serotype 24F capsular polysaccharide wherein said S. 20pneumoniae serotype 24F capsular polysaccharide has a Ribose content of about 100% whencompared to native S. pneumoniae serotype 24F capsular polysaccharide wherein the Ribosecontent is considered to be about 100%.275. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-274wherein the carrier protein of the glycoconjugates is the fusion protein CP1. 25276. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-274wherein the carrier protein of the glycoconjugate is H. influenzae protein D.277. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-274wherein the carrier protein of the glycoconjugate is TT, DT, CRM 197 or a C5a peptidase fromStreptococcus (SCP). 30278. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-274wherein the carrier protein of the glycoconjugate is DT.279. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-274wherein the carrier protein of the glycoconjugate is TT.280. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-274 35wherein the carrier protein of the glycoconjugate is CRM 197 or a C5a peptidase fromStreptococcus (SCP). 155281. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-274wherein the carrier protein of the glycoconjugate is a C5a peptidase from Streptococcus(SCP).282. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-274wherein the carrier protein of the glycoconjugate is CRM 197. 5283. The S. pneumoniae serotype 24F glycoconjugate of any one of paragraphs 255-282prepared using reductive amination chemistry.284. A process for preparing a S. pneumoniae serotype 24F glycoconjugate by conjugating anisolated serotype 24F capsular polysaccharide to a carrier protein comprising the step of:(a) reacting an isolated serotype 24F capsular polysaccharide with an oxidizing agent; (b) 10compounding the activated polysaccharide of step (a) with a carrier protein; and (c) reactingthe compounded activated polysaccharide and carrier protein with a reducing agent to form aglycoconjugate.285. The process of paragraph 284, wherein before the oxidation step (a) the isolated serotype24F capsular polysaccharide is sized. 15286. The process of paragraph 284, wherein the size of the isolated serotype 24F capsularpolysaccharide is reduced by mechanical homogenization.287. The process of paragraph 284, wherein the size of the isolated serotype 24Fpolysaccharide is reduced by high pressure homogenization.288. The process of any one of paragraphs 284-287, wherein the isolated serotype 24F 20capsular polysaccharide is not sized by acid hydrolysis.289. The process of paragraph 284, wherein the isolated serotype 24F capsular polysaccharideis not sized before oxidation.290. The process of any one of paragraphs 284-289, wherein the oxidation step (a) is carriedout at a pH of between 4.5 and 6.5. 25291. The process of any one of paragraphs 284-289, wherein the oxidation step (a) is carriedout at a pH of between 5.0 and 6.0.292. The process of any one of paragraphs 284-289, wherein the oxidation step (a) is carriedout at a pH about 5.0.293. The process of any one of paragraphs 284-292, wherein the activated serotype 24F 30polysaccharide has a weight average molecular weight (Mw) of between 50 kDa and 400 kDa.294. The process of any one of paragraphs 284-292, wherein the activated serotype 24Fpolysaccharide has a weight average molecular weight (Mw) of between 120 kDa and 250kDa.295. The process of any one of paragraphs 284-292, wherein the activated serotype 24F 35polysaccharide has a weight average molecular weight (Mw) of between 120 kDa and 200kDa. 156296. The process of any one of paragraphs 284-295, wherein the activated serotype 24Fpolysaccharide retains at least 75% of the branched Ribose.297. The process of any one of paragraphs 284-295, wherein the activated serotype 24Fpolysaccharide retains at least 90% of the branched Ribose.298. The process of any one of paragraphs 284-295, wherein the activated serotype 24F 5polysaccharide retains at least 95% of the branched Ribose.299. The process of any one of paragraphs 284-295, wherein the activated serotype 24Fpolysaccharide retains about 100% of the branched Ribose.300. The process of any one of paragraphs 284-299, wherein the oxidizing agent is periodate.301. The process of any one of paragraphs 284-299, wherein the oxidizing agent is sodium 10periodate.302. The process of any one of paragraphs 284-299, wherein the oxidizing agent is sodiummetaperiodate.303. The process of any one of paragraphs 284-301, wherein the oxidation step (a) comprisesreacting the polysaccharide with 0.1-2 molar equivalents of periodate. 15304. The process of any one of paragraphs 284-301, wherein the oxidation step (a) comprisesreacting the polysaccharide with 0.5-1.5 molar equivalents of periodate.305. The process of any one of paragraphs 284-301, wherein the oxidation step (a) comprisesreacting the polysaccharide with 0.9-1.1 molar equivalents of periodate.306. The process of any one of paragraphs 284-305, wherein the degree of oxidation of the 20activated serotype 24F polysaccharide is between 2 and 20.307. The process of any one of paragraphs 284-305, wherein the degree of oxidation of theactivated serotype 24F polysaccharide is between 4 and 15.308. The process of any one of paragraphs 284-305, wherein the degree of oxidation of theactivated serotype 24F polysaccharide is 9 ±3. 25309. The process of any one of paragraphs 284-308, wherein the activated serotype 24Fpolysaccharide and the carrier protein are lyophilised before step b).310. The process of any one of paragraphs 284-309, wherein lyophilisation occurs after stepa).311. The process of any one of paragraphs 284-310, wherein the activated polysaccharide is 30lyophilised after step a) and the carrier protein is also lyophilised.312. The process of any one of paragraphs 284-310, wherein the activated serotype 24Fpolysaccharide is lyophilised after step a) and the carrier protein is also lyophilised, and theactivated polysaccharide and the carrier protein are reconstituted in the same solution.313. The process of any one of paragraphs 284-312, wherein the activated serotype 24F 35polysaccharide and the carrier protein are Iyophilised independently.314. The process of any one of paragraphs 284-312, wherein the activated serotype 24Fpolysaccharide and the carrier protein are Iyophilised together (co-lyophilized). 157315. The process of any one of paragraphs 284-314, wherein the initial input ratio (weight byweight) of activated serotype 24F capsular polysaccharide to carrier protein at step b) isbetween 2:1 and 0.5:1.316. The process of any one of paragraphs 284-314, wherein the initial input ratio (weight byweight) of activated serotype 24F capsular polysaccharide to carrier protein at step b) is 5between 1.2:1 and 0.6:1.317. The process of any one of paragraphs 284-314, wherein the initial input ratio (weight byweight) of activated serotype 24F capsular polysaccharide to carrier protein at step b) isbetween 0.9:1 and 0.7:1.318. The process of any one of paragraphs 284-317, wherein the reduction reaction (c) is 10carried out in aqueous solvent.319. The process of any one of paragraphs 284-317, wherein the reduction reaction (c) iscarried out in aprotic solvent.320. The process of any one of paragraphs 284-317, wherein the reduction reaction (c) iscarried out in the presence of dimethylsulphoxide (DMSO) or dimethylformamide (DMF). 15321. The process of any one of paragraphs 284-317, wherein the reduction reaction (c) iscarried out in the presence of dimethylsulphoxide (DMSO).322. The process of any one of paragraphs 284-317, wherein the reduction reaction (c) iscarried out in DMSO (dimethylsulfoxide) or in DMF (dimethylformamide)) solvent.323. The process of any one of paragraphs 284-317, wherein the reduction reaction (c) is 20carried out in DMSO (dimethylsulfoxide) solvent.324. The process of any one of paragraphs 284-323, wherein the reducing agent is sodiumcyanoborohydride, sodium triacetoxyborohydride, sodium or zinc borohydride in the presenceof Bronsted or Lewis acids, amine boranes such as pyridine borane, 2-Picoline Borane, 2,6-diborane-methanol, dimethylamine-borane, t-BuMeiPrN-BH3, benzylamine-BH3 or 5-ethyl-2- 25methylpyridine borane (PEMB).325. The process of any one of paragraphs 284-323, wherein the reducing agent is sodiumtriacetoxyborohydride.326. The process of any one of paragraphs 284-323, wherein the reducing agent is sodiumcyanoborohydride in the present of nickel. 30327. The process of any one of paragraphs 284-323, wherein the reducing agent is sodiumcyanoborohydride.328. The process of any one of paragraphs 284-327, wherein between 0.2 and 5 molarequivalents of reducing agent is used in step c).329. The process of any one of paragraphs 284-327, wherein between 0.5 and 2.5 molar 35equivalents of reducing agent is used in step c).330. The process of any one of paragraphs 284-327, wherein between 1.5 and 2.5 molarequivalent of reducing agent is used in step c). 158331. The process of any one of paragraphs 284-330, wherein following the reduction reaction(c), unreacted aldehyde groups remaining in the conjugates are capped using a suitablecapping agent.332. The process of paragraph 331, wherein said capping agent is sodium borohydride(NaBH4). 5333. The process of any one of paragraphs 284-332, wherein capping is achieved by mixingthe product of step c) with 1 to 20 molar equivalents of sodium borohydride.334. The process of any one of paragraphs 284-332, wherein capping is achieved by mixingthe product of step c) with 1 to 3 molar equivalents of sodium borohydride.335. The process of any one of paragraphs 284-334, comprising the step of purifying the 10glycoconjugate after it is produced.336. The process of any one of paragraphs 284-335, wherein the carrier protein is the fusionprotein CP1.337. The process of any one of paragraphs 284-335, wherein the carrier protein is H. influenzaeprotein D. 15338. The process of any one of paragraphs 284-335, wherein the carrier protein is TT, DT,CRM 197 or a C5a peptidase from Streptococcus (SCP).339. The process of any one of paragraphs 284-335, wherein the carrier protein is DT.340. The process of any one of paragraphs 284-335, wherein the carrier protein is TT.341. The process of any one of paragraphs 284-335, wherein the carrier protein is CRM 197 or a 20C5a peptidase from Streptococcus (SCP).342. The process of any one of paragraphs 284-335, wherein the carrier protein is a C5apeptidase from Streptococcus (SCP).343. The process of any one of paragraphs 284-335, wherein the carrier protein is CRM 197.344. A S. pneumoniae serotype 24F glycoconjugate obtained according to the process of any 25one of paragraphs 284-343.345. A S. pneumoniae serotype 35B glycoconjugate comprising a serotype 35B capsularpolysaccharide wherein the weight average molecular weight (Mw) of said polysaccharide isbetween 15 kDa and 100 kDa.346. The S. pneumoniae serotype 35B glycoconjugate of paragraph 345 wherein the weight 30average molecular weight (Mw) of said polysaccharide is between 25 kDa and 50 kDa. 347. The S. pneumoniae serotype 35B glycoconjugate of paragraph 345 wherein the weightaverage molecular weight (Mw) of said polysaccharide is between 30 kDa and 40 kDa.348. The S. pneumoniae serotype 35B glycoconjugate of any one of paragraphs 345-347having a weight average molecular weight (Mw) of between 250 kDa and 7,500 kDa. 35349. The S. pneumoniae serotype 35B glycoconjugate of any one of paragraphs 345-347having a weight average molecular weight (Mw) of between 500 kDa and 5,000 kDa. 159350. The S. pneumoniae serotype 35B glycoconjugate of any one of paragraphs 345-347having a weight average molecular weight (Mw) of between 1,000 kDa and 4,000 kDa.351. The S. pneumoniae serotype 35B glycoconjugate of any one of paragraphs 345-350wherein the serotype 35B polysaccharide to carrier protein ratio (w/w) in the glycoconjugateis between 0.4 and 3.0. 5352. The S. pneumoniae serotype 35B glycoconjugate of any one of paragraphs 345-350wherein the serotype 35B polysaccharide to carrier protein ratio (w/w) in the glycoconjugateis between 0.4 and 2.0.353. The S. pneumoniae serotype 35B glycoconjugate of any one of paragraphs 345-350wherein the serotype 35B polysaccharide to carrier protein ratio (w/w) in the glycoconjugate 10is between 0.5 and 1.5.354. The S. pneumoniae serotype 35B glycoconjugate of any one of paragraphs 345-353wherein the degree of conjugation is between 2 and 15.355. The S. pneumoniae serotype 35B glycoconjugate of any one of paragraphs 345-353wherein the degree of conjugation is between 5 and 10. 15356. The S. pneumoniae serotype 35B glycoconjugate of any one of paragraphs 345-355comprising less than about 40% of free serotype 35B polysaccharide compared to the totalamount of serotype 35B polysaccharide.357. The S. pneumoniae serotype 35B glycoconjugate of any one of paragraphs 345-355comprising less than about 20% of free serotype 35B polysaccharide compared to the total 20amount of serotype 35B polysaccharide.358. The S. pneumoniae serotype 35B glycoconjugate of any one of paragraphs 345-355comprising less than about 10% of free serotype 35B polysaccharide compared to the totalamount of serotype 35B polysaccharide.359. The S. pneumoniae serotype 35B glycoconjugate of any one of paragraphs 345-358 25wherein at least 40% of the serotype 35B glycoconjugate has a Kd below or equal to 0.3 in aCL-4B column.360. The S. pneumoniae serotype 35B glycoconjugate of any one of paragraphs 345-358wherein at least 60% of the glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.361. The S. pneumoniae serotype 35B glycoconjugate of any one of paragraphs 345-358 30wherein between 50% and 80% of the serotype 35B glycoconjugate has a Kd below or equalto 0.3 in a CL-4B column.362. The S. pneumoniae serotype 35B glycoconjugate of any one of paragraphs 345-361wherein the carrier protein of the glycoconjugates is the fusion protein CP1.363. The S. pneumoniae serotype 35B glycoconjugate of any one of 345-361 wherein the 35carrier protein of the glycoconjugate is H. influenzae protein D. 160364. The S. pneumoniae serotype 35B glycoconjugate of any one of paragraphs 345-361wherein the carrier protein of the glycoconjugate is TT, DT, CRM 197 or a C5a peptidase fromStreptococcus (SCP).365. The S. pneumoniae serotype 35B glycoconjugate of any one of paragraphs 345-361wherein the carrier protein of the glycoconjugate is DT. 5366. The S. pneumoniae serotype 35B glycoconjugate of any one of paragraphs 345-361wherein the carrier protein of the glycoconjugate is TT.367. The S. pneumoniae serotype 35B glycoconjugate of any one of paragraphs 345-361wherein the carrier protein of the glycoconjugate is CRM 197 or a C5a peptidase fromStreptococcus (SCP). 10368. The S. pneumoniae serotype 35B glycoconjugate of any one of paragraphs 345-361wherein the carrier protein of the glycoconjugate is a C5a peptidase from Streptococcus(SCP).369. The S. pneumoniae serotype 35B glycoconjugate of any one of paragraphs 345-361wherein the carrier protein of the glycoconjugate is CRM 197. 15370. The S. pneumoniae serotype 35B glycoconjugate of any one of paragraphs 345-369prepared using reductive amination chemistry.371. A process for preparing a S. pneumoniae serotype 35B glycoconjugate by conjugating anisolated serotype 35B capsular polysaccharide to a carrier protein comprising the step of:(a) reacting an isolated serotype 35B capsular polysaccharide with an oxidizing agent; (b) 20compounding the activated polysaccharide of step (a) with a carrier protein; and (c) reactingthe compounded activated polysaccharide and carrier protein with a reducing agent to form aglycoconjugate.372. The process of paragraph 371, wherein the isolated serotype 35B capsular polysaccharideis not sized before the oxidation step (a). 25373. The process of paragraphs 371-372, further comprising a step (a’) between step (a) and(b), said step being: (a’) quenching the oxidation reaction by addition of a quenching agentresulting in an activated serotype 35B capsular polysaccharide.374. A process for preparing a S. pneumoniae serotype 35B glycoconjugate by conjugating anisolated serotype 35B capsular polysaccharide to a carrier protein comprising the step of: (a) 30reacting said isolated serotype 35B capsular polysaccharide with an oxidizing agent; (a’)quenching the oxidation reaction by addition of a quenching agent resulting in an activatedserotype 35B capsular polysaccharide; (b) compounding the activated polysaccharide of step(a’) with a carrier protein; and (c) reacting the compounded activated polysaccharide andcarrier protein with a reducing agent to form a glycoconjugate. 35375. The process of any one of paragraphs 371-374, wherein the oxidation step (a) is carriedout at a pH of between 5.0 and 7.0. 161376. The process of any one of paragraphs 371-374, wherein the oxidation step (a) is carriedout at a pH of between 5.5 and 6.5.377. The process of any one of paragraphs 371-374, wherein the oxidation step (a) is carriedout at a pH about 6.0.378. The process of any one of paragraphs 371-377, wherein the oxidizing agent is periodate. 5379. The process of any one of paragraphs 371-377, wherein the oxidizing agent is sodiumperiodate.380. The process of any one of paragraphs 371-377, wherein the oxidizing agent is sodiummetaperiodate.381. The process of any one of paragraphs 371-380, wherein the oxidation step (a) comprises 10reacting the polysaccharide with 0.05-0.2 molar equivalents of periodate.382. The process of any one of paragraphs 371-380, wherein the oxidation step (a) comprisesreacting the polysaccharide with 0.09-0.11 molar equivalents of periodate.383. The process of any one of paragraphs 371-380, wherein the oxidation step (a) comprisesreacting the polysaccharide with about 0.1 molar equivalents of periodate. 15384. The process of any one of paragraphs 373-383, wherein the quenching agent is selectedfrom vicinal diols, 1,2-aminoalcohols, amino acids, glutathione, sulfite, bisulfate, dithionite,metabisulfite, thiosulfate, phosphites, hypophosphites or phosphorous acid.385. The process of any one of paragraphs 373-383, wherein the quenching agent is a 1,2-aminoalcohols of formula (I): 20 N HOH R (I)wherein R is selected from H, methyl, ethyl, propyl or isopropyl.386. The process of any one of paragraphs 373-383, wherein the quenching agent is sodiumor potassium salts of sulfite, bisulfate, dithionite, metabisulfite, thiosulfate, phosphites,hypophosphites or phosphorous acid. 25387. The process of any one of paragraphs 373-383, wherein the quenching agent is an aminoacid.388. The process of paragraph 387 wherein said amino acid is serine, threonine, cysteine,cystine, methionine, proline, hydroxyproline, tryptophan, tyrosine or histidine.389. The process of any one of paragraphs 373-383, wherein the quenching agent is a sulfite 30such as bisulfate, dithionite, metabisulfite, thiosulfate.390. The process of any one of paragraphs 373-383, wherein the quenching agent is is acompound comprising two vicinal hydroxyl groups (vicinal diols).391. The process of any one of paragraphs 373-383, wherein the quenching agent is acompound comprising two hydroxyl groups covalently linked to two adjacent carbon atoms. 35 162392. The process of any one of paragraphs 373-383, wherein the quenching agent is is acompound of formula (II): OH O H RR (II)wherein R and R are each independently selected from H, methyl, ethyl, propyl or isopropyl.393. The process of any one of paragraphs 373-383, wherein the quenching agent is glycerol, 5ethylene glycol, propan-1,2-diol, butan-1,2-diol or butan-2,3-diol, or ascorbic acid.394. The process of any one of paragraphs 373-383, wherein the quenching agent is butan-2,3-diol.395. An activation process comprising the step of:(a) reacting an isolated serotype 35B polysaccharide with periodate; 10(b) quenching the oxidation reaction by addition of butan-2,3-diol resulting in an activatedserotype 35B polysaccharide.396. The process of any one of paragraphs 373-395, wherein the activated serotype 35Bpolysaccharide has a weight average molecular weight (Mw) of between 15 kDa and 100 kDa.397. The process of any one of paragraphs 373-395, wherein the activated serotype 35B 15polysaccharide has a weight average molecular weight (Mw) of between 25 kDa and 50 kDa.398. The process of any one of paragraphs 373-395, wherein the activated serotype 35Bpolysaccharide has a weight average molecular weight (Mw) of between 30 kDa and 40 kDa.399. The process of any one of paragraphs 373-398, wherein the degree of oxidation of theactivated serotype 35B polysaccharide is between 2 and 20. 20400. The process of any one of paragraphs 373-398, wherein the degree of oxidation of theactivated serotype 35B polysaccharide is between 4 and 15.401. The process of any one of paragraphs 373-398, wherein the degree of oxidation of theactivated serotype 35B polysaccharide is 9 ±3.402. The process of any one of paragraphs 373-401, wherein the activated serotype 35B 25polysaccharide and the carrier protein are lyophilised before step b).403. The process of any one of paragraphs 373-402, wherein lyophilisation occurs after stepa).404. The process of any one of paragraphs 373-401, wherein the activated polysaccharide islyophilised after step a) and the carrier protein is also lyophilised. 30405. The process of any one of paragraphs 373-401, wherein the activated serotype 35Bpolysaccharide is lyophilised after step a) and the carrier protein is also lyophilised, and theactivated polysaccharide and the carrier protein are reconstituted in the same solution.406. The process of any one of paragraphs 373-405, wherein the activated serotype 35Bpolysaccharide and the carrier protein are Iyophilised independently. 35 163407. The process of any one of paragraphs 373-405, wherein the activated serotype 35Bpolysaccharide and the carrier protein are Iyophilised together (co-lyophilized).408. The process of any one of paragraphs 373-407, wherein the initial input ratio (weight byweight) of activated serotype 35B capsular polysaccharide to carrier protein at step b) isbetween 2:1 and 0.5:1. 5409. The process of any one of paragraphs 373-407, wherein the initial input ratio (weight byweight) of activated serotype 35B capsular polysaccharide to carrier protein at step b) isbetween 1.2:1 and 0.6:1.410. The process of any one of paragraphs 373-407, wherein the initial input ratio (weight byweight) of activated serotype 35B capsular polysaccharide to carrier protein at step b) is 10between 0.9:1 and 0.7:1.411. The process of any one of paragraphs 373-410, wherein the reduction reaction (c) iscarried out in aqueous solvent.412. The process of any one of paragraphs 373-410, wherein the reduction reaction (c) iscarried out in aprotic solvent. 15413. The process of any one of paragraphs 373-410, wherein the reduction reaction (c) iscarried out in the presence of dimethylsulphoxide (DMSO) or dimethylformamide (DMF).414. The process of any one of paragraphs 373-410, wherein the reduction reaction (c) iscarried out in the presence of dimethylsulphoxide (DMSO).415. The process of any one of paragraphs 373-410, wherein the reduction reaction (c) is 20carried out in DMSO (dimethylsulfoxide) or in DMF (dimethylformamide)) solvent.416. The process of any one of paragraphs 373-410, wherein the reduction reaction (c) iscarried out in DMSO (dimethylsulfoxide) solvent.417. The process of any one of paragraphs 373-416, wherein the reducing agent is sodiumcyanoborohydride, sodium triacetoxyborohydride, sodium or zinc borohydride in the presence 25of Bronsted or Lewis acids, amine boranes such as pyridine borane, 2-Picoline Borane, 2,6-diborane-methanol, dimethylamine-borane, t-BuMeiPrN-BH3, benzylamine-BH3 or 5-ethyl-2-methylpyridine borane (PEMB).418. The process of any one of paragraphs 373-416, wherein the reducing agent is sodiumtriacetoxyborohydride. 30419. The process of any one of paragraphs 373-416, wherein the reducing agent is sodiumcyanoborohydride in the present of nickel.420. The process of any one of paragraphs 373-416, wherein the reducing agent is sodiumcyanoborohydride.421. The process of any one of paragraphs 373-420, wherein between 0.2 and 5 molar 35equivalents of reducing agent is used in step c).422. The process of any one of paragraphs 373-420, wherein between 0.5 and 1.5 molarequivalents of reducing agent is used in step c). 164423. The process of any one of paragraphs 373-420, wherein between 0.9 and 1.1 molarequivalent of reducing agent is used in step c).424. The process of any one of paragraphs 373-423, wherein following the reduction reaction(c), unreacted aldehyde groups remaining in the conjugates are capped using a suitablecapping agent. 5425. The process of paragraph 424, wherein said capping agent is sodium borohydride(NaBH4).426. The process of any one of paragraphs 424-425, wherein capping is achieved by mixingthe product of step c) with 1 to 20 molar equivalents of sodium borohydride.427. The process of any one of paragraphs 424-425, wherein capping is achieved by mixing 10the product of step c) with 1 to 3 molar equivalents of sodium borohydride.428. The process of any one of paragraphs 373-427, comprising the step of purifying theglycoconjugate after it is produced.429. The process of any one of paragraphs 373-428, wherein the carrier protein is the fusionprotein CP1. 15430. The process of any one of paragraphs 373-428, wherein the carrier protein is H. influenzaeprotein D.431. The process of any one of paragraphs 373-428, wherein the carrier protein is TT, DT,CRM 197 or a C5a peptidase from Streptococcus (SCP).432. The process of any one of paragraphs 373-428, wherein the carrier protein is DT. 20433. The process of any one of paragraphs 373-428, wherein the carrier protein is TT.434. The process of any one of paragraphs 373-428, wherein the carrier protein is CRM 197 or aC5a peptidase from Streptococcus (SCP).435. The process of any one of paragraphs 373-428, wherein the carrier protein is a C5apeptidase from Streptococcus (SCP). 25436. The process of any one of paragraphs 373-428, wherein the carrier protein is CRM 197.437. A S. pneumoniae serotype 35B glycoconjugate obtained according to the process of anyone of paragraphs 373-436.438. An immunogenic composition comprising a glycoconjugate of any one of paragraphs 1-26, 79-109, 171-197, 254-283, 344-370 or 437. 30439. The immunogenic composition of paragraph 438 comprising 1 to 25 glycoconjugates fromdifferent serotypes of S. pneumoniae.440. An immunogenic composition comprising a S. pneumoniae serotype 15A glycoconjugateof any one of paragraphs 1-26 or 79.441. An immunogenic composition comprising a S. pneumoniae serotype 23A glycoconjugate 35of any one of paragraphs 80-109 or 171.442. An immunogenic composition comprising a S. pneumoniae serotype 23B glycoconjugateof any one of paragraphs 172-197 or 254. 165443. An immunogenic composition comprising a S. pneumoniae serotype 24F glycoconjugateof any one of paragraphs 255-283 or 344.444. An immunogenic composition comprising a S. pneumoniae serotype 35B glycoconjugateof any one of paragraphs 345-370 or 437.445. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotype 515A, 23A, 23B, 24F and 35B.446. The immunogenic composition of paragraph 445 wherein said S. pneumoniae serotype15A glycoconjugate is any one of paragraphs 1-26 or 79, said S. pneumoniae serotype 23Aglycoconjugate is any one of paragraphs 80-109 or 171, said S. pneumoniae serotype 23Bglycoconjugate is any one of paragraphs 172-197 or 254, said S. pneumoniae serotype 24F 10glycoconjugate is any one of paragraphs 255-283 or 344 and said S. pneumoniae serotype35B glycoconjugate is any one of paragraphs 345-370 or 437.447. An immunogenic composition comprising from 14 to 25 pneumococcal glycoconjugatesfrom different serotypes of S. pneumoniae, wherein said serotypes are selected fromserotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 1523A, 23B, 23F, 24F, 33F and 35B.448. The immunogenic composition of paragraph 447 wherein said S. pneumoniae serotype15A glycoconjugate is any one of paragraphs 1-26 or 79, said S. pneumoniae serotype 23Aglycoconjugate is any one of paragraphs 80-109 or 171, said S. pneumoniae serotype 23Bglycoconjugate is any one of paragraphs 172-197 or 254, said S. pneumoniae serotype 24F 20glycoconjugate is any one of paragraphs 255-283 or 344 and said S. pneumoniae serotype35B glycoconjugate is any one of paragraphs 345-370 or 437.449. An immunogenic composition comprising from 21 to 25 pneumococcal glycoconjugatesfrom different serotypes of S. pneumoniae, wherein said serotypes are selected fromserotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 2523A, 23B, 23F, 24F, 33F and 35B.450. The immunogenic composition of paragraph 449 wherein said S. pneumoniae serotype15A glycoconjugate is any one of paragraphs 1-26 or 79, said S. pneumoniae serotype 23Aglycoconjugate is any one of paragraphs 80-109 or 171, said S. pneumoniae serotype 23Bglycoconjugate is any one of paragraphs 172-197 or 254, said S. pneumoniae serotype 24F 30glycoconjugate is any one of paragraphs 255-283 or 344 and said S. pneumoniae serotype35B glycoconjugate is any one of paragraphs 345-370 or 437.451. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F andadditionally comprises from 1 to 5 glycoconjugates from S. pneumoniae serotypes 15A, 23A, 3523B, 24F and/or 35B.452. The immunogenic composition of paragraph 451 wherein said S. pneumoniae serotype15A glycoconjugate is any one of paragraphs 1-26 or 79, said S. pneumoniae serotype 23A 166glycoconjugate is any one of paragraphs 80-109 or 171, said S. pneumoniae serotype 23Bglycoconjugate is any one of paragraphs 172-197 or 254, said S. pneumoniae serotype 24Fglycoconjugate is any one of paragraphs 255-283 or 344 and said S. pneumoniae serotype35B glycoconjugate is any one of paragraphs 345-370 or 437.453. The immunogenic composition of paragraph 451 or 452 which is a 21, 22, 23, 24 or 25- 5valent pneumococcal conjugate composition.454. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F andadditionally comprising one glycoconjugate from S. pneumoniae serotypes 15A, 23A, 23B,24F or 35B. 10455. The immunogenic composition of paragraph 454 which is a 21-valent pneumococcalconjugate composition.456. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F andadditionally comprises 2 glycoconjugates selected from S. pneumoniae serotypes 15A, 23A, 1523B, 24F and 35B.457. The immunogenic composition of paragraph 456 which is a 22-valent pneumococcalconjugate composition.458. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F and 20additionally comprises 3 glycoconjugates selected from S. pneumoniae serotypes 15A, 23A,23B, 24F and 35B.459. The immunogenic composition of paragraph 458 which is a 23-valent pneumococcalconjugate composition.460. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes 251, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F andadditionally comprises 4 glycoconjugates selected from S. pneumoniae serotypes 15A, 23A,23B, 24F and 35B.461. The immunogenic composition of paragraph 460 which is a 24-valent pneumococcalconjugate composition. 30462. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23F and 33F.463. The immunogenic composition of paragraph 462 which is a 21-valent pneumococcalconjugate composition.464. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes 351, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23A, 23F and 33F.465. The immunogenic composition of paragraph 464 which is a 21-valent pneumococcalconjugate composition. 167466. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23B, 23F and 33F.467. The immunogenic composition of paragraph 466 which is a 21-valent pneumococcalconjugate composition.468. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes 51, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 24F and 33F.469. The immunogenic composition of paragraph 468 which is a 21-valent pneumococcalconjugate composition.470. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F and 35B. 10471. The immunogenic composition of paragraph 470 which is a 21-valent pneumococcalconjugate composition.472. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23F and33F. 15473. The immunogenic composition of paragraph 472 which is a 22-valent pneumococcalconjugate composition.474. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23B, 23F and33F. 20475. The immunogenic composition of paragraph 474 which is a 22-valent pneumococcalconjugate composition.476. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23F, 24F and33F. 25477. The immunogenic composition of paragraph 476 which is a 22-valent pneumococcalconjugate composition.478. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23F, 33F and35B. 30479. The immunogenic composition of paragraph 478 which is a 22-valent pneumococcalconjugate composition.480. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F and33F. 35481. The immunogenic composition of paragraph 480 which is a 22-valent pneumococcalconjugate composition. 168482. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23A, 23F, 24F and33F.483. The immunogenic composition of paragraph 482 which is a 22-valent pneumococcalconjugate composition. 5484. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23A, 23F, 33F and35B.485. The immunogenic composition of paragraph 484 which is a 22-valent pneumococcalconjugate composition. 10486. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23B, 23F, 24F and33F.487. The immunogenic composition of paragraph 486 which is a 22-valent pneumococcalconjugate composition. 15488. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23B, 23F, 33F and35B.489. The immunogenic composition of paragraph 488 which is a 22-valent pneumococcalconjugate composition. 20490. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 24F, 33F and35B.491. The immunogenic composition of paragraph 490 which is a 22-valent pneumococcalconjugate composition. 25492. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B,23F and 33F.493. The immunogenic composition of paragraph 492 which is a 23-valent pneumococcalconjugate composition. 30494. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23F, 24Fand 33F.495. The immunogenic composition of paragraph 494 which is a 23-valent pneumococcalconjugate composition. 35496. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23F, 33Fand 35B. 169497. The immunogenic composition of paragraph 496 which is a 23-valent pneumococcalconjugate composition.498. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23B, 23F, 24Fand 33F. 5499. The immunogenic composition of paragraph 498 which is a 23-valent pneumococcalconjugate composition.500. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23B, 23F, 33Fand 35B. 10501. The immunogenic composition of paragraph 500 which is a 23-valent pneumococcalconjugate composition.502. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23F, 24F, 33Fand 35B. 15503. The immunogenic composition of paragraph 502 which is a 23-valent pneumococcalconjugate composition.504. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24Fand 33F. 20505. The immunogenic composition of paragraph 504 which is a 23-valent pneumococcalconjugate composition.506. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 33Fand 35B. 25507. The immunogenic composition of paragraph 506 which is a 23-valent pneumococcalconjugate composition.508. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23A, 23F, 24F, 33Fand 35B. 30509. The immunogenic composition of paragraph 508 which is a 23-valent pneumococcalconjugate composition.510. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23B, 23F, 24F, 33Fand 35B. 35511. The immunogenic composition of paragraph 510 which is a 23-valent pneumococcalconjugate composition. 170512. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B,23F, 24F and 33F.513. The immunogenic composition of paragraph 512 which is a 24-valent pneumococcalconjugate composition. 5514. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B,23F, 33F and 35B.515. The immunogenic composition of paragraph 514 which is a 24-valent pneumococcalconjugate composition. 10516. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23F,33F, 24F and 35B.517. The immunogenic composition of paragraph 516 which is a 24-valent pneumococcalconjugate composition. 15518. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23B, 23F,24F, 33F and 35B.519. The immunogenic composition of paragraph 518 which is a 24-valent pneumococcalconjugate composition. 20520. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F,24F, 33F and 35B.521. The immunogenic composition of paragraph 520 which is a 24-valent pneumococcalconjugate composition. 25522. The immunogenic composition of any one of paragraphs 454 to 521 wherein said S.pneumoniae serotype 15A glycoconjugate is any one of paragraphs 1-26 or 79, said S.pneumoniae serotype 23A glycoconjugate is any one of paragraphs 80-109 or 171, said S.pneumoniae serotype 23B glycoconjugate is any one of paragraphs 172-197 or 254, said S.pneumoniae serotype 24F glycoconjugate is any one of paragraphs 255-283 or 344 and/or 30said S. pneumoniae serotype 35B glycoconjugate is any one of paragraphs 345-370 or 437.523. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B,23F, 24F, 33F and 35B.524. The immunogenic composition of paragraph 523 which is a 25-valent pneumococcal 35conjugate composition.525. The immunogenic composition of paragraph 524 or 525 wherein said S. pneumoniaeserotype 15A glycoconjugate is any one of paragraphs 1-26 or 79, said S. pneumoniae 171serotype 23A glycoconjugate is any one of paragraphs 80-109 or 171, said S. pneumoniaeserotype 23B glycoconjugate is any one of paragraphs 172-197 or 254, said S. pneumoniaeserotype 24F glycoconjugate is any one of paragraphs 255-283 or 344 and/or said S.pneumoniae serotype 35B glycoconjugate is any one of paragraphs 345-370 or 437.526. The immunogenic composition of any one of paragraphs 454 to 525 wherein all the 5glycoconjugates are individually conjugated to the carrier protein.527. The immunogenic composition of any one of paragraphs 454 to 526 wherein theglycoconjugates are conjugated to CRM 197.528. The immunogenic composition of any one of paragraphs 454 to 527 wherein theglycoconjugate from S. pneumoniae serotype 3 is conjugated to CRM 197. 10529. The immunogenic composition of any one of paragraphs 454 to 527 wherein theglycoconjugate from S. pneumoniae serotype 3 is conjugated to SCP.530. The immunogenic composition of any one of paragraphs 454 to 529 wherein theglycoconjugate from S. pneumoniae serotype 22F is conjugated to CRM 197.531. The immunogenic composition of any one of paragraphs 454 to 530 wherein the 15glycoconjugate from S. pneumoniae serotype 33F is conjugated to CRM 197.532. The immunogenic composition of any one of paragraphs 454 to 531 wherein theglycoconjugate from S. pneumoniae serotype 15B is conjugated to CRM 197.533. The immunogenic composition of any one of paragraphs 454 to 532 wherein theglycoconjugate from S. pneumoniae serotype 12F is conjugated to CRM 197. 20534. The immunogenic composition of any one of paragraphs 454 to 533 wherein theglycoconjugate from S. pneumoniae serotype 10A is conjugated to CRM 197.535. The immunogenic composition of any one of paragraphs 454 to 534 wherein theglycoconjugate from S. pneumoniae serotype 11A is conjugated to CRM 197.536. The immunogenic composition of any one of paragraphs 454 to 535 wherein the 25glycoconjugate from S. pneumoniae serotype 8 is conjugated to CRM 197.537. The immunogenic composition of any one of paragraphs 454 to 536 wherein theglycoconjugates from S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F areconjugated to CRM 197.538. The immunogenic composition of any one of paragraphs 454 to 537 wherein the 30glycoconjugates from S. pneumoniae serotypes 1, 5 and 7F are conjugated to CRM 197.539. The immunogenic composition of any one of paragraphs 454 to 538 wherein theglycoconjugates from S. pneumoniae serotypes 6A and 19A are conjugated to CRM 197.540. The immunogenic composition of any one of paragraphs 454 to 528 wherein the theglycoconjugates are all individually conjugated to CRM 197. 35541. The immunogenic composition of any one of paragraphs 454 to 528 wherein theglycoconjugate from S. pneumoniae serotype 3 is conjugated to SCP and the otherglycoconjugates are all individually conjugated to CRM 197. 172542. The immunogenic composition of any one of paragraphs 454 to 528 wherein theglycoconjugate from S. pneumoniae serotype 3 is conjugated to SCP, at least one otherglycoconjugate is conjugated to TT and the other glycoconjugate(s) is/are all individuallyconjugated to CRM 197.543. The immunogenic composition of any one of paragraphs 454 to 528 wherein the 5glycoconjugate from S. pneumoniae serotype 3 is conjugated to SCP, one otherglycoconjugate is conjugated to TT and the other glycoconjugate(s) is/are all individuallyconjugated to CRM 197.544. The immunogenic composition of any one of paragraphs 454 to 528 wherein theglycoconjugate from S. pneumoniae serotype 3 is conjugated to SCP, at least two other 10glycoconjugates are conjugated to TT and the other glycoconjugate(s) is/are all individuallyconjugated to CRM 197.545. The immunogenic composition of any one of paragraphs 454 to 528 wherein theglycoconjugate from S. pneumoniae serotype 3 is conjugated to SCP, two otherglycoconjugates are conjugated to TT and the other glycoconjugate(s) is/are all individually 15conjugated to CRM 197.546. The immunogenic composition of any one of paragraphs 454 to 528 wherein theglycoconjugate from S. pneumoniae serotype 3 is conjugated to SCP, at least three otherglycoconjugates are conjugated to TT and the other glycoconjugate(s) is/are all individuallyconjugated to CRM 197. 20547. The immunogenic composition of any one of paragraphs 454 to 528 wherein theglycoconjugate from S. pneumoniae serotype 3 is conjugated to SCP, three otherglycoconjugates areconjugated to TT and the other glycoconjugate(s) is/are all individuallyconjugated to CRM 197.548. The immunogenic composition of any one of paragraphs 454 to 528 wherein the 25glycoconjugate from S. pneumoniae serotype 3 is conjugated to SCP, at least four otherglycoconjugates are conjugated to TT and the other glycoconjugate(s) is/are all individuallyconjugated to CRM 197.549. The immunogenic composition of any one of paragraphs 454 to 528 wherein theglycoconjugate from S. pneumoniae serotype 3 is conjugated to SCP, four other 30glycoconjugates are conjugated to TT and the other glycoconjugate(s) is/are all individuallyconjugated to CRM 197.550. The immunogenic composition of any one of paragraphs 454 to 528 wherein theglycoconjugate from S. pneumoniae serotype 3 is conjugated to SCP, at least five otherglycoconjugates are conjugated to TT and the other glycoconjugate(s) is/are all individually 35conjugated to CRM 197.551. The immunogenic composition of any one of paragraphs 454 to 528 wherein theglycoconjugate from S. pneumoniae serotype 3 is conjugated to SCP, five other 173glycoconjugates are conjugated to TT and the other glycoconjugate(s) is/are all individuallyconjugated to CRM 197.552. The immunogenic composition of any one of paragraphs 454 to 528 wherein theglycoconjugate from S. pneumoniae serotype 3 is conjugated to SCP, at least one otherglycoconjugate is conjugated to SCP and the other glycoconjugate(s) is/are all individually 5conjugated to CRM 197.553. The immunogenic composition of any one of paragraphs 454 to 528 wherein theglycoconjugate from S. pneumoniae serotype 3 is conjugated to SCP, one otherglycoconjugate is conjugated to SCP and the other glycoconjugate(s) is/are all individuallyconjugated to CRM 197. 10554. The immunogenic composition of any one of paragraphs 454 to 528 wherein theglycoconjugate from S. pneumoniae serotype 3 is conjugated to SCP, at least two otherglycoconjugates are conjugated to SCP and the other glycoconjugate(s) is/are all individuallyconjugated to CRM 197.555. The immunogenic composition of any one of paragraphs 454 to 528 wherein the 15glycoconjugate from S. pneumoniae serotype 3 is conjugated to SCP, two otherglycoconjugates are conjugated to SCP and the other glycoconjugate(s) is/are all individuallyconjugated to CRM 197.556. The immunogenic composition of any one of paragraphs 454 to 528 wherein theglycoconjugate from S. pneumoniae serotype 3 is conjugated to SCP, at least three other 20glycoconjugates are conjugated to SCP and the other glycoconjugate(s) is/are all individuallyconjugated to CRM 197.557. The immunogenic composition of any one of paragraphs 454 to 528 wherein theglycoconjugate from S. pneumoniae serotype 3 is conjugated to SCP, three otherglycoconjugates are conjugated to SCP and the other glycoconjugate(s) is/are all individually 25conjugated to CRM 197.558. The immunogenic composition of any one of paragraphs 454 to 528 wherein theglycoconjugate from S. pneumoniae serotype 3 is conjugated to SCP, at least four otherglycoconjugates are conjugated to SCP and the other glycoconjugate(s) is/are all individuallyconjugated to CRM 197. 30559. The immunogenic composition of any one of paragraphs 454 to 528 wherein theglycoconjugate from S. pneumoniae serotype 3 is conjugated to SCP, four otherglycoconjugates are conjugated to SCP and the other glycoconjugate(s) is/are all individuallyconjugated to CRM 197.560. The immunogenic composition of any one of paragraphs 454 to 528 wherein the 35glycoconjugate from S. pneumoniae serotype 3 is conjugated to SCP, at least five otherglycoconjugates are conjugated to SCP and the other glycoconjugate(s) is/are all individuallyconjugated to CRM 197. 174561. The immunogenic composition of any one of paragraphs 454 to 528 wherein theglycoconjugate from S. pneumoniae serotype 3 is conjugated to SCP, five otherglycoconjugates are conjugated to SCP and the other glycoconjugate(s) is/are all individuallyconjugated to CRM 197.562. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes 51, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B,23F, 24F, 33F and 35B, wherein the glycoconjugate from S. pneumoniae serotype 3 isconjugated to SCP and the other glycoconjugates are all individually conjugated to CRM 197.563. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 1023F, 24F, 33F and 35B, wherein the glycoconjugate from S. pneumoniae serotype 3 isconjugated to SCP and the other glycoconjugates are all individually conjugated to CRM 197which is a 25-valent pneumococcal conjugate compositions.564. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 1523F, 24F, 33F and 35B, wherein the glycoconjugates are all individually conjugated toCRM 197.565. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B,23F, 24F, 33F and 35B, wherein the glycoconjugates are all individually conjugated to CRM 197 20which is a 25-valent pneumococcal conjugate compositions.566. The immunogenic composition of any one of paragraphs 454 to 528 wherein saidglycoconjugate from S. pneumoniae serotype 3 comprises a serotype 3 saccharide covalentlyconjugated to a carrier protein (CP) through a spacer and have the general formula (VII): (VII), 25wherein X is selected from the group consisting of CH2(CH2)n’, (CH 2CH2O) mCH2CH2,NHCO(CH2)n’, NHCO(CH2CH2O)mCH2CH2, OCH 2(CH2) n’ and O(CH 2CH2O)mCH2CH2; where n’is selected from 1 to 10 and m is selected from 1 to 4,and wherein X' is selected from the group consisting of CH2O(CH 2)n’’CH2C=O,CH2O(CH 2CH2O)m’(CH2)n’’CH2C=O, where n’’ is selected from 0 to 10 and m’ is selected from 30to 4.567. The immunogenic composition of any one of paragraphs 454 to 528 wherein saidglycoconjugate from S. pneumoniae serotype 3 comprises a serotype 3 saccharide covalently 175conjugated to a carrier protein (CP) through a spacer and have the general formula (VII),wherein X is CH 2(CH2) n’, where n’ is 2 and wherein X' is CH 2O(CH 2) n’’CH 2C=O where n’’ is 1.568. The immunogenic composition of any one of paragraphs 454 to 528 wherein saidglycoconjugate from S. pneumoniae serotype 3 is produced according to a method,comprising the steps of: 5(a) reacting an isolated Streptococcus pneumoniae serotype 3 capsular polysaccharide witha carbonic acid derivative and an azido linker in an aprotic solvent to produce an activatedazido polysaccharide,(b) reacting a carrier protein with an agent bearing an N-Hydroxysuccinimide (NHS) moietyand an alkyne group where the NHS moiety reacts with the amino groups to form an amide 10linkage thereby obtaining an alkyne functionalized carrier protein,(c) reacting the activated azido polysaccharide of step (a) with the activated alkyne-carrierprotein of step (b) by Cu+1 mediated azide-alkyne cycloaddition reaction to form aglycoconjugate.569. The immunogenic composition of paragraph 568 wherein the isolated Streptococcus 15pneumoniae serotype 3 polysaccharide is sized before the activation step (a).570. The immunogenic composition of paragraph 568 wherein the isolated Streptococcuspneumoniae serotype 3 polysaccharide is sized to a weight average molecular weightbetween 100 kDa and 200 kDa.571. The immunogenic composition of any one of paragraphs 568-570 wherein said carbonic 20acid derivative is selected from the group consisting of 1,1’-carbonyldiimidazole (CDI), 1,1’-carbonyl-di-(1,2,4-triazole) (CDT), disuccinimidyl carbonate (DSC) and N-hydroxysuccinimidyl chloroformate.572. The immunogenic composition of any one of paragraphs 568-570 wherein said carbonicacid derivative is 1,1’-carbonyldiimidazole (CDI). 25573. The immunogenic composition of any one of paragraphs 568-570 wherein said carbonicacid derivative is 1,1'-Carbonyl-di-(1,2,4-triazole) (CDT).574. The immunogenic composition of any one of paragraphs 568-573 wherein said azidolinker is a compound of formula (I), (I) 30wherein X is selected from the group consisting of CH2(CH2)n, (CH 2CH 2O)mCH2CH 2,NHCO(CH2)n, NHCO(CH2CH2O)mCH2CH2, OCH 2(CH2)n and O(CH 2CH2O)mCH2CH2; where nis selected from 1 to 10 and m is selected from 1 to 4.575. The immunogenic composition of any one of paragraphs 568-573 wherein said azidolinker is a compound of formula (II), 35 (II) 176576. The immunogenic composition of any one of paragraphs 568-575 wherein said agentbearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group is an agent bearing anN-Hydroxysuccinimide (NHS) moiety and a terminal alkyne.577. The immunogenic composition of any one of paragraphs 568-575 wherein said agentbearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group is an agent bearing an 5N-Hydroxysuccinimide (NHS) moiety and a cycloalkyne.578. The immunogenic composition of any one of paragraphs 568-575 wherein said agentbearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group is a compound offormula (III), (III)where X is selected from the group consisting of CH2O(CH 2)nCH 2C=O andCH2O(CH 2CH2O)m(CH2)nCH2C=O, where n is selected from 0 to 10 and m is selected from 0to 4. 15579. The immunogenic composition of any one of paragraphs 568-575 wherein said agentbearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group is a compound offormula (IV): (IV)580. The immunogenic composition of any one of paragraphs 568-579 wherein step a) 20comprises reacting the isolated Streptococcus pneumoniae serotype 3 capsularpolysaccharide with a carbonic acid derivative followed by reacting the carbonic acidderivative-activated polysaccharide with an azido linker in an aprotic solvent to produce anactivated azido polysaccharide.581. The immunogenic composition of any one of paragraphs 568-580 wherein at step a) the 25isolated Streptococcus pneumoniae serotype 3 capsular polysaccharide is reacted with saidcarbonic acid derivative in an aprotic solvent.582. The immunogenic composition of any one of paragraphs 568-581 wherein at step a) theisolated Streptococcus pneumoniae serotype 3 capsular polysaccharide is reacted with acarbonic acid derivative in a solution consisting essentially of dimethylsulphoxide (DMSO). 30583. The immunogenic composition of any one of paragraphs 568-582 wherein at step a) theisolated Streptococcus pneumoniae serotype 3 capsular polysaccharide is reacted with CDIin an aprotic solvent comprising 0.1% to 1% (v/v) water.
X 177584. The immunogenic composition of any one of paragraphs 568-582 wherein at step a) theisolated Streptococcus pneumoniae serotype 3 capsular polysaccharide is reacted with CDIin DMSO comprising 0.1% to 1% (v/v) water.585. The immunogenic composition of any one of paragraphs 568-584 wherein at step a)carbonic acid derivative activation is followed by the addition of water. 5586. The immunogenic composition of any paragraph 585 wherein water is added to bring thetotal water content in the mixture to between about 1% to about 10% (v/v).587. The immunogenic composition of any one of paragraphs 568-586 wherein step a) furthercomprises reacting the carbonic acid derivative-activated polysaccharide with an amount ofazido linker that is between 0.01-10 molar equivalent to the amount of polysaccharide 10Repeat Unit of the activated polysaccharide.588. The immunogenic composition of any one of paragraphs 568-587 wherein the degree ofactivation of the activated polysaccharide following step a) is between 0.5 to 50%.589. The immunogenic composition of any one of paragraphs 568-588 wherein step b)comprises reacting the carrier protein with an amount of agent bearing an N- 15Hydroxysuccinimide (NHS) moiety and an alkyne group that is 0.1-10 molar equivalents tothe lysines on the carrier.590. The immunogenic composition of any one of paragraphs 568-589 wherein the degree ofactivation of the activated carrier following step b) is between 1 and 50.591. The immunogenic composition of any one of paragraphs 568-590 wherein wherein the 20conjugation reaction c) is carried out in aqueous buffer in the presence of copper (I) ascatalyst.592. The immunogenic composition of any one of paragraphs 568-590 wherein theconjugation reaction c) is carried out in aqueous buffer in the presence an oxidant and ofcopper (I) as catalyst. 25593. The immunogenic composition of any one of paragraphs 568-590 wherein theconjugation reaction c) is carried out in aqueous buffer in the presence of copper (I) ascatalyst and ascorbate as oxidant, wherein the reaction mixture further comprises THPTA(tris(3-hydroxypropyltriazolylmethyl)amine) and aminoguanidine.594. The immunogenic composition of any one of paragraphs 568-593 wherein the initial 30input ratio (weight by weight) of activated azido polysaccharide to activated alkyne-carrier atsetp c) is between 0.1 and 3.595. The immunogenic composition of any one of paragraphs 568-594 wherein following stepc), the method further comprises a step of capping the unreacted azido groups remained inthe conjugate with an azido group capping agent. 35596. The immunogenic composition of paragraph 595 wherein, said azido group cappingagent is a compound of formula (V), 178 (V)wherein X is (CH2)n wherein n is selected from 1 to 15.597. The immunogenic composition of paragraph 595 wherein said azido group capping agentis propargyl alcohol.598. The immunogenic composition of any one of paragraphs 595-597 wherein the capping of 5the unreacted azido groups is performed with an amount of capping agent that is between0.05 to 20 molar equivalents to the amount of polysaccharide repeat unit of the activatedpolysaccharide.599. The immunogenic composition of any one of paragraphs 568-598 wherein following stepc), the method further comprises a step of capping the unreacted alkyne groups remained in 10the conjugate with an alkyne group capping agent.600. The immunogenic composition of paragraph 599 wherein said alkyne group capping agentis an agent bearing an azido group.601. The immunogenic composition of paragraph 600 wherein said alkyne group capping agentis a compound of formula (VI), 15 (VI)wherein X is (CH2)n wherein n is selected from 1 to 15.602. The immunogenic composition of paragraphs 600 wherein said alkyne group cappingagent is 3-azido-1-propanol.603. The immunogenic composition of any one of paragraphs 599-602 wherein the capping of 20the unreacted alkyne groups is performed with an amount of capping agent that is between0.05 to 20 molar equivalents to the amount of polysaccharide repeat unit of the activatedpolysaccharide.604. The immunogenic composition of any one of paragraphs 454 to 528 wherein saidglycoconjugate from S. pneumoniae serotype 3 is prepared using reductive amination 25chemistry.605. The immunogenic composition of any one of paragraphs 454 to 528 wherein saidglycoconjugate from S. pneumoniae serotype 3 is produced according to a method,comprising the steps of:(a) reacting an isolated Streptococcus pneumoniae serotype 3 capsular polysaccharide with 30an oxidizing agent;(b) compounding the activated polysaccharide of step (a) with a carrier protein; and(c) reacting the compounded activated polysaccharide and carrier protein with a reducingagent to form a glycoconjugate.606. The immunogenic composition of paragraph 605 wherein, the isolated Streptococcus 35pneumoniae serotype 3 capsular polysaccharide is sized before the activation step (a). 179607. The immunogenic composition of paragraph 605 wherein, the isolated Streptococcuspneumoniae serotype 3 capsular polysaccharide is sized before the activation step (a) to aweight average molecular weight between 100 kDa and 200 kDa.608. The immunogenic composition of any one of paragraphs 454 to 528 wherein saidglycoconjugate from S. pneumoniae serotype 3 is produced according to a method, 5comprising the steps of:(a) reacting an isolated Streptococcus pneumoniae serotype 3 capsular polysaccharide withan oxidizing agent;(a’) quenching the oxidation reaction by addition of a quenching agent;(b) compounding the activated polysaccharide of step (a) or (a’) with a carrier protein; and 10(c) reacting the compounded activated polysaccharide and carrier protein with a reducingagent to form a glycoconjugate.609. The immunogenic composition of paragraph 608 wherein, the isolated Streptococcuspneumoniae serotype 3 capsular polysaccharide is sized before the activation step (a).610. The immunogenic composition of paragraph 608 wherein, the isolated Streptococcus 15pneumoniae serotype 3 capsular polysaccharide is sized before the activation step (a) to aweight average molecular weight between 100 kDa and 200 kDa.611. The immunogenic composition of any one of paragraphs 605 to 610 wherein said oxidizingagent is periodate.612. The immunogenic composition of any one of paragraphs 605 to 610 wherein said oxidizing 20agent is periodic acid.613. The immunogenic composition of any one of paragraphs 605 to 612 wherein step a)comprises reacting the isolated Streptococcus pneumoniae serotype 3 capsularpolysaccharide with 0.01-2 molar equivalents of periodate.614. The immunogenic composition of any one of paragraphs 605 to 613 wherein the degree 25of oxidation of the activated serotype 3 polysaccharide is between 2 and 8.615. The immunogenic composition of any one of paragraphs 605 to 613 wherein the degreeof oxidation of the activated serotype 3 polysaccharide is between 11 to 19.616. The immunogenic composition of any one of paragraphs 605 to 613 wherein the degreeof oxidation of the activated serotype 3 polysaccharide is about 15. 30617. The immunogenic composition of any one of paragraphs 605 to 616 wherein the initialinput ratio (weight by weight) of activated serotype 3 capsular polysaccharide to carrier proteinat step b) is between 4:1 and 0.1:1.618. The immunogenic composition of any one of paragraphs 605 to 616 wherein the initialinput ratio (weight by weight) of activated serotype 3 capsular polysaccharide to carrier protein 35is between 1.5:1 and 0.5:1.619. The immunogenic composition of any one of paragraphs 605 to 618 wherein the reductionreaction (c) is carried out in aqueous solvent. 180620. The immunogenic composition of any one of paragraphs 605 to 618 wherein the reductionreaction (c) is carried out in aprotic solvent.621. The immunogenic composition of any one of paragraphs 605 to 618 wherein the reductionreaction (c) is carried out in a solution consisting essentially of dimethylsulphoxide (DMSO).622. The immunogenic composition of any one of paragraphs 605 to 621 wherein the reducing 5agent is sodium cyanoborohydride, sodium triacetoxyborohydride, sodium or zinc borohydridein the presence of Bronsted or Lewis acids, amine boranes such as pyridine borane, 2-Picoline Borane, 2,6-diborane-methanol, dimethylamine-borane, t-BuMeiPrN-BH3,benzylamine-BH3 or 5-ethyl-2-methylpyridine borane (PEMB).623. The immunogenic composition of any one of paragraphs 605 to 621 wherein the reducing 10agent is sodium cyanoborohydride.624. The immunogenic composition of any one of paragraphs 605 to 622 wherein between 0.2and 20 molar equivalents of reducing agent is used in step c).625. The immunogenic composition of any one of paragraphs 605 to 622 wherein between 0.5and 3 molar equivalents of reducing agent is used in step c). 15626. The immunogenic composition of any one of paragraphs 605 to 625 wherein, the productof step c) is reacted with with 1 to 20 molar equivalents of sodium borohydride for 15 mins-15hrs.627. The immunogenic composition of any one of paragraphs 454 to 626 wherein theglycoconjugate from S. pneumoniae serotype 3 comprises a serotype 3 capsular 20polysaccharide wherein the weight average molecular weight (Mw) of said polysaccharide isbetween 50 kDa and 1,000 kDa.628. The immunogenic composition of any one of paragraphs 454 to 626 wherein theglycoconjugate from S. pneumoniae serotype 3 comprises a serotype 3 capsularpolysaccharide wherein the weight average molecular weight (Mw) of said polysaccharide is 25between 100 kDa and 300 kDa.629. The immunogenic composition of any one of paragraphs 454 to 626 wherein theglycoconjugate from S. pneumoniae serotype 3 comprises a serotype 3 capsularpolysaccharide wherein the weight average molecular weight (Mw) of said polysaccharide isbetween 100 kDa and 200 kDa. 30630. The immunogenic composition of any one of paragraphs 454 to 626 wherein theglycoconjugate from S. pneumoniae serotype 3 comprises a serotype 3 capsularpolysaccharide wherein the weight average molecular weight (Mw) of said polysaccharide isbetween 200 kDa and 300 kDa.631. The immunogenic composition of any one of paragraphs 454 to 626 wherein the 35glycoconjugate from S. pneumoniae serotype 3 comprises a serotype 3 capsularpolysaccharide wherein the weight average molecular weight (Mw) of said polysaccharide isbetween 100 kDa and 300 kDa. 181632. The immunogenic composition of any one of paragraphs 454 to 631 wherein theglycoconjugate from S. pneumoniae serotype 3 has a weight average molecular weight (Mw)of between 250 kDa and 20,000 kDa.633. The immunogenic composition of any one of paragraphs 454 to 631 wherein theglycoconjugate from S. pneumoniae serotype 3 has a weight average molecular weight (Mw) 5of between 500 kDa and 15,000 kDa.634. The immunogenic composition of any one of paragraphs 454 to 631 wherein theglycoconjugate from S. pneumoniae serotype 3 has a weight average molecular weight (Mw)of between 500 kDa and 10,000 kDa.635. The immunogenic composition of any one of paragraphs 454 to 631 wherein the 10glycoconjugate from S. pneumoniae serotype 3 has a weight average molecular weight (Mw)of between 500 kDa and 5,000 kDa.636. The immunogenic composition of any one of paragraphs 454 to 631 wherein theglycoconjugate from S. pneumoniae serotype 3 has a weight average molecular weight (Mw)of between 600 kDa and 3,000 kDa. 15637. The immunogenic composition of any one of paragraphs 454 to 636 wherein the degreeof conjugation of the serotype 3 glycoconjugate is between 2 and 15.638. The immunogenic composition of any one of paragraphs 454 to 636 wherein the degreeof conjugation of the serotype 3 glycoconjugate is between 4 and 7.639. The immunogenic composition of any one of paragraphs 454 to 638 wherein the ratio of 20serotype 3 polysaccharide to carrier protein in the serotype 3 glycoconjugate is between 0.5and 3.0 (w/w).640. The immunogenic composition of any one of paragraphs 454 to 638 wherein the ratio ofserotype 3 polysaccharide to carrier protein in the serotype 3 glycoconjugate is between 0.5and 1.5 (w/w). 25641. The immunogenic composition of any one of paragraphs 454 to 638 wherein the ratio ofserotype 3 polysaccharide to carrier protein in the serotype 3 glycoconjugate is between 0.9and 1.1 (w/w).642. The immunogenic composition of any one of paragraphs 454 to 641 wherein said serotypeglycoconjugate comprises at least one covalent linkage between the carrier protein and the 30polysaccharide for every 4 saccharide repeat units of the polysaccharide.643. The immunogenic composition of any one of paragraphs 454 to 641 wherein said serotypeglycoconjugate comprises at least one covalent linkage between the carrier protein and thepolysaccharide for every 10 saccharide repeat units of the polysaccharide.644. The immunogenic composition of any one of paragraphs 454 to 641 wherein said serotype 35glycoconjugate comprises at least one covalent linkage between the carrier protein and thepolysaccharide for every 15 saccharide repeat units of the polysaccharide. 182645. The immunogenic composition of any one of paragraphs 454 to 641 wherein said serotypeglycoconjugate comprises at least one covalent linkage between the carrier protein and thepolysaccharide for every 25 saccharide repeat units of the polysaccharide.646. The immunogenic composition of any one of paragraphs 454 to 641 wherein said serotypeglycoconjugate comprises at least one covalent linkage between the carrier protein and the 5polysaccharide for every 50 saccharide repeat units of the polysaccharide.647. The immunogenic composition of any one of paragraphs 454 to 641 wherein said serotypeglycoconjugate comprises at least one covalent linkage between the carrier protein and thepolysaccharide for every 100 saccharide repeat units of the polysaccharide.648. The immunogenic composition of any one of paragraphs 454 to 641 wherein said serotype 10glycoconjugate comprises at least one covalent linkage between the carrier protein and thepolysaccharide for every 5 to 10 saccharide repeat units of the polysaccharide.649. The immunogenic composition of any one of paragraphs 454 to 641 wherein said serotypeglycoconjugate comprises at least one covalent linkage between the carrier protein and thepolysaccharide for every 10 to 20 saccharide repeat units of the polysaccharide. 15650. The immunogenic composition of any one of paragraphs 454 to 649 comprising less thanabout 50% of free serotype 3 polysaccharide compared to the total amount of serotype 3polysaccharide.651. The immunogenic composition of any one of paragraphs 454 to 649 comprising less thanabout 40% of free serotype 3 polysaccharide compared to the total amount of serotype 3 20polysaccharide.652. The immunogenic composition of any one of paragraphs 454 to 649 comprising less thanabout 25% of free serotype 3 polysaccharide compared to the total amount of serotype 3polysaccharide.653. The immunogenic composition of any one of paragraphs 454 to 649 comprising less than 25about 20% of free serotype 3 polysaccharide compared to the total amount of serotype 3polysaccharide.654. The immunogenic composition of any one of paragraphs 454 to 649 comprising less thanabout 15% of free serotype 3 polysaccharide compared to the total amount of serotype 3polysaccharide. 30655. The immunogenic composition of any one of paragraphs 454 to 654 wherein at least 30%of the serotype 3 glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.656. The immunogenic composition of any one of paragraphs 454 to 654 wherein at least 40%of the serotype 3 glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.657. The immunogenic composition of any one of paragraphs 454 to 654 wherein at least 45%, 3550%, 55%, 60%, 65%, 70%, 75%, 80%, or 85% of the serotype 3 glycoconjugate has a Kdbelow or equal to 0.3 in a CL-4B column. 183658. The immunogenic composition of any one of paragraphs 454 to 654 wherein at least 60%of the serotype 3 glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.659. The immunogenic composition of any one of paragraphs 454 to 654 wherein between 50%and 80% of the serotype 3 glycoconjugate has a K d below or equal to 0.3 in a CL-4B column.660. The immunogenic composition of any one of paragraphs 454 to 654 wherein between 65% 5and 80% of the serotype 3 glycoconjugate has a K d below or equal to 0.3 in a CL-4B column.661. The glycoconjugate of paragraph 24, 107, 195, 281 or 368 wherein the carrier protein isan enzymatically inactive SCP.662. The process of paragraph 77, 169, 252, 342 or 435 wherein the carrier protein is is anenzymatically inactive SCP. 10663. The immunogenic composition of paragraph 529 or any one of paragraphs 541-561wherein said SPC is an enzymatically inactive SCP.664. The immunogenic composition of paragraph 562 wherein said is an enzymatically inactiveSCP.665. The immunogenic composition of paragraph 563 wherein said SPC is is an enzymatically 15inactive SCP.666. The glycoconjugate of paragraph 24, 107, 195, 281 or 368 wherein the carrier protein isan enzymatically inactive SCP from GBS (SCPB).667. The process of paragraph 77, 169, 252, 342 or 435 wherein the carrier protein is anenzymatically inactive SCP from GBS (SCPB). 20668. The immunogenic composition of paragraph 529 or any one of paragraphs 541-561wherein said SPC is an enzymatically inactive SCP from GBS (SCPB).669. The immunogenic composition of paragraph 562 wherein said SPC is an SCP from GBS(SCPB).670. The immunogenic composition of paragraph 563 wherein said SPC is an enzymatically 25inactive SCP from GBS (SCPB).671. The glycoconjugate of paragraph 24, 107, 195, 281 or 368 wherein the carrier protein is afragment of an SCPB.672. The process of paragraph 77, 169, 252, 342 or 435 wherein the carrier protein is afragment of an SCPB. 30673. The immunogenic composition of paragraph 529 or any one of paragraphs 541-561wherein said SPC is a fragment of an SCPB.674. The immunogenic composition of paragraph 562 wherein said SPC is a fragment of anSCPB.675. The immunogenic composition of paragraph 563 wherein said SPC is a fragment of an 35SCPB.676. The glycoconjugate of paragraph 24, 107, 195, 281 or 368 wherein the carrier protein is afragment of an SCP which comprises the protease domain, the protease-associated domain 184(PA domain) and the three fibronectin type III (Fn) domains but does not comprise the exportsignal presequence, the pro-sequence and the cell wall anchor domain.677. The process of paragraph 77, 169, 252, 342 or 435 wherein the carrier is a fragment of anSCP which comprises the protease domain, the protease-associated domain (PA domain)and the three fibronectin type III (Fn) domains but does not comprise the export signal 5presequence, the pro-sequence and the cell wall anchor domain.678. The immunogenic composition of paragraph 529 or any one of paragraphs 541-561wherein said SPC is a fragment of an SCP which comprises the protease domain, theprotease-associated domain (PA domain) and the three fibronectin type III (Fn) domains butdoes not comprise the export signal presequence, the pro-sequence and the cell wall anchor 10domain.679. The immunogenic composition of paragraph 562 wherein said SPC is a fragment of anSCP which comprises the protease domain, the protease-associated domain (PA domain)and the three fibronectin type III (Fn) domains but does not comprise the export signalpresequence, the pro-sequence and the cell wall anchor domain. 15680. The immunogenic composition of paragraph 563 wherein said SPC is a fragment of anSCP which comprises the protease domain, the protease-associated domain (PA domain)and the three fibronectin type III (Fn) domains but does not comprise the export signalpresequence, the pro-sequence and the cell wall anchor domain.681. The glycoconjugate of paragraph 24, 107, 195, 281 or 368 wherein the carrier protein is 20an enzymatically inactive fragment of SCP comprising the protease domain, the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains but does notcomprise the export signal presequence, the pro-sequence and the cell wall anchor domain.682. The process of paragraph 77, 169, 252, 342 or 435 wherein the carrier protein is anenzymatically inactive fragment of SCP comprising the protease domain, the protease- 25associated domain (PA domain) and the three fibronectin type III (Fn) domains but does notcomprise the export signal presequence, the pro-sequence and the cell wall anchor domain.683. The immunogenic composition of paragraph 529 or any one of paragraphs 541-561wherein said SPC is an enzymatically inactive fragment of SCP comprising the proteasedomain, the protease-associated domain (PA domain) and the three fibronectin type III (Fn) 30domains but does not comprise the export signal presequence, the pro-sequence and the cellwall anchor domain.684. The immunogenic composition of paragraph 562 wherein said SPCis an enzymaticallyinactive fragment of SCP comprising the protease domain, the protease-associated domain(PA domain) and the three fibronectin type III (Fn) domains but does not comprise the export 35signal presequence, the pro-sequence and the cell wall anchor domain.685. The immunogenic composition of paragraph 563 wherein said SPC is an enzymaticallyinactive fragment of SCP comprising the protease domain, the protease-associated domain 185(PA domain) and the three fibronectin type III (Fn) domains but does not comprise the exportsignal presequence, the pro-sequence and the cell wall anchor domain.686. The glycoconjugate of paragraph 24, 107, 195, 281 or 368 wherein the carrier protein isan enzymatically inactive fragment of SCP which comprises the protease domain, theprotease-associated domain (PA domain) and the three fibronectin type III (Fn) domains but 5does not comprise the export signal presequence, the pro-sequence and the cell wall anchordomain, where said inactivation is accomplished by replacing at least one amino acid of thewild type sequence and wherein said replacement is selected from the group consisting ofD130A, H193A, N295A and S512A where the numbers indicate the amino acid residueposition in the peptidase according to the numbering of SEQ ID NO: 1 of WO00/34487. 10687. The process of paragraph 77, 169, 252, 342 or 435 wherein the carrier protein is anenzymatically inactive fragment of SCP which comprises the protease domain, the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains but does notcomprise the export signal presequence, the pro-sequence and the cell wall anchor domain,where said inactivation is accomplished by replacing at least one amino acid of the wild type 15sequence and wherein said replacement is selected from the group consisting of D130A,H193A, N295A and S512A where the numbers indicate the amino acid residue position in thepeptidase according to the numbering of SEQ ID NO: 1 of WO00/34487.688. The immunogenic composition of paragraph 529 or any one of paragraphs 541-561wherein said SPC is an enzymatically inactive fragment of SCP which comprises the protease 20domain, the protease-associated domain (PA domain) and the three fibronectin type III (Fn)domains but does not comprise the export signal presequence, the pro-sequence and the cellwall anchor domain, where said inactivation is accomplished by replacing at least one aminoacid of the wild type sequence and wherein said replacement is selected from the groupconsisting of D130A, H193A, N295A and S512A where the numbers indicate the amino acid 25residue position in the peptidase according to the numbering of SEQ ID NO: 1 ofWO00/34487.689. The immunogenic composition of paragraph 562 wherein said is an enzymatically inactivefragment of SCP which comprises the protease domain, the protease-associated domain (PAdomain) and the three fibronectin type III (Fn) domains but does not comprise the export signal 30presequence, the pro-sequence and the cell wall anchor domain, where said inactivation isaccomplished by replacing at least one amino acid of the wild type sequence and whereinsaid replacement is selected from the group consisting of D130A, H193A, N295A and S512Awhere the numbers indicate the amino acid residue position in the peptidase according to thenumbering of SEQ ID NO: 1 of WO00/34487. 35690. The immunogenic composition of paragraph 563 wherein said SPC is an enzymaticallyinactive fragment of SCP which comprises the protease domain, the protease-associateddomain (PA domain) and the three fibronectin type III (Fn) domains but does not comprise the 186export signal presequence, the pro-sequence and the cell wall anchor domain, where saidinactivation is accomplished by replacing at least one amino acid of the wild type sequenceand wherein said replacement is selected from the group consisting of D130A, H193A, N295Aand S512A where the numbers indicate the amino acid residue position in the peptidaseaccording to the numbering of SEQ ID NO: 1 of WO00/34487. 5691. The glycoconjugate of paragraph 24, 107, 195, 281 or 368 wherein the carrier protein isan enzymatically inactive fragment of SCP which comprises the protease domain, theprotease-associated domain (PA domain) and the three fibronectin type III (Fn) domains butdoes not comprise the export signal presequence, the pro-sequence and the cell wall anchordomain, where said inactivation is accomplished by replacing at least two amino acids of the 10wild type sequence wherein said at least two amino acids replacements are D130A andS512A where the numbers indicate the amino acid residue position in the peptidase accordingto the numbering of SEQ ID NO: 1 of WO00/34487.692. The process of paragraph 77, 169, 252, 342 or 435 wherein the carrier is an enzymaticallyinactive fragment of SCP which comprises the protease domain, the protease-associated 15domain (PA domain) and the three fibronectin type III (Fn) domains but does not comprise theexport signal presequence, the pro-sequence and the cell wall anchor domain, where saidinactivation is accomplished by replacing at least two amino acids of the wild type sequencewherein said at least two amino acids replacements are D130A and S512A where thenumbers indicate the amino acid residue position in the peptidase according to the numbering 20of SEQ ID NO: 1 of WO00/34487.693. The immunogenic composition of paragraph 529 or any one of paragraphs 541-561wherein said SPC is an enzymatically inactive fragment of SCP which comprises the proteasedomain, the protease-associated domain (PA domain) and the three fibronectin type III (Fn)domains but does not comprise the export signal presequence, the pro-sequence and the cell 25wall anchor domain, where said inactivation is accomplished by replacing at least two aminoacids of the wild type sequence wherein said at least two amino acids replacements areD130A and S512A where the numbers indicate the amino acid residue position in thepeptidase according to the numbering of SEQ ID NO: 1 of WO00/34487.694. The immunogenic composition of paragraph 562 wherein said SPC is an enzymatically 30inactive fragment of SCP which comprises the protease domain, the protease-associateddomain (PA domain) and the three fibronectin type III (Fn) domains but does not comprise theexport signal presequence, the pro-sequence and the cell wall anchor domain, where saidinactivation is accomplished by replacing at least two amino acids of the wild type sequencewherein said at least two amino acids replacements are D130A and S512A where the 35numbers indicate the amino acid residue position in the peptidase according to the numberingof SEQ ID NO: 1 of WO00/34487. 187695. The immunogenic composition of paragraph 563 wherein said is an enzymatically inactivefragment of SCP which comprises the protease domain, the protease-associated domain (PAdomain) and the three fibronectin type III (Fn) domains but does not comprise the export signalpresequence, the pro-sequence and the cell wall anchor domain, where said inactivation isaccomplished by replacing at least two amino acids of the wild type sequence wherein said 5at least two amino acids replacements are D130A and S512A where the numbers indicatethe amino acid residue position in the peptidase according to the numbering of SEQ ID NO:of WO00/34487.696. The glycoconjugate of paragraph 24, 107, 195, 281 or 368 wherein the carrier protein isan enzymatically inactive fragment of SCP consisting of a polypeptide having at least 95% 10identity with SEQ ID NO: 1.697. The process of paragraph 77, 169, 252, 342 or 435 wherein the carrier protein is afragment of an SCPB.698. The immunogenic composition of paragraph 529 or any one of paragraphs 541-561wherein said SPC is an enzymatically inactive fragment of SCP consisting of a polypeptide 15having at least 95% identity with SEQ ID NO: 1.699. The immunogenic composition of paragraph 562 wherein said SPC is an enzymaticallyinactive fragment of SCP consisting of a polypeptide having at least 95% identity with SEQ IDNO: 1.700. The immunogenic composition of paragraph 563 wherein said SPC is an enzymatically 20inactive fragment of SCP consisting of a polypeptide having at least 95% identity with SEQ IDNO: 1.701. The glycoconjugate of paragraph 24, 107, 195, 281 or 368 wherein the carrier protein isan enzymatically inactive fragment of SCP consisting of a polypeptide having at least 95%identity with SEQ ID NO: 2. 25702. The process of paragraph 77, 169, 252, 342 or 435 wherein the carrier protein is anenzymatically inactive fragment of SCP consisting of a polypeptide having at least 95%identity with SEQ ID NO: 2.703. The immunogenic composition of paragraph 529 or any one of paragraphs 541-561wherein said SPC is an enzymatically inactive fragment of SCP consisting of a polypeptide 30having at least 95% identity with SEQ ID NO: 2.704. The immunogenic composition of paragraph 562 wherein said SPC is an enzymaticallyinactive fragment of SCP consisting of a polypeptide having at least 95% identity with SEQ IDNO: 2.705. The immunogenic composition of paragraph 563 wherein said SPC is an enzymatically 35inactive fragment of SCP consisting of a polypeptide having at least 95% identity with SEQ IDNO: 2. 188706. The glycoconjugate of paragraph 24, 107, 195, 281 or 368 wherein the carrier protein isan enzymatically inactive fragment of SCP which consists of SEQ ID NO: 1.707. The process of paragraph 77, 169, 252, 342 or 435 wherein the carrier protein is anenzymatically inactive fragment of SCP which consists of SEQ ID NO: 1.708. The immunogenic composition of paragraph 529 or any one of paragraphs 541-561 5wherein said SPC is an enzymatically inactive fragment of SCP which consists of SEQ ID NO:1.709. The immunogenic composition of paragraph 562 wherein said SPC is an enzymaticallyinactive fragment of SCP which consists of SEQ ID NO: 1.710. The immunogenic composition of paragraph 563 wherein said SPC is an enzymatically 10inactive fragment of SCP which consists of SEQ ID NO: 1.711. The glycoconjugate of paragraph 24, 107, 195, 281 or 368 wherein the carrier protein isan enzymatically inactive fragment of SCP which consists of SEQ ID NO: 2.712. The process of paragraph 77, 169, 252, 342 or 435 wherein the carrier protein is anenzymatically inactive fragment of SCP which consists of SEQ ID NO: 2. 15713. The immunogenic composition of paragraph 529 or any one of paragraphs 541-561wherein said SPC is an enzymatically inactive fragment of SCP which consists of SEQ ID NO:2.714. The immunogenic composition of paragraph 562 wherein said SPC is an enzymaticallyinactive fragment of SCP which consists of SEQ ID NO: 2. 20715. The immunogenic composition of paragraph 563 wherein said SPC is an enzymaticallyinactive fragment of SCP which consists of SEQ ID NO: 2.
As used herein, the term "about" means within a statistically meaningful range of a value, suchas a stated concentration range, time frame, molecular weight, temperature or pH. Such a rangecan be within an order of magnitude, typically within 20%, more typically within 10%, and even 25more typically within 5% or within 1% of a given value or range. Sometimes, such a range canbe within the experimental error typical of standard methods used for the measurement and/ordetermination of a given value or range. The allowable variation encompassed by the term"about" will depend upon the particular system under study, and can be readily appreciated byone of ordinary skill in the art. Whenever a range is recited within this application, every whole 30number integer within the range is also contemplated as an embodiment of the disclosure.The terms "comprising", "comprise" and "comprises" herein are intended by the inventors to beoptionally substitutable with the terms "consisting essentially of", "consist essentially of", "consistsessentially of", "consisting of', "consist of' and "consists of', respectively, in every instance.All publications and patent applications mentioned in the specification are indicative of the level 35of those skilled in the art to which this invention pertains. All references or patent applicationscited within this patent specification are incorporated by reference herein. 189The invention is illustrated in the accompanying examples. The examples below are carried outusing standard techniques, which are well known and routine to those of skill in the art, exceptwhere otherwise described in detail. The examples are illustrative, but do not limit the invention.
EXAMPLE 5 Example 1: Preparation of serotype 15A Polysaccharide – CRM 197 Conjugate 1.1. Preparation of Streptococcus pneumoniae serotype 15A polysaccharide Serotype 15A capsular polysaccharides can be obtained directly from bacteria using isolation 10procedures known to one of ordinary skill in the art (see for example methods disclosed in U.S.Patent App. Pub. No. 2008057688 or WO2008118752). The serotype 15A Streptococcuspneumonia was grown in a bioreactor and the fermentation broth was inactivated. Thepolysaccharide was then isolated and purified by ultrafiltration and diafiltration.The purified Streptococcus pneumoniae serotype 15A polysaccharide was sized by high pressuremicrofluidizer to produce the size-reduced 15A polysaccharide. 1.2. Oxidation of Streptococcus pneumoniae serotype 15A capsular polysaccharide A calculated volume of 1.0 M potassium acetate buffer (pH 5.5) and water-for-injection (WFI) was 20added to the polysaccharide solution to achieve a final polysaccharide concentration of 2.0 g/Land a final concentration of 50mM potassium acetate buffer, if required pH was adjusted to 5.0,approximately. The diluted polysaccharide was then heated to 35 °C. Oxidation was initiated bythe addition of 1.0 molar equivalents (MEq) of sodium periodate. The oxidation reaction was keptfor 24 hrs at 35 °C. 25 After reaching the target reaction time, the activated polysaccharide was cooled to roomtemperature and concentrated using 10K MWCO Millipore ultrafiltration cassettes. Thediafiltration was then performed against 20-fold diavolume of WFI. The purified activatedsaccharide was characterized by (i) Molecular Weight by SEC-MALLS and (ii) Degree of 30Oxidation (DO). 1.3 Conjugation of activated Streptococcus pneumoniae serotype 15A polysaccharide with CRM 197 The conjugation process consists of the following steps: 35a. Compounding and lyophilization of activated polysaccharide with sucrose excipientb. Reconstitution of the lyophilized polysaccharide and CRM 197.c. Conjugation of activated polysaccharide to CRM197 and cappingd. Purification of the conjugate 190 a. Compounding with sucrose The activated polysaccharide is compounded with sucrose to a ratio of 10 grams of sucrose pergram of activated polysaccharide. The compounded mixture was then shell frozen andlyophilized. b. Reconstitution of lyophilized activated polysaccharide and CRM 197 protein in DMSO 5Lyophilized activated polysaccharide was reconstituted in anhydrous dimethyl sulfoxide (DMSO).the same amount of anhydrous DMSO was added to the calculated CRM 197 for reconstitution. c. Conjugation of activated polysaccharide to CRM 197 and capping Reconstituted activated polysaccharide was added to the reconstituted CRM 197 (in DMSO) in theconjugation reactor. The final polysaccharide concentration is 4 g/L. Conjugation was performed 10by adding 1.0 MEq of sodium cyanoborohydride to the reaction mixture. The reaction wasincubated at 23 ± 2 °C for 24 hrs. Termination of conjugation reaction was done by adding 2 MEqof sodium borohydride. The capping reaction was proceeded for 3 hrs. d. Purification of conjugate The conjugate solution was then diluted into 5-10x (by volume) 5 mM succinate/saline (pH 6.0) 15and a 50X diafiltration was performed against 5 mM succinate/saline (pH 6.0) using 100K MWCOMillipore ultrafiltration cassettes. The purified conjugate was filtered through a 0.45 μm/0.22 μmfilter, and can be stored at 2-8 ºC.
Table 1 below comprises characterizing data for serotype 15A polysaccharide-CRM 197 conjugates 20obtained by the method of this invention. Table 1 Serotype 15A Conjugates Conjugate# 1 2 3 4 5 6 DO 4.7 4.8 5.3 5.3 10.1 2.7 Act Poly Mw (kDa) 107 133 171 152 164 107 SPR (Input Ratio) 1.0 1.0 1.0 1.0 0.8 1.0Conjugation yield(%)53 60 56 46 60 SPR (Output Ratio) 1.0 0.8 1.0 1.0 0.8 0.9Free Saccharide(%)<5 6 15 22 10Conjugate Mw(kDa)2386 2247 3113 1832 4850 1390 Modified Lys (AAA) N/A N/A N/A 15.5 4.8 10SPR= Saccharide Protein Ratio 191 Example 2: Preparation of Serotype 23A Polysaccharide – CRM 197 Conjugate 2.1. Preparation of Streptococcus pneumoniae serotype 23A polysaccharide Purified and size-reduced serotype 23A polysaccharides was obtained in a similar fashion asdisclosed in example 1.1. 5 2.2. Oxidation of Streptococcus pneumoniae serotype 23A capsular polysaccharide A calculated volume of 1.0 M potassium acetate buffer and water-for-injection (WFI) was addedto the polysaccharide solution to achieve a final polysaccharide concentration of 2.0g/L and a finalconcentration of 50mM potassium acetate buffer, if required pH was adjusted to 5.5, 10approximately. Oxidation was initiated by the addition of 0.45 molar equivalents (MEq) of sodiumperiodate. The oxidation reaction was proceeded for 18 hrs.After reaching the target reaction time, the activated polysaccharide was concentrated using 10KMWCO Millipore ultrafiltration cassettes. The diafiltration was then performed against 20-folddiavolume of WFI. The purified activated saccharide was characterized by (i) Molecular Weight 15by SEC-MALLS and (ii) Degree of Oxidation (DO). 2.3 Conjugation of activated Streptococcus pneumoniae serotype 23A polysaccharide with CRM 197 The conjugation process consists of the following steps:a. Compounding and lyophilization of activated polysaccharide with sucrose excipientb. Reconstitution of the lyophilized polysaccharide and CRM 197.c. Conjugation of activated polysaccharide to CRM197 and cappingd. Purification of the conjugate 25 a. Compounding with sucrose The activated polysaccharide is compounded with sucrose to a ratio of 25 grams of sucrose pergram of activated polysaccharide. The compounded mixture was then shell frozen andlyophilized. 30 b. Reconstitution of lyophilized activated polysaccharide and CRM 197 protein in DMSO Lyophilized activated polysaccharide was reconstituted in anhydrous dimethyl sulfoxide (DMSO).the same amount of anhydrous DMSO was added to the calculated CRM 197 for reconstitution. c. Conjugation of activated polysaccharide to CRM 197 and capping Reconstituted activated polysaccharide was added to the reconstituted CRM 197 (in DMSO) in theconjugation reactor. The final polysaccharide concentration is 1 g/L. Conjugation was performed 192by adding 1.0 MEq of sodium cyanoborohydride to the reaction mixture. The reaction wasincubated at 23 ± 2 °C for 24 hrs. Termination of conjugation reaction was done by adding 2 MEqof sodium borohydride. The capping reaction was proceeded for 3 hrs. d. Purification of conjugate 5The conjugate solution was then diluted into 5-10x (by volume) 5 mM succinate/saline (pH 6.0)and a 50X diafiltration was performed against 5 mM succinate/saline (pH 6.0) using 100K MWCOMillipore ultrafiltration cassettes. The purified conjugate was filtered through a 0.45 μm/0.22 μmfilter, and can be stored at 2-8 ºC.Table 2 below comprises characterizing data for serotype 23A polysaccharide-CRM 197 conjugatesobtained by the method of this invention. Table 2 Serotype 23A Conjugates Conjugate# 1 2 3 DO 5.3 5.4 7.0 Act Poly Mw (kDa) 192 178 184 SPR (Input Ratio) 0.8 0.8 0.7Conjugation yield(%)51 76 SPR (Output Ratio) 0.8 0.7 0.9 Free Saccharide (%) 13 10 5 Conjugate Mw (kDa) 6150 5075 5423 Modified Lys (AAA) N/A 15 14 Example 3: Preparation of Serotype 23B Polysaccharide – CRM 197 Conjugate 15 3.1. Preparation of Streptococcus pneumoniae serotype 23B polysaccharide Purified and size-reduced serotype 23B polysaccharides was obtained in a similar fashion asdisclosed in example 1.1. 3.2. Oxidation of Streptococcus pneumoniae serotype 23B capsular polysaccharide A calculated volume of 1.0 M potassium acetate buffer and water-for-injection (WFI) was addedto the polysaccharide solution to achieve a final polysaccharide concentration of 2.0g/L and a finalconcentration of 50mM potassium acetate buffer, if required pH was adjusted to 5.0, 193approximately. The solution was then cooled to 5oC. Oxidation was initiated by the addition of 0.2molar equivalents (MEq) of sodium periodate. The oxidation reaction was proceeded for 18 hrs.
After reaching the target reaction time, the activated polysaccharide was concentrated using 30KMWCO Millipore ultrafiltration cassettes. The diafiltration was then performed against 20-fold 5diavolume of WFI. The purified activated saccharide was characterized by (i) Molecular Weightby SEC-MALLS and (ii) Degree of Oxidation (DO). 3.3 Conjugation an activated Streptococcus pneumoniae serotype 23B polysaccharide with CRM 197 10 The conjugation process consists of the following steps:a. Compounding and lyophilization of activated polysaccharide with sucrose excipientb. Reconstitution of the lyophilized polysaccharide and CRM 197.c. Conjugation of activated polysaccharide to CRM197 and capping 15d. Purification of the conjugate a. Compounding with sucrose The activated polysaccharide is compounded with sucrose to a ratio of 10 grams of sucrose pergram of activated polysaccharide. The compounded mixture was then shell frozen and 20lyophilized. b. Reconstitution of lyophilized activated polysaccharide and CRM 197 protein in DMSO Lyophilized activated polysaccharide was reconstituted in anhydrous dimethyl sulfoxide (DMSO).the same amount of anhydrous DMSO was added to the calculated CRM 197 for reconstitution. 25 c. Conjugation of activated polysaccharide to CRM 197 and capping Reconstituted activated polysaccharide was added to the reconstituted CRM 197 (in DMSO) in theconjugation reactor. The final polysaccharide concentration is 3 g/L. Conjugation was performedby adding 1.0 MEq of sodium cyanoborohydride to the reaction mixture. The reaction was 30incubated at 23 ± 2 °C for 24 hrs. Termination of conjugation reaction was done by adding 2 MEqof sodium borohydride. The capping reaction was proceeded for 3 hrs. d. Purification of conjugate The conjugate solution was then diluted into 5-10x (by volume) 5 mM succinate/saline (pH 6.0) 35and a 50X diafiltration was performed against 5 mM succinate/saline (pH 6.0) using 100K MWCOMillipore ultrafiltration cassettes. The purified conjugate was filtered through a 0.45 μm/0.22 μmfilter, and can be stored at 2-8 ºC. 194 Table 3 below comprises characterizing data for serotype 23B polysaccharide-CRM 197 conjugatesobtained by the method of this invention. Table 3 Serotype 23B Conjugates Conjugate# 1 2 3 4 DO 10.3 9.7 5.7 12 Act Poly Mw (kDa) 162 173 183 163 SPR (Input Ratio) 0.9 0.9 0.8 0.8Conjugation yield(%)49 52 58 SPR (Output Ratio) 0.75 0.8 0.6 0.75 Free Saccharide (%) 13 9 5 8 Conjugate Mw (kDa) 1025 1107 767 1493 Modified Lys (AAA) 15.9 N/A 4.2 6.5 Example 4: Preparation of Serotype 24F Polysaccharide – CRM 197 Conjugate 4.1. Preparation of Streptococcus pneumoniae serotype 24F polysaccharide Purified and size-reduced serotype 24F polysaccharides was obtained in a similar fashion asdisclosed in example 1.1. 10 4.2. Oxidation of Streptococcus pneumoniae serotype 24F capsular polysaccharide A calculated volume of 1.0 M potassium acetate buffer and water-for-injection (WFI) was addedto the polysaccharide solution to achieve a final polysaccharide concentration of 2.0g/L and a finalconcentration of 50mM potassium acetate buffer, if required pH was adjusted to 5.0, 15approximately. The solution was then cooled to 5oC. Oxidation was initiated by the addition of 0.3molar equivalents (MEq) of sodium periodate. The oxidation reaction was proceeded for 18 hrs.
After reaching the target reaction time, the activated polysaccharide was concentrated using 10KMWCO Millipore ultrafiltration cassettes. The diafiltration was then performed against 20-fold 20diavolume of WFI. The purified activated saccharide was characterized by (i) Molecular Weightby SEC-MALLS and (ii) Degree of Oxidation (DO). 195 4.3 Conjugation an activated Streptococcus pneumoniae serotype 24F polysaccharide with CRM 197 The conjugation process consists of the following steps:a. Compounding and lyophilization of activated polysaccharide with sucrose excipient 5b. Reconstitution of the lyophilized polysaccharide and CRM 197.c. Conjugation of activated polysaccharide to CRM197 and cappingd. Purification of the conjugate a. Compounding with sucrose 10The activated polysaccharide is compounded with sucrose to a ratio of 25 grams of sucrose pergram of activated polysaccharide. The compounded mixture was then shell frozen andlyophilized. b. Reconstitution of lyophilized activated polysaccharide and CRM 197 protein in DMSO 15Lyophilized activated polysaccharide was reconstituted in anhydrous dimethyl sulfoxide (DMSO).the same amount of anhydrous DMSO was added to the calculated CRM 197 for reconstitution. c. Conjugation of activated polysaccharide to CRM 197 and capping Reconstituted activated polysaccharide was added to the reconstituted CRM 197 (in DMSO) in the 20conjugation reactor. The final polysaccharide concentration is 0.7 g/L. Conjugation wasperformed by adding 1.0 MEq of sodium cyanoborohydride to the reaction mixture. The reactionwas incubated at 23 ± 2 °C for 5 hrs. Termination of conjugation reaction was done by adding 2MEq of sodium borohydride. The capping reaction was proceeded for 2 hrs. d. Purification of conjugate The conjugate solution was then diluted into 5-10x (by volume) 5 mM succinate/saline (pH 6.0)and a 50X diafiltration was performed against 5 mM succinate/saline (pH 6.0) using 100K MWCOMillipore ultrafiltration cassettes. The purified conjugate was filtered through a 0.45 μm/0.22 μm 30filter, and can be stored at 2-8 ºC.
Table 4 below comprises characterizing data for serotype 24F polysaccharide-CRM 197 conjugatesobtained by the method of this invention.35 196 Table 4 Serotype 24F Conjugates Conjugate# 1 2 3 4 DO 9 9.5 9.7 9.4 Act Poly Mw (kDa) 182 178 234 147 SPR (Input Ratio) 0.8 0.8 0.8 0.8 Conjugation yield (%) 82 61 49 78 SPR (Output Ratio) 0.95 0.73 0.94 1.1 Free Saccharide (%) 10 14 9 24 Conjugate Mw (kDa) 5757 5084 3189 2354 Modified Lys (AAA) 7.8 N/A N/A N/A Example 5: Preparation of Serotype 35B Polysaccharide – CRM 197 Conjugate 5.1. Preparation of Streptococcus pneumoniae serotype 35B polysaccharide Purified serotype 35B polysaccharides was obtained in a similar fashion as disclosed in example1.1, except no mechanical sizing was used to reduce the size of polysaccharide. .2. Oxidation of Streptococcus pneumoniae serotype 35B capsular polysaccharide 10A calculated volume of 1.0M potassium phosphate buffer and water-for-injection (WFI) was addedto the polysaccharide solution to achieve a final polysaccharide concentration of 2.0g/L and a finalconcentration of 50mM potassium phosphate buffer, if required pH was adjusted to 6.0,approximately. Oxidation was initiated by the addition of 0.1 molar equivalents (MEq) of sodiumperiodate. The oxidation reaction was proceeded for 2 hrs. 15After reaching the target reaction time, the activated polysaccharide was concentrated using 5KMWCO Millipore ultrafiltration cassettes. The diafiltration was then performed against 20-folddiavolume of WFI. The purified activated saccharide was characterized by (i) Molecular Weightby SEC-MALLS and (ii) Degree of Oxidation (DO). 5.3 Conjugation an activated Streptococcus pneumoniae serotype 35B polysaccharide with CRM 197 The conjugation process consists of the following steps:a. Compounding and lyophilization of activated polysaccharide with sucrose excipient 25 197b. Reconstitution of the lyophilized polysaccharide and CRM 197.c. Conjugation of activated polysaccharide to CRM197 and cappingd. Purification of the conjugate a. Compounding with sucrose 5The activated polysaccharide is compounded with sucrose to a ratio of 10 grams of sucrose pergram of activated polysaccharide. The compounded mixture was then shell frozen andlyophilized. b. Reconstitution of lyophilized activated polysaccharide and CRM 197 protein in DMSO 10Lyophilized activated polysaccharide was reconstituted in anhydrous dimethyl sulfoxide (DMSO).the same amount of anhydrous DMSO was added to the calculated CRM 197 for reconstitution. c. Conjugation of activated polysaccharide to CRM 197 and capping Reconstituted activated polysaccharide was added to the reconstituted CRM 197 (in DMSO) in the 15conjugation reactor. The final polysaccharide concentration is 4 g/L. Conjugation was performedby adding 1.0 MEq of sodium cyanoborohydride to the reaction mixture. The reaction wasincubated at 23 ± 2 °C for 24 hrs. Termination of conjugation reaction was done by adding 2 MEqof sodium borohydride. The capping reaction was proceeded for 3 hrs. d. Purification of conjugate The conjugate solution was then diluted into 5-10x (by volume) 5 mM succinate/saline (pH 6.0)and a 50X diafiltration was performed against 5 mM succinate/saline (pH 6.0) using 100K MWCOMillipore ultrafiltration cassettes. The purified conjugate was filtered through a 0.45 μm/0.22 μmfilter, and can be stored at 2-8 ºC. 25 Table 5 below comprises characterizing data for serotype 35B polysaccharide-CRM 197 conjugatesobtained by the method of this invention. Table 5 Serotype 35B Conjugates Conjugate# 1 2 3 4 5 6 DO 8 8 8 8 11 16 Act Poly Mw (kDa) 32 32 32 32 46 60 SPR (Input Ratio) 0.8 0.8 0.8 0.8 0.8 0.8Conjugation yield(%)50 50 57 64 55 198 SPR (Output Ratio) 0.62 0.70 0.76 0.70 0.97 0.74 Free Saccharide (%) 14 7 8 5 13 5 Conjugate Mw (kDa) 1746 1266 1705 2682 1610 3013 Modified Lys (AAA) N/A N/A N/A N/A 5.4 4.2 Example 6: Structural characterization of hydrolyzed serotype 23A polysaccharide via NMR Polysaccharide conjugates are generated by conjugating the antigen (polysaccharide)with the carrier protein. The size of the final conjugates depends on the size of the polysaccharideused. Generally, the polysaccharide molecular weight as extracted and purified from the bacteriais not suitable to generate conjugate vaccine. Therefore, the polysaccharides are sized beforethey are made ready to conjugate with the carrier protein. 10Surprisingly, it was observed that sizing 23A polysaccharide via acid hydrolysis (asrecommended for example in WO2019050814 or in WO2019050818) followed by activation usingNaIO4 resulted in poor conjugation. The impact of acid hydrolysis sizing on the structure of Pn-23A polysaccharide has been investigated.Sample preparation: Native Pn-23A polysaccharide was incubated with 0.1N acetic acid 15at 80°C for 2, 4 and 6 hrs. The acid hydrolyzed samples were dialyzed against water and thelyophilized. Lyophilized samples were weighed and dissolved in D2O. The samples were bathsonicated for 20 minutes at 50°C. Final concentration of the sample was 14mg/mL. Native samplewas also sized using mechanical homogenizer with 10pass at 15k psi pressure. The sizedsamples were transferred into the NMR tube for NMR data collection and analysis. 20NMR Data collection: All data was collected at 75°C using Bruker 600 MHz spectrometerequipped with BBO cryoprobe. The NMR data was processed using NvX and analyzed usingNMRViewJ (NvJ). The following experiments were carried out to do the NMR analysis:1) 1D 1H (d1 5s; ns 32)2) 2D 1H-13C HSQC (d1 1s; ns 4; TD 256; SW 50@82ppm) 25Results:The molecular weight of the sized Pn-23A was determined using SEC-MALLS. The sizedPn-23A molecular weights were respectively 214kDa (2 hrs of acid hydrolysis), 137kDa (4hrs ofacid hydrolysis) and 90kDa (6hrs of acid hydrolysis).The structure of the Pn-23A is shown in Figure 1. It has been found that acid hydrolysis 30can affect serotype 23A polysaccharide structure integrity.Figure 2 shows the stack plot of anomeric and methyl region of 1D 1H spectra of Pn-23Apolysaccharides sized via sonication (Sized Sonication) and acid hydrolysis for 2 hours (2Hrs), 4 199hours (4Hrs) and 6 hours (6Hrs). The anomeric and methyl signals are annotated. Highlightedbars (3 grey bars) clearly shows the increase of the unknow signals as the hydrolysis time isincreasingThe plot of the signal intensities of selected resonances (representing from each sugarresidues: A1, A6, B1, C1, D1 and D6) against the increasing hydrolysis time illustrates the 5structural changes upon hydrolysis (Figure 3). There would be no change in the signal intensity ifa certain resonance would not be affected by hydrolysis. It is evident from Figure 3 that loss ofthe signal intensity is observed in residues C and D, thus suggesting that there are significantstructural changes upon hydrolysis.Complete structural analysis of the hydrolyzed sample was done using NMR 10spectroscopy. The new resonances that were observed (Figure 2) were completely assigned.One of those resonances were anomeric signal from residue C of the hydrolyzed Pn-23Apolysaccharide, which will show an increase in the signal intensity as hydrolysis time increases(Figure 3, lower panel C1).These changes were also observed in 1DP and 2DH-P HMBC spectra of the various 15sized samples were analyzed. Figure 4 shows the 1DP NMR spectra of hydrolyzed Pn-23Apolysaccharide (right panel) and 2DH-P HMBC spectrum (left panel) of 6Hrs hydrolyzed Pn-23A polysaccharide. The 1DP NMR spectrum of Pn-23A polysaccharide hydrolyzed for 6 hrsclearly shows different populations of Pn-23A polysaccharide present after hydrolysis. The 2DH-P HMBC spectra was used to shows the Phosphorus to carbon correlations of these three 20different populations (respectively ~79%, ~13% and ~8%).Complete structural analysis of the hydrolyzed Pn-23A polysaccharide suggest that about79% of the Pn-23A polysaccharide is intact after 6 hrs of hydrolysis, whereas about 13% of Pn-23A polysaccharide loses the residue D (Rhamnose) sugar upon hydrolysis. Another about 8%of the population loses the Rhamnose sugar along with structural modification of the phospho- 25glycerol (see Figure 5).Figure 6 shows the stack plot of anomeric and methyl regions of 1DH spectra of sizedvia sonication (Sized Sonication), homogenization (Sized Homogenized) and hydrolysis(Hydrolized (2hrs)) done under process condition using 0.1N acetic acid for 2hrs at 80°C.Hydrolysis of Pn-23A polysaccharide under process condition generate about 10% of the 30hydrolyzed Pn-23A polysaccharide, where the Rhamnose sugar has been cleaved from the mainchain, thus altering the structure of Pn-23A.Activation of Pn-23A polysaccharide after sizing using acid hydrolysis leads to alterationof the polysaccharide structure and thus might have an impact on the immunogenicity of aconjugate obtained with this altered polysaccharide. 35 The mechanical sizing Pn-23A polysaccharide via sonication or homogenization resultsin no structural cleavage of the pendent Rhamnose sugar thus keeping the native polysaccharidestructure intact. 200 Example 7: Structural characterization of hydrolyzed serotype 24F polysaccharide via NMR Polysaccharide conjugates are generated by conjugating the antigen (polysaccharide)with the carrier protein. The size of the final conjugates depends on the size of the polysaccharide 5used. Generally, the polysaccharide molecular weight as extracted and purified from the bacteriais not suitable to generate conjugate vaccine. Therefore, the polysaccharides are sized beforethey are made ready to conjugate with the carrier protein.Surprisingly, it was observed that sizing 24F polysaccharide via acid hydrolysis (asrecommended for example in WO2019050815 or in WO2019050818) impacts the structure of the 10polysaccharide. The activation and conjugation of Pn-24F polysaccharide was not affected by thehydrolysis because primary activation site in Pn-24F was left intact upon hydrolysis. However, thestructure of the polysaccharide is modified and thus might have an impact on the immunogenicityof a conjugate obtained with this altered polysaccharide.Sample preparation: Native Pn-24F polysaccharide was incubated with 0.1N acetic acid 15at 80°C for 2 hrs or with 0.2N Acetic acid, 90°C, 50min. The acid hydrolyzed samples weredialyzed against water and the lyophilized. Hydrolyzed Pn-24F was weighed and dissolved inD2O. The sample was bath sonicated for 20 minutes at 50°C. Final concentration of the samplewas 25 mg/mL. The samples were transferred into the NMR tube for NMR data collection andanalysis. 20NMR Data collection: All data was collected at 75°C using Bruker 600 MHz spectrometerequipped with TCI cryoprobe. The NMR data was processed using NvX and analyzed usingNMRViewJ (NvJ). The following experiments were carried out to do the NMR analysis:1) 1DH (d1 5s; ns 32)2)H-C HSQC (d1 1s; ns 4; TD1 256; SW 65ppm@81ppm) 253) 1DP (d1 1s; ns 32)4) 2DH-P HMBC (d1 1s; ns 16; TD 64; SW 3@0ppm) The structure of the repeat unit of Pn-24F polysaccharide is shown at Figure 7.The molecular weight of the hydrolyzed Pn-24F was determined using SEC-MALLS. The 30native Pn-24F polysaccharide molecular weight was 790kDa, whereas the two hydrolyzed Pn-24F polysaccharides studied have molecular weights of 72KDa (hydrolysis in 0.2N Acetic acid,90°C, 50min) and 111kDa (hydrolysis in 0.1N acetic acid at 80°C for 2 hrs).1DH spectra of the hydrolyzed Pn-24F polysaccharides is provided at Figure 8 and 9.The insert tables in Figure 8 and 9 show the excellent agreement between the normalized area 35under the anomeric proton peaks and the expected theoretical area, except for the residue E1suggesting a loss of Ribf sugar (highlighted in the insert Table). 2011DH spectra of two lots of hydrolyzed Pn-24F polysaccharides (incubated with 0.1Nacetic acid at 80°C for 2 hrs (upper spectra) or with 0.2N Acetic acid, 90°C, 50min (middlespectra)) is compared with the mechanically sized Pn-24 polysaccharide (sonication; lowerspectra) (Figure 10). The anomeric and some other signals are annotated. The grey bars denotethe changes in the signal observed around anomeric, N-Acetyl and Rhamnose methyl signals. 5These differences in the signals are due to the structural changes seen in the polysaccharideupon hydrolysis. One of the significant changes observed is the decrease in the E1 anomericsignal intensity. The decrease in the E1 signal intensity (values 0.75 and 0.61 in the tables)suggest that upon hydrolysis the Ribf residue is being hydrolyzed.Similarly, the overlaid 2DH-C HSQC spectra (not shown) of sized and hydrolyzed Pn- 1024F polysaccharides show changes in the anomeric, ring and methyl resonances. The new peaksupon hydrolysis are annotated on the spectra.Figure 11 shows the schematic of the structural changes seen upon hydrolysis of Pn-24Fpolysaccharide. From the NMR data it is quite evident that Ribf residue is being cleaved uponhydrolysis (in the two conditions tested, i.e. 0.1N acetic acid at 80°C for 2 hrs or with 0.2N Acetic 15acid, 90°C, 50min).With 0.2N Acetic acid, 90°C, 50min as hydrolysis conditions, 39% of the Ribf residue ofthe Pn-24 polysaccharide is hydrolyzed (only 61% of the repeating units remain intact), whereas25% of polysaccharide is hydrolyzed using 0.1N acetic acid at 80°C for 2 hrs (only 75% of therepeating units remain intact). 20Acid hydrolysis of Pn-24F polysaccharide cleaves the Ribf sugar. About 25% and 39% ofthe Pn-24F polysaccharide has been found to have no Ribf sugar, whereas about 75% or 61%remain intact. There is no such a structural change when using mechanical sizing (sonication).It was also observed that hydrolysis with 0.2N Acetic acid, 90°C, 50min leads to amolecular weight reduced to about 72kda, which is not conducive for conjugation. Milder 25hydrolysis conditions (0.1N acetic acid at 80°C for 2 hrs) lead to a higher molecular weight butabout a quarter of the Ribf sugar were still lost.
Example 8: Formulation of a 25-valent Pneumococcal Conjugate Vaccine A 25 valent conjugates composition comprising glycoconjugates from S. pneumoniaeserotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A,23B, 23F, 24F, 33F and 35B (25vPnC) was formulated. All serotypes were individually conjugatedto CRM 197 except serotype 3 which was conjugated to SCP with click chemistry.S. pneumoniae glycoconjugates from serotypes 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 3519F and 23F were produced as disclosed in WO 2006/110381, glycoconjugate from S.pneumoniae serotype 3 was produced as disclosed in WO2022/249106 (SCP with click 202chemistry) and glycoconjugates from S. pneumoniae from serotypes 8, 10A, 11A, 12F, 15B, 22Fand 33F were produced as disclosed in WO2015/110941.The required volumes of bulk concentrates were calculated based on the batch volumeand the bulk saccharide concentrations. The preparation was filtered through a 0.2 µm MilliporePES membrane, followed by the addition of AlPO 4. 5- Form 1 consisted in 2.2 µg of each of glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5,6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and35B individually conjugated to CRM 197 (except serotype 3 which was conjugated to SCP), 4.4 µgof glycoconjugate from S. pneumoniae serotype 6B conjugated to CRM 197, 5 mM succinate bufferpH 5.8, 0.02% (w/v) polysorbate 80 (PS80), 150 mM NaCl and 0.25 mg/mL aluminum as AlPO4 10for a dose of 0.5 mL. CRM 197, content was about 60 µg for a dose of 0.5mL.- Form 2 consisted in 2.2 µg of each of glycoconjugates from S. pneumoniae serotypes 1, 3 , 4,5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33Fand 35B individually conjugated to CRM 197 (except serotype 3 which was conjugated to SCP), 4.4µg of glycoconjugate from S. pneumoniae serotype 6B conjugated to CRM 197, 5 mM succinate 15buffer pH 5.8, 0.02% (w/v) PS80, 150 mM NaCl, 20 mM CaCl2 and 0.25 mg/mL aluminum asAlPO4 for a dose of 0.5 mL. CRM 197, content was about 60 µg for a dose of 0.5mL.- Form 3 consisted in 2.2 µg of each of glycoconjugates from S. pneumoniae serotypes 1, 3 , 4,5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33Fand 35B individually conjugated to CRM 197 (except serotype 3 which was conjugated to SCP), 4.4 20µg of glycoconjugate from S. pneumoniae serotype 6B conjugated to CRM 197, 5 mM succinatebuffer pH 5.8, 40 mM Sodium Phosphate, 0.02% (w/v) PS80, 245 mM NaCl and 0.25 mg/mLaluminum as AlPO4 for a dose of 0.5 mL. CRM 197, content was about 60 µg for a dose of 0.5mL.- Form 4 consisted in 2.2 µg of each of glycoconjugates from S. pneumoniae serotypes 1, 3 , 4,5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F 25and 35B individually conjugated to CRM 197 (except serotype 3 which was conjugated to SCP), 4.4µg of glycoconjugate from S. pneumoniae serotype 6B conjugated to CRM 197, 30 mM HistidinepH 5.8, 0.02% (w/v) PS80, 245 mM NaCl and 0.25 mg/mL aluminum as AlPO4 for a dose of 0.5mL. CRM 197, content was about 60 µg for a dose of 0.5mL. Example 9: Immunogenicity of the 25-Valent immunogenic composition in rats The immunogenicity of 25-valent immunogenic compositions (see Example 8, S.pneumoniae serotypes 1, 3 , 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F,22F, 23A, 23B, 23F, 24F, 33F and 35B individually conjugated to CRM 197 (except serotype 3 35which was conjugated to SCP)) was assessed in Rats using multiplexed direct Lumineximmunoassays (dLIAs) to measure serotype-specific IgG concentrations in sera and serotype-specific OPAs. 203All vaccine preparations were formulated to contain 0.44 µg for each pneumococcalconjugate including click-SCP serotype 3 (except 6B, at 0.88 µg/dose) with 62.5 µg AlPO 4 per0.25mL dose, in the matrix described at Example 8 (Form 1, Form 2, Form 3 and Form 4). Halfthese doses have also been tested (see Table 7 and 9)Rats (8-10 weeks old; female Wistar han rats; 10 rats per group) were immunized 5subcutaneously (250 μL) at Weeks 0 and 3 and bled at Week 0 (Wk0) and 2 weeks following thesecond dose (Week 5 post vaccination (Wk5)). Weeks 0 and 5 sera were evaluated in dLIA andOPA.To quantify the total polysaccharide binding antibody (IgG) specific to each pneumococcalpolysaccharide (PnPS), rat sera were evaluated in three direct Luminex immunoassays (dLIAs; 1013-plex dLIA, PREVNAR 13® serotypes, 7-plex dLIA, additional PREVNAR 20® serotypes, 5-plex dLIA for the 5 additional serotypes). The 13-plex assay measures anti-PnPS antibodiesspecific to the 13 serotypes included in the 13-valent pneumococcal conjugate (PnC) vaccine (1,3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and the 7-plex assay measures anti-PnPSantibodies to the additional serotypes in PREVNAR 20® (8, 10A, 11A, 12F, 15B, 22F, 33F). The 155-plex assay measures anti-PnPS antibodies to additional serotypes (15A, 23A, 23B, 24F, and35B). Each assay contains a combination of 13, or 7, or 5 spectrally distinct magneticmicrospheres coupled to PnPS conjugates (PnPS-PLL conjugates: PnPS conjugated to poly-L-Lysine).Briefly, reference standard, controls and test sera were first pre-adsorbed with two Pn 20absorbents; CWPS1 (cell wall polysaccharide from PnA containing C-polysaccharide) andCWPS2 (CWP from acapsular S. pneumoniae serotype 2) to block non-specific antibodies frombinding to the PnPS coating antigen. Following reabsorption, the PnPS-coupled microsphereswere incubated with appropriately diluted reference standard serum, controls or rat test sera.After incubation, each mixture was washed and an R-Phycoerythrin-conjugated goat anti-rat IgG 25secondary antibody was added. Fluorescent signals (expressed as median fluorescenceintensities (MFIs)) were measured using a Bio-Plex reader and correlated to the amount of boundPnPS-specific IgG. Values for test sera are reported as (Units/mL, U/mL).
Table 6 below shows IgG titers of rats vaccinated with pneumococcal conjugate vaccine 30at a 0.44 µg/dose (except 6B, at 0.88 µg/dose). 204 Table 6 Antigen - 25V 25V 25V 25V Serotype Matrix Form 1 Form 1 Form 2 Form 3 Form 4 1 Wk0 GMC 0.06 0.06 0.06 0.06 0.06 Wk5 GMC 0.06 7.71 7.36 5.96 5.52 95% CI 0.06-0.06 3.96-15.00 2.33-23.27 1.92-18.52 1.90-16.05 GMC Ratio 1 128 123 99 92 Wk0 GMC 0.17 0.13 0.13 0.13 0.13 Wk5 GMC 0.17 736.66 720.98 195.25 626.50 95% CI 0.09-0.32372.55-1456.63310.29-1675.2455.96-681.30220.05-1783.74 GMC Ratio 1 5667 5546 1502 4819 Wk0 GMC 0.06 0.06 0.06 0.06 0.06 Wk5 GMC 0.06 74.27 47.72 24.75 49.02 95% CI 0.06-0.0638.22-144.3020.43-111.4211.78-52.01 15.29-157.19 GMC Ratio 1 1238 795 412 817 Wk0 GMC 0.06 0.06 0.06 0.06 0.06 Wk5 GMC 0.06 9.81 17.82 3.64 3.89 95% CI 0.06-0.06 4.02-23.95 6.05-52.54 1.22-10.82 0.70-21.98 GMC Ratio 1 163 297 61 65 6A Wk0 GMC 0.06 0.06 0.06 0.06 0.06 Wk5 GMC 0.06 13.61 17.69 13.15 4.68 95% CI 0.06-0.06 4.91-37.73 7.50-41.68 5.72-30.21 0.73-30.49 GMC Ratio 1 227 295 219 78 6B Wk0 GMC 0.06 0.06 0.06 0.06 0.06 Wk5 GMC 0.06 67.21 44.57 63.20 8.75 95% CI 0.06-0.0617.65-255.8714.97-132.6922.53-177.30 1.58-48.75 GMC Ratio 1 1120 743 1053 146 7F Wk0 GMC 0.06 0.06 0.06 0.06 0.06 Wk5 GMC 0.06 1.15 6.47 0.79 1.18 95% CI 0.06-0.06 0.37-3.56 1.63-25.72 0.15-4.19 0.43-3.22 GMC Ratio 1 19 108 13 20 9V Wk0 GMC 0.06 0.06 0.06 0.06 0.06 Wk5 GMC 0.06 115.31 87.92 82.45 37.29 95% CI 0.06-0.0662.68-212.1332.79-235.7636.05-188.57 8.43-165.00 GMC Ratio 1 1922 1465 1374 621 14 Wk0 GMC 0.06 0.06 0.06 0.06 0.06 Wk5 GMC 0.06 0.13 0.16 0.09 0.14 95% CI 0.06-0.06 0.07-0.24 0.08-0.37 0.06-0.15 0.08-0.27 GMC Ratio 1 2 3 2 2 18C Wk0 GMC 0.07 0.07 0.07 0.07 0.07 Wk5 GMC 0.07 60.48 83.28 38.15 51.26 95% CI 0.07-0.0724.10-151.7839.94-173.6319.62-74.18 25.60-102.68 GMC Ratio 1 864 1190 545 732 19A Wk0 GMC 0.06 0.06 0.06 0.06 0.06 Wk5 GMC 0.06 163.88 157.06 95.13 72.17 95% CI 0.06-0.06104.61-256.73100.36-245.7959.48-152.13 30.78-169.24 GMC Ratio 1 2731 2618 1585 1203 205 19F Wk0 GMC 0.07 0.07 0.07 0.07 0.07 Wk5 GMC 0.07 96.09 161.23 116.91 95.13 95% CI 0.07-0.0736.96-249.7891.28-284.7865.46-208.80 28.79-314.31 GMC Ratio 1 1373 2303 1670 1359 23F Wk0 GMC 0.13 0.13 0.13 0.13 0.13 Wk5 GMC 0.13 63.99 214.30 47.92 43.32 95% CI 0.13-0.1315.52-263.7946.24-993.1918.30-125.47 20.25-92.66 GMC Ratio 1 492 1648 369 333 Wk0 GMC 3.75 3.75 3.75 3.75 3.75 Wk5 GMC 3.75 97.71 249.92 167.88 119.76 95% CI 3.75-3.7538.52-247.88139.94-446.3499.56-283.07 59.89-239.49 GMC Ratio 1 26 67 45 32 10A Wk0 GMC 4.28 3.76 3.76 3.76 3.76 Wk5 GMC 4.26 14.53 73.00 11.50 34.87 95% CI 3.21-5.65 5.45-38.7521.82-244.203.72-35.55 8.93-136.12 GMC Ratio 1 4 19 3 9 11A Wk0 GMC 0.82 0.82 0.82 0.82 0.82 Wk5 GMC 0.82 170.50 284.00 202.59 87.21 95% CI 0.82-0.8294.02-309.19130.38-618.61115.52-355.2739.29-193.61 GMC Ratio 1 208 346 247 106 12F Wk0 GMC 1.00 1.00 1.00 1.00 1.00 Wk5 GMC 1.00 13.72 12.58 4.50 17.08 95% CI 1.00-1.00 5.10-36.87 3.13-50.50 1.21-16.71 3.80-76.71 GMC Ratio 1 14 13 4 17 15B Wk0 GMC 0.25 0.25 0.25 0.25 0.25 Wk5 GMC 0.25 51.20 29.24 29.38 22.85 95% CI 0.25-0.25 30.34-86.3913.99-61.0913.04-66.19 8.96-58.28 GMC Ratio 1 205 117 118 91 22F Wk0 GMC 0.92 0.92 0.92 0.92 0.92 Wk5 GMC 0.92 518.64 560.03 426.95 316.80 95% CI 0.92-0.92392.47-685.36323.18-970.46276.36-659.60154.87-648.02 GMC Ratio 1 564 609 464 344 33F Wk0 GMC 0.67 0.67 0.67 0.67 0.67 Wk5 GMC 0.67 36.52 47.31 36.34 16.86 95% CI 0.67-0.67 17.48-76.2918.06-123.9413.12-100.63 7.25-39.21 GMC Ratio 1 55 71 54 25 15A Wk0 GMC 0.03 0.03 0.05 0.04 0.03 Wk5 GMC 0.06 8.94 8.34 1.73 2.73 95% CI 0.06-0.06 3.72-21.50 2.73-25.53 0.57-5.18 1.10-6.76 GMC Ratio 2 329 184 41 107 23A Wk0 GMC 0.03 0.02 0.03 0.03 0.03 Wk5 GMC 0.03 0.04 0.13 0.04 0.06 95% CI 0.03-0.03 0.02-0.07 0.02-0.75 0.02-0.09 0.02-0.19 GMC Ratio 1 2 5 2 2 23B Wk0 GMC 0.01 0.01 0.01 0.01 0.01 Wk5 GMC 0.01 8.44 19.27 7.02 1.81 95% CI 0.01-0.01 2.84-25.10 6.81-54.53 1.80-27.34 0.34-9.69 206 GMC Ratio 1 993 2267 826 212 24F Wk0 GMC 0.03 0.03 0.03 0.03 0.03 Wk5 GMC 0.03 0.12 0.36 0.05 0.05 95% CI 0.03-0.03 0.03-0.53 0.09-1.49 0.03-0.08 0.03-0.09 GMC Ratio 1 5 14 2 2 35B Wk0 GMC 0.04 0.03 0.03 0.04 0.03 Wk5 GMC 0.11 41.81 63.23 56.04 28.07 95% CI 0.03-0.39 19.39-90.1741.97-95.2534.97-89.83 9.26-85.06 GMC Ratio 3 1491 2480 1597 1101 GMC: Geomean Concentration95% CI: 95% Confidence IntervalGMC Ratio: Wk 5: Wk 0Table 7 below shows IgG titers of rats vaccinated with pneumococcal conjugate vaccineat a 0.22 µg/dose (except 6B, at 0.44 µg/dose).
Table 7 Antigen - 25V 25V 25V 25V Serotype Matrix Form 1 Form 1 Form 2 Form 3 Form 4 1 Wk0 GMC 0.06 0.06 0.06 0.06 0.06 Wk5 GMC 0.06 10.77 13.52 5.93 12.21 95% CI 0.06-0.06 3.56-32.60 5.30-34.48 1.74-20.25 3.72-40.10 GMC Ratio 1 179 225 99 203 Wk0 GMC 0.17 0.13 0.14 0.13 0.13 Wk5 GMC 0.17 634.25 1314.56 476.17 323.14 95% CI 0.09-0.32264.75-1519.47576.77-2996.08221.88-1021.9287.92-1187.70 GMC Ratio 1 4879 9358 3663 2486 Wk0 GMC 0.06 0.06 0.06 0.06 0.06 Wk5 GMC 0.06 33.75 88.43 33.30 87.65 95% CI 0.06-0.0611.16-102.0832.91-237.6414.29-77.59 24.90-308.51 GMC Ratio 1 563 1474 555 1461 Wk0 GMC 0.06 0.06 0.06 0.06 0.06 Wk5 GMC 0.06 9.16 26.76 6.73 11.61 95% CI 0.06-0.06 1.62-52.48 5.00-143.19 1.65-27.48 3.78-35.66 GMC Ratio 1 153 446 112 193 6A Wk0 GMC 0.06 0.06 0.06 0.06 0.06 Wk5 GMC 0.06 9.25 27.68 8.41 10.04 95% CI 0.06-0.06 2.43-35.22 10.46-73.25 3.29-21.47 2.30-44.26 GMC Ratio 1 154 461 140 167 6B Wk0 GMC 0.06 0.06 0.06 0.06 0.06 Wk5 GMC 0.06 53.07 28.21 22.55 45.72 95% CI 0.06-0.0614.97-188.1411.21-70.98 6.19-82.09 10.05-207.99 GMC Ratio 1 884 470 376 762 7F Wk0 GMC 0.06 0.06 0.06 0.06 0.06 Wk5 GMC 0.06 0.82 1.72 0.90 0.62 95% CI 0.06-0.06 0.21-3.10 0.33-8.91 0.31-2.61 0.19-2.04 GMC Ratio 1 14 29 15 10 207 9V Wk0 GMC 0.06 0.06 0.06 0.06 0.06 Wk5 GMC 0.06 113.14 79.07 62.79 79.26 95% CI 0.06-0.0671.49-179.0452.70-188.6421.63-182.3132.68-192.23 GMC Ratio 1 1886 1318 1047 1321 14 Wk0 GMC 0.06 0.06 0.06 0.06 0.06 Wk5 GMC 0.06 0.12 0.12 0.13 0.13 95% CI 0.06-0.06 0.08-0.20 0.09-0.18 0.09-0.18 0.10-0.18 GMC Ratio 1 2 2 2 2 18C Wk0 GMC 0.07 0.07 0.07 0.07 0.07 Wk5 GMC 0.07 94.90 65.96 31.12 21.46 95% CI 0.07-0.0723.77-378.8621.86-198.999.39-103.12 4.70-97.92 GMC Ratio 1 1356 942 445 307 19A Wk0 GMC 0.06 0.06 0.06 0.06 0.06 Wk5 GMC 0.06 192.00 268.25 100.83 88.00 95% CI 0.06-0.06104.17-353.86158.14-455.0447.47-214.1636.99-209.35 GMC Ratio 1 3200 4471 1680 1467 19F Wk0 GMC 0.07 0.07 0.07 0.07 0.07 Wk5 GMC 0.07 228.83 414.83 175.70 116.12 95% CI 0.07-0.0795.19-550.12218.52-787.49117.75-262.1747.93-281.34 GMC Ratio 1 3269 5926 2510 1659 23F Wk0 GMC 0.13 0.13 0.13 0.13 0.13 Wk5 GMC 0.13 125.24 142.59 27.45 51.80 95% CI 0.13-0.1323.14-677.9669.37-293.086.45-116.92 13.37-200.60 GMC Ratio 1 963 1097 211 398 Wk0 GMC 3.75 3.75 3.75 3.75 3.75 Wk5 GMC 3.75 220.26 360.03 77.03 209.84 95% CI 3.75-3.75111.24-436.13174.56-742.5837.44-158.47120.61-365.09 GMC Ratio 1 59 96 21 56 10A Wk0 GMC 4.28 3.76 4.13 5.87 3.76 Wk5 GMC 4.26 20.12 57.65 20.36 44.00 95% CI 3.21-5.65 6.43-63.0011.92-278.926.51-63.63 21.31-90.85 GMC Ratio 1 5 14 3 12 11A Wk0 GMC 0.82 0.82 0.82 0.82 0.82 Wk5 GMC 0.82 118.74 283.52 74.22 156.01 95% CI 0.82-0.8266.47-212.11145.96-550.7242.15-130.6888.93-273.70 GMC Ratio 1 145 346 91 190 12F Wk0 GMC 1.00 1.00 1.00 1.00 1.00 Wk5 GMC 1.00 28.67 73.93 10.39 27.40 95% CI 1.00-1.00 6.01-136.6519.77-276.472.74-39.35 7.35-102.15 GMC Ratio 1 29 74 10 27 15B Wk0 GMC 0.25 0.25 0.25 0.25 0.25 Wk5 GMC 0.25 26.21 83.16 22.25 32.32 95% CI 0.25-0.25 6.65-103.2030.90-223.798.22-60.26 16.37-63.81 GMC Ratio 105 333 89 129 208 22F Wk0 GMC 0.92 0.92 0.92 0.92 0.92 Wk5 GMC 0.92 592.71 1000.79 331.24 537.25 95% CI 0.92-0.92277.59-1265.55514.28-1947.53197.56-555.56332.53-808.01 GMC Ratio 1 644 1088 360 584 33F Wk0 GMC 0.67 0.67 0.67 0.67 0.67 Wk5 GMC 0.67 21.54 38.49 15.34 26.61 95% CI 0.67-0.67 9.86-47.05 16.28-91.03 8.96-26.27 11.07-63.97 GMC Ratio 1 32 57 23 40 15A Wk0 GMC 0.03 0.03 0.03 0.05 0.04 Wk5 GMC 0.06 8.35 10.30 3.45 3.78 95% CI 0.06-0.06 2.53-27.52 1.73-61.15 0.84-14.25 1.23-11.57 GMC Ratio 2 290 337 70 92 23A Wk0 GMC 0.03 0.02 0.03 0.03 0.03 Wk5 GMC 0.03 0.17 0.12 0.05 0.08 95% CI 0.03-0.03 0.03-1.07 0.05-0.30 0.02-0.10 0.03-0.21 GMC Ratio 1 8 5 2 3 23B Wk0 GMC 0.01 0.01 0.01 0.01 0.01 Wk5 GMC 0.01 7.33 11.39 8.87 3.27 95% CI 0.01-0.01 2.65-20.22 1.12-117.62 1.67-47.13 0.96-10.75 GMC Ratio 1 791 1340 1043 385 24F Wk0 GMC 0.03 0.03 0.03 0.03 0.03 Wk5 GMC 0.03 0.49 0.64 0.14 0.32 95% CI 0.03-0.03 0.12-1.97 0.13-3.20 0.03-0.66 0.06-1.78 GMC Ratio 1 19 25 6 12 35B Wk0 GMC 0.04 0.03 0.04 0.03 0.03 Wk5 GMC 0.11 40.72 45.06 25.40 33.38 95% CI 0.03-0.3916.58-100.0024.28-83.63 9.69-66.55 12.44-89.53 GMC Ratio 3 1597 1257 996 998 GMC: Geomean Concentration95% CI: 95% Confidence IntervalGMC Ratio: Wk 5: Wk 0OPA assays have been developed for S. pneumoniae serotypes present in the 25-valentvaccinea and several additional serotypes such as as 15C, 29 and 35D. OPAs were performedfor the analysis of the sera obtained from rats for select serotypes: 3, 6A, 6B, 11A, 15B, 19A, 19F,15A, 23A, 23B, 24F, 35B, 15C, 29 and 35D. Heat-inactivated sera were serially diluted 2.5-foldin Hank’s balanced saline solution supplemented with 0.1% gelatin. Target bacteria were added 10to assay plates and were incubated for 30 min at 25°C/37°C on a shaker. Baby rabbit complement(3- to 4-week old, Pel-Freez, 12% final concentration) and differentiated HL-60 cells were thenadded to each well and the assay plates were incubated for 45 minutes at 37 ℃ with shaking. Atthe conclusion of the assay, aliquots of assay reaction mixture are plated onto microcolony filterplates, incubated at 37°C, 5% CO2 overnight and the resulting colonies that were then stained 15with Coomassie Brilliant Blue stain. Colonies were imaged and enumerated on a CellularTechnology Limited (CTL) ImmunoSpot Analyzer®. Details of the assay conditions are serotypespecific. The interpolated OPA antibody titer is the reciprocal of the dilution that yields a 50% 209reduction in the number of bacterial colonies when compared to the control wells that did notcontain serum.
Table 8 below shows OPA GMT titers of rats vaccinated with pneumococcal conjugatevaccines at a 0.44µg dose (except 6B, at 0.88 µg/dose). 5 Table 8 Antigen - 25V 25V 25V 25V Serotype Matrix Form 1 Form 1 Form 2 Form 3 Form 4 3 GMT 5 702 771 57 206 95% CI 5-5 380-1294 234-2543 6-523 69-618 GMT Ratio N/A 140 154 11 41 6A GMT 7 2814 3178 996 544 95% CI 5-111334-59371745-5789 540-1836 158-1886 GMT Ratio N/A 389 439 138 75 6B GMT 5 1069 1654 875 242 95% CI 5-5 431-2652 969-2823 410-1870 74-794 GMT Ratio N/A 214 331 175 48 11A GMT 10689 21867 28097 22705 27708 95% CI 2568-4447618195-2628023656-3337018334-2811724214-31708 GMT Ratio N/A 2 3 2 3 15B GMT 6 19046 14718 8101 6171 95% CI 4-911668-310907951-27245 3979-16491 2060-18491 GMT Ratio N/A 3230 2496 1374 1047 19A GMT 216 989 1005 522 508 95% CI 83-564 638-1534 659-1532 420-649 341-756 GMT Ratio N/A 5 5 2 2 19F GMT 70 474 558 256 309 95% CI 36-138 240-935 388-802 150-438 172-555 GMT Ratio N/A 7 8 4 4 15A GMT 31 30884 15473 10116 9159 95% CI 20-4824086-396016833-35038 4038-25343 2688-31204 GMT Ratio N/A 1009 506 331 299 23A GMT 5 324 238 448 96 95% CI 5-5 86-1229 54-1056 128-1570 20-456 GMT Ratio N/A 65 48 90 19 23B GMT 2107 2914 4306 2380 1988 95% CI 1729-25681907-44502958-6269 1732-3272 1543-2562 GMT Ratio N/A 1 2 1 1 24F GMT 23 365 836 116 135 95% CI 18-29 120-1105 216-3239 52-256 41-445 GMT Ratio N/A 16 36 5 6 35B GMT 88 16090 22842 20986 18590 95% CI 17-4596466-4003114872-3508512941-340329676-35716 GMT Ratio N/A 183 259 238 211 210 15C GMT 6 15170 12002 8506 1584 95% CI 4-77348-313167064-20390 4438-16305 149-16838 GMT Ratio N/A 2755 2180 1545 288 29 GMT 6 1170 2720 1164 1093 95% CI 4-9 241-5682 1101-6721 563-2404 414-2882 GMT Ratio N/A 191 447 191 179 35D GMT 120 15951 30059 21421 21034 95% CI 29-5036316-4028624827-3639415666-2929113469-32847 GMT Ratio N/A 134 252 179 176 GMT: OPA Geomean Titers95% CI: 95% Confidence IntervalGMT Ratio: Wk 5 : ControlN/A: Not Applicable 5 Table 9 below shows OPA GMT titers of rats vaccinated with pneumococcal conjugatevaccines at a 0.22µg/dose (except 6B, at 0.44 µg/dose). Table 9 Antigen 25V 25V 25V 25V Serotype Matrix Form 1 Form 1 Form 2 Form 3 Form 4 3 GMT 5 484 823 239 185 95% CI 5-5 204-1151 395-1711 120-475 47-728 GMT Ratio N/A 97 165 48 37 6A GMT 7 2033 2037 943 564 95% CI 5-11 1033-3999 1063-3903 469-1897 157-2027 GMT Ratio N/A 281 281 130 78 6B GMT 5 1234 1103 389 455 95% CI 5-5 468-3252 668-1821 157-965 112-1853 GMT Ratio N/A 247 221 78 91 11A GMT 10689 23541 24477 26428 21448 95% CI 2568-4447619374-2860517758-3373920549-3398916781-27415 GMT Ratio N/A 2 2 2 2 15B GMT 6 13520 18058 12740 8839 95% CI 4-9 6660-2744710213-319317048-230283564-21924 GMT Ratio N/A 2293 3062 2161 1499 19A GMT 216 1394 1502 763 605 95% CI 83-564 723-2690 886-2544 470-1240 395-926 GMT Ratio N/A 6 7 4 3 19F GMT 70 714 800 436 389 95% CI 36-138 437-1164 471-1359 338-561 222-682 GMT Ratio N/A 10 11 6 6 15A GMT 31 20178 19730 18949 19019 95% CI 20-4813351-3049510840-3591110816-331968666-41746 GMT Ratio N/A 659 645 619 621 23A GMT 5 493 1400 279 441 95% CI 5-5 96-2537 776-2527 67-1157 109-1776 GMT Ratio N/A 99 280 56 88 211 23B GMT 2107 3345 3806 2740 1636 95% CI 1729-25681916-5840 2664-5437 1724-4356 1198-2234 GMT Ratio N/A 2 2 1 1 24F GMT 23 852 761 276 352 95% CI 18-29 252-2883 262-2213 72-1059 114-1085 GMT Ratio N/A 37 33 12 15 35B GMT 88 24570 21388 21260 15289 95% CI 17-45912786-4721314980-3053813114-344647939-29443 GMT Ratio N/A 279 243 241 174 15C GMT 6 10778 14907 10280 5289 95% CI 4-7 5010-23188 7688-289044323-24448835-33518 GMT Ratio N/A 1958 2707 1867 961 29 GMT 6 1983 1996 3061 1208 95% CI 4-9 729-5392 965-4129 1866-5022 500-2918 GMT Ratio N/A 325 328 503 198 35D GMT 120 25472 23336 30055 17187 95% CI 29-50314450-4490017208-3164723755-380269940-29716 GMT Ratio N/A 213 195 252 144 GMT: OPA Geomean Titers95% CI: 95% Confidence IntervalGMT Ratio: Wk 5 : ControlN/A: Not Applicable 5 There was an increase in serotype-specific IgG and OPA responses following 2immunizations of rats with 25vPnC (Table 6). Serum IgG levels increased between 2 to 5546-foldabove baseline based on the serotype and matrix. Pre immune sera (Week 0) had undetectablelevels of PnPS-specific IgG for all the 25vPnC serotypes. Due to the limited sera available, OPA 10titers were tested only for a select number of serotypes (Table 8). Serum OPA titers increasedbetween 2 to 2496-fold above titers measured in naïve rat sera, except for serotypes 11A and23B, which had high background OPA titers in naïve animals. Overall, rats vaccinated with25vPnC formulated with different matrices elicited antigen specific immune responses.25vPnC formulated with different matrices when administered to rats, elicited a robust 15humoral response that was both specific for PnPS and associated with functional killing of thebacterium.Rat sera was also analyzed for OPA titers for several non-vaccine serotypes. Pn35D, 29,and 15C OPA titers were high in all PCV25 vaccinated rats, indicating potential cross-reactivity. Example 10: Immunogenicity of the 25-Valent immunogenic composition in mice The immunogenicity of 25-valent immunogenic compositions (see Example 8, S.pneumoniae serotypes 1, 3 , 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F,22F, 23A, 23B, 23F, 24F, 33F and 35B individually conjugated to CRM 197 (except serotype 3 25 212which was conjugated to SCP)) was assessed in mice using serotype-specific OPAs to measureimmunogenicity.All vaccine preparations were formulated to contain 0.11 µg for each pneumococcalconjugate including click-SCP serotype 3 (except 6B, at 0.22 µg/dose) with AlPO 4, in the matrixdescribed at Example 8 (Form 1, Form 2, Form 3 and Form 4). 5Groups of 25 mice were immunized via the subcutaneous route on week 0. The mice wereboosted with the same dose of conjugate vaccine on week 3 and then bled at week 5. Serotype-specific OPAs were performed on week 5 sera samples.OPAs were performed as explained above (see Example 9) for the analysis of the seraobtained from mice for select serotypes: 3, 6A, 6B, 9V, 11A, 15B, 19A, 19F. 10 Table 10 below shows OPA GMT titers of mice vaccinated with pneumococcal conjugatevaccines at a 0.11 µg/dose (except 6B, at 0.22 µg/dose).
Table 10 15 Antigen - 25V 25V 25V 25V Serotype Matrix Form 1 Form 1 Form 2 Form 3 Form 4 GMT 12 2444 2548 1608 1965 95% CI 4-35 1522-3926 1693-3835 1135-2277 1256-30746A GMT 5 1473 1362 1496 1667 95% CI 5-5 517-4202 747-2485 1008-2219 1007-27596B GMT 5 270 102 226 122 95% CI 5-5 116-630 45-235 122-419 51-2899V GMT 5 67 62 74 151 95% CI 5,5 35-129 29-128 41-133 81-28211A GMT 262 3799 1983 1868 2029 95% CI 213-323 2528-5712 1327-2965 1310-2662 1313-313715B GMT 716 22781 4693 8050 9404 95% CI 447-1147 16901-30707 2934-7508 5395-12011 6305-1402519A GMT 5 35 61 46 36 95% CI 5-5 18-71 29-132 23-93 16-7719F GMT 5 89 93 162 151 95% CI 5,5 38-207 49-175 92-287 87-264GMT: OPA Geomean95% CI: 95% Confidence Interval 213Table 11 below shows OPA GMT titers of mice vaccinated with pneumococcal conjugatevaccines at a 0.055 µg/dose (except 6B, at 0.11 µg/dose). Table 11 Antigen - 25V 25V 25V 25V Serotype Matrix Form 1 Form 1 Form 2 Form 3 Form 4 GMT 12 2945 2702 2184 1800 95% CI 4-35 2168-4001 1938-3766 1484-3215 1329-24376A GMT 5 742 845 1574 1082 95% CI 5-5 317-1738 424-1688 894-2774 659-17806B GMT 5 102 158 201 119 95% CI 5-542-244 77-326 92-440 51-2769V GMT 5 77 57 97 81 95% CI 5,5 42-143 23-142 53-179 48-13911A GMT 262 2323 1991 2056 2571 95% CI 213-323 1339-4028 1202-3298 1381-3061 1691-390915B GMT 716 12926 9813 7852 14229 95% CI 447-1147 9415-17747 6559-14680 4577-13473 9398-2154519A GMT 5 63 39 39 48 95% CI 5-5 30-133 17-87 20-78 24-9519F GMT 5 119 108 116 112 95% CI 5,5 57-249 48-245 69-195 60-209GMT: OPA Geomean95% CI: 95% Confidence Interval 5 Example 11: Immunogenicity of the 25-Valent immunogenic composition in Infnat Rhesus Macaques (IRM) Infant rhesus macaques (IRM) immunologically respond to conjugated but not unconjugatedpolysaccharides, and are a suitable model to predict serotype specific immune responses inhuman infants. Published studies also demonstrated that infant rhesus macaque OPA titerscorrelate with human infant OPA titers (Xie J et al., Pediatr Infect Dis J 2020;39(1):70-7).Age and sex matched IRM (3-6 months old) were randomly divided (Table 12). Table 12 Vaccine ST3 Conjugate Chemistry Antigen Dose ( μg) AlPO4 Dose ( μg) Number IRM Vaccination Route PCV25A CRM-RAC 2.2 (6B: 4.4 μg) 125 8 IMPCV25B SCP-Click 2.2 (6B: 4.4 μg) 125 8 IM Infants were vaccinated intramuscular on both limbs with a dose of 0.25 mL/limb under sedation.IRM received 2.2 μg/dose of each conjugate (but for 6B at 4.4 μg/dose) of PCV25 which also 20 214contain 125 μg/dose of AlPO4. The serotypes included in PCV25 vaccine are 1, 3, 4, 5, 6A, 6B,7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F, 15A, 23A, 23B, 24F, and35B. Serotype 3 included were either a Click-SCP conjugate or a RAC/aqueous-CRM 197conjugate (see WO2022/249106, RAC/aqueous for Reductive Amination in aqueous, Click forclick chemistry) . Pre-bleeds to assess baseline serotype-specific sera titers were collected 1 5week (wk= -1) before primary vaccination (D0). Two repeat vaccinations were administered atweek 8 and week 16 following primary vaccination. Whole blood for sera was collected at weeksand 8 (post-dose 1; PD1); weeks 9, 12 and 16 (PD2) and weeks 17, 20, 32 and 52 (PD3).
Microcolony opsonophagocytic assays (mcOPA) were performed (see e.g. WO2022/249106). 10For the Pn3 mcOPA, reaction mixtures composed of target bacterial cells and heat-inactivatedtest serum are incubated for 30 minutes at 25ºC in an environmental shaker. Differentiated HL-tissue culture cells (effector cells) and baby rabbit complement are then added to the reactionmixture, and incubated for 45 minutes at 37ºC in an environmental shaker. Functional anti-S.pneumoniae antibody titers are determined by measuring bacterial survival in mcOPA reactions 15containing the test serum. The assay mixture is plated and grown overnight.On day 2, the number of non-phagocytosed live bacteria is determined. The mcOPA antibody titeris the reciprocal of the serum dilution resulting in 50% reduction in the number of bacterial colonieswhen compared to the bacteria-effector cell-complement control wells that do not contain serum.Direct Luminex Immunoassays (dLIA) for Quantitation of Sera IgG were also conducted (see 20Example 9).
PCV25 with Click-SCP Conjugated serotype 3 (ST3) Induced Enhanced ST3-specific OPA/IgGResponse Compared to PCV25 with RAC-CRM ST3ST3 specific OPA titers were more than 10-fold higher (13.9 fold higher) in IRM vaccinated with 25PCV25/Click-SCP ST3 compared to IRM vaccinated with PCV25/RAC-CRM ST3 post dose 1(Table 13, see GMT). ST3 specific IgG concentration were more than 20-fold higher (21 foldhigher) in IRM vaccinated with PCV25/Click-SCP ST3 compared to IRM vaccinated withPCV25/RAC-CRM ST3 post dose 1 (Table 13, see GMC). and Table 13 30 Vaccine GMT GMC (µg/ml) PCV25A 26 0.47PCV25B 382 9.7GMT: OPA Geomean titer PD1GMC: Geomean Concentration (µg/ml) PD1 215Following vaccination of IRM with PCV25/Click-SCP ST3 (PCV25B), serotype specific IgGresponse were observed for non ST3 vaccine serotypes post dose 1 which were boosted withadditional doses as shown with post dose 3 data (Table 14). Table 14 Serotype Vaccines/Conjugate Dose IgG Geomean Concentration Fold Increase (PD1:PD3) PCV25B (Click/SCP-Pn3) 2.2 μg (6B - 4.4 μg) PD1 week 4 PD3 week 4 GMC Lower 95% CI Upper 95% CI GMC Lower 95% CI Upper 95% CI 0.130 0.043 0.420 0.900 0.270 3.100 6.929.700 4.700 20.000 6.400 3.400 12.000 0.660.240 0.130 0.460 1.600 0.500 5.300 6.670.024 0.007 0.083 0.100 0.020 0.540 4.17 6A0.010 0.004 0.029 0.440 0.071 2.800 44.00 6B0.014 0.007 0.027 0.310 0.060 1.700 22.14 7F1.700 0.490 5.700 1.600 0.530 4.800 0.94 9V0.016 0.007 0.039 0.680 0.200 2.300 42.50 140.009 0.004 0.024 0.300 0.068 1.300 32.26 18C1.000 0.310 3.500 4.500 2.100 9.600 4.50 19A0.043 0.018 0.100 0.420 0.180 1.000 9.77 19F0.120 0.023 0.590 1.000 0.400 2.700 8.33 23F0.006 0.004 0.008 0.130 0.032 0.520 23.21 80.630 0.330 1.200 0.530 0.270 1.000 0.84 10A1.400 0.760 2.600 2.700 1.400 5.000 1.93 11A4.000 2.000 7.800 2.200 1.000 4.800 0.55 12F0.012 0.004 0.040 0.310 0.082 1.100 25.83 15B1.300 0.330 4.800 3.400 1.200 9.400 2.62 22F1.200 0.320 4.800 3.300 1.100 9.900 2.75 33F0.140 0.058 0.340 0.570 0.230 1.400 4.07 15A0.041 0.011 0.150 0.160 0.037 0.710 3.90 23A0.020 0.007 0.059 0.033 0.007 0.160 1.65 23B0.033 0.008 0.130 0.100 0.021 0.470 3.03 24F0.020 0.007 0.059 0.056 0.030 0.100 2.80 35B0.460 0.210 0.990 1.300 0.790 2.100 2.83Overall data suggest that compared to PCV25/RAC-CRM ST3, PCV25/Click-SCP ST3substantially improved ST3 specific OPA/IgG response (>10 fold) while generating serotype 216specific response to other serotypes included in PCV25. The data suggest that PCV25 with Click-SCP ST3 can enhance protection against ST3 mediated IPD as compared to previous vaccineformulation, while broadening serotype coverage to emerging non-vaccine serotypes.
Although the foregoing invention has been described in some detail by way of illustration and 5example for purposes of clarity of understanding, certain changes and modifications may bepracticed within the scope of the appended claims.
Claims (13)
1. 217 Claims 1. An immunogenic composition comprising glycoconjugates from S. pneumoniae serotypes 1,3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F andadditionally comprises from 1 to 5 glycoconjugates from S. pneumoniae serotypes 15A, 23A,23B, 24F and/or 35B.
2. The immunogenic composition of claim 1 which is a 21, 22, 23, 24 or 25-valent pneumococcalconjugate composition.
3. The immunogenic composition of claim 1 comprising glycoconjugates from S. pneumoniaeserotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F,23A, 23B, 23F, 24F, 33F and 35B.
4. The immunogenic composition of claim 3 which is a 25-valent pneumococcal conjugatecomposition.
5. The immunogenic composition of any one of claims 1-4 wherein:- said S. pneumoniae serotype 15A glycoconjugate comprises a serotype 15A capsularpolysaccharide having a weight average molecular weight (Mw) between 75 kDa and250 kDa and/or;- said S. pneumoniae serotype 15A glycoconjugate has a weight average molecularweight (Mw) of between 1,000 kDa and 6,000 kDa and/or;- the serotype 15A polysaccharide to carrier protein ratio (w/w) in the S. pneumoniaeserotype 15A glycoconjugate is between 0.5 and 1.5 and/or;- the degree of conjugation of said S. pneumoniae serotype 15A glycoconjugate isbetween 5 and 10 and/or;- said S. pneumoniae serotype 15A glycoconjugate comprises less than about 25% offree serotype 15A polysaccharide compared to the total amount of serotype 15Apolysaccharide and/or;- between 50% and 90% of said serotype 15A glycoconjugate has a Kd below or equalto 0.3 in a CL-4B column.
6. The immunogenic composition of any one of claims 1-5 wherein the carrier protein of said S.pneumoniae serotype 15A glycoconjugate is CRM 197.
7. The immunogenic composition of any one of claims 1-6 wherein said S. pneumoniae serotype15A glycoconjugate is prepared using reductive amination chemistry.
8. The immunogenic composition of any one of claims 1-7 wherein:- said S. pneumoniae serotype 23A glycoconjugate comprises a serotype 23A capsularpolysaccharide having a weight average molecular weight (Mw) between 110 kDaand 250 kDa and/or;- said S. pneumoniae serotype 23A glycoconjugate has a weight average molecularweight (Mw) of between 1,000 kDa and 7,500 kDa and/or; 218- the serotype 23A polysaccharide to carrier protein ratio (w/w) in the S. pneumoniaeserotype 23A glycoconjugate is between 0.5 and 1.7 and/or;- the degree of conjugation of said S. pneumoniae serotype 23A glycoconjugate isbetween 5 and 15 and/or;- said S. pneumoniae serotype 23A glycoconjugate comprises less than about 25% offree serotype 23A polysaccharide compared to the total amount of serotype 23Apolysaccharide and/or;- between 50% and 90% of said serotype 23A glycoconjugate has a Kd below or equalto 0.3 in a CL-4B column and/or;- said S. pneumoniae serotype 23A glycoconjugate comprises a S. pneumoniaeserotype 23A capsular polysaccharide wherein said S. pneumoniae serotype 23Acapsular polysaccharide has a branched Rhamnose content greater than 95% whencompared to native S. pneumoniae serotype 23A capsular polysaccharide wherein thebranched Rhamnose content is considered to be about 100%.
9. The immunogenic composition of any one of claims 1-8 wherein the carrier protein of said S.pneumoniae serotype 23A glycoconjugate is CRM 197.
10. The immunogenic composition of any one of claims 1-9 wherein said S. pneumoniae serotype23A glycoconjugate is prepared using reductive amination chemistry.
11. The immunogenic composition of any one of claims 1-10 wherein:- said S. pneumoniae serotype 23B glycoconjugate comprises a serotype 23B capsularpolysaccharide having a weight average molecular weight (Mw) between 75 kDa and250 kDa.- said S. pneumoniae serotype 23B glycoconjugate has a weight average molecularweight (Mw) of between 500 kDa and 4,000 kDa and/or;- the serotype 23B polysaccharide to carrier protein ratio (w/w) in the S. pneumoniaeserotype 23B glycoconjugate is between 0.5 and 1.5 and/or;- the degree of conjugation of said S. pneumoniae serotype 23B glycoconjugate isbetween 5 and 12 and/or;- said S. pneumoniae serotype 23B glycoconjugate comprises less than about 25% offree serotype 23B polysaccharide compared to the total amount of serotype 23Bpolysaccharide and/or;- between 40% and 60% of said serotype 23B glycoconjugate has a Kd below or equalto 0.3 in a CL-4B column.
12. The immunogenic composition of any one of claims 1-11 wherein the carrier protein of saidS. pneumoniae serotype 23B glycoconjugate is CRM 197.
13. The immunogenic composition of any one of claims 1-12 wherein said S. pneumoniaeserotype 23B glycoconjugate is prepared using reductive amination chemistry. The immunogenic composition of any one of claims 1-13 wherein:- said S. pneumoniae serotype 24F glycoconjugate comprises a serotype 24F capsularpolysaccharide having a weight average molecular weight (Mw) between 120 kDaand 250 kDa and/or;- said S. pneumoniae serotype 24F glycoconjugate has a weight average molecularweight (Mw) of between 1,500 kDa and 7,500 kDa and/or;- the serotype 24F polysaccharide to carrier protein ratio (w/w) in the S. pneumoniaeserotype 24F glycoconjugate is between 0.7 and 1.5 and/or;- the degree of conjugation of said S. pneumoniae serotype 24F glycoconjugate isbetween 5 and 12 and/or;- said S. pneumoniae serotype 24F glycoconjugate comprises less than about 25% offree serotype 24F polysaccharide compared to the total amount of serotype 24Fpolysaccharide and/or;- between 50% and 90% of said serotype 24F glycoconjugate has a Kd below or equalto 0.3 in a CL-4B column and/or;- said S. pneumoniae serotype 24F glycoconjugate comprises a S. pneumoniaeserotype 24F capsular polysaccharide wherein said S. pneumoniae serotype 24Fcapsular polysaccharide has a Ribose content greater than 95% when compared tonative S. pneumoniae serotype 24F capsular polysaccharide wherein the Ribosecontent is considered to be about 100%.15. The immunogenic composition of any one of claims 1-14 wherein the carrier protein of saidS. pneumoniae serotype 24F glycoconjugate is CRM 197.16. The immunogenic composition of any one of claims 1-15 wherein said S. pneumoniaeserotype 24F glycoconjugate is prepared using reductive amination chemistry.17. The immunogenic composition of any one of claims 1-16 wherein:- said S. pneumoniae serotype 35B glycoconjugate comprises a serotype 35B capsularpolysaccharide having a weight average molecular weight (Mw) between 25 kDa andkDa and/or;- said S. pneumoniae serotype 35B glycoconjugate has a weight average molecularweight (Mw) of between 500 kDa and 5,000 kDa and/or;- the serotype 35B polysaccharide to carrier protein ratio (w/w) in the S. pneumoniaeserotype 35B glycoconjugate is between 0.4 and 2.0 and/or;- the degree of conjugation of said S. pneumoniae serotype 35B glycoconjugate isbetween 5 and 10 and/or; 220- S. pneumoniae serotype 35B glycoconjugate comprises less than about 20% of freeserotype 35B polysaccharide compared to the total amount of serotype 35Bpolysaccharide and/or;- between 50% and 80% of said serotype 35B glycoconjugate has a Kd below or equalto 0.3 in a CL-4B column.18. The immunogenic composition of any one of claims 1-17 wherein the carrier protein of saidS. pneumoniae serotype 35B glycoconjugate is CRM 197.19. The immunogenic composition of any one of claims 1-18 wherein said S. pneumoniaeserotype 35B glycoconjugate is prepared using reductive amination chemistry.20. The immunogenic composition of any one of claims 1-19 wherein all the glycoconjugates areindividually conjugated to the carrier protein.21. The immunogenic composition of any one of claims 1-20 wherein the glycoconjugate from S.pneumoniae serotype 3 is conjugated to CRM 197.22. The immunogenic composition of any one of claims 1-20 wherein the glycoconjugate from S.pneumoniae serotype 3 is conjugated to SCP.23. The immunogenic composition of any one of claims 1-22 wherein the glycoconjugates fromS. pneumoniae serotype 8, 10A, 11A, 12F, 15B, 22F, 33F are conjugated to CRM 197.24. The immunogenic composition of any one of claims 1-23 wherein the glycoconjugates fromS. pneumoniae serotypes 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F are conjugatedto CRM 197.25. The immunogenic composition of any one of claims 1-21 wherein the glycoconjugates are allindividually conjugated to CRM 197.26. The immunogenic composition of any one of claims 1-20 wherein the glycoconjugate from S.pneumoniae serotype 3 is conjugated to SCP and the other glycoconjugates are allindividually conjugated to CRM 197.27. The immunogenic composition of any one of claims 1 to 26 wherein said glycoconjugate fromS. pneumoniae serotype 3 comprises a serotype 3 saccharide covalently conjugated to acarrier protein (CP) through a spacer and have the general formula (VII): (VII),wherein X is selected from the group consisting of CH2(CH2)n’, (CH 2CH2O) mCH2CH2,NHCO(CH2)n’, NHCO(CH2CH2O)mCH2CH2, OCH 2(CH2) n’ and O(CH 2CH2O)mCH2CH2; where n’is selected from 1 to 10 and m is selected from 1 to 4, 221and wherein X' is selected from the group consisting of CH2O(CH 2)n’’CH2C=O,CH2O(CH 2CH2O)m’(CH2)n’’CH2C=O, where n’’ is selected from 0 to 10 and m’ is selected fromto 4. Dr. Hadassa Waterman Patent Attorney G.E. Ehrlich (1995) Ltd. 35 HaMasger Street Sky Tower, 13th Floor Tel Aviv 6721407
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263384626P | 2022-11-22 | 2022-11-22 | |
| US202363593565P | 2023-10-27 | 2023-10-27 | |
| PCT/IB2023/061689 WO2024110839A2 (en) | 2022-11-22 | 2023-11-20 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL321062A true IL321062A (en) | 2025-07-01 |
Family
ID=88975732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL321062A IL321062A (en) | 2022-11-22 | 2023-11-20 | Immunopreparations containing capsular saccharide conjugate antigens and their uses |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240181028A1 (en) |
| EP (1) | EP4622665A2 (en) |
| JP (1) | JP2025537898A (en) |
| KR (1) | KR20250107930A (en) |
| CN (1) | CN120265317A (en) |
| AU (1) | AU2023385908A1 (en) |
| IL (1) | IL321062A (en) |
| MX (1) | MX2025005300A (en) |
| PE (1) | PE20251701A1 (en) |
| TW (1) | TWI887857B (en) |
| WO (1) | WO2024110839A2 (en) |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
| US4950740A (en) | 1987-03-17 | 1990-08-21 | Cetus Corporation | Recombinant diphtheria vaccines |
| GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
| DE3841091A1 (en) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE |
| CA2006700A1 (en) | 1989-01-17 | 1990-07-17 | Antonello Pessi | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
| AU651949B2 (en) | 1989-07-14 | 1994-08-11 | American Cyanamid Company | Cytokine and hormone carriers for conjugate vaccines |
| IT1237764B (en) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES. |
| SE466259B (en) | 1990-05-31 | 1992-01-20 | Arne Forsgren | PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE |
| ATE128628T1 (en) | 1990-08-13 | 1995-10-15 | American Cyanamid Co | FIBER HEMAGGLUTININ FROM BORDETELLA PERTUSSIS AS A CARRIER FOR CONJUGATE VACCINE. |
| EP0625910B1 (en) | 1992-02-11 | 2003-07-23 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Dual carrier immunogenic construct |
| IT1262896B (en) | 1992-03-06 | 1996-07-22 | CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES. | |
| JP3506431B2 (en) | 1992-05-06 | 2004-03-15 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Diphtheria toxin receptor binding domain |
| DE69313134T2 (en) | 1992-06-25 | 1998-02-26 | Smithkline Beecham Biolog | VACCINE COMPOSITION CONTAINING ADJUVANTIES |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| DK0616034T3 (en) | 1993-03-05 | 2005-02-21 | Wyeth Corp | Plasmid for the preparation of CRM protein and diphtheria toxin |
| KR100310510B1 (en) | 1993-03-23 | 2002-07-04 | 장 스테판느 | Vaccine composition containing 3-0-deacetylated monophosphoryl lipid A |
| EP0720485B1 (en) | 1993-09-22 | 2003-11-19 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
| US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| US5846547A (en) | 1996-01-22 | 1998-12-08 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
| US6355255B1 (en) | 1998-12-07 | 2002-03-12 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
| CA2281838A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders |
| US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
| EP1003531B1 (en) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| EP1279401B1 (en) | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| US6218371B1 (en) | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| BR9909915A (en) | 1998-04-09 | 2000-12-26 | Smithkline Beecham Biolog | Adjuvant compositions |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| ES2284287T3 (en) | 1998-10-16 | 2007-11-01 | Glaxosmithkline Biologicals S.A. | ADJUSTMENT SYSTEMS AND VACCINES. |
| CA2355364C (en) | 1998-12-21 | 2014-03-18 | Medimmune, Inc. | Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
| PL205041B1 (en) | 1998-12-23 | 2010-03-31 | Id Biomedical Corp | Isolated polynucleotide, vector comprising isolated polynucleotide, vector transformed or transfected host cell, method for production of isolated polypeptide coded by isolated polynucleotide, isolated polypeptide, chimeric polypeptide, composition for vaccines and its use in treating streptococcus infection |
| CA2366152A1 (en) | 1999-03-19 | 2000-09-28 | Smithkline Beecham Biologicals S.A. | Streptococcus pneumoniae vaccine |
| WO2000061761A2 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| DK1187629T3 (en) | 1999-04-19 | 2005-01-17 | Glaxosmithkline Biolog Sa | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| HK1049106A1 (en) | 1999-09-24 | 2003-05-02 | Smithkline Beecham Biologicals S.A. | Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| IL148671A0 (en) | 1999-09-24 | 2002-09-12 | Smithkline Beecham Biolog | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| WO2001098334A2 (en) | 2000-06-20 | 2001-12-27 | Shire Biochem Inc. | Streptococcus antigens |
| AU2002309706A1 (en) | 2001-05-11 | 2002-11-25 | Aventis Pasteur, Inc. | Novel meningitis conjugate vaccine |
| US7262024B2 (en) | 2001-12-20 | 2007-08-28 | Id Biomedical Corporation | Streptococcus antigens |
| MXPA05009579A (en) | 2003-03-13 | 2005-11-17 | Glaxosmithkline Biolog Sa | Purification process for bacterial cytolysin. |
| EP1603950A2 (en) | 2003-03-17 | 2005-12-14 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
| GB0421083D0 (en) | 2004-09-22 | 2004-10-27 | Glaxosmithkline Biolog Sa | Purification process |
| PL1866342T3 (en) | 2005-04-08 | 2019-04-30 | Wyeth Llc | Separation of contaminants from streptococcus pneumoniae polysaccharide by ph manipulation |
| US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| IL308456A (en) | 2005-04-08 | 2024-01-01 | Wyeth Llc | Multivalent pneumococcal polysacharide-protein conjugate composition |
| KR100885786B1 (en) | 2006-09-06 | 2009-02-26 | 주식회사 하이닉스반도체 | Bit line formation method of semiconductor memory device |
| CA2665169C (en) | 2006-10-10 | 2017-02-21 | Wyeth | Purification of streptococcus pneumoniae type 3 polysaccharides |
| HUE039169T2 (en) | 2007-03-23 | 2018-12-28 | Wyeth Llc | Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides |
| EA200901578A1 (en) | 2007-06-26 | 2010-08-30 | Глаксосмитклайн Байолоджикалс С.А. | VACCINE CONTAINING CONJUGATES OF CAPSULAR POLYSACCHARIDES STREPTOCOCCUS PNEUMONIAE |
| DK2424562T3 (en) | 2009-04-30 | 2015-12-07 | Coley Pharm Group Inc | Pneumococcal vaccine and uses thereof |
| GB201003922D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
| GB201103836D0 (en) | 2011-03-07 | 2011-04-20 | Glaxosmithkline Biolog Sa | Conjugation process |
| RU2632651C2 (en) | 2011-05-11 | 2017-10-06 | Чилдрен'С Медикал Сентер Корпорейшн | Modified biotin-binding protein, fusion proteins based thereon and their application |
| PT2885007T (en) | 2012-08-16 | 2018-12-10 | Pfizer | Glycoconjugation processes and compositions |
| RU2672053C2 (en) | 2012-12-20 | 2018-11-09 | Пфайзер Инк. | Glycoconjugation process |
| JP6416249B2 (en) | 2013-07-07 | 2018-10-31 | マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー | Synthetic vaccine against Streptococcus pneumoniae type 1 |
| EP2851092A1 (en) | 2013-09-18 | 2015-03-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Protein and peptide-free synthetic vaccines against streptococcus pneumoniae type 3 |
| CN103495161B (en) | 2013-10-08 | 2019-06-18 | 江苏康泰生物医学技术有限公司 | A kind of mixture and preparation method thereof of polynary pneumococcal capsular polysaccharide-protein conjugate |
| BR112016015835B1 (en) | 2014-01-21 | 2023-12-26 | Pfizer Inc | PROCESS FOR PREPARING CONJUGATES COMPRISING CAPSULAR POLYSACCHARIDES OF STREPTOCOCCUS PNEUMONIAE |
| IL312327B2 (en) * | 2014-01-21 | 2026-02-01 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| JP6622804B2 (en) | 2014-12-12 | 2019-12-18 | マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー | Vaccine against Streptococcus pneumoniae serotype 4 |
| EP3303357B1 (en) | 2015-06-08 | 2021-05-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Vaccines against streptococcus pneumoniae serotype 5 |
| CN109311924B (en) | 2016-04-14 | 2020-04-17 | 马克斯·普朗克科学促进学会 | Improved preparation of vaccines against streptococcus pneumoniae type 3 |
| EP3474890B1 (en) | 2016-06-22 | 2026-05-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumococcal polysaccharide-protein conjugate composition |
| CN109789198B (en) * | 2016-09-30 | 2024-08-16 | 生物E有限公司 | Multivalent pneumococcal vaccine composition comprising polysaccharide-protein conjugate |
| WO2018144439A1 (en) | 2017-01-31 | 2018-08-09 | Merck Sharp & Dohme Corp. | Methods for making polysaccharide-protein conjugates |
| JP7680185B2 (en) | 2017-02-24 | 2025-05-20 | メルク・シャープ・アンド・ドーム・エルエルシー | Enhanced immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates |
| WO2019050818A1 (en) | 2017-09-07 | 2019-03-14 | Merck Sharp & Dohme Corp. | Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein |
| HUE068482T2 (en) | 2017-09-07 | 2025-01-28 | Merck Sharp & Dohme Llc | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
| CA3074706A1 (en) | 2017-09-07 | 2019-03-14 | Merck Sharp & Dohme Corp. | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
| BR112020015696A2 (en) | 2018-02-05 | 2020-12-08 | Sanofi Pasteur, Inc. | COMPOSITION OF MULTIVALENT PNEUMOCOCCAL POLYSACARID-PROTEIN CONJUGATE |
| WO2019152921A1 (en) * | 2018-02-05 | 2019-08-08 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| EA202190318A1 (en) * | 2018-07-21 | 2021-04-29 | Байолоджикал И Лимитед | VACCINE COMPOSITIONS CONTAINING A PRESERVATIVE SYSTEM |
| CN112969474A (en) | 2018-09-12 | 2021-06-15 | 艾芬尼维克斯公司 | Multivalent pneumococcal vaccine |
| CN109045292A (en) * | 2018-11-08 | 2018-12-21 | 山东大学 | A kind of A group streptococcus Oligosaccharide Protein conjugate and the preparation method and application thereof |
| US20220016229A1 (en) | 2018-12-12 | 2022-01-20 | Pfizer Inc. | Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof |
| EP3897705A2 (en) * | 2018-12-19 | 2021-10-27 | Merck Sharp & Dohme Corp. | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| JP7239509B6 (en) | 2019-02-22 | 2023-03-28 | ファイザー・インク | Method for purifying bacterial polysaccharides |
| JP2022542316A (en) * | 2019-07-31 | 2022-09-30 | サノフィ パスツール インコーポレイテッド | Polyvalent pneumococcal polysaccharide-protein conjugate compositions and methods of use thereof |
| KR20220146451A (en) * | 2020-01-17 | 2022-11-01 | 인벤트프라이즈 엘엘씨 | Multivalent Streptococcus Vaccine |
| EP4203995A1 (en) * | 2020-08-26 | 2023-07-05 | Pfizer Inc. | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| US20230405137A1 (en) * | 2020-11-10 | 2023-12-21 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| EP4297776A1 (en) * | 2021-02-26 | 2024-01-03 | Biological E Limited | Activated-quenched polysaccharide and improved methods for quantification of polysaccharide in a vaccine composition |
| JP7714690B2 (en) * | 2021-05-28 | 2025-07-29 | ファイザー・インク | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
-
2023
- 2023-11-20 EP EP23813863.0A patent/EP4622665A2/en active Pending
- 2023-11-20 AU AU2023385908A patent/AU2023385908A1/en active Pending
- 2023-11-20 WO PCT/IB2023/061689 patent/WO2024110839A2/en not_active Ceased
- 2023-11-20 JP JP2025529769A patent/JP2025537898A/en active Pending
- 2023-11-20 KR KR1020257020216A patent/KR20250107930A/en active Pending
- 2023-11-20 IL IL321062A patent/IL321062A/en unknown
- 2023-11-20 CN CN202380080296.XA patent/CN120265317A/en active Pending
- 2023-11-20 US US18/513,738 patent/US20240181028A1/en active Pending
- 2023-11-20 PE PE2025001036A patent/PE20251701A1/en unknown
- 2023-11-21 TW TW112144898A patent/TWI887857B/en active
-
2025
- 2025-05-06 MX MX2025005300A patent/MX2025005300A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI887857B (en) | 2025-06-21 |
| WO2024110839A2 (en) | 2024-05-30 |
| WO2024110839A3 (en) | 2024-07-18 |
| US20240181028A1 (en) | 2024-06-06 |
| JP2025537898A (en) | 2025-11-20 |
| TW202426041A (en) | 2024-07-01 |
| EP4622665A2 (en) | 2025-10-01 |
| MX2025005300A (en) | 2025-06-02 |
| KR20250107930A (en) | 2025-07-14 |
| CN120265317A (en) | 2025-07-04 |
| AU2023385908A1 (en) | 2025-05-15 |
| PE20251701A1 (en) | 2025-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022281543B2 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| JP2025020211A (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| AU2018208844B2 (en) | Immunogenic compositions for use in pneumococcal vaccines | |
| JP7585203B2 (en) | Immunogenic multi-heteroantigenic polysaccharide-protein conjugates and uses thereof | |
| IL303998A (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof | |
| KR20170102009A (en) | Immunogenic compositions for use in pneumococcal vaccines | |
| WO2022249107A2 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| CA3247998A1 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| CA3252845A1 (en) | Process for producing fertilizer from a biogas stream | |
| US20240181028A1 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| TWI910585B (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| US20240350608A1 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| TW202600584A (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| EP4701656A1 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| WO2025057078A1 (en) | Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof | |
| HK1242601B (en) | Immunogenic compositions for use in pneumococcal vaccines |